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Abstract
CD55 is one of the complement regulatory/inhibitory proteins and is over-expressed
on a wide range of solid tumours. CD55 is also known to be deposited within tumour
stroma and is secreted in an active soluble form, mediated by matrix
metalloproteinase-7. The complement cascade forms part of the innate immune
system and culminates in cell lysis of targeted cells. As a complement regulatory
protein, the primary function of CD55 is to accelerate the decay of complement
components preventing formation of the membrane attack complex.
CD55 is also known to be a ligand for the T cell early activation antigen CD97, and
their interaction has been shown to inhibit the proliferation of activated T cells.
This project aimed to develop anti-tumour immunotherapeutics aimed at exploiting
CD55 as a tumour associated antigen. Initial strategies were to develop monoclonal
antibodies, specific to identified epitopes from within the CD55 protein sequence,
capable of binding, and neutralising CD55’s decay accelerating activity. Developed
antibodies would also have the potential to induce antibody dependent cell
cytotoxicity, thus blocking CD55 protection of tumours and mediating an active anti-
tumour response. Antibodies were raised specific to CD55 derived linear peptides,
which have been used for the assessment of CD55 expression in breast tumour
sections. Monoclonal antibodies failed to recognise natively expressed protein on
viable tumour cells and alternate strategies were developed.
An effective immunotherapy for the treatment of cancer would engage both cellular
and humoral mediated responses for effective clearance of target cells. In order to
achieve this, a DNA vaccine incorporating a human IgG Fc tail was developed
expressing the active sites of CD55, containing HLA-A*201 restricted heteroclitic
epitopes. The vaccines were used to immunise HLA-A*201 HHDII transgenic mice
and CD55 specific responses were assessed. One of the vaccines analysed, elicited
CD55 specific antibodies capable of recognising tumour cells in vitro and also
generated epitope specific CD8
+
T cell mediated lysis of epitope bearing cells. The
frequency of CD55 specific T cells was obtained via antigen specific IFNJ release
ix
ELISPOT assays and the cytokine profile of responses generated was assessed via
luminex analysis.
In conclusion, CD55 remains a viable target for immunotherapies aimed at CD55
bearing tumours. DNA vaccines encoding modified epitopes are capable or raising
cellular and humoral responses to this antigen and further studies should be completed
in order to determine anti-cancer effects in tumour bearing models.
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1Chapter 1: Introduction
1.1: Immunity
Immunity is said to be ‘a state of protection from the invasive or pathogenic effects of
potential infective microbes, or to the effects of potentially toxic antigenic
substances’. The immune system has both specific and non-specific components;
acquired or specific immunity utilises the activity of cellular responses encompassing
lymphocytes and their products, while the innate defence mechanism provides first
line protection until acquired responses can develop.
1.2: Innate Immunity
Generally, most invading microorganisms encountered by the immune system are
constitutively recognised, due to the presence of molecules such as
lipopolysaccharides (LPS), which have evolved with the human immune system
(Hamann et al., 1998). Such organisms are readily cleared by this innate non-adaptive
response. However, if the innate system is eluded, specific immunity, which
supplements and augments non-specific pathways, produces a more effective total
response. It is this comprehensive interaction between the innate arm of the immune
system and the adaptive branch that enables complete immune effector functions.
Many pathogens, particularly prokaryotes possess molecular structures which are not
shared with ‘host’ organisms but which are homologous with other related pathogens.
These structures are often invariant and are loosely identified as PAMPs or pathogen
associated molecular patterns (Blach-Olszewska et al., 2005). Examples include
flagellin of bacterial flagella, peptidoglycan of gram-positive bacteria,
lipopolysaccharides (LPS) of gram-negative bacteria, double stranded DNA of some
viruses and unmethylated DNA. Within the innate immune system many pattern
recognition receptors (PRRs) have evolved that constitutively recognise PAMPs and
initiate host responses. PRRs can be loosely grouped into three categories, secreted
molecules which circulate within the lymphatic and blood systems and phagocytic
receptors present on cells such as macrophages that bind pathogens for phagocytosis.
The final group of PRRs are cell surface receptors which bind specific PAMPs and
initiate signal transduction pathways which lead to the production and release of
2effector molecules (cytokines). Many of these innate receptors have been identified
and include the Toll-like receptors. More recently, intracellular microbial ‘sensors’
such as the NOD like receptors (NLRs) and the RIG-like helicases (RLHs) have been
identified which survey the cytoplasm for the presence of intracellular invasion
(Meylan et. al., 2006)
1.3: Toll Like receptors (TLRs)
A class of PPRs called Toll like receptors (TLRs), reviewed by Underhill and
Ozinsky, 2002, recognise pathogens or pathogen derived products and initiate
signalling events leading to activation of innate host defences. TLR signalling
initiates acute inflammatory responses by the induction of antimicrobial genes and
inflammatory cytokines and chemokines (Janeway et. al., 2002, and Takeda et. al.,
2003). Figure 1.1 summarises some of the TLRs currently identified and their
associated ligands and responses generated.
Figure 1.1: Toll receptors, ligands and generated responses
PAMP Pathogen/Stimulus TLR Response
Triacyl lipopeptides TLR1
Flagellin Many bacteria TLR5 Initiates inflammation
ssRNA Imiquimod TLR7,TLR8 Stimulates DC
maturation
Lipoproteins Eubacteria TLR2 Initiates inflammation
CpG Various microbial
pathogens
TLR9 Initiates inflammation
HSP; 60,70 and GP69 Stressed cells TLR4 (HSP60),
TLR2/4 (HSP70 &
GP69)
Stress response, protein
folding
Fibronectin,
Fibrinogen, hearin
Many sources TLR4 DC maturation,
inflammatory-gene
induction
dsRNA RNA virses TLR3 Immune system
recognition and
pathogen clearance
Peptidoglycan Most bacteria TLR2, CD14
TLR6 forms
heterodimer with TLR2
Initiates inflammation
(TLR2)/enhancement
(TLR4)
Lipoteichoic Acid Many gram-positive
bacteria
TLR2, TLR4 Initiates inflammation
Adapted from: Beg, 2002; Aderem and Ulevitch, 2000; Akira 2003, Pandey and Agrawal 2006.
The primary role of PRRs is to provide immediate protection from invading
pathogens, mediated through activation of complement and phagocytosis. In addition,
anti- microbial peptides and proteins are induced by TLRs on multiple cell types.
TLRs also induce cytokines such as IL-1E and TNF and chemokines that collectively
3induce acute inflammatory responses to pathogens. TLRs also induce enhanced
phagocytosis mediated by macrophages and induce type I interferons in response to
viral DNA or RNA in order to clear viral infections. TLRs expressed by DCs, in
response to microbial infection, initiate signalling events that lead to DC maturation.
This process up-regulates MHC expression bearing pathogen derived peptides and
also expression of the B7 family of co-stimulatory molecules.
TLRs have also been associated with adaptive responses and with tolerance
mechanisms. Central tolerance allows for the deletion of thymocytes with high
affinity to self antigens within the thymus. Current understanding suggests that while
TLRs do not play a significant role in thymic negative selection, it is well established
that expression of co-stimulatory molecules on antigen presenting cells is essential for
its induction, although it is not currently determined whether TLRs control co-
stimulatory molecule induction on thymic APCs (Chandrashekhar et. al., 2004).
1.4: Cells of the Innate Immune System
The innate system is composed of a number of specialised cells that recognise and
respond to pathogens or cellular stress. These include NK cells, NKT cells and JG T
cells. Antigen presenting cells are innate cells that interact with the acquired immune
system in order to form a bridge between the innate and adaptive immune systems.
1.5: NK cells
NK cells are one of the cellular mediators of innate defence and are of lymphoid
origin. They can recognise and kill aberrant cells and generate soluble factors,
chemokines and cytokines, which have both anti-microbial effects and priming effects
on other cells of the immune system.
NK cell progenitors are generated from CD34
+
haematopoietic stem cells within the
bone marrow and require stromal cell contact for maturation.
4Early acting cytokines stimulate progenitor cells to differentiate into NK precursor
cells within the bone marrow stroma (figure 1.2 represents the development from
progenitor to mature NK cell). C-kit ligand and Flt-3 ligand directly induce the
expression of IL-2RE, enabling IL-2 or IL-15 responsiveness committing these
precursors to the NK cell lineage (Mrozek et. al., 1996 and Williams et.al., 1997).
The heterogeneity of bone marrow immature NK cells is considerable and mature NK
cells have been shown to fall into two subsets. In the blood 90% of NK cells are
CD56
DIM
and express high levels of CD16(FCRIII) possessing low proliferative
capacity and are identified as ‘killers’, and 10% are CD56
BRIGHT
with low CD16
levels (Robertson and Ritz, 1990), being identified as cytokine producers.
NK cell activity is mediated by a variety of cytokines by possessing multiple cytokine
receptors as well as by expressing both cytokines and chemokines themselves. IL-15
is prominent in NK cell activity, by driving maturation, proliferation, cytotoxicity and
promoting further cytokine production (Fehniger and Caligiuri, 2001). IL-15 alone
drives GM-CSF production while in concert with IL-12, drives NK cells to produce
IFNJ and TNFD (Carson, Giri and Lindemann, 1994). These cytokines also act
synergistically to promote MIP-1D/CCL3 (macrophage inflammatory protein) and
MIP-1E/CCL4 (Fehniger et. al., 1999 and 2002).
c-kit ligand
IL-15Flt-3 ligand
CD34
+
Flt3
+
Ckit
+
CD34
bright
IL-2/IL-
15RE+
IL-15RD+
CD56
-
NK Progenitor NK Precursor Mature NK cell
IL-2/IL-15RE+
IL-15RD+
NKR
+
CD56
+
CD16
+/-
Figure 1.2: Maturation of NK cells. Adapted from Colucci et. al.,
2003.
BM stroma
5Developing NK cells acquire a complex repertoire of activating and inhibitory
receptors, determining responses through a fine balance between activation and
inhibition (Borrego et. al., 2002).
The main mechanism for NK cell mediated cytolysis is dependent on perforin and
granzyme activity although alternate mechanisms for inducing lysis have been
identified, mediated through the role of FASL and tumour-necrosis factor related
apoptosis inducing ligand (TRAIL) dependent receptors (Smyth et. al., 2002).
The main groups of identified NK cell receptors can be divided into three main
families, namely the killer immunoglobulin-like receptors (KIRs), immunoglobulin
like transcripts (ILTs) and C-type lectin receptors. KIRs are surface inhibitory
receptors specific for allelic forms of HLA class I molecules expressed by NK and T
cell subsets and are reviewed by Moretta et al., (2004). Upon engagement with their
respective class I molecules, KIRs block NK cell activation and function. KIR
sequences are highly polymorphic and haplotypes are shown to vary in the number of
genes they contain (Moretta et al., 2004). Figure 1.3 shows a brief summary of many
of the currently identified NK cell receptors.
Figure 1.3: Summary of some of the diverse range of characterised NK cell
inhibitory and activating receptors.
Inhibitory Activating
Receptor Structural
type
Ligand Receptor Structural
type
Ligand
KIR2DL Ig HLA-C KIR2DS Ig HLA-C
KIR3DL Ig HLA-B,C KIR3DS Ig HLA-B
LILRB1,2 Ig HLA class I LILRA3 Ig Unknown
CD94:NKG2A Lectin HLA-E CD94:NKG2C/E Lectin HLA-E
LAIR-1 Ig Unknown LAIR-2 Ig Unknown
NKG2D Lectin MIC-A,B
& others
NKp30 Ig Unknown
NKp44 Ig Unknown
NKp46 Ig Unknown
CD16 Ig Fc
Adapted from Janeway et. al., The Immune System, 2005. Receptors organised according to signalling
potential, structural type and associated ligands. KIR nomenclature, 2DL and 3DL correspond to
rceptors possessing long cytoplasmic tails and two or three immunoglobulin-like domains. 3DS
corresponds to receptors possessing short cytoplasmic tails and 3 Ig-like domains.
6Whereas all KIRs and leukocyte associated immunoglobulin like receptors (LAIRs)
are expressed by NK cells, only a few of the leukocyte immunoglobulin like receptors
(LILRs) are expressed by NK cells. NKp30, NKp44 and NKp46 are collectively
known as the natural cytotoxicity receptors, which are important for tumour cell
killing and are exclusively expressed by NK cells (Moretta et. al., 2000).
NK cells also mediate antibody dependent cellular cytotoxicity through an Fc receptor
complex (CD16) which enables NK cells to engage in the elimination of antibody
targeted cells.
This varied combination of stimulatory responses produced through multiple co-
stimulatory receptors; shape the overall immune response, dependent upon the nature
of the environment created by infections. While there is limited evidence to support
this, the presence of NKG2D found on NK, JGT and CD8+ T cells binds the stress
induced ligand MICA, which reduces the TCR activation threshold, making NKG2D
a co-stimulatory molecule effective at the tissue site (Groh et al., 2001).
1.6: NKT cells
NKT lymphocytes were originally characterised in mice as cells expressing both a T
cell antigen receptor (TCR) and NK1.1 (NKR-P1 or CD161c, a C-lectin type NK
receptor (Bendelac et. al., 1997). More recently however, NKT cells have been
defined as cell that almost always have an invariant VD 14-JD 18 rearrangement and
reactivity to the glycophospholipid D-galactosylceramide (DGalCer) when presented
by the class I-like molecule CD1d (Godfrey et. al.,2004). NKT cells arise in the
thymus and their positive selection is mediated by CD1d expressing bone marrow-
derived cells. NKT cells development also requires the expression of NFNB1
(Sivakumar et. al.,2003 and Stanic et. al., 2004) and the expression of the gene for the
inhibitor of NB kinase, Ikk2 (Schmidt-Supprian et. al.,2004). Townsend et. al., 2004
showed that differentiation of NKT cells requires the transcription factor T-bet (T-box
expressed in T cells), a factor identified for the induction of IFNJ synthesis and Th1
immunity in several cell types. NKT cells form a mature, immune competent
population capable of producing IL-4 and IFNJ immediately following TCR
stimulation (Stetson et. al., 2003). The typical response of NKT cells is the rapid and
7copious production of cytokines, particularly Th1 and Th2 cytokines as mentioned
earlier. However, TCR activated NKT cells produce many other cytokines including
IL-2, tumour necrosis factor (TNF), IL-5, IL-13 and GM-CSF. This mixture of
responses opens several questions as to how a regulated response is generated and
evidence favours several explanations which are not mutually exclusive. One
possibility is that the quality of the TCR signal influences the profile produced, by
analogy with the effects of altered peptide ligands on CD4
+
T cells. This is supported
by OCH, an DGalCer analog reportedly stimulated a higher ratio of IL-4 to IFNJ
secretion when added to total spleen cultures (Miyamoto et. al., 2001 and Stanic et.
al., 2003). In contrast, C-glycoside analog of DGalCer reportedly stimulates a higher
ratio of IFNJ to IL-4. Cytokine production resulting from TCR stimulation is also not
influenced by IL-4, IL-12 or other factors that influence cytokine production of
conventional T cells (Kronenberg, 2005). Another possibility is that integration of
signals from different types of receptors influence the pattern of cytokines produced
by NKT cells. This is supported as although IL-12 is not required for NKT cell IFNJ
production following DGalCer stimulation, IL-12 can stimulate IFNJ production in
the absence of DGalCer (Leite-De Moraes et. al., 1999 and 1998). Cross linking of
NK1.1 has also been shown to achieve this. Most ligands identified as being
associated with NKT cells recognise CD1d in conjunction with hydrophobic ligands,
namely glycolipids (Burden et. al., 1999 and Benlagha et. al.,2000).
NKT cells also respond to tumour derived lipid extracts, including phospholipids, in
the context of CD1d which suggests the presence of a natural lipid ligand, possibly
altered within the tumour tissue (Gumperz et. al., 2000). Numerous sources identify
that NKT cells recognise a diverse array of hydrophobic ligands, indicating the
potential for antigen specific activation and the possibility of self tolerance of these
cells. The ability of NKT to produce IL-4 has suggested their ability to drive
differentiation of Th2 responses although investigations using NKT deficient (CD1d
-/-
or E2m-/-) mice have not supported a role for these cells in such responses (Hong et.
al., 1999). However, there is evidence to suggest that NKT cells do play an important
function in Th2 responses, VD14 TCR transgenic mice which have a tenfold increase
in NKT cell numbers, possess elevated serum IgE and IL-4 levels (Bendelac et. al.,
1996), whilst NKT cell activation In Vivo promotes Th2 associated immunity (Burden
8et. al., 1999 and Kitamura et. al., 2000). NKT cells have also been shown to be
involved in Th1 inhibition through the action of various cytokines, namely IL-4, IL-
10 and TGF-E. Sonoda et. al.,(1999) showed NKT cells are essential for controlling
anterior chamber-associated immune- deviation (ACAID) which prevents the eye
from damage by inflammatory immune responses. Bone marrow (BM) derived NKT
cells have also been observed to prevent graft versus host disease following BM
transplantation in an IL-4 dependent manner, which highlights the involvement of
these cells in the prevention inflammatory immune responses (Zeng et.al., 1999).
NKT cells have been shown in some models to mediate cytotoxic responses to tumour
lines In Vitro, suggesting a role for tumour rejection (Smyth et. al., 2000). In Vivo
treatment of mice with IL-12 induces tumour rejection which has been suggested to
be NKT cell mediated (Dale et. al., 2000) however, alternative studies (Takeda et. al.,
2000 and Smyth et. al., 2000) indicate that IL-12 induced tumour rejection may be
model and dose dependent. Finally, Takahashi et. al., (2000) have shown that NKT
cell subsets stimulated In Vitro with DGalCer-pulsed dendritic cells, mediate perforin
dependent cytotoxicity against the U937 tumour cell line.
T cell receptors are diverse and specific for multiple antigens. DE heterodimers
associate with four invariant membrane proteins. Three of these are collectively
known as the CD3 complex and associates with a third protein identified as the ]
chain. These CD3 complex proteins form the T cell receptor complex with the TCR
and transduce signals following interaction of the D-E heterodimer with antigen.
During B and T cell development, sub populations of cells differentiate with restricted
B and T cell receptor repertoires which possess high copies of particular clones. This
enables responsiveness by reducing the need for clonal expansion and differentiation
upon primary infection.
1.7: JG T cells
This population plays a pivotal role in immune regulation, tumour surveillance and
primary responses (Hayday et al., 2003). JG T cells are derived from thymic
precursors which also differentiate into DE T cells and are positively selected on
cognate self antigen. These cells can recognise antigens without the requirement of
9processing or presentation (Groh et al., 2002 and Davis et al., 1999). A subset of JG T
cells (VJ9.VG2 T cells) respond to mycobacterial compounds, secrete Th1 cytokines
and proliferate during bacterial infections. These cells represent 1-5% of the
circulating T cell population, and it is suggested that their development is determined
by the strength of signals received through the T cell receptor (Pennington et al.,
2005). These cells have identified several aspects of cellular immunology, non MHC
restricted activation of human T cells and T cells possessing limited TCR diversity
within certain tissues. JG T cells can both effect and suppress immune functions, and
have been shown to promote B cell production of antibodies in immunodeficient
animals, suggesting a mechanism promoting the observed high antibody titres in
AIDS patients (Smith et al., 2000).
1.8: Complement soluble mediators
Secreted molecules incorporate more than thirty proteins of the complement cascade
which circulate in inactive forms known as zymogens within plasma. Activation of
these proteins occurs within tissues and the blood itself, initiating a complex cascade
of proteins culminating in opsonisation of target pathogens and formation of the
membrane attack complex (MAC) which disrupts the cell membranes of invading
organisms. The complement cascade is further discussed in section 1.17 and details
how complement components tag microbial surfaces and initiate their elimination,
either via MAC formation or through interaction with receptors on many cells of the
immune system.
As the complement system is at a continual ‘tick over’ state many host cells that
come into contact with serum components express complement regulatory proteins in
order to prevent ‘bystander’ attack. The main regulators are CD55, CD46 and CD59
and are further discussed in section 1.20.
1.9: Acquired Immunity
Antigen specific responses, not involving pre-evolved recognition of cellular motifs,
are mediated by acquired immune mechanisms. Professional Antigen Presenting
Cells (APCs) and T cells are equipped to respond to specific peptide antigens
presented by major histocompatibility (MHC) molecules. Antigen recognition is a
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two phase process requiring activation of naïve T cells via presentation of antigen to
the T cell receptor. This is mediated by TCR binding peptide/MHC complexes
activating T cells, which then migrate to sites of infection mediated by chemical
signals. The second phase of T cell responses is the direct killing of target cells
expressing the same peptide antigens in the context of MHC class I. While Dendritic
cells are involved in the initial phase, APCs located within the site of infection may be
required to mediate CTL mediated killing
1.10: Antigen presenting cells (APC)
Four main categories of antigen presenting cells have been identified which are able
to modulate cellular immune responses through antigen presentation pathways. These
include monocytes, dendritic cells, B cells and endothelial cells, (Verhsselt., 1997), all
of which possess innate receptors for a multitude of cytokines. Stimulation of these
receptors results in cell activation and increased expression of MHC molecules, Fc
receptors, co-stimulatory molecules such as B7 and CD11, adhesion molecules and
further cytokines and enzymes.
1.11: Dendritic cells
DCs are said to be the one of the central players in all immune responses of the innate
and adaptive immune system, involved in maintenance of inflammatory conditions
and being critical to self tolerance induction and maintenance (Rossi et al., 2005).
DCs are referred to as professional antigen presenting cells due to their ability to
activate naïve T cells. Immature DCs found in non-lymphoid tissues have been
shown to possess a strong ability for antigen capture and processing, but appear to be
poor at presentation to naïve T cells. Maturation of DCs has been shown to reverse
these characteristics and can be induced by stimulation with many cytokines, IL-1,
CD40-L (Brossart et al., 1998), endotoxin (Brossart et al., 1998) and by cross linking
CD43 (Corinti et al., 1999). Brossart et al., have identified that while mature DCs can
be derived from CD14 progenitor cells when cultured in the presence of GM-CSF and
IL-4, GM-CSF may not be the most vital cytokine required as CD40 ligation alone
promotes the differentiation and maturation of DCs without GM-CSF or IL-4. Most
DCs are classified based upon their location, Langerhans cells within the epidermis
and mucous membranes within the heart, kidney and lungs, interdigitating DCs in the
T cell areas of secondary lymphoid tissue and thymic medulla and circulating DCs
11
which constitute 0.1% of the blood leukocytes (Hashimoto et al., 1999). Another
population sub set is the plasmacytoid DC (pcDC) which has been observed in
secondary lymphoid tissues and in certain malignancies and inflammatory conditions.
Austyn (2002) describes the capacity of plasmacytoid DCs to induce regulatory T
cells, suppressing immune responses. Austyn states that while this subtype may be
involved in the induction of tolerance to self antigens, both in the thymus and
periphery, they can contribute to innate defences against viral infection and can also
acquire the ability to initiate adaptive immune responses. It also appears that due to
pcDCs apparent selective recruitment to certain tumours, their role in cancer
immunity is of significant importance. Serial analysis of gene expression (SAGE)
and flow cytometry have been used to identify tags from DCs and monocytes and
genes involved with MHC molecules and cytoskeletal structure are shown to be up-
regulated within DCs (Hashimoto et al., 1999).
The primary function of dendritic cells is to capture antigens within the tissues and
present them to T cells within lymphoid organs (Yang et al., 1998) and at the site of
infection. They maintain surveillance of their environment by both binding and
processing antigens (Fanger et al., 1996). Upon stimulation with innate antigens such
as LPS or cytokines, several responses of DCs can be observed, the up-regulation of
MHC class II, reduction in Fc receptors and production of IL-12. It is during this
process that DCs migrate to T-cell areas of lymphoid organs in order to present signal
1 and 2 to CD4
+
and CD8
+
T cells (Coyle et al., 2001). Binding of the anaphylatoxins
C3b or C4b to antigen enhances APC function in the activation of T cell clones via
complement receptors upon APCs (Arvieux et al., 1999).
Langerhans cells are bone marrow (BM) derived and, in contrast to tissue
macrophages are not phagocytic and act via the process of bulk endocytosis (Murphy
et al., 1986; Yanagihara et al., 1998). These cells play an important role in cutaneous
cellular responses and are involved in contact hypersensitivity through interaction of
MHC class II. Follicular dendritic cells are not leukocytes and are of stromal origin
and interact with B cells within germinal centres (Tew et al., 2001).
It has been recently shown in several studies that DCs and NK cells reciprocally
activate one another during immune responses, the original concept of this cross-talk
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being identified in 1999 by Fernandez et al., in which the In Vivo anti-tumour
response of mouse NK cells was enhanced by DCs. DC activation of resting NK cells
In Vitro often requires direct cell to cell contact, but DC derived cytokines including
IL-12, IL-18 and type I interferon are also required for the induction of various NK
effector functions (Hamerman et al.,2005, Granucci et al., 2004). Fewer studies have
been carried out assessing the nature of NK cell activation of DCs, although Picciolli
et al., 2002, showed that NK cells pre-activated with IL-2 are potent activators of
DCs, both alone and in the presence of inflammatory stimuli. They also identified
that the outcome of NK-DC interaction is tightly regulated by the ratio of the two cell
types. Low NK: DC ratios result in DC maturation whereas high NK: DC ratios result
in NK mediated killing of DCs. Several possibilities have been raised for the site of
interaction between these cell types. Sites of inflammation are suggested, as resident
immature DCs can be found and NK cells migrate to these sites in response to
inflammatory mediators. Buentke et al., 2002 have shown that NK cells and DCs are
in direct contact at the dermal sites of yeast infection. Alternatively, Ferlazzo et al.,
2004, showed that human NK cells are found within both inflamed and non-inflamed
lymph tissues where they may contact maturing DCs which have migrated from sites
of inflammation or infection.
1.12: Monocytes
Activated monocytes and macrophages are involved in both acquired and innate
immune responses and direct their responses through several mechanisms including
phagocytosis. Monocytes display a variety of activation states similar to Dendritic
cells and both cell types possess Fc and complement receptors (C3R) that enable them
to phagocytose opsonised cells and antigenic complexes. While playing critical roles
in the removal of pathogens, toxins and dying cells, they are also involved in the
presentation of antigen to effector T cells. Monocytes however, are unable to
stimulate naïve T cells and possess Toll like receptors that bind bacterial components
such as mannose and LPS. Monocytes and macrophages are able to generate
cytokines such as IL-12, IL-1, IL-10 and TNFD (Kakumu et al., 1997). The combined
effects of IL-1 and TNFD on T cells are shown to induce IL-2 receptor expression and
IL-10 has a direct effect on B cell activation (Gan et al., 1999). IL-10 is also known
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to direct monocytes maturation into macrophages (Allavena et al., 1998) while down
regulating cytokines from macrophages (Moore et al., 1994).
1.13: T-cells
There are two predominant T cell subtypes that are involved in the mediation of
acquired immunity, namely CD4
+
T cells (helper T cells) and CD8
+
T cells [cytotoxic
T cells (CTLs)]. Internally processed proteins are generated by the proteosomal
complex and generated peptides are loaded onto MHC class I, which is present on
most normal host cells. MHC class II molecules are expressed by Anitgen Presenting
Cells and present processed antigen, obtained from external proteins, which is
recognised by the T cell receptor on CD4
+
cells. APCs express both class I and II
MHC molecules and present antigen to receptors on other cells. T cells are activated
when ‘signal 1’ is generated via the MHC/peptide-T cell receptor interaction, in
combination with ‘signal 2’, which is derived from the interaction between CD80 and
CD86 on APCs which are recognised by CD28 on T cells. The combined signals
stimulate T cells to secrete a range of cytokines. Post activation, T cells migrate to
the site of antigen stimulation, driven by chemotaxis in response to proinflammatory
signals released at sites of infection (Banchereau and Steinman, 1998). Helper T cells
(CD4
+
) secrete multiple cytokines which direct and perpetuate immune responses
dependent upon danger signals presented. CD4
+
mediated help is described as being
of either Th1 or Th2 in specificity (Infante et al., 1999). Th1 responses constitute
release of cytokines, including IL-12 and IFNJ, which are essential for cell mediated
immunity (Behar et al., 1995). Binding of IFNJ onto tumour cells is known to
upregulate MHC class I (increasing expression of tumour antigens) and Fas, which
binds Fas ligand expressed on T and NK cells, inducing apoptosis of colon
carcinomas and hepatocellular carcinoma cells, thereby increasing recognition and
potential killing by CTLs (Wang et al., 1997). Th2 responses involve expression of
cytokines such as IL-10, IL-4 and IL-6, which are critical for humoral mediated
immunity and the development of antibodies (Infante et al., 1999). CD8
+
CTLs
mediate the direct killing of infected host cells, expressing peptides from
intracellularly processed pathogens, and potentially, tumour cells expressing altered
self antigens.
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1.14: B-Cells
B cells are important mediators of humoral immunity expressing immunoglobulins
(Ig) as surface molecules in combination with the secretion of soluble
immunoglobulins. These proteins bind antigens, recognising specific peptide
sequences with respect to tertiary structure (Gold et al., 2002). Binding of surface Ig
to external antigens stimulates internalisation of the complex, enabling processing and
presentation of antigenic peptides in the context of MHC class II pathways (Defrance
et al., 2002). Thymus independent antigens, such as microbial components, are
capable of directly activating B cells, while most antigens are not involved with direct
activation of B cells and require accessory signals provided by helper T cells (Thymus
dependent antigens). It is recognition of identical antigens by activated helper T cells
that bind B cells, through CD40, and signal proliferation. Activated helper T cells
produce cytokines such as Il-4, IL-5 and IL-6 that promote differentiation and clonal
expansion of B cells into plasma Ig secreting cells (Infante et al., 1999; Gause et al.,
2001). Differentiation of B cells into plasma cells restricts their ability to interact with
alternate antigens via surface immunoglobulins and also with T cells. B cell
interaction with follicular DCs in the germinal centres of lymph nodes induces
maturation into memory B cells capable of secreting antigen neutralising antibodies
without the requirement for thymus dependent interactions. Figure 1.4 summarises
the maturation of B cells.
1.15: Effector Cells
Co-stimulation of effector cells within the tumour environment is being extensively
studied, and evidence suggests that multiple stimulatory pathways are required for
CTL recognition and cytotoxic function. Receptor /ligand systems identified include
PD-L1/PD-L2 expressed by tissue cells and the respective PD-1 receptor on CTLs, B-
cells and myeloid cells (Freeman et al., 2000) and CD4
+
T cells (Latchman et al.,
2001). More recently, OX40 has been shown to be expressed on activated T cells
with ligation of the OX40-Ligand leading to clonal expansion and proliferation of
these T cells (Sugamura et al., 2004). Binding of this receptor on CD4
+
T cells also
increases the expansion of antigen specific T helper cells (Weinberg et al., 1998), and
this interaction is also shown to be essential in the generation of memory T cells and
their survival mediated by OX40 ligand expression on APCs. OX40 therapy in
tumour bearing animals through the use of OX40 antibodies or OX40-ligand
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immunoglobin fusion proteins has been shown to enhance anti-tumour immune
responses and generated increased tumour free survival in various models (Ali et al.,
2004).
Figure 1.4: Summary of B cell Maturation
1.16: Complement
The complement system is a major effector of the humoral /innate branch of the
immune system, and components of this early defence mechanism involve a classical
and alternative pathway of activation (Matzinger, 1994).
The complement system consists of more than thirty soluble glycoproteins, which are
largely synthesized by liver hepatocytes, blood monocytes, tissue macrophages and
epithelial cells of the gastrointestinal and genitourinary tracts. The complement
components interact in a regulated enzymatic cascade, stimulating products which
facilitate antigen clearance and generate an inflammatory response. Both the classical
and alternative activation pathways result in production of a macromolecular
membrane-attack complex (MAC) that is able to induce lysis of many cells, bacteria
and viruses. The whole cascade enables rapid destruction of many invading
organisms and mediates the solubilisation and clearance of immune complexes.
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1.17: Complement cascade and activation pathways
The two major activation routes for complement include the alternative and classical
pathways (Kinoshita, 1991). However, a third pathway known as the lectin route has
been described (Reid, 1994). Figure 1.5 diagrammatically represents an overview of
the complement cascade, identifying the three initiating stages and the terminal
pathway which leads to the formation of the MAC complex.
The classical pathway is commonly initiated by the formation of soluble antibody
complexes bound to particulate antigen or antigenic targets upon whole cells, e.g.
bacteria, and involves the ‘heat labile’ serum components C1, C2, C3 and C4.
Antigen/antibody complexes induce conformational changes within the Fc region of
the IgG or IgM molecule, exposing a binding site for the C1 component. Upon
binding, C1q then C1r undergo conformational changes, activating C1r protease,
which cleaves C1s, forming an active enzyme. C1s in turn cleaves C4 and C2 leading
to formation of soluble C4a and reactive C4b, which forms a magnesium dependent
reversible complex with C2. C4b2a complex is then generated which is the C3/C5
convertase of the classical pathway (CP). It is this convertase which is able to cleave
multiple C3 and C5 molecules, greatly enhancing the initial signal.
The Alternative Pathway, unlike the CP, does not require the presence of antibodies,
and is initiated by various cell surface constituents, which are foreign to the host. The
AP is continuously activated at low levels within plasma, and C3 can undergo
spontaneous hydrolysis with Bb to form the initial fluid phase convertase of the
alternative pathway. It is the C3b component, which binds to foreign surface
antigens, and binds factor B in a Mg
++
dependent manner. The B region is cleaved by
factor D and becomes the actual C3 convertase of the AP, C3bBb. The AP can also
be initiated by the CP, as C3bBb cleaves C3 molecules into C3b subunits of new C3
convertases and forms a positive feedback loop. C3b deposition also leads to
opsonisation for phagocytosis and generation of C5b, which initiates activation of the
terminal pathway.
The lectin pathway for complement activation is similar to the classical pathway,
except that it is initiated by mannose binding lectin (MBL) that recognises
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carbohydrates containing mannose or N-acetyl glucosamine residues on bacteria and
other micro-organisms.
MBL is homologous to C1q and binds to serine proteases to form C1-like complexes.
The cell bound structure catalytically cleaves C2 and C4, and progression of the
pathway continues like that of the classical pathway.
The Terminal pathway becomes initiated when either the CP or AP C5 convertase
cleaves C5 to form C5b. This in turn binds to C6, which is released by
polymorphonuclear leukocytes at sites of inflammation, allowing recognition of C7.
This C5b-7 complex is hydrophobic in nature and binds to lipid membranes, C8, and
multiple C9 molecules. When polymerisation of the C9 structures occurs, penetration
of the cell membrane, MAC development and perforation of the target is achieved.
1.18: Anaphylatoxins C3a and C5a
C3a and C5a are products of all three activation pathways and are involved in the
generation of inflammation via histamine, leukotrienes and other mediator release
from mast cells and basophils. These Anaphylatoxins also induce vasodilation and
contraction of smooth muscle leading to increases in vascular permeability, while C3a
receptors present on neutrophils, monocytes and eosinophils have direct modulatory
effects on B cells. C5a has also been shown to attract phagocytic cells and trigger
lysosomal enzyme release. Both C3a and C5a are chemotactic and induce migration
of leukocytes to inflammation sites (Till et al., 1986, Frank & Fries, 1991,), as well as
inducing aggregation of platelets. Many cell types express receptors to C5a and C3a
including hepatocytes that have shown to become activated upon C5a binding
stimulating synthesis of acute phase proteins (McCoy et al, 1995). These acute phase
reactants promote the inflammatory stimulus mediating the immune response, and
include C-reactive protein that is capable of opsonisation, agglutination and
activation/enhanced stimulation of the classical pathway. This generation of
inflammatory responses help protect tissues by removing infectious agents.
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Complement receptor 1 (CR1) on the surface of macrophages and neutrophils binds to
pathogen bound C3b or C4b and facilitates uptake and phagocytosis. In this respect
the components act as opsonins, being the principal function of complement, and act
by enhancing phagocytosis initiated by binding of IgG to Fc receptors or by IFNJ
stimulation of the effector cell.
Complement receptor 2 (CR2) is expressed by B cells and forms part of its co-
receptor complex. The CR2 interaction with iC3b, C3d or C3dg fragment upon the
pathogens surface amplifies the signal initiated when the B cell receptor associates
with its specific antigen.
Complement receptors 3 and 4 are E-integrins and associate with pathogen bound
iC3b. They are expressed by phagocytes and augment Fc receptor and CR1 activation
of phagocytosis. However unlike CR1 interaction with C3b, iC3b association with
CR3 is sufficient to stimulate phagocytosis alone. These complement receptors also
act as cellular adhesion molecules and are involved in leukocyte adhesion to
endothelial cells during inflammation.
Figure 1.6: Summary of complement receptor protein distribution and function
Receptor Ligand Function Cell types
CR1 C3b, C4b Promotes C3b and C4b decay.
Stimulates phagocytosis and
erythrocyte transport of
immune complexes
Erythrocytes,
macrophages, B
cells and FDCs
CR2 C3d, C3dg, iC3b Part of B cell co-receptor B cells and FDCs
CR3 iC3b Stimulates phagocytosis Macrophages,
monocytes,leukoctes
and FDCs
CR4 iC3b Stimulates phagocytosis Macrophages,
monocytes,
polymorphonuclear
leukocytes
1.20: Complement regulation
Complement is continually active at a slow ‘tick over’ rate on all cells of the body; the
very nature of the pathways allows a small stimulus to generate a large and potentially
harmful response in the absence of regulation. Uncontrolled activation would not
only produce harmful effects, but would result in the exhaustion of complement
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proteins, leaving an individual compromised. It is due to this that the complement
pathway is tightly regulated by several mechanisms, including inherent instability of
pathway enzymes and MAC precursors and membrane bound regulators of
complement, which prevent non-specific ‘bystander’ attack of autologous cells. The
membrane bound regulators of complement activation include complement receptor 1
(CD35), decay accelerating factor (CD55), membrane cofactor protein (CD46) and
protectin (CD59). Figure 1.7 displays a summary of complement regulation.
CD46 (Membrane cofactor protein) contains four Short Consensus Repeat domains, is
a glycoprotein containing a transmembrane domain, and acts as a cofactor for factor 1
and promotes the cleavage of C3b to enzymatically inactive iC3B or C4b to C4c and
d (Seya et.al. 1989). Factor H is also critical to this reaction as, in its presence, factor
1 is able to cleave C3b. CD46, while not decaying C3 convertase itself, aids CD55
decay accelerating activity and is expressed on all circulating cells, including
platelets, T cells and B cells, but not on human erythrocytes. CD46 has been shown
to only inactivate C3b which is bound to the same cell, which indicates a requirement
for correct orientation of MCP to C3b on the membrane (Seya et. al., 1989).
Figure 1.7: Regulators of the complement cascade
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Kojima et. al. (1993) state that CD46 preferentially inactivates alternative pathway
convertases and C3b molecules covalently bound to other membrane proteins
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including C3b dimers. Seya indicates that in the absence of factor I, CD46 is able to
stabilise both pathway convertases leading to increased C3 deposition. Cross-linking
of CD46 on activated monocytes is shown to down regulate IL-12 production, which
is vital for maintaining a Th1 response (Smith et al, 1997 and Kaminski et al, 1999).
Th1 responses drive cell-mediated activity enabling destruction of bacteria and
viruses, and interestingly, the measles virus uses CD46 as a ligand to gain entry into
monocytes, thus inhibiting IL-12 production (Karp et al, 1996)
Complement receptor 1 is also a transmembrane glycoprotein that possesses decay
accelerating activity, and cofactor ability for factor 1 in cleaving cell bound C3b to
iC3b and subsequently C3d and fluid phase C3c.
CD59 (Protectin) is widely expressed on most circulating cells including erythrocytes,
and functions to inhibit the later stages of the terminal pathway. This is achieved by
binding to the C5b-8 complex, allowing binding of one C9 subunit, but preventing
subsequent unfolding and membrane insertion, preventing further C9 binding and
membrane disruption. CD59 has also been associated with erythrocytes binding to T
cells via the adhesion molecule CD2 (Whitlow et al, 1990). This interaction has been
suggested to be an important co-stimulatory association for T cell activation (Menu et
al, 1994). CD59 has been shown to cluster/associate with other GPI anchored
molecules, which contain tyrosine kinases (Stefanova et al, 1991), and has been
shown to be present in the form of a homodimer on nucleated cells. This dimerisation
is suggested to be important for signalling through CD59 (Hatanaka et al, 1998).
Recent work on CD59 expression patterns on breast carcinoma sections has also
shown that a loss of CD59 is associated with poor patient prognosis, which
contributes to theory that complement regulatory proteins are all associated and
regulation is balanced between varying specific functions (Madjd et. al., 2003 and
Watson et. al., 2005).
1.21: CD55 structure and function
CD55 or Decay Accelerating Factor is a 70,000 MW membrane protein that is
anchored by a C-terminal glycolipid (Medof et.al. 1986) and protects cells from
autologous complement deposition. From the amino terminus it consists of four Short
Consensus Repeat (SCR) domains, each containing approximately 60 amino acids.
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The four SCR domains are followed by a region rich in extensively glycosylated Ser,
Thr and Pro residues, which contain sites for the addition of O-linked
oligosaccharides. The 17 terminal amino acids are essential for the formation of a
glycophosphatidylinositol (GPI) anchor that links the functional protein to the cell
membrane. Figure 1.8 demonstrates the structure of complete CD55. The CD55 gene
is located within the complement regulatory locus on the long arm of chromosome 1,
band q3.2 (Lublin et.al. 1987); it spans approximately 40kb and is comprised of 11
exons.
Figure 1.8: Structure of CD55 (DAF)
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CD55 functions to accelerate the decay of either C4b2a or C3bBb and corresponding
C5 convertases. CD55 acts intrinsically by rapidly dissociating C2a and Bb from C4b
and C3b respectively which are bound to the cell membrane to which it is anchored
and not on convertases bound to alternate targets, thus preventing assembly of the C3
convertase (Fujita et. al. 1987). CD55 regulatory activity is displayed in Figure 1.9.
Evidence has shown that CD55 activity is predominantly upon preformed convertase
complexes containing Bb or C2a and that binding of either fB or C2 to C3b or C5
respectively (Fujita et al., 1987). Binding affinity analysis of CD55 and its
complement associated ligands has identified significant differences between
interactions with single subunits and complete complexes (Figure 1.10).
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Figure 1.9: CD55 inhibition of complement activation pathways (C4b2a catalytic
C3 convertase of the classical activation pathway)
C4b C4b C4b
C2a C2a
C2a
DAF DAF DAF
CD55 has a low affinity interaction with both C3b and C4b on the cell surface enabling their release
from the regulator post convertase decay, allowing ‘recycling’ of CD55, enabling further interactions
with newly formed convertases (Morgan & Harris 1999).
Figure 1.10: Summary of convertase subunits and apparent association
Unit Apparent association
constant (appKa)
C3b 45nM
-1
Bb 67 nM
-1
Alternative
C3
Convertase C3Bb 910 nM
-1
C4b 0.45 nM
-1
Classical
C3
Convertase
C4b2a 530 nM
-1
The difference between association constants clearly identifies that for the alternative
pathway convertase there is an increase of 15 to 20 times for the complex and that for
the classical pathway convertase of more than 1000 times (Pangburn et al.,1986).
Pangburns’s research assessed CD55’s ability to accelerate release of radio labelled
Bb from C3bBb bound to zymosan in the presence of various inhibitors of
complement. The SCR domains of CD55 are commonly found within C3b/4b
binding proteins and can be cross-linked to either subunit on the cell surface,
indicating that the inhibitor is in close contact with these fragments (Kinoshita et al.,
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1986, and Reid et al., 1986). The apparent low affinity association of the subunits is
likely vital for CD55 effective activity, enabling dissociation from the smaller units
post decay of the intact complex, allowing further interaction with other convertase
structures.
Decay accelerating activity is located in SCR domains 2 and 3 for the classical
pathway and domains 2 to 4 for the alternative pathways (Brodbeck et. al. 1996).
Disruption of hydrophobic C
147
and F
148
residues within the SCR 3 domain have
shown to produce significant inhibition of DAF regulatory activity within both the
Alternate and Classical Pathways. Although SCR 1 is usually stated to show no
involvement in CD55’s complement regulatory function, antibody blocking studies
have shown that CD55 SCR 1-2 hybrid transfectants possess the ability to regulate AP
activity (Christiansen et. al. 2000).
X-ray crystallography has identified that critical contacts are formed with a
hydrophobic region located between SCR domains 1 and 2, and that mutation of
residues in previous analysis may have simply altered the structure of this
hydrophobic patch.
The nature of some of the critical residues has also been supported by a molecular
model for factor H, based on NMR data. Factor H shares both structural and
functional homology to CD55 and this model predicted that convertase interaction
sites may include a positively charged region extending from SCR 2 into a groove at
the SCR2/3 interface, R
100
, R
101
, KKK
125-127
, and with a hydrophobic pocket within
SCR3, V
121
, F
123
, L
147
, F
148
and L
171
(Kuttner-Kondo., 1996).
The primary function of SCR 1,2 and 3 appear to be mediating CD97 binding, which
is a leukocyte antigen belonging to the family of seven trans-membrane spanning
proteins (Hamann et. al. 1998). It has been suggested that CD97 is involved in the
initiation of inflammatory responses, and its structure indicates signal transducing
capacity, implying that CD55 is involved in alternative functions other than C
regulation (Gray et. al.1996). The Ser/Thr/Pro region of CD55, while having no
direct convertase regulatory activity, acts as an essential spacer region, projecting
SCR domains from the plasma membrane, enabling function (Coyne et. al. 1992).
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CD55 deficiency is associated with PNH (Paroxysmal Nocturnal Haemoglobinuria),
which is characterised by sensitivity of erythrocytes to autologous complement
mediated lysis. Leukocytes and platelets are also affected, as they are generated from
haematopoietic stem cells which lack the ability to add GPI anchors to the CD55
protein (Kinoshita et. al. 1985).
The ‘Inab’ phenotype has been described in individuals who exhibit total loss of
CD55 expression (Telen et. al. 1993). However, these individuals do not suffer from
erythrocyte haemolysis, indicating the role CD59 has in protecting these cells from
complement attack.
1.22: CD55 expression and distribution
Decay accelerating factor is widely expressed on most circulating cells including
erythrocytes, leukocytes, NK cells and endothelial cells. DAF has also been located
in the urinary, gastrointestinal and exocrine systems (Medof et. al. 1987 and Cosio et.
al. 1989), placenta, spermatozoa, eyes, and is associated with the sub endothelial
matrix (Hindmarsh et. al. 1998). Soluble forms have also been identified in several
biological fluids including synovial fluid, CSF and urine (Cosio et. al. 1989).
Various tumour lines have been shown to over-express CD55 including colorectal,
gastric, ovarian and osteosarcoma cells (Spendlove et. al. 1999). These altered
expression levels can be up to 100 fold greater than normal cells (Li et.al. 2001), and
while this over-expression conveys resistance to complement mediated attack (Koretz
et. al. 1992), it is therefore potentially a cofactor for tumour development. Strong
CD55 expression has also been observed in stromal tissue (Niehans et. al. 1996), and
it is suggested that this may be due to shedding from tumour cells, a theory supported
by the presence of soluble CD55 within serum and all forms being capable of
inhibiting complement activity. CD55 presence within the extracellular matrix
(ECM) is shown to be up regulated on tumours in response to increased production of
vascular endothelial growth factor (VEGF). Morgan et. al. (2002) showed that VEGF
stimulates the release of matrix degrading metalloproteinases, specifically MMP-7,
which in turn releases intact CD55 from the ECM. As elevated CD55 levels are often
much greater than needed for complement regulation, this would imply that decay
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accelerating factor possesses alternative functions other than C regulation (Carrington
et. al. 2001).
1.23: CD55 as a signal transducer
GPI anchored molecules are often involved in cell signalling and DAF has been
shown to associate with other membrane proteins and trigger cell activation. The GPI
anchor of CD55 has been shown to be vital for signalling, as when it is replaced with
the transmembrane and cytoplasmic domains of membrane cofactor protein, all
signalling is subsequently lost (Shenoy-Scaria et. al. 1992). Although the complete
signalling pathway for decay accelerating factor is unknown, it is understood that
DAF associates with src family tyrosine kinases in microdomains within the
membrane, called lipid rafts or detergent-insoluble glycolipid enriched domains
(DIGs). Upregulation of glucose consumption and phagocytosis has been noted when
CD55 is stimulated by monoclonal antibodies on phagocytes (Shibuya et. al. 1992).
CD97 has also been shown to act as ligand for SCR 1 to 3 of CD55 and is thought to
transduce signals from CD55 to cytoplasmic molecules (Fujita et. al. 1987). In 1988,
Davis et. al. showed that a mitogenic signal could be transduced within T
lymphocytes by costimulating CD55 following sub-mitogenic stimulation with PHA,
resulting in T cell proliferation. Phosphatidylinositol phospholipase C treatment of T
cells, cleaving the GPI Anchor of CD55, abrogated this costimulation indicating that
T lymphocytes are stimulated via this mechanism. Spendlove et al. (2006), have
shown that soluble, recombinant CD55 inhibits T cell activation and proliferation, an
effect that can be blocked by the addition of CD55 (SCR 1-3) specific antibodies.
Current research continues to examine the signalling events involved with this
interaction.
1.24: Complement as a target for immunotherapy
While complement is a vital mechanism of the immune system, as a key mediator of
inflammation, it is also a major causative agent in host tissue destruction. Both
clinical and experimental evidence has identified complement activity in several
inflammatory diseases and recently in neuro-degenerative disorders such as
Alzheimer’s disease and Multiple Sclerosis (Kirschfink et. al. 2001).
The complement system plays a pivotal role in the rapid destructive rejection of xeno-
transplanted organs, a process call Hyperacute Rejection (HAR). Two main
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approaches for complement inhibition have been suggested: the blockade of
interactions between native xenoreactive antibodies and xenograft endothelium;
targeting the D galactosyl epitope [major xenoantigen (Rother and Squinto 1996)];
and blockade of complement activation with either soluble inhibitors or transgenic
models expressing human regulators. Leventhal et. al. (1994) showed that cobra
venom factor prolonged transplant survival by depleting C3a and C5a levels.
However, by generating and increasing convertase activity, increased endothelial
damage was also observed. Soluble complement regulators have been shown to
restrict the action of complement within body fluids at multiple sites of the cascade
reaction, as when C1 inhibitor is combined with heparin, inhibition of classical
pathway activity occurs (Dalmasso and Platt 1993). Protection of exogenous cells has
also been achieved by transfection with the cDNA of human membrane cofactor
protein (CD46), decay accelerating factor (CD55) and protectin (CD49). Heckl-
Ostreicher et. al. (1996) produced porcine endothelial cells expressing human CD59
that, both with and without the addition of soluble regulators, inhibited complement
mediated cell lysis. Xenoperfused human DAF and CD59 transgenic pig hearts and
kidneys have been produced expressing analogous and elevated levels of complement
regulators compared to normal human epithelium, capable of inhibiting complement
activation and producing a reduction of morphological alterations, which are usually
indicative of HAR.
1.25: Cancer: Tumour development and immunity
Cancer has become the major cause of mortality in the developed world, with 1 in 3
people in the UK alone being diagnosed at some point in their lifetime, with 25% of
all deaths being cancer related (Cancer Research UK, data compiled for 2002).
Tumour cells are derived from many normal host cells with the tumour extracellular
matrix providing structural support and being a rich source of vital components for
maintaining growth.
Tumours develop through the successive development of genetic variations. This
instability enables tumour cells to potentially mutate at an increased rate, providing
responsiveness to varying environmental stresses, and out grow normal host cells.
Genetic instability is often identified in tumour development and is derived from the
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degree of heterogeneity within individual tumours and also between tumours of the
same type (Shih et al., 2001). Microsatellite instability is shown to enable nucleotide
mutation rates which are up to three orders of magnitude greater than in cells
possessing normal mis-match repair genes (Bielas et. al., 2006). Solid tumours have
also been shown to display chromosomal instability, although most tumour cells
appear to develop displaying either chromosomal or nucleotide instability (Cahill et
al., 1999). Tumours can develop from the accumulation of many somatic mutations
within a single cell, often originating from a single spontaneous mutation during the
normal growth and development cycle (Calvert et al., 2002). Three common gene
types are known to incorporate these mutations, namely DNA repair genes (p53-cell
cycle), oncogenes (ATM-repairs DNA breakages) and tumour suppressor genes
(BRCA1- regulate cell growth), (Nowak et al., 2002).
Initial dogma suggested that tumour cells were invisible to the immune system due to
the thymic deletion of T cells recognising self antigens. Several studies opposed this
argument and have shown that immune responses are directed towards tumour targets.
CTLs have been cloned from patients bearing regressing tumours, demonstrating that
T lymphocytes are able to recognise and lyse tumour cells (Boon et al,.1997 and
Rosenberg 1999). Identified tumour associated antigens so recognised have been
classified into six main categories including, viral antigens [HPV (Human Papilloma
Virus); EBV (Epstein Barr Virus)], Cancer Testis (CT) antigens (MAGE, NY-ESO-
1), over-expressed self antigen (Her2/neu, P53), fusion proteins (bcr-abl), mutated
antigens (MUM-1,p53, CDF-4) and differentiation antigens (MelanA/MART-1,
tyrosinase, gp100). Sahin et al., (1995) demonstrated that high titres of IgG
antibodies could be isolated from tumour patients with specificity to a range of
antigens, which were also recognised by CD8
+
T cells and are displayed in the cancer
immunome/SEREX database. IFNJ receptor or signal transducer and activator of
transcription-1 (STAT-1) knockout mice showed the presence of increased
susceptibility to spontaneous and carcinogen induced tumour development. IFNJ was
identified as enhancing cell mediated immunity in conjunction with having direct
cytotoxic effects upon tumour cells. Following these observations RAG2
-/-
mice,
deficient in all T, natural killer and B cells were identified as being significantly more
susceptible to spontaneous and carcinogen induced tumour formation (Shankaran et.
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al., 2001). This group also showed that formed tumours were more immunogenic
than tumours developing in immunocompetent mice (Dunn et al., 2002).
Matzinger (1994), states that the immune system responds to danger signals as
opposed to foreign antigens. It appears that prevention of autoimmune disease,
recognition of self antigens, is controlled by several pathways acting in synergy.
Within the thymus, auto reactive T cells are selectively deleted and regulatory T cells
are developed. Regulatory T cells can also be stimulated within the periphery in order
to promote anergic responses to self antigens. Naïve T cells bind to cognate peptide-
MHC complexes and if this signal is combined with co-stimulatory signals, T cell
activation is induced. Therefore, in cases of cellular damage, self reactive T cells may
become activated due to the combined signals of danger (co-stimulatory molecules on
APCs) combined with antigen recognition. Once damage is repaired, APCs would no
longer deliver co-stimulatory signals and remaining T cells encountering self antigen
will be either anergised or driven to become regulatory T cells.
The principles of immunosurveillance and immunoediting are reviewed by Dunn et al
(2004) and (2002). The principles described suggest that the immune system actively
sculpts tumour cells and that there are three main stages leading to tumour formation.
The elimination phase describes how early tumour cells form and express distinct
tumour specific markers, generating proinflammatory signals that initiate molecules
of both the innate and adaptive immune system, which results in the eradication of
mutated/altered self cells. The equilibrium phase states that some cells may survive
this initial attack and are ‘edited’ by the immune system, promoting loss of antigens
or stimulatory signals generating new populations of tumour variants. The third phase
is identified by the ‘escape’ of tumour variants that are no longer detected by immune
effectors.
During tumour development, healthy cells are present which do not provide danger
signals to the immune system which is said to be immunologically ignorant
(Zinkernagel 2002). As the tumour develops, some cells become necrotic and release
intracellular components and ‘danger signals’. Necrotic cells also release many
cytokines in order to stimulate new blood vessel formation. VEGF, an angiogenic
cytokine is released and also inhibits activation of APCs (Gabrilovitch et al., 1996),
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which may prevent immune recognition/responses and may possibly promote
regulatory T cell formation. Many solid tumours secrete cytokines such as
transforming growth factor E (TGFE) and IL-10 in order to promote protection from
tissue damaging effects such as delayed type hypersensitivity responses. Cytokines
may not only inhibit immune responses but may switch responses to Th2 responses
preventing CTL mediated attack (Heriot et al., 2000). It appears that selective
pressure exerted by the immune system, while preventing development of many
potential tumour cells, actually sculpts cell variants to develop mechanisms of escape,
which may ultimately lead to tumour formation. Therefore it is vital to continue
assessment of up-regulated tumour antigens in order to understand methods of
immune evasion and to identify potential antigenic targets that may be exploited.
1.26: Development of anti-cancer immunotherapeutics
The discovery that tumours can be recognised by the immune system has lead to
extensive characterisation of molecular mechanisms underlying recognition. Many
tumour associated antigens have been identified and have enabled the development of
several immunological approaches in the development of cancer vaccines. Strategies
include exploitation of molecularly defined T cell epitopes, antibody based strategies,
cytokine therapies, immune modulators, DNA vaccines, whole cell vaccination
strategies, hormone based therapies and combinations of all of these methods.
Therapeutic vaccines are required to stimulate both cellular (Cytotoxic T cells and T
helper cells) and humoral responses, generating antibodies. Prophylactic vaccines for
cancer present numerous obstacles in that tumour cells may present a variety of
potential antigens. The administration of vaccines should be tailored to individuals
and difficulties arise when predicting who will generate specific tumours. However,
the advent of genomic screening for cancer and identification of predisposition could
enable the prophylactic treatment of high risk patients.
Main line treatment of cancer still involves surgery to remove the tumour and/or the
administration of secondary treatments such as radio/chemotherapy and
drugs/chemicals aimed at targeting cancer cells. The development of immunological
strategies, augmenting immune responses and overcoming regulatory mechanisms,
offers greater treatment specificity than many current strategies. The main classes of
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immunotherapy in phase II and III clinical trials are adjuvants, antigens and
immunostimulants, cell therapies and monoclonal antibodies as reviewed by Durrant
et al., (2003).
Cytokines and adjuvants are generally used to augment existing immune responses to
specific antigenic targets and a limited number have been approved for treatment of
cancer, including IL-2 for the treatment of melanomas and certain blood cancers. An
array of monoclonal antibodies has been developed and are being utilised in clinical
settings as mentioned in section 1.27. Many antibodies function by binding target
antigens, coating target cells and recruiting immune effector mechanisms for
destruction of the tumour cells. Several antibodies also act by signalling events
within tumour cells, inhibiting growth signals, or by preventing the binding of
cytokines to their respective receptors.
Immune stimulants are utilised to promote immune responses and in many cases to
promote a Th1 phenotype, enhancing cellular responses with particular focus on
cytotoxic T cells. Several immune stimulants target the activity of antigen presenting
cells, thus augmenting cytokine responses that promote T cell activation. An example
of an immune stimulant is Histamine dihydrochloride (Ceplene
TM
), which has been
shown to enhance cytokine mediators in stimulating T cells (Hamill et al., 2003 and
Schmidt et al., 2002). Clinical trials have assessed this compound, alone and in
combination with IL-2, for the treatment of metastatic melanoma (phase III). QS-21
(Stimulon
TM
) is a saponin extracted from the bark of quillaja saponaria and has been
used as adjuvant in phase III melanoma trials (Sondak et al., 2002). It promotes both
cellular and humoral responses when mixed with soluble antigens and is shown to
stimulate antibodies to GM2 when administered with GM2-keyhole limpet
haemocyanin (Chapman et al., 2000).
As previously mentioned, cytokines are produced at sites of inflammation to stimulate
and regulate many immune effectors. Actimmune

(IFNJ1b) has been used to
promote the activity of effector T cells and has been launched in the U.S. for use with
severe malignant osteoporosis. In early phase I and II clinical trials, it has been used
with some success in the treatment of ovarian cancer (Durrant et al., 2003).
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Cellular vaccines use tumour cells or cell lysates obtained from cancer bearing
patients. These combinations of mixed tumour antigens have the potential to
stimulate both cellular and antibody mediated immune responses. However, many
responses observed appear to be weak, potentially due to the non pathogenic nature of
the antigens given as opposed to viral or bacterial antigens. Canavaxin
TM
is a
polyvalent melanoma vaccine comprising of three cell lines expressing over 20
characterised antigens. The abundance of antigens presented in a single depot is
thought to promote both CD4
+
and CD8
+
cellular immunity, which is boosted by the
presence of BCG acting as an immune stimulant. Analysis has shown that responding
melanoma patients demonstrate cellular delayed type hypersensitivity responses to
certain antigens, which suggests a correlation between immune response with clinical
outcome (Hsueh et al., 2002).
Dendritic cell vaccines are viewed as potentially successful therapies as DCs are
required to stimulate naïve T cell responses. Two main approaches are currently used
in clinical settings: DCs are isolated from patients which are then pulsed with tumour
antigens and re-administered back to the patients; Heat Shock Proteins, which
chaperone MHC binding peptides from patients’ tumours, are isolated and injected
back into the patients. They bind to receptors on dendritic cells, enabling processing
and presentation of tumour antigens (Basu et al., 2001). HSPPC-96 (Oncophage

)
has been used within phase III melanoma trials and patients were shown to generate
an increase in melanoma specific T cell activity, with 5 out of 23 patients showing
long term survival (Assikis et al., 2003).
Synthetic vaccines incorporate synthesised molecules that are used to stimulate
specific antibody mediated or cellular responses. GMK is a vaccine to ganglioside
(GM2) which over-expressed in many cancer types such as melanoma, breast and
prostate. Synthetic GM2 is conjugated to KLH, which acts as a carrier protein,
providing T helper cell responses, promoting maturation of humoral responses from
IgM to IgG antibodies. The adjuvant QS-21 is also added to the treatment and early
phase I/II trials patients were shown to developGM2 specific antibodies that killed
tumour cells (Chapman et al., 2000).
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Anti idiotype vaccines are also used in clinical settings, utilising antibodies that
mimic tumour antigens. These antibodies stimulate host responses to the immunogen
and thus drive the development of CTLs which also recognise the tumour antigen.
Mitumomab (Bec2) is an example of an anti idiotype that has been used in early trials
showing increased survival rates of patients with small cell lung cancers (Chapman et
al., 2003). BEC2 is an investigational anti-idiotypic monoclonal antibody that is
designed to prevent or delay the recurrence of certain types of tumours. The BEC2
antibody mimics the ganglioside GD3 which is a tumour associated antigen. By
mimicking this antigen, BEC2 stimulates a stronger immune response to cells
expressing natural GD3. In limited pilot studies, preliminary findings suggest that
BEC2 has the potential to stimulate the body's immune system to identify and
eliminate residual tumour cells, preventing the recurrence of tumours, and prolonging
survival in patients with limited disease small cell lung carcinoma. The company in
cooperation with its partner Merck KGaA is currently evaluating BEC2 in an
international Phase III clinical trial for this indication.
1.27: Antibodies as therapeutic agents
The first indication that monoclonal antibodies could be used as therapeutic agents
was published in 1982, showing that a ‘tailor made’ mouse anti-idiotype antibody was
developed and used on one patient with B cell lymphoma. The subject showed a
complete response to this brief treatment indicated by a remission period for 17 years
(Miller et. al. 1982). This finding sparked a new field of research aiming to develop
the ‘magic bullet’ for the treatment of many diseases including cancer. However
early animal and human trials failed to reproduce the efficacy of the initial anti-
idiotype study. Commonly observed problems included the high levels of toxicity
produced by antibody conjugates and the development of HAMA (Human Anti
Mouse Antibody) responses which prevent the efficacy of repeated antibody therapy.
An exception to this is the success of the mouse monoclonal antibody orthoclone
OKT3 which was approved by the FDA for organ graft rejection in1986.
During the last decade, development in molecular and recombinant DNA technology
has enabled significant advancement in the production of high affinity, non-
immunogenic, highly efficacious monoclonal antibodies. One of the most significant
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criteria for antibodies which are to be used in clinical applications is the ability for
repeat high dosing of subjects without producing high toxicity levels. Several
strategies have been developed to overcome the HAMA response:- Human/ Mouse
chimeric molecules containing human constant sequences with mouse variable
domains, humanised antibodies where the only murine domain is that of the
Complementarity Determining Regions (CDRs) and completely human antibodies
produced via phage libraries and transgenic mice (Vaughan et. al. 1998). All these
modifications allow a reduction in immunogenicity, although chimeric, humanised
and complete human antibodies may still induce antibody responses to variable
regions, although this has been shown to occur in less than 12 percent of immune
competent cases (Clark M, 2000). Molecular modification also increases the ability
of antibodies to recruit host effector responses either via the complement system or
through the activity of cytotoxic cells, which is achieved by including human IgG
constant regions, a potent ability for the treatment of malignancy. Humanisation of
murine immunoglobulins has improved their effectiveness in immunotherapy, as half
lives can be increased from approximately 20 hours (rodent) to more than 21 days.
The presence of the human Fc region enables binding to endothelial FcRn (Brambell)
receptors which salvage molecules and enable avoidance of intra-cellular breakdown.
Addition of human Fc regions also reduces the development of human anti-mouse
antibody (HAMA) responses, and enhances capacity for complement recruitment and
induction of antibody dependent cell cytotoxicity responses.
There are several possible modes of action to be considered in antibody development
in order to generate a specific and effective therapy. There are three main modalities,
those which act by blocking or modulating responses such as through the inhibition of
growth signals within target cells, targeting specific antigens thereby opsonising the
cellular targets and inducing effectors, or by inducing signal transduction pathways
through cell receptors in order to generate a specific response (stimulation of
apoptosis or co stimulation of immune effectors turning weak responses into effective
anti tumour activity). Conjugate therapy has also shown to be an effective treatment
of malignancies by combining antibodies with cytotoxics, such as chemotherapeutic
agents or radio isotopes, delivering the active agent directly to the tumour site.
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Many monoclonal antibodies are undergoing trials and several have been approved by
the FDA for treatment of a multitude of conditions. Figure 1.11 shows the current
status of several therapeutic antibodies. Many of the monoclonal antibodies currently
used are for the treatment of malignancy and utilise different modalities to induce
their anti tumour effects.
Figure 1.11: Summary of current FDA approved antibodies
Year FDA
approved
Product Target Indication
1986 Muromonab-CD3 (OKT-
3)
CD-3 Transplant rejection
1994 Abciximab (ReoPro) GP11a/111b Percutaneous
transluminal coronary
angioplasty
1997 Rituximab (Rituxan) CD20 B cell lymphoma
1997 Dacliximab (Zenapax) IL-2r Transplant rejecton
1998 Basiliximab (Simulect) IL-2r Transplant rejection
1998 Infliximab (Remicade) TNF Crohn’s disease,
Rheumatoid arthritis
1998 Palivizumab (Synagis) RSV
Respiritory
Syncytial Virus
RSV in infants
1998 Trastuzumab (Herceptin) HER-2/neu Breast cancer
lymphomas, prostate
cancer
2000 Mylotarg (Gemtuzumab
Ozogamicin, CMA-676)
CD33 Acute Myelogenous
Leukemia
2002 Ibritumomab
tituxetanytium
90
(Zevalin,IDEC-Y2B8)
CD-20 Non-Hodgkin’s
Lymphoma
2002 Alemtuzumab (Campath,
Campath-1H)
CD-52 B cell chronic
lymphocytic
leukaemia
2003 Tositumomab I
131
(Bexxar)
CD20 Low grade Non-
Hodgkin’s Lymphoma
Pending
(Germany
1995)
Edrecolomab (Panorex) Anti idiotype
antibody for
protein 17-1A
(Ep-CAM)
Colorectal cancer
2005 Epratuzumab
(LymphoCide)
Fast track product
designation post Phase II
trials
CD-22 B cell malignancies
Treatment of moderate
to severe SLE
2004 Cetuximab (IMC-C225)
Erbitux (Imclone)
Epidermal
growth factor
Colorectal,pancreatic
& Head and Neck
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receptor
(EGFR)
cancers
Phase III
trial 2004
Mitumomab (IMC-Bec-2) Anti idiotype
against
ganglioside
GD3
Small cell lung cancer
2003 Phase
II/III trial
indicated no
increased
survival
ABX-CBL (Abgenix)
New Focus ABX-EGF-
Panitumumab (fully
human MoAb)
CD 147
EGFr
Steroid resistant graft
Vs host disease
(GVHD)
Lung, breast and
colorectal cancer
Rituximab (Rituxan) is a chimeric human/murine monoclonal IgG1 specific for the
CD20 antigen present on normal and malignant mature B lymphocytes. 80 percent of
all Non-Hodgkin’s Lymphomas are B cell malignancies and >90% express CD20,
which is not found on hematopoietic stem cells (White.C, et. al. 2001). Rituximab
has shown therapeutic efficacy in triggering the tyrosine phosphorylation of
intracellular proteins, specifically activation of protein kinase C and upregulation of
Myc (Cragg et.al. 1999). Several studies have shown that cross linking of the B cell
receptor with antibody stimulates both growth arrest and apoptosis in both normal and
malignant cells (Glennie et.al. 2000). As Rituximab possesses human gamma 1 heavy
chain and kappa light chain constant regions, it is effective in mediating ADCC and
CDC in the presence of human complement, and within mature B cells it also
sensitises chemoresistant cells to toxins and chemotherapy agents (White et.al. 2001).
Rituximab was given FDA approval in 1997 for use in refractory low grade or
follicular lymphoma that express CD20 antigens. An interesting factor is the role in
which complement regulatory proteins have been shown to affect the outcome of
rituximab therapy. While rituximab is known to generate both CDC and ADCC
responses, Golay et al (2000) showed that complement mediated lysis varied from
100% lysis to complete resistance on several Burkitt’s lymphoma cell lines. They
also showed that by blocking CD55 with specific antibodies, CDC responses were
increased, indicating that heterogeneity of rituximab responsiveness is in part,
affected by complement regulatory proteins. Cerny et al (2002) also confirmed how
blocking of both CD55 and CD59 can overcome rituximab resistance and potentially
sensitise target tumour cells to apoptosis and complement mediated lysis. These
novel findings promoted Bannerji et al (2003) to determine whether CD55 expression
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could be utilised to determine rituximab therapy outcome, however findings indicted
CD55 and CD59 levels did not predict clinical responsiveness to rituximab therapy in
chronic lymphocytic leukaemia patients. Di Gaetano et al, (2003) demonstrate that
complement activation is fundamental for rituximab therapeutic activity in vivo by
using syngeneic knockout mice lacking C1q. This also promotes the use of
complement regulatory protein inhibitors for combined potential therapeutics.
Trastuzumab (Herceptin) is a humanised IgG1 monoclonal antibody derived from
Chinese hamster ovaries specifically targeting human epidermal growth factor
receptor 2. This receptor signals via the Ras pathway to increase cyclin D1
expression, which is correlated with reduced sensitivity to hormonal and endocrine
therapy. Trastuzumab therapy alone has produced responses in 15 percent of patients
with metastatic breast cancer (Johnson, 2001), and a randomised trial has indicated
that in combination with chemotherapy, median survival is increased by 25 percent
(Slamon D, 2001). Trastuzumab was given FDA approval for single and combination
therapy for breast cancer overexpressing HER2 (c-erbB-2) in patients that have shown
limited responses to chemotherapy alone.
Gemtuzumab Ozogamicin (Mylotarg) is a recombinant humanised antibody
conjugated with the cytotoxic anti-tumour antibiotic calicheamicin (Wyeth
Laboratories, PA). It binds CD33 antigen, which is an adhesion protein, expressed on
the surfaces of leukaemic blasts and immature normal cells of the myeloid lineage.
CD33 is not found on the surface of normal haematopoietic stem cells. Upon binding
to its antigen, myelotarg is internalised and releases the calicheamicin derivative into
the cells, which binds to DNA, resulting in DNA double strand breaks and cell death.
Adverse reactions noted in clinical trials have included bone marrow suppression with
median recovery of neutropenia of approximately 40 days, related fevers and less
commonly hepatotoxicity. Myelotarg is approved in the treatment of patients with
CD33 positive acute myeloid leukaemia in first relapse.
CD52 is an antigen expressed on normal and malignant lymphocytes, macrophages,
eosinophils and monocytes (Nemecek et al, 2002). Alemtuzumab (Campath-IH) is a
humanised rat IgG1 antibody reactive with CD52 and is approved for the treatment of
B cell chronic lymphocytic leukaemia (Berlex laboratories, Richmond, CA). This
antibody is thought to produce an anti leukaemic effect via the activation of
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complement and antibody-dependent cytotoxic effector mechanisms. However, its
efficacy has been shown to be transient if not followed by other therapies such as
haematopoietic stem cell transplantation (Nemecek et al, 2002).
Tositumomab I
131
(Bexxar) is a murine monoclonal IgG targeting the CD20 antigen
on B-lymphocytes, which is labelled with Iodine
131
. It has been used in the treatment
of low-grade Non-Hodgkin’s lymphoma and has two modes of effect. By targeting
the CD20 antigen, apoptosis is induced and the antibody is also able to mediate
antibody dependent cellular cytotoxicity. Tositumomab also acts by delivering
ionising radiation to the tumour site. Kaminski et. al. (1996) showed that a non
myeloblative dose regime in 34 patients with NHL gave a 79 percent overall response
rate and only 14 percent of cases developed HAMA responses. Tositumomab was
given FDA approval in 2003 for the treatment of patients with CD20 positive,
follicular, non-Hodgkin's lymphoma (NHL), with and without transformation, whose
disease is refractory to Rituximab.
Edrecolomab (Panorex) is a murine IgG2a monoclonal antibody directed against the
surface glycoprotein 17-1 antigen/ epithelial cell adhesion molecule (Ep-CAM). It is
shown in cases of colorectal carcinoma that following surgical resection of primary
tumours, outgrowth of distant metastasis remains difficult to prevent. However,
adjuvant monoclonal antibody therapy may provide an effective method to prevent/
reduce the spread of tumour cells. Antibodies such as Panorex activate the classical
pathway of complement activation, which can result in direct lysis of tumour cells or
act by the recruitment of leukocytes to the tumour site. However, in clinical trials
52% of patients still show recurrence of disease after 7 years, which has been
associated with the enhanced expression of complement regulatory proteins shown on
tumours (Gelderman et al, 2002).
Epratuzumab (Amgen) is an anti CD22, humanised monoclonal antibody which is
being assessed for the potential treatment of Lymphoma, non-Hodgkin’s Lymphoma
(NHL) and certain auto-immune conditions. Epratuzumab has been used in
conjunction with rituximab treatment in relapsed and refractory NHL and generated a
beneficial antilymphoma effect without showing an increase in toxicity. Amgen have
also developed conjugated forms of epratuzumab with the radioisotope
90
Y which is
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being used in a phase III clinical trial for the potent treatment of aggressive lymphoma
(Juweid, 2003). In June 2003 epratuzumab received orphan drug status in the United
States as a treatment for NHL.
ERBITUX
TM
(Cetuximab) is an IgG1 antibody which targets and blocks Epidermal
Growth Factor Receptor (EGFR), which is expressed on the surface of cancer cells in
multiple tumour types. Erbitux binds EGFR and prevents interaction of natural
ligands with their receptor, preventing phosphorylation of signalling pathways. It has
been analysed in second line colorectal cancer, lung, pancreatic, ovarian, head and
neck cancers. Adverse affects include rash, diarrhoea, nausea abdominal pain and
vomiting.
ABX-CBL IgM murine antibody which targets CD147 and initiates killing via
complement mediated lysis. Human CD147/neurothelin or EMMPRIN is a member
of the immunoglobulin super-family and is weakly expressed on human leukocytes,
granulocytes and red blood cells. ABX-CBL depletes activated T and B cells as well
as resting and activated monocytes and dendritic cells in vitro, whereas resting
lymphocytes remain unaffected (Joachim Deeg et al, 2001). It is has been assessed in
patients with steroid-refractory graft versus host disease, generating 44% survival
rates 6 months following treatment (Joachim et al, 2001).
Immune conjugates have thus been assessed and some success has been achieved, as
is the case for tositumomab. However, immunotoxins have shown limited success, as
several trials have shown the emergence of dose limiting toxicities such as vascular
leak syndrome, hypersensitivity reactions and CNS toxicity (White e. al. 2001).
ADEPT (antibody directed enzyme prodrug therapy) utilises antibodies conjugated to
prodrugs which are directed to the tumour site and activated by local enzymes. This
methodology is at an early stage in development and several clinical trials are being
carried out utilising prodrugs with short half lives, in order to reduce the necessity for
antibody clearance to reduce the level of toxicity generated (Francis et. al. 2002).
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1.28: DNA Immunisation
Common methodology for antibody development is based upon cDNA sequence data,
from which peptides can be synthesised and utilised for immunisation protocols.
However, such strategies are often inefficient, particularly when antibodies are
required to recognise a native protein for use in conformational assays such as flow
cytometry or in therapeutic applications. Over the last decade, research into genetic
or DNA immunisation has enabled many previous problems to be overcome. In 1990,
Wolff et al., showed that mice immunised with a naked DNA plasmid showed
expression of reporter proteins within muscle cells at the site of immunisation. This
technology was then shown to stimulate specific immune responses (Tang et al,
1992), and over the following years, stimulation of both humoral and cellular
responses have been widely reported (Donnelly et al., 1997; Tighe et al., 1998). This
technology platform has been used to generate antibodies through DNA
immunisation, with cDNA sequences encoding specific proteins enabling the animal’s
immune system to respond to the foreign protein. Although the quantity of protein
produced In Vivo following DNA immunisation is shown to be low, within the
picogram to nanogram range, efficient immune responses are achieved. This is
because the foreign protein is expressed directly in or is quickly taken up by
professional antigen presenting cells (Takashima and Morita, 1999). Relatively small
numbers of activated APCs have been shown following In Vitro immunisation to be
sufficient to stimulate T cells (Casares et al., 1997). Enhancement of genetic
immunisation has also been shown to be effective due to the presence of CpG-motifs
found within the plasmid backbone of the DNA itself, activating both dendritic cells
(Jakob et al., 1998) and B cells (Krieg et al 1995). Generation of high affinity
antibodies has been shown to be achievable through DNA immunisation in many
cases, in particular by Kilpatrick et al., whom in 1998 showed that generation of
mature IgG subclasses could be obtained. Single chain Fv antibodies have also been
obtained from single chain libraries generated from genetically immunised mice
(Chowdhury et al., 1998). The benefits of DNA immunisation over many previously
conventional protocols are numerous. A concern with purified proteins is that there is
always the potential for the presence of contaminating proteins, compared to genetic
immunisations which drive a response to only the expressed desired target. A major
factor is that protein targets are produced In Vivo, incorporating correct folding and
enabling post-translational modifications to occur, maintaining native protein
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conformation. This being advantageous compared to purified proteins which may
become degraded or never obtain native conformation. There is also potential that
DNA immunisations, due to low levels of protein being produced, may generate high
affinity antibodies, as indicated by Boyle et al. (1997) when generating antibodies to
ovalbumin. They showed that although total IgG levels were similar between genetic
immunisation compared to standard protein immunisation protocol, avidity of anti-
sera generated from the DNA immunisations were found to be 100-1000 times
greater.
Berzofsky et al. (2001) review methods for designing and optimising vaccines, and
show that DNA vaccines can be extremely efficient at priming immune responses. As
mentioned, specific protein can be expressed in vivo for processing and presentation
by class II MHC, direct transfection of DCs also enables peptide generation and
presentation by class I MHC for the driving of CTL mediated responses. Many DNA
vaccines have been developed for the treatment of HIV (Wang et al., 1998) and
Malaria (Hanke, Schneider et al, 1998), incorporating CTL epitopes into expressed
proteins. This same strategy can be used in the treatment of cancer, incorporating
CTL epitopes of tumour antigens for the generation of combined cellular and humoral
immunity. Several vectors including viral and bacterial have been developed in order
to generate effective anti tumour responses by transfection of autologous and
allogenic cell lines for cell based vaccines and also for direct delivery of tumour
antigens to antigen presenting cells. An example of a viral vector is the DISC-HSV
(disabled infectious single cycle herpes simplex virus), which is only capable of a
single round of infection, preventing further infection of other cells. Deepak
Assudani et al. (2006) state the immunotherapeutic potential of this vector encoding
GM-CSF in murine carcinoma models, which resulted in regression of tumours in
70% of mice assessed.
1.29: Anti-tumour immunotherapeutics targeting CD55 as potential therapy
Mutations in SCR 3 of CD55 have been shown to produce the most disruptive effects
on its complement regulatory activity, when compared to mutations in other domains
(Coyne et. al.1992). An array of antibodies to specific domains within decay
accelerating factor (CD55) were tested for their ability to block its regulatory activity,
and only two antibodies, specific to SCR 3, completely abolished its function.
42
Blok et. al. (1997), showed that a bispecific antibody recognising CD55 and tumour
cell antigen G250 induced C3 deposition and tumour cell lysis, and that opsonised
cells became sensitised to complement mediated lysis. Similarly Zhong et. al. (1995)
showed that increased tumour killing could be achieved by CD55 blockade with an
antibody to SCR3 of CD55.
Enhancement of CTL epitopes has been used to convert subdominant epitopes into
more efficacious sequences, increasing vaccine potency by improving peptide affinity
for MHC class I molecules, thereby enhancing peptide competition for MHC
complexes on antigen presenting cells. This strategy has been assessed in several
cancer models in order to generate increased antigen specific CD8
+
responses
(Parkhurst et al., 1996, Rosenberg et al., 1998 and Irvine et al., 1999).
Combining immunotherapeutic strategies targeting CD55 could potentially produce a
complete anti-tumour response recruiting multiple arms of the immune system. This
total effective treatment would incorporate complement recruitment to the site of
tumours via antibody dependent cellular cytotoxicity; neutralisation of CD55
complement regulatory activity upon tumour cells and within tumour stroma through
antibody mediated inhibition; prevention of T cell inhibition caused by interaction
with tumour CD55 via antibody blockade and recruitment of cell mediated
cytotoxicity through immunisation with target-tumour associated antigens.
1.30: Heteroclitic epitopes induce tumour immunity
Cytotoxic T cells (CTLs) play a dominant role in the rejection of tumours, mediated
through recognition of target antigens presented by self MHC encoded class I
molecules. Binding of T cell receptors to their cognate peptide/MHC complex on
tumour cells initiates target cell lysis by the CTL, resulting in tumour elimination. In
order for CTL precursors to become activated two signals are required: a stimulatory
signal which is transmitted via the T cell receptor-CD3 complex, and a co-stimulatory
signal which is delivered by professional antigen presenting cells. Within the thymus,
a strong signal 1 can induce negative selection of immature T cells regardless of
signal 2 (Nossal et. al., 1994). In the periphery, the same strong signal 1 can initiate
immunity or anergy, dependent upon the presence of signal 2. Differentiated/effector
T cells, in contrast to T cell precursors, are capable of mediating target cell lysis
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driven by only a weak signal 1 without the presence of signal 2 (Sette et. al., 1994).
Therefore a group of antigenic peptides exist which, while not capable of directly
priming immune responses, may serve as targets of activated effector T cells.
Many tumour antigens have escaped immune recognition either by generating a
strong signal 1, promoting deletion of self reactive T cells or generating self reactive
regulatory T cells, or by being of low affinity and thus poor immunogens. Therefore,
the use of low affinity tumour epitopes as immunogens is counter productive in the
generation of strong anti-epitope/tumour CTL responses. A direct correlation
between antigen immunogenicity and MHC binding affinity/stability of MHC/peptide
complexes for class I epitopes has been demonstrated by several groups (Sette et. al.,
1994 and Van der Burg et. al., 1996). Dyall et. al. (1998) summarise that if low
affinity epitopes from within tumour antigens can be modified, these potentially
immunogenic variants could prime CTL responses that are cross reactive with original
target peptide sequences. This would exploit a repertoire that may exist specific to
the primary sequence which may not be activated due to low affinity, but which may
be available for activation by more immunogenic/high affinity variants. In 1979,
Solinger et. al. assessed variants of a cytochrome C peptide, and they identified
peptides of higher biological potency than the initial peptides as heteroclitic. Crystal
structure analysis (Madden et. al., 1995, Garcia et. al., 1996 and Garboczi et. al.,
1996) identified that of the 8 to 10 amino acids of peptides binding to MHC class I,
half are exposed to the T cell receptor, with the remaining residues being buried
within the class I molecule. Dyall et. al. (1998) summarise that ‘heterocliticity’ has
been achieved by amino acid substitution of bases contacting either the class I
molecule, the T cell receptor or substitutions of both, all improving the affinity of
interaction between peptides and their target molecules.
Numerous studies have utilised heteroclitic epitopes for immunisation against
tumours, promoting responses to weak immunogenic self proteins. Dyall et. al.
(1998) utilised heteroclitic peptides from a tyrosinase expressed by melanoma cells,
and successfully induced CTL mediated regression and moderate protection from
tumours in C57/bl mice. Tourdot et. al. (2000) demonstrate the potential for this
strategy, assessing thirty two peptides derived from viral and tumour antigens which
have undergone residue modification. Modified peptides were shown to possess an
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increased affinity for MHC class I, and In Vivo analysis identified that enhanced
sequences stimulated peptide specific CTL responses which were also specific to
naturally processed native epitopes. Graff-Dubois et. al. (2002) analysed the potential
for a heteroclitic peptide to be used as a candidate for broad spectrum tumour
vaccination. A MAGE-A antigen was identified from multiple tumour types and a
heteroclitic peptide was produced. This peptide induced CTLs in HHD HLA-A*0201
transgenic mice, recognising HLA-A2 low affinity peptides derived from MAGE-A1,
-A2, -A3, -A4, -A6, -A10 and –A12. These effector cells responded to endogenous
antigens in an HLA-A2 restricted manner and recognised human HLA-A2
+
MAGE-
A
+
tumour cells of various histological origin. Gold et. al. (2003) produced a DNA
plasmid construct expressing a variant of the human melanoma antigen gp100. The
construct contained a heteroclitic epitope displaying a higher affinity for MHC, which
induced protective tumour immunity in melanoma bearing H-2
b
mice when used as a
vaccine. Ramage et. al. (2004), generated a DNA vaccine encoding human Tie-2,
which is a tumour associated antigen expressed on endothelial cells of tumour
vasculature. Anchor modifications were carried out to enhance epitope affinity for
HLA-A*201, with the most successful constructs driving CTL mediated responses
specific to not only both the immunising peptide and the native protein, but also to
HLA-A*0201 endothelial cells expressing Tie-2. These results and others, confirm
the relevance of heteroclitic epitope immunisation for the stimulation of antigen
specific tumour vaccines.
1.31: HHD transgenic mice as a suitable model for DNA vaccine assessment
This project aims to identify epitopes that could be presented by the common human
class I antigen HLA-*201. Several strains of class I transgenic mice which still
express murine H-2 class I molecules have been derived. However, several previous
studies, as summarised by Pascalo et. al. (1997), identified that these mice often
preferentially develop H-2 restricted CD8
+
responses. Firat et. al. (1999) suggest that
unless the third domain of the human molecule is substituted with a mouse domain,
the CTL repertoire is inefficiently mobilised from the periphery due to poor
interaction with mouse CD8
+
molecules. To overcome the observed bias, the HHD
model was developed in which the H-2D
b
and mouse E2 microglobulin genes were
45
disrupted and a chimeric human D1, D2 and mouse D3 HLA-A2.1 heavy chain
covalently linked to the human E2 light chain was incorporated (Figure 1.12).
Figure 1.12: Schematic representation of HHD II, HLA-A2.1 monochains
Adapted from Pascalo et. al. (1997). Red area = Human Origin, Blue area = Mouse Origin.
Several groups have assessed this mouse model, demonstrating that HHD mice can be
utilised as a versatile model for pre-clinical evaluation of HLA-A2.1 restricted human
tumour associated CTL epitopes. Firat et. al. (1999) assessed a melanoma-based
poly-epitope viral construct and demonstrated that CTL responses were observed,
specific to five HLA-A2.1 restricted epitopes within single animals. They conclude,
through direct comparison, that the size of HLA-A2.1 educated CD8
+
peripheral T
cell repertoire is larger in HHD than in A2A2K
b
transgenic mice. Ramage et. al
(2004) observed a greater frequency of antigen specific CTLs in HHD mice,
compared to A2A2K
b
transgenic mice, immunised with a DNA vaccine expressing
an HLA-A2.1 restricted Tie-2 self antigen. They concluded that the HHD model is
useful for studying CD8
+
responses to over expressed self antigens, while
acknowledging that direct comparison with the human system should incorporate the
potential for discrepancies between human and mouse T cell repertoires.
D2 D1
Dҏҏ3 +Em
N - Terminal
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1.32: Study Outline
The aims of this project were to generate potential immunotherapeutics targeting the
tumour associated antigen CD55. Several methodologies were incorporated in order
to develop CD55 neutralising antibodies, and a DNA vaccine with the potential to
stimulate both cellular and humoral responses against tumour cells expressing this
target molecule.
x Develop monoclonal antibodies specific to active domains of human CD55
capable of targeting tumour cells and neutralising CD55 decay
accelerating activity.
Raise antibodies through combination of peptide and whole cell vaccination
strategies. Assessment to be carried out through combination of ELISA,
FACS and complement deposition assays.
x Develop DNA vaccine capable of eliciting both humoral and cellular
responses to human CD55.
Generate a DNA construct expressing wild type CD55 linked to human IgG Fc
tail for stimulation of therapeutic antibodies capable of targeting tumour cells
expressing CD55.
Incorporation of heteroclitic epitopes into DNA construct for stimulation of
HLA-A*201 restricted CD8
+
cytotoxic T cells capable of mediating lysis of
CD55 bearing tumour cells.
CD55 SCR 1-3 Fc DNA Vaccine
Wild type and Heteroclitic epitopes
Humoral Responses
Antibody production
x Isotype (ELISA)
x Specificity
(ELISA/FACS)
Cellular Responses
CD8
+
T cells
x Antigen specific killing
(
51
Cr release)
x Antigen specific cytokine
release (IFNJ & IL-4
ELISPOT)
x Avidity (ELISPOT)
x Cytokine profile (Luminex)
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Chapter 2: Materials and Methods
All procedures were carried out using aseptic technique where appropriate and all
safety regulations were followed. Standard protocols were either developed or
followed for all assays and, where necessary, modifications are incorporated into the
protocols for use in specific conditions. All animal work was carried out under a
Home Office approved project licence.
2.1 Immunisation Strategies
2.1.1 Peptide prediction and synthesis for immunisation of BALB/c mice
The peptide sequence for SCR 3 domain of human CD55 was obtained from
SWISSPROT software (www.expasy.org), accession number P90174. The sequence
was entered into the ProtScale program to generate a hydrophobicity plot identifying
three potential antigenic regions predicted to be located at the surface of the protein.
The peptides were synthesised by John Keyte at the BSAU, Nottingham University.
The three peptides were coupled to the carriers KLH (Keyhole Limpet Haemocyanin)
and ovalbumin via their N-terminal cystein group using the heterobifunctional cross
linking reagent sulpho-MBS (Perbio Science, Cheshire,UK). The carrier protein is
dissolved to a concentration of 10mg/ml in PBS and a 25mg/ml MBS is dissolved in
dimethylformamide. A 0.1 volume of MBS is added drop-wise to the carrier protein,
avoiding high local concentration, and was mixed at room temperature for 30minutes.
The activated carrier is then separated from free MBS by filtration on a sephadex G25
or PD10 column (Amersham Pharmacia Biotech, Sweden) in PBS. Target peptide is
then dissolved in PBS and added to the carrier in a ratio of 1 Mole of peptide to 50
amino acids of carrier. The final pH is adjusted to 7-7.5 and the mixture is stirred for
three hours at room temperature.
The peptide-KLH conjugates were dialysed for 4 hours at 4qC against PBS using
‘slide-a-lyzer’ cassettes (Pierce/QB Perbio. Rockford. IL.USA). The peptides were
emulsified with either Complete or Incomplete Freund’s adjuvant (Sigma, Dorset,
UK), prior to immunisation as table 3.1.
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2.1.2 Heteroclitic epitope prediction
In the context of this study, heteroclitic epitopes are defined as class I MHC restricted
CTL epitopes whose MHC binding residues can be modified to increase binding
affinity without altering CTL receptor recognition.
As per section 2.1.1 the complete protein sequence of human CD55 accession number
P90174 [SWISSPROT software (www.expasy.org)] was obtained and used within
several on-line epitope prediction algorithms.
“BIMAS” developed by Parker et al. (1994), access via:
http://www.bimas.dcrt.nih.gov/cgibin/molbio/ken_parker_combofrom
“SYFPEITHI” developed by H.G. Rammensee et al. (1999), access via:
http://syfpeithi.bmi-heidelberg.com
“HLA Ligand/Motif Database” under the direction of William Hildebrand and funded
by the National Institute of Health. University of Oklahoma Health Sciences Center.
“MHCPEP” – database for MHC ligands and peptide motifs. Rammensee et al.
(1999), access via:
http://www.uni-tuebingen.de/uni/kxi/
2.1.3 Peptide immunisation and Sera collection from BALB/c mice
Female BALB/c mice used were aged between 6 and 8 weeks (Charles River, UK)
and cared for by the staff at the Biomedical Services Unit at the University of
Nottingham.
Immunisations were carried out at two weekly intervals in a maximum volume of
100Pl (sample diluted in PBS) using a 1 ml insulin syringe (BD Bioscience, Spain).
Immunogen and adjuvant were combined in 1:1 ratio and administered intravenously,
sub-cutaneously and intra-peritoneally. Serum was collected via tail bleed extraction,
centrifuged at 13,000 rpm for 5 minutes to remove blood cells and serum was stored
at -20qC. For whole cell immunisation, target cells were harvested and washed in
sterile Phosphate Buffered Saline (PBS). Cells were resuspended in PBS, 10
5
cells
per 50ȝl and combined in a 1:1 ratio with incomplete Freund’s adjuvant. 100ȝl of
immunogen were administered intra peritoneally as per protocol (Table 3.1).
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2.1.4 HHD II transgenic mice
Mice from the HHD II transgenic mouse colony at the animal unit at Nottingham
Trent University were used as HLA-A2 mouse models for DNA immunisations.
Male and female HLA-A*201/k
b
(derived by Nicholas Holmes, Department of
Pathology, Cambridge University, Cambridge, UK) between six and twelve weeks of
age were used.
2.1.5 Preparation of DNA micro-carriers (gold bullets)
100µl of 0.05M spermidine was combined with 8.3mg of 1 micron gold particles
(BioRad) and mixed in a sonicating water bath (Sonomatic, Jencons Scientific Ltd,
Leighton Buzzard, UK). 18µg of plasmid DNA at a concentration of 1mg/ml was
added to the mixture and sonicated prior to the addition of 100µl of 1M Cacl2 (drop
wise). The DNA/gold particle mixture was allowed to stand at room temperature for
10 minutes and then centrifuged at 13,000rpm for 1 minute. The gold pellet was then
resuspended in 100% ethanol (Sigma Aldrich). The sample was sonicated and the
wash procedure repeated a further two times prior to re-suspension in 1ml of
0.025mg/lm polyvinylpyrrolidone (PVP) (BioRad) diluted in ethanol.
1.5m of tefzel tubing (BioRad) was loaded into the DNA preparation station (BioRad)
and dried by passing nitrogen through the tubing for 15 minutes. The DNA coated
micro-carriers were loaded onto the tefzel tubing and left to bind for 15 minutes prior
to withdrawal of the ethanol. The tubing was rotated 180q prior to continuous rotation
for 5 minutes, after 30 seconds nitrogen was passed through the tubing to dry the gold
particles. The tubing was removed from the station and 0.5 inch sections of tubing,
containing the DNA/gold micro carriers were cut and stored at 4qC with desiccant
overnight for use in immunisation the following day.
2.1.6 Mouse immunisation with Helios
TM
Gene Gun
The Abdomens of mice to be immunised were shaved of fur and the spacer of the
gene gun was placed gently onto the skin. A single shot of DNA coated gold micro-
carriers, using 400psi pressure of helium was administered.
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2.1.7 Epitope-peptide preparation for In Vitro Analysis
Peptides synthesised by Alta Bioscience, Birmingham, UK, were suspended in 100µl
of sterile DMSO (Dimethyl Sulphoxide) (Sigma, Poole, UK) at a concentration of
40mg/ml. Peptides were then combined with sterile PBS at a 1:1 ratio to produce
peptide in solution at 20mg/ml concentration.
2.1.8 MHC stabilisation assay with T2 (TAP
-/-
) cell line
T2 lymphoblastoid cells are deficient in the intracellular peptide transporter TAP
(transporters associated with antigen processing), which is used to translocate
peptides, that are generated within the cell cytosol by the protesome, to the rough
endoplasmic reticulum for assembly within the major histocompatibility complex. As
a consequence of peptide binding, the class I MHC molecule displays increased
stability and dissociates from both calnexin and the TAP protein. In deficient cells,
MHC is not stabilised with internal peptide and upon presentation at the surface
membrane it is recycled back within the cell. T2 cells can be used to externally load
peptide into the binding site of MHC class I molecules which in turn stabilises this
molecule at the cell surface. T2 cells are also HLA-A2 restricted and can be used to
assess the binding affinity of synthesised peptides, which were predicted to bind, and
thus stabilise MHC class I molecules. This project aimed to identify epitopes with
moderate to high affinity for MHC class I and the T2 stabilisation assay was used as a
viable assessment of predicted binding.
T2 cells are sub cultured and re-fed one day prior to stabilisation assay in order to
maintain high viability in this live assay. T2 cells are harvested, pooled and washed
via centrifugation at 12000 rpm in serum free media. Cells were washed twice and
the cell pellet was resuspended in complete media and cells were counted with trypan
blue staining. Cells were diluted to a concentration of 1 x 10
6
/ml and 100µl aliquots
were seeded in a 96 U-well tissue culture plate. All samples are assessed in triplicate
and controls wells set up without stimulus and with two concentrations of DMSO for
compensation of results. 50µl of peptides were added at concentrations of 400µg/ml
and 100µg/ml along with 50µl of 500ng/ml E2 microglobulin to each well. The total
assay volume was 200µl of complete media. Plates were incubated for at least 16
hours at 37qC with 5% CO2. 50µl of 2.5mg/ml of brefeldin A (Sigma) was added per
well and plates incubated for a further hour at 37qC. Cells were then transferred to a
51
96 U-well flexi plate that was centrifuged at 1000 rpm for 4 minutes and supernatant
blotted from the wells. Cells were then resuspended in 50µl of PBS and this wash
step was repeated a further two times. Cells were analysed by indirect labelling of
cells with 50µl of 1:100 BB7.2 antibody (HLA-A2 specific) for 30 minutes on ice.
Cells were washed as before in PBS two times and 50µl of 1:100 goat anti mouse
FITC conjugated (Fab)2 antibodies were added per well and plates were incubated on
ice for a further 30 minutes. Cells were washed in PBS three times prior to re-
suspension in 200µl of PBS. Labelled cells were then analysed by flow cytometry.
2.2 Eukaryotic cell culture and modification
2.2.1 Eukaryotic cell culture (Storage, defrosting & maintenance)
All cell culture was carried out using aseptic technique in a class II safety cabinet.
791T : Human ostesarcoma (in house)
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
Colo 205 : ECACC # 87061208
Human Caucasian colon adenocarcinoma producing
carcinoembryonic antigen
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
CHO : ECACC # 85050302
Chinese Hamster Ovary subclone displaying
epithelial morphology
Dulbecco’s Modified Eagle’s Medium F12 HAM
(Sigma)
2mM L-Glutamine (Sigma)
10% H.I. Foetal Bovine Serum (Sigma)
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CHO DAF Hi : CHO cells transfected with CD55 Apex construct
Dulbecco’s Modified Eagle’s Medium F12 HAM
(Sigma)
2mM L-Glutamine (Sigma)
10% H.I. Foetal Bovine Serum (Sigma)
10ȝg/ml Puromycin (Sigma)
NSO : ECACC # 85110503
Mouse (BALB/c) Lymphoblastoid Myeloma
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
Hybridoma : Mouse NSO and splenocyte fusion
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
1 x HAT Supplement (1 vial 50 x HAT/ 500ml)
(Sigma)
NIH 3T3 : ECACC # 86052701
Mouse (BALB/c)
DMEM (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
EL4 : ECACC # 85121301
Mouse C57BL/6N ascites lymphoma lyphoblast
DMEM (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
Murine : Murine cells harvested from immunised and naive
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Splenocytes mice
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
5ml strptomycin/penicillin solution (Sigma)
0.05mM E-mercaptoethanol
10mM Hepes buffer (Sigma)
T2 : Lymphoblastoid
RPMI 1640 (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
CHO SF : ECACC # 00102307
Chinese Hamster Ovary cell line adapted for growth
without protein
CD CHO media (Gibco, Invitrogen,US)
1 x HT Supplement
2MM L-Glutamine
PT67 : Packaging cell line Obtained from Clontech
(California, USA)
NIH/3T3 based cell line expressing 10A1 viral
envelope protein
DMEM (Sigma)
2mM L-Glutamine (Sigma)
10% Heat Inactivated (H.I.) Foetal Bovine Serum
(Sigma)
Penicillin (100U/ml) and streptomycin (100µg/ml)
All stock cells were obtained from liquid nitrogen storage. The cells were submerged
in a 37qC water bath to ensure complete thawing. Cells were transferred to 25ml
universal tubes and 1 ml of complete media, cell specific, was added drop-wise to the
cells under agitation. A further 5ml of complete media was added slowly to the tubes
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whilst gentle agitation was applied. The volume was then increased with complete
media to 25ml and the tubes were centrifuged at 1200 rpm for 5 minutes at room
temperature. The supernatant was aspirated from the cell pellets which were
resuspended in complete media. All cells were then washed with complete media and
finally resuspended in media and transferred to T25 tissue culture flasks (Corning).
All cells were cultured at 37qC in 5% CO2 and were maintained by regular
replacement of complete culture media and splitting to maintain log phase growth.
If large cell numbers were required, cells were transferred to T175 culture flasks.
Cells were cultured until approximately 80% confluency was reached, at which point
they were split in order to maintain healthy cultures. Supernatant was aspirated from
adherent cell lines and replaced with 10ml 1 x Trypsin/EDTA (Sigma) and incubated
for 10 minutes at 37qC. Non- adherent lines were transferred to 50ml tubes and
centrifuged at 1200 rpm for 5 minutes. Trypsinised cells were transferred to 25 ml
universal tubes and complete media was added up to 25ml total volume (Serum
contained in the media inactivates trypsin activity). Tubes were centrifuged at 1200
rpm for 5 minutes at room temperature and all supernatants were aspirated from the
pellets. Cells were resuspended in 10 ml of complete media and 1ml was transferred
to a new flask and the cells were maintained
Cells which were to be used in experimental procedures are counted using a
haemocytometer with trypan blue (Sigma), staining for viability assessment and used
as stated. Some cells were frozen in order to maintain stocks and were resuspended at
5 x 10
6
cells/ml in 8% DMSO (Dimethyl Sulfoxide) / FCS (v/v) and 1ml was added
per cryovial (Nalgene, USA). Vials were frozen by reducing the temperature by 1qC
per minute to a temperature of -80qC by placing the vials in isopropanol containers, at
which point cells were transferred to liquid nitrogen storage (-270qC).
2.2.2 Puromycin antibiotic selection kill curve
An antibiotic resistance kill curve was set up determine the minimal concentration of
puromycin required to kill un-transfected CHO (Chinese Hamster Ovary) cells. 2 x
10
5
cells were seeded into six 100mm x 20mm cell culture dishes (Corning, NY,
USA) and 10ml DMEM, 10% FCS was added per plate. Puromycin (Sigma) was
added at varying concentrations: 0, 2.5, 5, 7.5, 10 and 12.5Pg/ml. The cells were
incubated at 37qC for 10 days and the selective media was replaced every three days.
55
Cell viability was observed in order to assess the minimal concentration required to
induce massive cell death at 5 days leading to complete cell death within two weeks.
10Pg/ml was determined to be the optimal selection concentration for this cell line
and was then used during antibiotic selection of pApex DNA transfected cells.
2.2.3 G418 Sulphate antibiotic selection kill curve
2 x 10
5
CHO-SF cells were cultured in 10cm cell culture dishes in 10ml of SF media
containing titrated concentrations of G418, 0, 50, 100, 200, 300, 400 500, 600, 700,
800, 900, and 1000 µg/ml. Cells were cultured for two weeks replacing medium
every three days to remove non-viable cells. 500µg/ml antibiotic selection produced
100% killing of cultured cells post two week culture while 600µg/ml concentration
prevented normal cell growth. 500µg/ml was chosen as optimal antibiotic
concentration to maintain selective pressure on G418 resistant Signal pIgplus
transfected cell lines.
2.2.4 Lipofectamine plus transfection of cells with plasmid DNA
Target cells were harvested and 1 x 10
5
cells were re-seeded per well in a 6 well tissue
culture plate (Corning). 5 ml of cell specific media was added per well and the cells
were incubated overnight at 37qC in order to obtain approximately 60-80%
confluency at the time of transfection. The DNA was pre-complexed by mixing
1.5Pg DNA [pApex-3P vector containing wild-type DAF (CD55) sequence donated
from Bruce Loveland (Austin Research Institute, Heidelberg, Australia)] or respective
plasmid, in 100Pl of serum free media, with lipofectamine, (Invitrogen, Paisley, UK),
8Pl diluted in 100Pl serum free media, and incubated for 15 minutes at room
temperature. Four separate DNA concentrations are used to determine optimal
concentration for high expression levels (0.5-2.0Pg DNA). The transfection
liposomal/DNA complex was mixed with 800Pl of serum free media. Cells were
washed with serum free media and incubated with the lipofectamine complex for 16
hours at 37qC with 5% CO2. 5ml cell specific media containing 10%FCS was added
to the cells and incubated overnight at 37qC. Fresh media was applied to the cells
which were continually cultured for a further 48hours. The media was again changed
with the addition of plasmid specific antibiotic (10Pg/ml puromycin for Apex
plasmid). Antibiotic selection maintains growth of successfully transfected cells
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expressing the relative antibiotic resistance gene. The cells were grown for several
days under continuous selective pressure (as assessed by antibiotic kill curve analysis
for each cell line) and assessed by flow cytometry using BRIC 216 [Anti-CD55
(SCR3 specific)], for expression of CD55 or via ELISA screening of cell supernatant
for the presence of expressed protein.
CD55 positive cell clones were expanded, under selective pressure, and sorted by
FACS with the aid of Dr. Adrian Robbins, University of Nottingham. High expressing
clones were then utilised for immunisation. Figure 2.1 displays vectors with their
respective antibiotics.
Figure 2.1: Summary of vectors and their appropriate antibiotic selection
Plasmid Antibiotic resistance
pApex-3P Puromycin
Signal pIgplus G418
pLXSN retroviral vector G418
2.2.5 Calcium phosphate transfection of cells with plasmid DNA
The ProFection mammalian transfection system (Promega) was used as per the
manufacturer’s guidelines as an alternative to liposome based transfection protocols.
1 x 10
5
cells were seeded with 4ml of culture media into each well of a six well tissue
culture plate. Plates were then incubated at 37qC with 5% CO2 for 16 hours until cells
reached between 50 and 80% confluency.
2 hours prior to cell transfection culture media was aspirated and replaced with fresh.
Kit components, 2M calcium chloride, endonuclease free water and 2 x hepes
buffered saline (HBS) were all thawed at room temperature. 6µg of plasmid DNA
was combined with 112µl of sterile deionised water, and 18µl of 2M calcium chloride
was vortexed with 150µl of 2 x HBS in a 1.5ml eppendorf tube. Then the DNA and
CaCl2 solutions were mixed drop-wise before incubating the combined solution for 30
minutes at room temperature. The transfection mixture was again vortexed prior to
addition to target cells, drop-wise, gently swirling the plates. The cells were then
incubated for 3 hours at 37C with 5% CO2. The cells were then washed in sterile PBS
and again in complete cell culture media. The cells were then fed with 4ml complete
media and incubated at 37qC with 5% CO2 for 48 hours. Appropriate antibiotic was
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then applied to the cells for selective expansion of successfully transfected cells.
Selection was maintained, changing media every three days for a further 14 days to
establish stable transfected lines.
Transfection efficiency can be increased by the addition of 25µM chloroquine to the
DNA/CaCl2/HBS transfection mixture. A glycerol shock procedure may also be
incorporated into the protocol, although particularly sensitive cells may be critically
damaged. Following the three hour incubation with the transfection reagents, cells
can be washed in PBS and then 1ml of 15% glycerol (in HBS) added for 2 minutes.
This solution is then aspirated and cells washed in HBS prior to addition of complete
media and cells incubated as standard. As an alternative to glycerol, 10% DMSO
diluted in PBS can be used for the same duration.
2.2.6 Transfection of eukaryotic cells with E-galactosidase
As a control experiment for the determination of optimal transfection conditions
specific to cell types, a E-galactosidase expressing plasmid can be used for the quick
determination of successful protocols. The standard transfection methods can be used
varying incubation times and DNA concentration. 48 hours following the transfection
protocol cells are fixed by incubating cells with 2ml of 4% paraformaldehyde (Sigma)
diluted in PBS, at 4qC for 5 minutes. Cells are then washed twice in cold PBS prior
to enzyme activity assessment by the addition of 2ml Xgal staining solution and
incubating the cells at 37qC with 5%CO2 for between 30 minutes and 34 hours. Cells
successfully transfected with the E-galactosidase plasmid will stain blues and can be
visualised by light microscopy. Transfection efficiency can be calculated by counting
all the cells in a viewed area, noting the number of positive, blue, cells. Efficiency is
calculated as a percentage of positive cells within the total cell population.
X-gal staining solution contains 1 volume of x-gal stain [20mg/ml X-gal in
dimethylformamide (DMF)] and 19 volumes of X-gal buffer (80mM Na2HPO4,
20mM NaH2PO4, 1.3mM MgCL2, 3mM K3FeCN6 and 3mM K4FeCN6). The staining
buffer is then 0.2 micron filter sterilised prior to use. All components are obtained
from Sigma.
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2.2.7 Viral transduction of eukaryotic cells
The retro-X transduction system (Clontech, BD biosciences, Palo Alto, CA, USA)
utilises the production viral particles expressing the desired DNA sequence for high
efficiency transduction of target cell lines.
The PT67 packaging cell line, which is able to package retroviral RNA’s into
infectious particles without the concomitant production of replication-competent
virus, was transfected with the pLXSN retroviral vector into which had been cloned
the full length CD55 DNA sequence. Successful transfected cells were cultured under
G418 antibiotic selective pressure. Transfected PT67 cells express infectious
replication incompetent retroviral particles containing the CD55 sequence into the cell
culture supernatant.
Retroviral procedures were carried out in a designated laboratory within a class II
safety cabinet, adhering to bio-safety level 2 guidelines.
2 x 10
5
PT67 cells were seeded onto 100mm tissue culture plates with 10ml of 10%
FCS, 1% penicillin and streptomycin in DMEM media the day prior to transfection.
Medium was aspirated and replaced with 10ml of fresh two hours prior to the
transfection procedure. All transfection reagents, 2M calcium chloride, endonuclease
free water and 2 x HBS were all thawed at room temperature. 10µg pLXSN/CD55
DNA was combined with 418µl of sterile deionised water, 62µl of 2M CaCl2 and
500µl of 2 x HBS were combined in an eppendorf and vortexed. The DNA and CaCl2
solutions were combined (DNA drop-wise to salt solution) and the mixture was
incubated at room temperature for 30 minutes. The transfection mixture was vortexed
prior to the drop-wise addition to the target cells, which were then incubated at 37qC
with 5%CO2 for 16 hours. The cells were then washed twice in complete media,
which was then replaced with 10ml of complete media and the cells were incubated
for a further 48 hours at 37qC. 500µg/ml of G418 antibiotic was then added to the
cells in fresh media and the culture was maintained for a further 14 days, regularly
replacing the culture media with fresh. Selective pressure was maintained in order to
produce a stable transfected cell line. Antibiotic selective pressure was removed
following the 14 day culture and cells were re-seeded in T175 tissue culture flasks
with 50ml of complete media. The cells were grown for a further 48 hours to enable
collection of virus particles within the culture supernatant. The collected supernatant
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was collected and passed through a 0.45µm polysulphonic filter and polybrene
(Sigma) was added to the supernatant at a concentration of 4µg.ml.
The day before transduction, 7 x 10
5
target cells were seeded into 100mm tissue
culture plates with 10ml of complete culture medium and incubated for 16 hours at
37qC with 5% CO2. The target cells were overlaid with viral supernatant and
incubated for 12 hours at 37qC with 5% CO2. The supernatant was aspirated from the
target cells and the media was replaced with viral supernatant and incubated for a
further 12 hours. The supernatant was aspirated and replaced with cell specific
complete culture media and incubated for 48 hours at 37qC with 5% CO2. G418
antibiotic was then applied for selection of successfully transduced cells. 600µg/ml
was determined as the optimal concentration for use with Colo 205 cells.
2.2.8 Analysis of CD55 expression
Expression of CD55 by transfected or transduced cell lines was assessed by indirect
labelling of cells with CD55 specific antibodies and analysed via flow cytometry. 5 x
10
5
cells were labelled and analysed per sample and all experimental procedures were
completed in triplicate. 791T, Colo205 and CHO DAF cells were labelled with 100Pl
of 5Pg/ml primary antibodies or 100Pl diluted serum (1/1000 and 1/10000) or 50Pl
hybridoma supernatant. Controls were set up as unlabelled cells and cell without
primary antibody. All samples were incubated for 1 hour at 4qC (on ice), and then
samples were spun at 13000 rpm for 20 seconds to form a cell pellet. Cells were
resuspended in 300Pl of PBS and this wash process was repeated 3 times. Cells were
then resuspended in 400Pl secondary antibody [1/400 FITC-conjugated rabbit anti-
mouse antibody (DAKO, A/5 Denmark)] diluted in PBS. Cells were incubated for 1
hour at 4qC and cells were then washed 4 times in PBS. The labelled cells were then
resuspended in 300Pl of 1 x Cellfix (BD Biosciences, Sunnyvale Ca. USA),
containing 1% paraformaldehyde. Cells were either read immediately on the
FACScan (Becton Dickinson), or stored overnight at 4qC and read the following day.
For flow cytometry analysis, cells were transferred to FACS tubes (BD).
2.2.9 Flow Cytometry
Fluorescein (FITC) is excited at a wavelength of 488nm and collected via a 10nm
bandwidth pass filter FL-1 (detection maximum = 518nm). Before samples are read,
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forward and side scatter are set at the correct voltages in order to view them in a
scatter plot. Utilising unlabelled cells, a main population can be gated so that out-
lying, dying or uncharacteristic, cells will be excluded from sample data. The
voltages are set so that unlabelled cells produce a mean linear fluorescence value of
10 on a log scale. This value of M.L.F is calculated by determining the average
fluorescence emitted by each cell compared to a total count of 5000 cells. This value
is then said to be the auto-fluorescence of the cell populations, allowing comparison
with cells possessing bound, labelled antibody on their surface. The FACScan
(Becton Dickinson) is then used to measure the M.L.F values of experimental Cell
samples and the results are displayed and analysed on CellQuest software on an Apple
Macintosh

computer.
2.2.10 Standard binding analysis of cell surface markers
Standard indirect or direct labelling of cells was achieved by following the protocol as
stated in section 2.2.8. Primary antibodies are coated onto target cells and FITC
conjugated secondary are bound to the primary for analysis by flow cytometry.
2.2.11 Isolation of CD55 expressing cells
Cells were sorted into sub populations at the Department of Immunology, Queens
Medical Centre, Nottingham by Dr Adrian Robins using the EPICS Altra flow
cytometer (Coulter). 1 x 10
7
cells to be sorted were labelled as per section 2.2.8 and
were resuspended in 10ml of PBS. The flow cytometer was then used to analyse the
cells and relative levels of expression were identified. With the cytometer, cell
populations expressing the greatest levels of CD55 were gated and collected. These
cells were then washed in media and re-seeded on tissue culture flasks.
2.2.12 Isolation and cloning of cells transfected for protein/antibody production
Transfected cells were occasionally difficult to maintain for stable production of
recombinant proteins or confirmation of expression for clonal expansion was
required, as in the case of hybridoma production. Cells were washed in complete
media and seeded in 96 well plates at titrating concentrations to obtain single cells per
well. These cells were then cultured at 37qC with 5% CO2 for the successful
expansion of monoclonal cell populations. Cells were cultured for approximately 5
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days and were then directly harvested or supernatants collected for assessment via
FACscan binding assay or by ELISA protein assessment. Positive cells were then
transferred to 6 well tissue culture plates before re-assessment and transfer to flasks
for large-scale production.
2.2.13 Production and purification of recombinant proteins and antibodies
Eukaryotic cells successfully transfected with DNA constructs (plasmids), were
cultured in complete cell specific media containing antibiotics specific to the plasmid
present, in order to maintain selective pressure until a stable line is produced.
Optimal antibiotic concentration was previously determined through the use of
relative antibiotic kill curve analysis. Successful transfectants and protein expression
was determined via ELISA screening of cell supernatants (section 2.3.4), and positive
cells were re-seeded in T75 culture flasks. Selective pressure was maintained and
cultures expressing the greatest levels of protein were transferred to T175 flasks, for
large scale protein production. CHO SF cells were cultured in 100ml of complete
media (serum free) at 37qC with 5% CO2, every four to five days cells were
harvested, supernatant pooled and 0.2micron filtered (stored at 4qC) and cells re-
seeded. Cell stocks were made (Section 2.2.1) and stored at -80qC.
Culture supernatant containing expressed protein was stored until sufficient quantities
were obtained for purification (~1 litre). Protein A Sepharose columns (Invitrogen,
,UK) were used to bind the protein via the human IgG (Fc) tail and were also used to
purify murine antibodies. A standard glycine release protocol was followed for
antibody and protein purification. Figure 2.2 displays standard protein purification
reagents.
Figure 2.2: Reagent composition for protein purification
Reagent Composition
100mM Glycine –HCL pH 2.7 0.75g of Glycine
100ml of distilled water
Adjust pH to 2.7 with 5M HCL
1M Tris-HCL 0.303g of Tris base
25ml distilled water
Adjust pH to 9 with 5M HCL
Na2HPO4 (Buffer A) 3.04g Na2HPO4
100ml of distilled water
NaH2PO4 ( Buffer B) 2.76g of NaH2PO4
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100ml of distilled water
Buffer C (20mM) Add buffer B to buffer A until pH = 7.4
All components obtained from Sigma, UK, and all reagents 0.2micron filter sterilised.
10ml of buffer C ran over protein A column at speed of 1ml per minute to equilibrate
column at 4qC (flow mediated with the use of vacuum pump) . Supernatant
containing either antibodies or recombinant protein was then ran over the column at
4qC at a speed of 1ml per minute for a duration long enough to allow complete
cycling of media at least two times through the protein A sepharose. 50ml of buffer C
was then passed over the column to remove residual supernatant and balance the pH.
A 500µl sample of run off buffer C was kept to determine whether any protein was
lost during the wash procedure. 20ml of glycine was slowly added, preventing
disruption of the protein A, and allowed to run through the column at 1ml per minute.
1ml fractions of eluted protein and glycine were collected in 1.5ml eppendorf tubes
containing 100µl of Tris-HCL. 20ml of buffer C was then ran over the column to
equilibrate the column and if the column was to be stored PBS containing 0.05%
sodium azide was applied to the protein A prior to storage at 4qC. The collected
samples were analysed by spectrophotometry and protein concentrations were
determined by reading optical density readings at 280nm, blanked against a sample
containing Tris-HCL and glycine. The samples containing protein were pooled and
injected into a Slide a Lyze cassette (Pierce), which was placed in 500ml of sterile
PBS and samples were dialysed at 4qC for 16 hours. Purified protein was then
quantified by spectrophotometry and BCA protein assay (section 2.2.14) and assessed
for viability via ELISA screen (section 2.3.4).
2.2.14 BCA protein quantification assay
Protein concentration was determined via spectrophotometric analysis, reading
absorbance values of diluted samples at a wavelength of 280mn. Concentrations were
confirmed using the BCA protein assay reagent kit (Pierce, Rockford, Illinois, USA)
following manufacturer’s guidelines. A standard curve was set up using 10 serial
dilutions of BSA (bovine serum albumin) diluted in PBS. 10µl of protein samples
and BSA standards were transferred to a 96 well plate, in triplicate and working
reagent was prepared, combining 400µl of 4% copper II sulphate with 9.6ml
bicinchoninic acid. 200µl of the working reagent was added to each well and the
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plate was incubated at 37qC for 30 minutes. The plate was agitated and absorbance of
samples was measured at 550nm. A standard curve of BSA concentration versus
O.D. measurements was plotted and values extrapolated for test protein samples.
2.3 Antibody, sera and protein assessment
2.3.1 Standard enzyme linked immunosorbent assay (ELISA)
Buffer Composition
Blocking buffer 1% bovine serum albumin (BSA) diluted
in sterile phosphate buffered saline PBS
Wash buffer 0.05% Tween 20 in PBS
Antibody buffer 0.1% BSA in wash buffer
Citrate phosphate buffer 4.53g citric acid
4.06g sodium hydrogen phosphate
Make up to 500ml in distilled water and
adjust to pH 4.0
ABTS developing solution
(2, 2’-azino-bis (3-ethylbenthiazoline-6-
sulfonic acid)
66µl ABTS
13µl hydrogen peroxide
5 ml citrate phosphate buffer
Reagents supplied by Sigma Aldrich
2.3.2 Screening of Sera from peptide and purified CD55 immunisations via
ELISA
Peptides and carriers (Ovalbumin and BSA) were diluted to 1mg/ml concentration in
PBS and the two solutions were mixed together. Glutaraldehyde (Sigma) was added
to a total volume concentration of 0.2%. The solution was mixed at room temperature
for one hour and then dialysed twice against PBS in a ‘slide-a-lyzer’ cassette (Pierce).
Conjugated peptides and purified CD55 were used to coat 96 well plates at a
concentration of 5Pg/ml (diluted in PBS), 100Pl per well, all wells were performed in
triplicate. Plates were incubated at 4qC overnight and peptide was flicked from
plates, which were washed two times with PBS 0.1% Tween-20
[(Polyoxyethylenesorbitan monolaurate) (Sigma)]. Plates were blocked with 5%
(w/v) Bovine Serum Albumin (Sigma; Basingstoke, UK) in PBS tween, 100Pl per
well and incubated for 1 hour at room temperature. Blocking solution was flicked
from plates, which were then washed 3 times in PBS tween. 100Pl of primary
antibody were added per well (diluted serum 1/100, 1/1000, 1/5000, 1/10000,
1/100000 or 5Pg/ml commercial antibody (Table B). For positive control of peptide
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ELISA, 5Pg/ml 105/AD7 antibody used to coat plate and 791T/36 antibody used as
primary. Plates were incubated for 1 hour at room temperature and plates were
flicked and wells washed 3 times with PBS tween. 100Pl per well of secondary
horseradish peroxidase conjugated anti mouse antibodies were added (1:400 PBS) and
incubated for 1 hour at room temperature. The plates were washed 5 times in PBS
tween and 100Pl per well of ABTS (2, 2’-azino-bis (3-ethylbenthiazoline-6-sulfonic
acid) (Sigma) substrate was added, which emits green light at a wavelength of 405nm.
This substrate system requires 15ml of buffer containing 40mM Citric acid and
30mMNa2HPO4 at pH 4.0, with 0.08% H2O2 and 200Pl ABTS. Plates were incubated
for 15 minutes at room temperature prior to optical density analysis on a plate reader
(Life Sciences, Basingstoke, UK).
2.3.3 Whole Cell Elisa
791T and Colo 205 cells were removed from culture flasks by incubation with 10ml
Trypsin/EDTA (Sigma) for 10 minutes at 37qC. Suspended cells were then washed
with complete media, centrifuged 1200 rpm for five minutes and supernatant was
aspirated away and cells resuspended in appropriate volume of media for counting. 5
x 10
4
cells were added per well on a 96 flat bottom plate in a total volume of 100Pl
complete media. Plates were incubated at 37qC overnight. Media was aspirated off
and cells were fixed with 100Pl/well 0.5% gluteraldehyde (Sigma) in PBS for 15
minutes at 37qC. Cells were washed 2 times in PBS (100Pl per well) and blocked
with 100Pl per well 5% BSA. Protocol continued as for peptide screen.
2.3.4 ELISA screen of SCR 1-3 Fc recombinant protein
Screening for the presence of recombinant protein within the supernatant of
transfected cells was used to determine the success of transfection protocols and
continually, for assessment of continued protein production in stable lines. 96 flat
well plates were coated with 100µl of 5µg/ml CD55 specific antibodies BRIC 216
and 791T/36. Plates were incubated for 16 hours at 4qC to enable optimum binding.
Plates were then washed three times in wash buffer and 100µl of cell supernatant was
added in triplicate samples. Control wells were set up omitting primary antibodies.
Plates were incubated for 1 hour at room temperature, supernatant discarded and
plates washed three times with buffer. 100µl of 1/1000 dilution of goat anti human
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(Fc specific) antibodies conjugated to horse radish peroxidase were added to all wells
and plates incubated for 1 hour at room temperature. Antibody was again discarded
and wells were washed five times with appropriate buffer. Plates were blotted dry
and 100µl ABTS developing solution was added per well. Plates were developed in
the dark for 15 minutes at room temperature and then analysed by reading the optical
density at 405nm on an Anthos htII plate reader (Anthos Labtec Instruments,
Salzburg, Austria).
2.3.5 Analysis of antibody responses generated in response to DNA immunisation
Assessments of murine antibody responses to DNA immunisation were required to
obtain the titre of responses generated and the relative specificity. Early analysis of
ELISA experiments following standard protocols indicated that direct coating of
plates with recombinant protein significantly reduced binding of CD55 specific
antibodies. Therefore, a capture assay protocol was developed utilising a primary
well coat of goat anti human Fc antibody in order to orientate the recombinant
protein. 100µl of 5µg/ml anti-human IgG Fc specific antibody was added per well on
a 96 flat bottom plate and incubated for 16 hours at 4qC. Plates were washed in
appropriate buffer three times and 100µl of blocking buffer was added per well and
incubated for a further 16 hours at 4qC. Blocking solution was discarded and plates
were washed in wash buffer three times and flicked dry. CD55 Fc fusion protein was
then bound to the plates by the addition of 100µl per well of 5µg/ml of target protein.
For specificity assessment, 100µl of 5µg/ml of human IgG antibodies (Sigma) were
also added per well as an assessment of anti-human Fc responses (control wells) with
the total anti sera. Plates were then incubated for 1 hour at room temperature and
excess protein removed. Plates were again washed in buffer and flicked dry. Serial
dilutions of anti-sera were prepared at concentrations of 1/100, 1/1000, 1/5000 and
1/10,000, dependent upon the total volume of sera available, diluted in sterile PBS.
100µl samples were added to wells, in triplicate, and incubated at room temperature
for 2 hours. CD55 specific antibodies (791T/36 and BRIC 216) were used as positive
controls and background recognition was assessed with the use of sera from syngeneic
un-immunised mice. Sera were discarded and plates washed in appropriate buffer
five times and plates were flicked dry. Rabbit anti mouse HRP conjugated antibody
(DAKO, Glostrup, Denmark) was used at a dilution of 1/1000 (PBS) and 100µl were
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added per well. Plates were then incubated for 1 hour at room temperature before
washing all wells with buffer five times to successfully remove non specific
peroxidase activity. The ABTS substrate system was used for detection of activity
and plates were analysed at 405 nm as per standard ELISA protocol.
2.3.6 Assessment of antibody isotype ratios developed in response to DNA
immunisation
The principle for this assessment was based on the antibody screen ELISA protocol
(section 2.3.4). To incorporate the difference in relative affinities of antibody
isotypes, a standard curve was developed incorporating CD55 specific IgG1 and IgG2a
isotype antibodies. The standard Fc capture ELISA (section 2.3.5) was utilised and
BRIC 216 and IA10 clone antibodies were serially diluted at concentrations of 10, 1,
0.03, 0.01, 0.003, 0.001, 0.0003 and 0.0001µg/ml and 100µl per well of these were
applied to the orientated SCR 1-3Fc fusion protein. Plates were then incubated for 1
hour at room temperature prior to three washes in appropriate buffer. Plates were
flicked dry and goat anti- mouse HRP conjugated antibodies (Serotec), specific to
mouse IgG1 and IgG2a, were added at 1/1000 dilution, 100µl per well and plates were
incubated for 1 hour at room temperature. Results for the assay were carried out
following standard procedures using the ABTS substrate system. Absorbance
readings at 405nm were then plotted against antibody concentrations for the
production of a CD55 specific, isotyped antibody standard curve. The standard curve
was then utilised to extrapolate values for assessed serum obtained from immunised
mice. Mouse sera were screened as per section 2.3.5, using diluted sera at
concentrations of 1/100, 1/1000 and 1/5000 (all in triplicate). The sera screen was
changed by the addition of goat anti mouse isotype specific HRP conjugates, as for
the standard curve. Plates were developed and analysed as per standard ELISA
development.
2.4 Peptide Immunisations: Development of monoclonal antibodies
2.4.1 Isolation of splenocytes
Mice are sacrificed as per schedule 1 protocol (cervical dislocation) and sprayed with
70% ethanol to sterilise working area. Using several sets of sterile dissecting
instruments, the spleen is removed from the mouse, excess fat and connective tissue is
67
removed and the spleen is transferred to a sterile 100 mm Petri dish. 5ml of serum
free RPMI 1640 is added to the dish and the spleen is washed with the media using a
syringe and 25-guage needle. The media is passed through the spleen several times
and finally the spleen is homogenised with sterile forceps. The homogenate is passed
through sterile gauze into a universal 25ml tube, total volume is increased to 25 ml
with serum free RPMI, and the tube is centrifuged at 1000rpm for 10 minutes. The
media is aspirated off, leaving approximately 1ml remaining in the cone of the tube,
and cells are resuspended in 5 ml serum free media and counted using trypan blue
(Sigma, UK).
2.4.2 Collection of large quantities of sera from immunised and naïve mice
Cardiac blood was collected using insulin syringes [microfine 11-100 insulin 12.7mm
syringe, 1ml capacity (Becton Dickinson, France)] at the time of splenocyte
collection.
2.4.3 Collection of Rat Peritoneal Exudate Cells (PECs)
Rat peritoneal exudate cells are used as growth support for hybridoma development,
supplying growth factors and allowing presence of macrophages to remove any cell
debris. A rat is sacrificed as per schedule 1 protocol and using a 20ml syringe and a
27 gauge needle, 20ml of RPMI 1640 media (Sigma, UK) is injected into the
peritoneal cavity. The media is aspirated to collect PE cells from within the cavity,
the media is withdrawn and cells are collected by centrifugation for 5 minutes at
1200rpm. The cells are resuspended and seeded over a 96 well, flat bottom plate at 2
x 10
5
cells per well. The rat PECs are placed in 200Pl total volume RPMI 1640
containing 10% foetal calf serum (Sigma, UK), and grown for approximately 5 days
at 37qC, 5% CO2.
2.4.4 Fusion of Mice splenocytes with NSO myeloma cells
Mice producing the highest sera titres are chosen to generate antibody-producing
hybridomas.
NSO cells are harvested, resuspended in serum free RPMI and counted for fusion with
splenocytes. Cells are combined in a ratio of 1: 5 (NSO: Splenocytes) eg. (2 x 10
7
: 1
x 10
8
) in a universal tube and centrifuged for 5 minutes at 1200rpm. The supernatant
is aspirated off and the combined cell pellet is resuspended in 800Pl PEG
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[Polyethylene Glycol (Sigma, UK)], gradually over 1 minute. The PEG breaks the
lipid membranes and allows fusion of the cell populations. The cells are agitated for 1
minute and then 1 ml of serum free RPMI 1640 is added over 1 minute while
continuing to agitate. A further 5ml of S/F media is added to the cell suspension over
a minute while continuing to agitate and finally the volume is slowly increased to
25ml with S/F media. The suspension is centrifuged for 5 minutes at 1200rpm and
the supernatant is removed. The cells are resuspended in15ml hybridoma media
[RPMI 1640, 10%FCS plus HAT supplement) Hypoxanthine Aminopterine
Thymidine)], Sigma, UK. The cell suspension is spread evenly across a 96 well plate,
containing rat PECs, and the cells are incubated at 37qC for approximately 8 days, by
which time successful hybridomas should begin to have grown through. Cells are re-
fed approximately every two days with fresh hybridoma media. Following 8 days
supernatants can be collected and analysed for the presence of antibodies. Positive
wells are harvested, washed in complete media and spread across 96 well plates in
order to generate a monoclonal population of antibody positive clones.
2.5 General experimental procedures
2.5.1 Obtaining Normal Human Serum (NHS)
10ml of blood were collected from a minimum of three healthy donors in non-
heparinised vacutainers (BD Biosciences, UK). Whole blood was stored at 4qC
overnight to allow clotting of erythrocytes. Serum was withdrawn and pooled in a
universal tube and centrifuged at 1500 rpm for 10 minutes in order to remove any
remaining cells. Serum was again pooled and stored in 500ȝl fractions at 4qC for no
longer than 2 weeks prior to use in complement deposition assays.
2.5.2 Complement Deposition Assay
Target cells (791T), were harvested and washed in complete media and PBS twice.
Cells were resuspended in 1 ml of PBS and counted using a haemocytometer, and
resuspended at a concentration of 1 x 10
6
/ml. 300ȝl were then used per test sample
(later to be divided into triplicate) and transferred to eppendorf tubes and primary
antibodies were added at a concentration of 50ȝg/ml diluted n PBS. BRIC 216 and
BRIC 220 (IBGRL) and 791T/36 were used as control antibodies to specific domains
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of CD55. 100ȝl of hybridoma supernatant also added as test antibodies per sample
(300ȝl added as to be split into triplicate). All tubes were agitated and incubated for 1
hour at 4qC. Control tubes also set up including completely unlabelled cells and
complete range of samples with primary antibodies, which will not be exposed to
complement. All tubes were centrifuged at 13000rpm for 20 seconds and supernatant
aspirated from the cell pellets. Pellets were resuspended in 300Pl of PBS and the
centrifugation step was repeated. Cell pellets were then resuspended in 300Pl of
either 5% NHS (v/v in PBS) or PBS alone. Cells were then split into triplicate with
100Pl total volume per sample. Cells were agitated and then incubated at 37qC for 2
hours, agitating briefly every 30 minutes. All tubes are centrifuged at 13000rpm for
20 seconds and then supernatants are aspirated from the cell pellets which are again
resuspended in 200Pl of PBS. This washing step is repeated a further two times with
cold PBS. The cell pellets are then resuspended in 100Pl 1/100 (v/v in PBS)
polyclonal rabbit anti- human FITC conjugate (Dako, Denmark). The tubes are
agitated and incubated at 4qC for 1 hour. Cells are washed a further three times with
PBS before being resuspended in 200Pl 1% cellfix (BD Biosciences, UK). Cells are
stored at 4qC until they are to be assessed by FACScan.
2.5.3 SDS PAGE (Polyacrylamide gel electrophoresis)
The Miniprotean 3 gel kit (BioRad) was utilised for all SDS-PAGE following the
manufacturer’s guidelines. Glass back plates and cover plates were cleaned with 70%
ethanol and once in acetone (Fisher Scientific) prior to being clamped into the gel-
casting frame. 10ml of resolving gel was prepared and Acrylamide percentage was
determined relative to the size of proteins to be electrophoresed. Ammonium
persulphate and TEMED were applied to the solution immediately prior to application
to the glass plates as it is this combination which catalyses the production of ions that
cause the gel to polymerise. The solution was then applied between the plates,
leaving approximately 2cm at the top of the plates for the stacking gel. 100µl of
butanol was added to the surface of the gel, which was then left for 20 minutes to set.
2 ml of stacking gel was prepared, again leaving the addition of TEMED and APS
until ready for application to the plates. The butanol was poured from the resolving
gel and the surface was washed with distilled water, blotting residual water from the
surface with blotting paper. The resolving gel was completed and applied to the
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plates, inserting a clean well comb (containing the appropriate size and number of
wells). Again the gel was allowed to solidify. The comb was removed and the wells
washed with distilled water prior to transfer of the plates to the electrophoresis
chamber. The central stage of the chamber was filled with running buffer and the
external section was filled with enough buffer to cover a quarter of the plates.
Samples to be electrophoresed were added to loading buffer in a 1:1 ratio, either
reducing or non-reducing dependent upon protein analysis, and samples were
denatured by a boiling step, heating to 95qC for 5 minutes. When a standard 10 well
comb is utilised, 15µl of sample is loaded into the wells, along with 10µl of
kaleidoscope pre-stained standards (BioRad) and if western blot analysis of proteins
was to be carried out, 2µl of broad range biotinylated markers (BioRad), mixed with
2µl of reducing sample loading buffer, was also loaded into one well. All samples
undergo the boiling procedure. A current of 40mA (powerpac 300, BioRad) was then
applied to the electrophoresis chamber and allowed to run for approximately 1 hour or
until the protein bands had sufficiently separated.
When proteins were to be assessed directly post electrophoresis, the gel was removed
from the glass plates and the stacking gel was cut from the resolving gel section. The
proteins were then fixed within the gel, to prevent diffusion, by coating the gel with
fixative solution for a minimum of 30 minutes on a shaking table. Proteins were then
visualised by the addition of Coomassie stain for a minimum of 2 hours, placed on a
shaking incubator. Background stain was removed from the gel by treatment with de-
stain solution for a minimum of 2 hours, placed on a shaking table. The protein gel
was then washed in distilled water and 1% glycerol for 10 minutes on a shaking table.
The gel was then dried in film. Figure 2.3 displays standards SDS PAGE reagents.
Figure 2.3: Standard reagent composition for SDS PAGE
Solution Components
1.5M Tris-HCL pH 8.8 54.4g Tris base in 200ml of distilled
water. Adjust pH to 8.8 with
concentrated HCL. Make total volume
up to 300ml with distilled water
0.5M Tris-HCL pH 6.8 12.1g Tris base in 150ml of distilled
water. Adjust pH to 6.8 with
concentrated HCL. Make total volume
up to 200ml with distilled water
10% (w/v) Sodium dodecyl sulphate
(SDS)
5g of SDS in 50 ml of distilled water
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10% (w/v) Bromphenol blue 1g of bromophenol blue in 1ml of
distilled water
SDS-PAGE loading buffer 4.2ml distilled water
1ml 0.5M Tris-HCL pH6.8
0.8ml glycerol
1.6ml 10% (w/v) SDS
+/- 0.4ml E2-mercaptoethanol
(Reducing/Non reducing)
0.02ml 10% (w/v) bromophenol blue
10% (w/v) Ammonium persulphate
(AMPS)
0.1g of AMPS in 1ml of distilled water
Use Immediately
SDS-PAGE running buffer (1x) 15g of Tris base (25mM)
72g glycine (192mM)
5g SDS (0.1% w/v)
Make up to 5 litres with distilled water
Transfer buffer 15g Tris base (25mM)
72g Glycine (192mM)
Make up to 4 litres with distilled water
Add 1000ml methanol (20% v/v)
Tris buffered saline (TBS) pH 7.6 20ml 1M Tris HCL pH 7.6 (20mM)
8g Sodium chloride (137mM)
Make up to 1000lml with distilled water
TBS-Tween (TBS-T) (wash buffer) 0.05% (v/v) Tween 20 in TBS
30% acrylamide solution Obtained from Severn Biotech Ltd,
Kidderminster, UK
TEMED Neat solution
All chemical components obtained from Sigma Aldrich.
2.5.4 Western Blotting
The anode (base plate) of the western blotter (Transblot SD, BioRad) was soaked with
western transfer buffer). For each gel to be transferred to nitrocellulose membrane
(Hybond C, Amersham Life Science), six pieces of filter paper and one piece of
membrane matching the dimensions of the resolving gel were cut and also soaked in
transfer buffer. Three layers of filter paper were placed on the anode with one piece
of membrane placed on top. A resolving gel containing unstained electrophoresed
protein samples was washed in western transfer buffer and then placed on top of the
nitrocellulose membrane noting the correct orientation. All proteins run are of net
negative charge and will move towards the anode. A further three pieces of soaked
filter paper were placed on top of the gel and a glass rod was lightly rolled over the
layers to ensure removal of any air bubbles. The top plate (cathode) of the western
blotter was then washed in transfer buffer and fixed in place. A current of 150mA
was passed through the plates for 1 ½ to 2 hours. The nitrocellulose membrane was
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then washed in PBS and used for immuno-blotting or allowed to air dry and stored at -
20qC. Figure 2.4 displays standard western blotting reagent composition.
Figure 2.4: Standard Western Blotting reagents
Solution Components
Towbin Transfer buffer 25mM Tris base (7.6g)
192mM Glycine (36.0g)
20% Ethanol (500ml)
Make up to 2500ml with distilled water and
adjust to pH 8.8
Fixative solution 25% Isopropanol (75ml)
10% Glacial acetic acid (30ml)
65% deionised water (195ml)
Coomassie staining solution 50% (v/v) Methanol
20% (v/v) Glacial acetic acid
0.0012% (w/v) Coomassie blue R-250
30% (v/v) deionised water
De-staining solution 5% Methanol
7% Glacial acetic acid
88% deionised water
1% BSA (bovine serum albumin) in PBSBlocking solution
(Dependent on potential cross
reactivity of antibodies)
1% BSA plus 5% Marvel
TM
diluted in PBS
2.5.5 Standard Immuno-blotting protocol
Following transfer of electrophoresed proteins to nitrocellulose membrane blots were
placed in either 1% bovine serum albumin (BSA, Sigma) or 5% Marvel
TM
milk
powder, dependent upon cross reactivity of antibodies to be used in the detection step.
Non specific binding sites were blocked for 16 hours at 4qC placed on a shaking table.
Membranes were then washed in PBS 0.05% Tween 20, three times for 10 minutes at
room temperature. Membranes were then incubated for 2 hours at room temperature
with specific primary antibodies diluted in blocking buffer (dilution for optimum
activity dependent on specific antibody, common dilution 1/1000). The membrane
was then washed for 30 minutes in PBS Tween, changing the wash buffer every 5
minutes and rinsed a further three times (quick washes). Membranes were then
placed in primary specific, horse radish peroxidase conjugated secondary antibody
diluted as per data sheet for optimal activity in blocking solution for 2 hours at room
temperature (1/2000 for rabbit anti mouse HRP), and placed on a shaking incubator.
Biotinlylated standard lanes were treated with 1/1000 streptavidin HRP conjugate
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(BioRad) diluted in 1% BSA, and incubated for2 hours at room temperature (under
agitation). Membranes were then washed four times for 10 minutes in fresh PBS
Tween. The chemiluminescence ECL detection system (Amersham Life Sciences)
was used to detect antibody recognition of protein bands in a dark room. 2ml of ECL
reagent (1.95ml solution A plus 50µl of solution B) was applied to each membrane
and incubated at room temperature for 5 minutes. Excess reagent was then removed
from the membrane, which was then wrapped in saran film, preventing incorporation
of air bubbles. The nitrocellulose membrane was then placed in a developing cassette
and covered with a piece of blue sensitive X ray film (GRI, Rayne, UK). Film was
initially exposed for 30 seconds before development and fixation in photographic
development agents. To obtain the clearest image, several pieces of photographic
film were exposed to the membrane for varying times prior to development. The film
was then washed in distilled water and allowed to air dry.
2.5.6 Assessment of RM1 antibody specificity to electrophoresed protein
The RM1 antibody was tested by western blot analysis against recombinant CD55
(SCR1-4-Fc. Harris CL 2000). Protein was electrophoresed on 8% SDS-
polyacrylamide gel under non-reducing conditions and transferred to nitrocellulose
(Amersham Life Sciences) for 1 ½ hours at 150mA in transblot apparatus (Bio Rad).
The membrane was blocked for 24 hours at 4qC in 2% MarvelTM, 3%BSA (Sigma)
and probed with 2Pg/ml anti CD55 antibodies, RM1, BRIC 216 (IBGRL) and
791T/36). Primary antibody was added at 1/1000 (v/v) and incubated at room
temperature for 1 hour in 5% BSA, washed in PBS-Tween (0.1%) and then incubated
with peroxidase conjugated rabbit anti-mouse secondary antibody for 1 hour at RT.
The blot was washed three times prior to developing with ECL reagent (Amersham
Life Sciences,).
2.5.7 Analysis of cytokine production within mouse sera and culture supernatant
(Luminex assay)
Bioplex kits were obtained from Bio Rad for use with their standard assay procedure.
A mouse cytokine/chemokine 10plex panel (#60-00006GK) was obtained for
assessment of IL-2, IL-3, IL-4, IL-5 IL-6 IL-10, IL-12p40, IL-12p70, IFNJ and
TNFD. The Luminex machine was calibrated daily following manufacturer’s
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guidelines prior to any subsequent use. 1 vial of mouse cytokine standards was
reconstituted with 500µl of assay media (matching growth media of cultures cells)
equating to 50,000pg/ml and incubated on ice for 30 minutes. The standards were
then diluted to give the following concentrations; 32,000pg/ml, 8000pg/ml,
2000pg/ml, 500pg/ml, 125pg/ml, 31.3pg/ml, 7.8pg/ml and 1.95pg/ml, all standards
were kept on ice. Beads were reconstituted by combining 1.25µl of beads per well
(sample) added to assay buffer (30µl per sample/well) and the solution was stored on
ice. Detection antibody was reconstituted by combining 0.625µl per sample with
15µl per sample of Diluent A (stored on ice). Streptavidin-PE was reconstituted by
combining 0.313µl Strep-PE/sample with 31µl per sample of Assay buffer, the
solution was stored in the dark on ice. The following staining procedure was carried
out for the complete assay. A 96 well non-protein binding plate (Millipore, UK) was
coated with 150µl per well of Assay buffer and then aspirated using a vacuum pump
(as per manufacturer’s guidelines), the plate being blotted dry to remove residual
buffer. 25µl per sample of beads were added to the plate per sample and the
supernatant was aspirated using the vacuum pump and the base of the plate was
blotted dry. All wells were then washed twice (25µl/well) with wash buffer,
aspirating all liquid with the vacuum pump. 25µl per well of both samples and
standards were added to separate wells. Cell culture supernatant was used undiluted
while serum samples were diluted (3:1) in mouse serum diluent as per manufacturer’s
guidelines. The plate was wrapped with foil and incubated at room temperature under
agitation for 1 hour. Supernatant was aspirated and wells were washed three times in
appropriate buffer as previously described. 12µl per well of detection antibody was
added and the plate was again covered and incubated for a further hour at room
temperature. All liquid was again aspirated and the plate was washed a further three
times with wash buffer and blotted dry. 25µl of Strep-PE was added per well and the
plate was covered and agitated for 10 minutes at room temperature for 10 minutes.
The plate was aspirated and washed three times in buffer prior to the addition of
125µl/well assay buffer. The plate was agitated for 30 seconds prior to assessment of
results on the Luminex machine. The standards were used to generate a standard
curve enabling calculation of sample concentrations.
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2.6 Development and analysis of DNA constructs
2.6.1 Standard Agarose gel electrophoresis
Standard ‘Minigel’ apparatus (Horizon 58’ Gibco BRL, Invitrogen Ltd, Paisley, UK)
was assembled following manufacturer’s guidelines. 100ml of a 1% agarose gel was
prepared in 1% Tris borate EDTA (TBE) buffer and heated in a microwave for ~60
seconds, until all the agarose had fully dissolved, with intermittent agitation to ensure
complete mixing. The mixture was then cooled to ~50qC and Ethidium bromide was
added at a concentration of 0.5µg/ml and gently swirled to ensure complete mixing.
This was performed in a fume cupboard as per safety regulations. The gel was then
poured into the minigel apparatus and an appropriate well spacer (comb) was inserted,
dependent upon sample size to be used. The gel was then left at room temperature to
allow the agarose to set. 1 x TBE solution was used as running buffer and sufficient
quantity was applied to cover the complete gel. The gel was then allowed to
equilibrate with the buffer for 10 minutes prior to removal of the comb.
DNA samples were combined with loading dye, 8µl sample plus 2µl dye,
[15%FICOLL (Pharmacia Biotech Ltd, St Albans, Hertfordshire, UK), 0.25% xylene
cyanole (Biorad, Hercules, California, USA), 0.25% bromophenol blue (Biorad)] all
dissolved in water. Samples were mixed via pipette action and loaded into the gel
wells. The gel apparatus was connected to an electric power supply (Pharmacia LKB-
GPS200, Pharmacia, Peapack, NJ, USA) and a voltage of ~90 Volts was applied for
~1 hour to ensure sufficient movement and separation of desired DNA fragments.
Analysis of electrophoresed samples was assessed by viewing on an ultraviolet trans-
illuminator (dual density transilluminator, UVP, San Gabriel, CA, USA), If further
band separation was required, the gel was placed in the electrophoresis equipment and
electrophoresed for the desired time. Pictures of assessed DNA were obtained using a
DS34 direct screen instant camera (Polaroid, UK)
2.6.2 High purity agarose electrophoresis
When high quality DNA was to be used post electrophoresis, for excision and
restriction digest analysis and/or incorporation into DNA constructs, 1.2% NuSieve
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agarose (Flowgen, Lichfield, UK) was used instead of the standard agarose. All other
procedures were followed as per the standard protocol.
2.6.3 Single enzyme restriction digestion of DNA
The reaction mixture was set up in sterile micro centrifuge tubes with all components
being stored and maintained on ice. Reaction components: 5µl DNA, 2µl restriction
enzyme, 3µl enzyme specific reaction buffer and 20µl of sterile water. The reaction
mix was then incubated at room temperature overnight at room temperature and
dependent upon the enzyme used a heat inactivation step was incorporated (65qC for
25 minutes). All restriction digests were then analysed via electrophoresis. In some
cases, further digestion of the DNA was required with other enzymes. The DNA was
excised from the gel and phenol chloroform extraction was then performed (Section
2.6.6) and ethanol precipitation (Section 2.6.7) was carried and the DNA pellet was
resuspended in 5µl of sterile water prior to further enzyme restriction.
2.6.4 Multiple restriction enzyme digestion of DNA
In cases where dual enzyme restriction digestion was required and buffer conditions
for optimal enzyme activity were compatible, the double digest was performed in a
single step. The reaction mixture was modified: 5µl DNA sample, 2µl restriction
enzyme A, 2µl restriction enzyme B, 3µl restriction enzyme reaction buffer and 18µl
sterile water. The protocol for single digestion was then followed. Figure 2.5
displays restriction enzyme conditions.
Figure 2.5: Summary of conditions used for restriction enzymes
Plasmid Restriction
Enzyme
Buffer Heat
Inactivation
Supplier
PCRII-TOPO Xba I
Not I
3 65qC New England
Biolabs
(NEB), USA
pCR3.1 Kpn I
Not I
1
3
N/A
65qC
NEB
Signal pIgplus Hind III
Not I
2 65qC NEB
pApex Bgl I
Pvu II
2 N/A NEB
Eco RI U 65qC NEB
Bam HI U N/A NEB
U = Unique restriction enzyme reaction buffer
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2.6.5 DNA extraction from agarose gel
Electrophoresed DNA was visualised under ultraviolet light and appropriate bands
were excised from the gel with a scalpel. The DNA was then obtained utilising the
Wizard DNA cleanup purification system (Promega, Southampton, UK), following
the manufacturer’s standard protocol. The excised gel fragments were dissolved in
100µl 1M mannitol (Sigma) and 1ml of wizard cleanup resin at 65qC for 30 minutes.
The DNA was isolated by passing the dissolved mixture through a cleanup filter
which was then washed with 2ml of 80% isopropyl alcohol (BDH Ltd, UK) and
eluted with 30µl of 70qC sterile water.
2.6.6 Removal of impurities from DNA samples via solvent extraction
In order to remove contaminants from DNA samples such as enzymes from previous
digestions, proteins were denaturised via solvent extraction. Sterile phosphate
buffered saline (PBS) was added to the DNA sample to increase the volume to 100µl.
50µl of phenol: chloroform: isoamyl alcohol (25:24:1) was added to the DNA, the
sample was ‘vortexed’ for 60 seconds and centrifuged at 13,000 rpm for 10 minutes in
a micro-centrifuge. The upper aqueous phase was then transferred to a sterile micro-
centrifuge tube, discarding the lower phase. 50µl of chloroform: isoamyl alcohol
(24:1) was then added, ‘vortexed’ and re-centrifuged. The upper layer, containing the
extracted DNA, was again transferred to a clean tube to carry out the ethanol
precipitation procedure.
2.6.7 Ethanol precipitation of DNA
Following solvent extraction 0.1 volumes of chilled 3M potassium acetate pH 5.2, and
2 volumes of chilled 100% ethanol (BDH Ltd, Poole, UK) were added to the eluted
DNA solution. This reaction was placed at -20qC for 30 minutes and centrifuged for
10 minutes at 13,000rpm in a micro-centrifuge. The precipitated DNA appears as a
‘glassy’ pellet and the supernatant was discarded. 200µl of chilled 70% ethanol was
added and the centrifugation step was repeated. The supernatant was discarded and
the DNA pellet was air dried to remove residual ethanol and resuspended in a desired
volume of sterile water.
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2.6.8 DNA quantification by spectrophotometry
Utilising a Genequant pro spectrophotometer (Amersham Pharmacia Biotech,
Uppsala, Sweden), a cleaned quartz cuvette was used to analyse the DNA for
quantification. A ‘blank’ measurement was obtained reading sterile water at a
wavelength of 260nm. Dilutions of the DNA sample were set up in sterile water and
their optical density was analysed at 260nm compared to the ‘blank’ result. The
sample concentration is calculated using the formula OD260 = 1 = 50µg/ml correcting
for the dilution factor. 260nm/280nm readings were also obtained for protein purity.
2.6.9 TA Cloning
The Topo TA cloning kit (Invitrogen) utilises the pCRII-TOPO plasmid which
incorporates the topoisomerase I enzyme which enables one step cloning of Taq
polymerase amplified products into a plasmid vector. Reactions were set up using 4µl
of PCR product, 1µl MgCl solution and 1µl pCRII-TOPO in sterile micro-centrifuge
tubes and incubated at room temperature. 2µl of this product could then be used to
transform competent bacteria as per section 2.6.11.
2.6.10 Ligation of DNA products into plasmid vectors
Reactions were set up: 1µl of restricted vector, 3µl insert (product), 1µl T4 DNA
ligase (New England Biolabs (UK) Ltd, Hitchin, Hertfordshire,UK), 1µl 10 x buffer
and 4µl sterile water in a sterile micro-centrifuge tube. The reaction mixture was then
placed at room temperature overnight. A sample of the ligation reaction can then be
assessed via agarose electrophoresis in order to obtain whether the insert has been
successfully incorporated. Further restriction analysis of ligation products may be
carried out in order to assess alternate products with their relative sizes, in order to
obtain whether ligation is completely successful.
2.6.11 Transformation of competent bacteria with plasmid DNA
Several strains of competent bacteria were used throughout this research including
DH5D (Gibco Life Technology, Invitrogen BV, Leek, The Netherlands), TOP10F
(Invitrogen BV) and XL1-Blue (Stratagene Europe, Amsterdam, The Netherlands).
50µl aliquots of competent cells were stored at -80qC and individual aliquots were
used per transformation. Cells were thawed on ice and transferred to a chilled
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eppendorf tube. 1µl of plasmid or ligation reaction were added to the cells and gently
mixed with a pipette tip. The cells were then incubated on ice for 30 minutes. pUc18
(Invitrogen) plasmid was used as a control transformation reaction and 1µl was used
with 1 vial of competent cells. Cells were then heat shocked by placing the tubes in a
42qC water bath for 30 seconds and directly transferred to ice for a further 2 minutes.
SOC media was heated to 37qC and 500µl were added to the transformed cells which
were then placed in a shaking incubator (G25, New Brunswick Scientific Co Inc,
Edison, New Jersey, USA) at 37qC for 60 minutes. The transformed cells were then
placed on ice and 75µl of the cells were seeded onto an LB agar plate containing
100µg/ml ampicillin, applying selective pressure to only enable growth of
successfully transformed cells (plasmids used contain an ampicillin resistance gene).
Seeded plates were then incubated at 37qC for at least 16 hours. Colonies were then
assessed for incorporation of plasmid DNA. Colonies were spiked with a pipette tip
and used in a PCR reaction with appropriate DNA primer to obtain a PCR product,
with non-transformed cell not producing a band as visualised by agarose gel
electrophoresis.
2.6.12 Small-scale production of plasmid DNA
The Qiaprep spin miniprep kit (Qiagen Ltd, Crawley, UK) was utilised following the
standard manufacturer’s protocol in order to generate a maximum of 20µg of plasmid
DNA. Colonies containing the desired plasmid were spiked with a wire loop and used
to inoculate 5ml of LB media, containing 100µg/ml ampicillin. The media was then
incubated in the shaking incubator for 16 hours at 37qC to allow culture of the
selected bacteria. The culture was then centrifuged for 20 seconds at 13,000rpm in a
micro centrifuge to obtain a bacterial cell pellet; approximately 200µl of the media
was stored at 4qC for large scale production. Alkaline lysis of the cell pellet was
performed using the reagents provided and the supernatant was passed through a
Qiaprep column and centrifuged at 13,000rpm for 30 seconds. The column was then
washed and the DNA, which binds to the column, was eluted by the addition of 50µl
of 42qC EB buffer. DNA mini preparations were then used for further analysis in
PCR and sequence determination.
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2.6.13 Large-scale production of plasmid DNA
Once mini preparations of plasmid DNA have been sequenced, large-scale production
of the DNA constructs was desired to make stocks and for further experimentation.
Utilising the Qiagen maxi plasmid purification system up to 500µg of plasmid DNA
can be generated. 5ml of ampicillin selective LB was inoculated with 200µl of stored
culture or was inoculated with a plasmid positive colony. This culture was then
incubated for 8 hours at 37qC in a shaking incubator. 1ml of this culture was then
used to inoculate 500ml of ampicillin selective media. This larger volume was then
split into two 1 litre flasks and incubated at 37qC for 16 hours (shaking). 500µl
aliquots were collected for glycerol stocks and the remaining culture was centrifuged
at 13,000 rpm for 10 minutes in order to obtain a bacterial pellet. The pellet was then
used in an alkaline lysis step in order to release the plasmid DNA. Bacterial
components of the lysates were then precipitated and filtered from the supernatant
containing the target DNA, which was bound to a Qiagen-tip 500 column. The
column was then washed and the plasmid DNA eluted. The DNA was then
precipitated with isopropyl alcohol and washed with 70% ethanol. The DNA was air
dried and resuspended in 500µl of endotoxin free water. DNA yield and purity was
then determined via spectrophotometry (Section 2.6.8).
2.6.14 Production of endotoxin free plasmid DNA (Immunisation quality)
DNA plasmid constructs were to be used as DNA immunisations and due to this,
removal of all bacterial endotoxin was required for a pure immunisation.
Endotoxins/Lipopolysaccharides are cell membrane components produced in gram-
negative bacteria and within humans and animals can activate components of the
innate immune system, such as complement, and also inhibit immune cell
transfection. Qiagen Ltd produces an endofree plasmid mega purification system,
which can be used to generate up to 2500µg of endotoxin free plasmid DNA.
The standard protocol was followed which copies the maxi plasmid purification
system except the filtered cell lysates are passed through Qiafilter mega cartridges and
filtered eluate is mixed with ER buffer, that removes endotoxins before being passed
through a Qiagen-tip 2500 column. The column was then washed and the DNA
eluted as before. Isopropyl alcohol precipitation and ethanol cleaning steps are used
as per the standard protocol, maintaining use of endotoxin free components. The
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DNA pellet obtained was resuspended in 500µl of endotoxin free water and analysed
by spectrophotometry.
2.6.15 DNA Sequence analysis
Sequence analysis was performed in the Department of Biochemistry, University of
Nottingham. Plasmids were sequenced using the appropriate primers with the BigDye
terminator cycle sequencing ready reaction (PE Applied Biosystems) and sequences
were electrophoresed using the ABI prism 373A DNA sequencer (Applied
Biosystems). Figure 2.6 displays the primer pairs used for each plasmid vector.
Figure 2.6: Vectors and their respective primer pairs
Primer PairVector
5’ 3’
pCR3.1 T7 pCR3.1
pCRII-TOPO M13 Forward M13 Reverse
Signal pIgplus T7 SIGR
Primer pairs used for amplification of multiple cloning sites in specific plasmids
2.6.16 Polymerase Chain Reactions (PCR)
Primer Sequence (5’ to 3’)
T7 TAATACGACTCACTATAGGG
M13 forward GTAAAACGACGGCCAGT
M13 reverse GGAAAACAGCTATGACCATG
pCR3.1 TAGAAGGCACAGTCGAGG
Xa 5’ GATCCCATCGAAGGTGGTGGTGGTGGTGG
Xa 3’ CCACCACCACCACCACCTTCGATGGGATC
SIGR CATGTGTGAGGTTTGTCACAAG
Primer sequences used for all PCR reactions, primers synthesised by the Department of Biochemistry,
University of Nottingham, UK.
2.6.17 Standard reaction protocol
The standard reaction mixture consisted of 100pmol 5’primer, 100pmol 3’primer,
200µM dNTPs, 10µl of 10 x reaction buffer and 84µl sterile water, all prepared in a
sterile micro-centrifuge tube. Either 20ng of template DNA or bacterial cells were
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spiked from a colony containing the target plasmid. Negative control reactions were
set up containing irrelevant primers and reaction mixes without template DNA. Each
reaction was covered with a layer of mineral oil (50µl) to prevent evaporation of the
reaction mixture. Tubes were placed in a PHC-3 thermal cycler (Techne, Cambridge,
UK), and a program was set up to include optimal temperatures for annealing and
extension steps. A ‘hot start’ was set up for optimal polymerase activity and
denaturation of the target DNA, heating samples to 95qC for 5 minutes before
addition of 1µl of Super Taq DNA polymerase (HT Biotechnology Ltd, UK). The
reaction samples then underwent thirty cycles of, 94qC for 30 seconds, 55qC for 55
seconds and 72qC for 55 seconds. A final extension step of 72qC for 10 minutes was
performed before final cooling to 4qC indefinitely. Successful generation of PCR
products was determined by agarose gel electrophoresis (Section 2.6.1).
2.6.18 Site directed mutagenesis protocol for removal of factor Xa cleavage site
from signal pIgplus plasmid
As signal pIgplus constructs were to be used for both In Vitro and In Vivo expression
of recombinant proteins linked to a human IgG Fc region, the factor Xa cleavage site
was removed from the plasmid to prevent cleavage of the Fc domain. This was
achieved utilising the QuickChange site directed mutagenesis kit (Stratagene, La
Jolla, California, USA) following all manufacturer’s guidelines. Primers were
designed to replace a Cysteine with a Glycine, thus preventing formation of the
cleavage site. 50ng of signal pIgplus plasmid DNA was added to 0.4µl 5’ Xa primer,
0.4µl 3’ Xa primer, 1µl dNTPs, 5µl of 10 x reaction buffer, 42.2µl sterile water and
1µl of pfu turbo, all placed in a micro-centrifuge tube. As per standard PCR protocol
the sample was overlaid with 50µl of mineral oil. The tube was placed in a thermal
cycler and the following program set up: 95qC for 30 seconds, 12 cycles of, 96qC for
30 seconds, 56qC for 1 minute, 69qC for 13 minutes and the final step was 4qC
indefinitely. Methylated bacterial DNA (non-mutated) was then digested by the
addition of 1µl of dpn1 enzyme and incubating the reaction mixture for 1 hour at
37qC. Chemically competent bacterial TOP 10F cells were then transformed with the
mutated DNA plasmid as per section 2.6.11. Mini preparation of plasmid DNA was
then performed (section 2.6.12) and retrieved DNA was sequenced for confirmation
of the successful point mutation.
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2.6.19 Site directed mutagenesis for incorporation of heteroclitic epitopes into the
SCR 1-3 Fc constructs
To generate a DNA vaccine incorporating heteroclitic epitopes within the SCR 1-3Fc
construct, identified epitopes needed to be inserted into the existing vaccine plasmid.
The standard Quickchange II site directed mutagenesis kit was used to insert point
mutations within the CD55 sequence following the manufacturer’s guidelines.
Primers were designed with base substitutions to incorporate the desired sequences
and were used in the standard reaction mix and thermal cycling protocol. Primers
were assessed for possible self-hybridisation and production of non-desirable
products, annealing temperatures and percentage of GC oligonucleotides. 5µl of 10 x
reaction buffer was combined with 10ng of template DNA, 125ng 5’ primer, 125ng
3’primer, 1µl dNTP mix, 3µl quick change buffer and the reaction volume was
increased to 50µl with sterile distilled water. 1µl pfu turbo (2.5U/µl) was added prior
to use with the thermal cycling procedure. The standard cycling protocol is displayed
within the table indicating alterations in the extension step relative the size of DNA to
be amplified (1 minute per kb of plasmid DNA). The standard procedure was then
followed for digestion of Methylated bacterial DNA. Figure 2.7 displays primers
designed for mutagenesis of incorporated epitopes.
Figure 2.7: Heteroclitic epitope primers
Primer Sequence 5’o 3’ Cycles
Forward CGG CTG CTG CTG CTG TTG CTG
TTG TGC CTG CC
Z69
(CD8)
Reverse GG CAG GCA CAA CAG CAA CAG
CAG CAG CAG CCG
1 x 95qC
16 x { 95qC for 30 seconds
55qC for 1 minute
68qC for 14 min. 17s
Forward CA CCA AAA CTA ACT TGC GTT
CAG AAT TTA AAA TGG TCC ACA
GC
Z143
(CD8)
Reverse GC TGT GGA CCA TTT TAA ATT
CTG AAC GCA AGT TAG TTT TGG
TG
1 x 95qC
16 x { 95qC for 30 seconds
55qC for 1 minute
68qC for 14 min. 17s
Forward CA GAT GTA CCT AAT GTC CAG
CCA GCT TTG GAA GGC
Z158m
(CD8)
Reverse GCC TTC CAA AGC TGG CTG GAC
ATT AGG TAC ATC TG
1 x 95qC
16 x { 95qC for 30 seconds
55qC for 1 minute
68qC for 14 min. 17s
Red bases represent substitutions used to incorporate point mutations within DNA sequence. Primers
synthesised by the Department of Biochemistry, University of Nottingham, UK.
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2.6.20 Bacterial cell culture
All bacterial cell culture was carried out using aseptic technique and following all
guidelines for genetic manipulation risk assessment. All cultures were grown under
selective conditions with appropriate antibiotics. Single colonies were obtained by
the streaking of cultures/glycerol stocks over LB agar plates and these were stored for
a maximum of three weeks at 4qC prior to incineration. In order to maintain stable
cultures containing desired plasmids, all stock and DNA preparations were made with
fresh colonies and cultures. Figure 2.8 displays components of culture media used.
Figure 2.8: Media components for bacterial cell culture
Medium Components
Luria Bertani
(LB)
10g bacto-tryptone (DIFCO, Becton Dickinson)
5g bacto-yeast extract (DIFCO)
10g sodium chloride (Fisher Scientific)
Make up to 950ml deionised water pH 7.0
LB Agar As per LB media plus 15g agar (DIFCO)
SOB 20g bacto-tryptone
5g bacto-yeast extract
0.5g sodium chloride
Make up to 950ml deionised water
Add 10ml of 250mM potassium chloride (BDH Ltd)
Adjust pH to 7.0
Final volume made up to 1 litre.
Immediately prior to use add 5ml of sterile 2M magnesium chloride
SOC As per SOB medium plus 20mM glucose (20 ml of sterile 1M glucose
solution added post sterilisation
All media autoclaved for 20 minutes at 15lb per in
2
2.6.21 Glycerol stock preparation of bacterial cultures
LB media cultures (containing 100µg/ml ampicillin), which had been used for
‘miniprep’ and ‘maxiprep’ generation of plasmid DNA were used to make cell stocks.
500µl aliquots of culture were mixed with 500µl sterile 30% (v/v) glycerol. Samples
were placed in cryovials, labelled and stored at -80qC.
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2.7 DNA immunisation: Analysis of cellular responses
2.7.1 Preparation of Lipopolysaccharide (LPS) blasts
Splenocytes were harvested from a syngeneic (per experiment) un-immunised mouse
as per section 2.4.1. The cells were then washed in culture media and resuspended at
a concentration of 1.5 x 10
6
/ml. LPS was then added at a concentration of 25µg/ml
with 0.05mM E-mercaptoethanol and 7µg/ml of dextran sulphate. Cells were then
transferred to T175 culture flasks at a maximum volume of 50ml per flask. The cells
were then incubated at 37qC in 5% CO2 for 2 days.
2.7.2 Preparation of murine CTL effector cells
Splenocytes were harvested from immunised mice as per section 2.4.1 were washed
in culture media and resuspended at a concentration of 4 x 10
6
/ml. 1ml aliquots were
seeded per well in 24 well culture plates in complete media. Between 5 x 10
4
and 1 x
10
6
LPS blasts, which were irradiated with 20Gy from Gammacell Caesium
157
source
to prevent proliferation, were added per well of immunised effector cells. Total
culture volume was 2ml of complete media. Prior to the addition of the irradiated
blasts, they were incubated with 10µg/ml of target peptides, which mimic desired
epitope targets (synthesised by Alta Biosciences, Birmingham, UK). The 24 well
plates were then incubated at 37qC with 5% CO2 for 6 days prior to assessment of
peptide specific CTL activity as assessed by chromium release assay (section 2.7.4).
2.7.3 Preparation of target cells for CTL assay
T2 cells were passaged one day prior to the chromium release assay in order to
maintain optimal cell viability. Cells were centrifuged at 12,000rpm for 5 minutes to
produce a cell pellet. The cells were then washed in serum free RPMI media two
times before re-suspension in complete media at a concentration of 1 x 10
6
/ml. All
counts were performed with trypan blue staining. 1ml aliquots were then pulsed with
100µg/ml of target peptides (immunising epitope) and 1.85MBq of sodium [
51
Cr]
chromate (Amersham Pharmacia biotech, Essex, UK) and incubated at 37qC in 5%
CO2 for 2 hours. The cells were then washed in complete culture media three times
before counting with trypan blue and re-suspension at a concentration of 5 x 10
4
cells
per ml.
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2.7.4 Chromium release assay
The In Vitro stimulated murine CTL effector cells were pooled on day 6 of culture
and washed in serum free media two times (Centrifugation at 1000rmp for 10
minutes). Cells were counted, assessing viability, and resuspended at 5 x 10
6
/ml and
100µl aliquots were seeded onto 96 U well plates in triplicate. Cells were titrated to
give a range of effector target ratios (E:T): 100:1, 50:1, 25:1 and 12:1 (5000 targets
per well). Prepared targets were then added in co-culture with the CTL effectors at
5000 cell per well. 200µl total assay volume was used with complete media and in
order to determine spontaneous and maximal lysis, wells without CTL effectors were
used in triplicate either containing target cells alone or in conjunction with 20µl of
triton X-100 detergent. Plates were then incubated for 4 hours at 37qC with 5% CO2.
50µl aliquots of the assay supernatants were transferred to 96 well lumaplates
(Packard Bioscience, Groningen, The Netherlands) containing solid scintillant and the
plates were allowed to air-dry overnight at room temperature. The plates were then
analysed on a Topcount scintillation counter (Canberra Packard, Pangbourne, UK).
The results were analysed and the relative percentage cytotoxicity was calculated
using the following formula: [(peptide specific
51
Cr release form CTL effectors –
spontaneous
51
Cr release) / (maximum
51
Cr release – spontaneous
51
Cr release)] x
100.
2.7.5 Enzyme linked Immunospot assay (ELISpot)
This assay was used to determine the frequency of epitope specific responses
generated by the DNA vaccines used. Analysis was performed for both IFNJ and IL4
specific production in response to In Vitro stimulation of immunised effectors with
target peptides. The assay was performed using cytokine specific development
modules and ELISpot blue colour modules from R & D Systems Europe Ltd
(Abingdon, Oxon, UK) as per the manufacturer’s guidelines. The total volume of
required cytokine specific capture antibody was determined and diluted at a ratio of
1:60 in PBS. 100µl of the diluted antibody was then applied to each well of a 96 well
PVDF membrane ‘Immunospot’ plate (multiscreen-IP, Millipore, Bedford, MA,
USA), plates were covered and placed at 4qC overnight. The capture antibody was
aspirated from the plate, which was then washed 4 times in sterile PBS containing
0.05% Tween 20. Care was taken to avoid damage to the plate’s membrane. The
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plates were blotted dry and the non specific binding sites were blocked with 200µl of
sterile filtered 1% BSA in PBS, and incubated at room temperature for 2 hours. The
blocking buffer was aspirated from the wells which were washed 3 times in PBS
Tween 20. The membrane was then equilibrated by the addition of 200µl of complete
cell culture media and placed at 37qC until seeding of immunised splenocytes was
required. The culture media was then aspirated and 1 x 10
6
splenocytes were seeded
per well in 100µl of culture media. Splenocytes were then stimulated under varying
conditions: 10µg/ml target peptide added per well in triplicate, negative controls were
wells containing only cells and wells with media alone and positive controls were set
up containing 1µg/ml phorbol 12-myristate 13 acetate (PMA) and 200nM ionomycin.
All wells contain a total assay volume of 200µl culture media. For the determination
of epitope specific effector frequency, titrations of both the number of seeded effector
cells and the concentration of peptide added were varied. Plates were then incubated
at 37qC in 5% CO2 for at least 16 hours. Plates are loosely wrapped in foil to prevent
the development of diffuse spots. The splenocytes were aspirated from the plates and
all wells were washed three times in PBS Tween. The total volume of cytokine
specific detection antibody was calculated and diluted at a 1:60 ratio in sterile 1%
BSA in PBS (sterile 0.2micron filtered). 100µl of the detection antibody was added
per well and the plates were incubated at 4qC for at least 16 hours. The plates were
then washed a further 4 times in PBS Tween, and blotted dry. 100µl of alkaline
phosphatase conjugated streptavidin, diluted 1:60 in 1%BSA, was added per well and
plates were incubated for 2 hours at room temperature. Plates were then washed five
times in PBS Tween and once in distilled water. 100µl of the substrate, 5-broomo-4-
chloro-3’indolylphosphate p-toludine salt (BCIP) and nitro blue tetrazolium chloride
(NBT) solution was added per well and the plate was incubated at room temperature,
in the dark, for 30 minutes. The BCIP/NBT solution was then aspirated from the
plates which were washed three times in distilled water and allowed to air dry at room
temperature. The plates were analysed using the Bioreader 3000 Pro (Camlab,
Cambridge, UK).
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2.8: Antibodies used throughout all experiments including concentrations and
mode of action.
Direct Primary
Antigen Fluorescent
conjugate
Species of
origin
Dilution
/Conentration
Volume (µl)
per100,000
cells
Supplier
and address
C3b (C3c
polyclonal)
FITC Rabbit 1/100 100 DAKO A/5,
Denmark
Indirect Primary
Antigen and
Isotype
Species of
origin
Dilution
/Concentration
Volume (µl)
per100,000
cells
Supplier and
address
CD55 SCR 1
[(BRIC 220)
(IgG1)]
Mouse 5-10µg/ml 100 IGBRL, Bristol,
UK
CD55 SCR 3
[(BRIC 216)
(IgG1)]
Mouse 5-10µg/ml 100 IGBRL, Bristol,
UK
CD55 SCR 2
[(BRIC 110)
(IgG1)]
Mouse 5-10µg/ml 100 IGBRL, Bristol,
UK
CD55 SCR 1-2
[(791T/36)
(IgG2b)]
Mouse 5-10µg/ml 100 Purified in
laboratory from
hybridoma
CD55 SCR 1
[(IA10) (IgG2a)]
Mouse 5-10µg/ml 100 BD Pharmingen,
Belgium
Control Ab
(IgG)
Human 5-10µg/ml 100 Sigma, Missouri,
USA
Human IgG (Fc
specific)
Goat 5-10µg/ml 100 Sigma, Missouri,
USA
Bovine Serum
Albumin (IgG
polyclonal)
Rabbit1 1/1000 100 Abcam,
Cambridge, UK
CD55 [(IC6)
(SCR3)]
Mouse 5-10µg/ml 100 GmbH,
Germany
CD55 [(IH4)
(SCR3)]
Mouse 5-10µg/ml 100 Dr B. Loveland
CD55 [(IA10)
(SCR3) (IgG2a)
Mouse 5-10µg/ml &
Titration
N/A BD PharMingen,
Belgium
HLA-A2 (BB7.2) Mouse 5-10µg/ml 100 Purified in
laboratory from
hybridoma
(ATCC
Rockville, MD,
USA)
365 (708) (IgG2b) Mouse 5-10µg/lm 100 Purified in
laboratory from
hybridoma
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Secondary
Antigen Fluorescent
conjugate
Species
of origin
Dilution
/Concentration
Volume
(µl)
per100,000
cells
Supplier and
address
Anti-
mouse IgG
FITC Goat 1/100 100 DAKO A/5,
Denmark
Anti-
mouse IgG
Hrp Goat 1/1000 100 DAKO A/5,
Denmark
Mouse
CD19
(IgG2a)
FITC Rat 1/1000 100 DAKO A/5,
Denmark
Mouse
IgG1
Hrp Goat 1/1000 N/A Serotec,Oxford,UK
Mouse
IgG2a
Hrp Goat 1/1000 N/A Serotec,Oxford,UK
Human
IgG (Fc
specific)
Hrp Goat 5-10µg/ml 100 Sigma,Missouri,USA
IGBRL: International Blood Group Reference Laboratory
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Chapter 3: Development of monoclonal antibodies capable
neutralising CD55
3.1: Introduction
Decay accelerating factor is highly expressed on many tumour cells, offering
protection from autologous, complement bystander attack. The presence of CD55 on
stromal cells surrounding tumours and the presence of soluble DAF would suggest
that its expression is an important cofactor for tumour development.
Mutations in SCR 3 of CD55 have been shown to produce the most disruptive effects
on its complement regulatory activity, when compared to mutations in other domains
(Coyne et. al. 1992). An array of antibodies to specific domains within decay
accelerating factor (CD55) were tested for their ability to block its regulatory activity,
and only two antibodies, specific to SCR 3, completely abolished its function.
Blok et. al. (1997), showed that a bispecific antibody recognising CD55 and tumour
cell antigen G250 induced C3 deposition and tumour cell lysis, and that opsonised
cells became sensitised to complement mediated lysis. Similarly Zhong et. al. (1995)
showed that increased tumour killing could be achieved by CD55 blockade with an
antibody to SCR3 of CD55.
The preliminary aim was to generate monoclonal antibodies specifically targeting the
SCR3 domain of decay accelerating factor, capable of neutralising its complement
regulatory activity. This would lead to enhanced C3 deposition on the surface of
tumour cells and ultimately produce elevated levels of tumour cell lysis and ultimately
regression.
In order to generate anti SCR3 monoclonal antibodies, a relevant immunogen was
required. Potentially immunogenic regions were identified with the use of
hydrophobicity plots and synthesised. Utilisation of peptides as immunogenic targets
enables generation of a specific response to a single epitope and therefore a peptide
immunisation strategy was chosen.
Sera from immunised mice was collected and CD55 specific responses were assessed
via ELISA, FACS binding and C3b deposition assays. Positive responders were
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immortalised in order to generate monoclonal antibodies to be assessed for CD55
neutralising capabilities.
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Results
3.2: Antigen prediction for generation of peptides
The peptide sequence for SCR3 domain of human CD55 was obtained via SWISS-
PROT software (Accession number P90174). The sequence was entered into the
ProtScale program in order to generate a hydrophobicity plot, illustrating regions
within the peptide sequence that show hydrophilic characteristics. These regions
indicate potential antigenic sites, which are likely to be exposed on the complete
folded protein surface. The Kyte-Doolitle scale is widely applied for delineating
hydrophobic character of a protein.
Figure 3.1 shows the individual values associated with all the amino acids present in
the target sequence as generated by this plot scale. All regions within the sequence
are given charge values relative to their position and adjacent amino acids. Sequences
with values greater than zero are said to be hydrophobic in nature, while those with
values less than zero are said to show hydrophilic properties and thus likely to be
exposed as antigenic targets for antibody development.
Figure 3.1: Protein Hydrophobicity Plot of SCR3 domain of CD55 for peptide
design.
SCR3 of CD55 peptide sequence:
162
KSCPNPGEIR NGQIDVPGGI LFGATISFSC NTGYKLFGST SSFCLISGSS
VQWSDPLPEC R
221
The peptide sequence of human Decay accelerating factor (accession #: P08174) was
obtained via SWISS-PROT software. The sequence of SCR3 domain was entered into the
ProtScale program in order to generate the Hydrophobicity plot: -
Regions with values greater than zero are hydrophobic in character.
Regions with values less than zero are hydrophilic and likely to be exposed on the surface of a
folded protein.
Kyte & Doolitle Scale used.
The individual values for the 20 amino acids are:
Ala : 1.8 Arg : -4.5 Asn: -3.5 Asp: -3.5 Cys: 2.5 Gln: -3.500
Glu : -3. Gly : -0.4 His: -3.2 Ile: 4.5 Leu: 3.8 Lys: -3.900
Met : 1.9 Phe: 2.8 Pro: -1.6 Ser: -0.8 Thr: -0.7 Trp: -0.900
Tyr : -1.3 Val : 4.2 Asx: -3.5 Glx: -3.5 Xaa: -0.49
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SCPNPGEIR NGQIDVPGGI LFGATISFSC NTGYKLFGST SSFCLISGSS VQWSDPLPEC R
162 221
The three highlighted regions were selected as potential antigenic targets for antibody
development. All peptides were unique to human CD55 when used in a BLAST search.
The sequence encoding the SCR3 of CD55 was aligned with SCR2 of CD46 to
determine if homology would enable prediction of molecular structure (Figure 3.2).
By comparing the crystal structure of CD46 with the SCR 3 domain of CD55 it was
possible to produce a 3 dimensional model (Figure 3.3) confirming the surface
locations of the chosen target peptides.
Figure 3.2: Alignment of CD55 SCR3 with CD46 SCR2
CD46 1-2 1 CEEPPTFEAM ELIGKPKPYY EIGERVDYKC KKGYFYIPPL ATHTICDRNH
CD55 3 1 KSCPNPGE IRNGQ-IDVP GGILFGATIS FSCNTGYKLF
CD46 1-2 51 TWLPVSDDAC YRETCPYIRD PLNGQAVPAN GTYEFGYQMH FICNEGYYLI
. .** . *** . * ** . * ** ** *.
CD55 3 39 GSTSSFCLIS GSSVQWSDPL PECRE
CD46 1-2 101 GEEILYCELK GSVAIWSGKP PICEKV
. * *. . ** *
The residues marked in red are highly conserved between all SCR domains.
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Figure 3.3: Prediction of 3 dimensional model of target peptides, generated by
comparison with crystal structure of CD46 short consensus repeat domains.
Representation of three loops of peptides predicted to be hydrophilic, occupying surface
locations on CD55.
The presence of four conserved cysteins, constrain the structure and conserved bulky
hydrophobic residues occupy the interior of the model. This leaves loops of protein (target
peptides) at the surface. Below is a view of the structure from beneath showing the predicted
surface locations of the chosen peptides. The dots surrounding the image represent predicted
surface shape occupied by hydrogen and water molecules.
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Hoppe-Woods (1980) & Janin (1978)
Three regions within the sequence were identified as potential surface epitopes for
peptide generation and immunisation:
CD55 3N
N’
CPNPGEIRNGQIDVPG
C’
16mer N terminal peptide
CD55 3M
N’
CNTGYKLFGST
C’
11mer Middle peptide
CD55 3C
N’
SVQWSDPLPEC
C’
11mer C terminal peptide
The three peptide sequences were used in a BLAST search and all were shown to be
unique, indicating that antibodies generated would be specific to these regions located
within complete CD55. As well as being chosen for predicted surface location and
hydrophobicity, the peptides were selected to include a cystein residue, which can be
used to attach the peptides to a carrier protein, such as KLH. The peptides were
synthesised by the BSAU at Nottingham using Fmoc chemistry assessing purity by
HPLC and mass spectrometry .
3.3: Immunisation Protocol
Three groups of three mice (N, M and C) were immunised with target peptides at two
weekly intervals, table C shows the immunisation protocol followed and the
subsequent analysis of tail bleeds and cell fusions carried out.
N-terminus
C-terminus
96
Table 3.1: Immunisation/Screen protocol.
Week Immunisation / Immunogen Bleed Screen
1 1q: 100Pg KLH conjugated peptide +
CFA s.c.
N/A N/A
3 2q: 100Pg KLH conjugated peptide +
IFA i.p.
N/A N/A
5 3q: 100Pg KLH conjugated peptide +
IFA i.p.
1q OVA-peptide (ELISA)
-peptide (ELISA)
7 4q: 105 CHO HI DAF cells + IFA i.p. 2q BSA-peptide (ELISA
Native CD55 (791T)cells
(ELISA)
Purified CD55 (ELISA)
9 5q: 100Pg KLH conjugated peptide +
IFA i.p.
3q BSA-peptide (ELISA)
11 6q: 100Pg KLH conjugated peptide +
IFA i.v.
N/A N/A
12 Collect splenocytes and fuse with
NSO
N/A Hybridoma screens against
peptide/ purified CD55 /
native antigen/Complement
deposition
Summary of table definitions:
KLH : Keyhole Limpet Haemocyanin (peptide carrier)
OVA : Ovalbumin (peptide carrier)
IFA : Incomplete Freund’s adjuvant
CHO HI : Chinese Hamster Ovary cells transfected to express CD55
DAF
N/A : Not Applicable
Combinations of screening protocols were developed in order to assess specificity of
generated antibodies. An Elisa screen was utilised to determine if recognition of
primary target peptide coupled to different carrier proteins could be observed and
FACS analysis was utilised to confirm whether antibodies recognised complete native
antigen as expressed on cells. Hybridomas were also screened via Elisa against target
peptides and purified CD55, again analysing whether the antibodies generated could
recognise native antigen formation. Finally hybridoma supernatants were assessed
via a complement deposition assay to determine if blocking of CD55 function could
be produced.
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3.4: Screening of mouse sera for presence of target specific antibodies
Three groups of mice were immunised with 100Pg KLH conjugated peptides (N, M
and C) with Complete and Incomplete Freund’s Adjuvant sub-cutaneously and intra-
peritonealy; tail bleeds were obtained 5 days post immunisation. Erythrocytes were
removed via centrifugation and the sera were collected, titrated and screened via
ELISA against target peptides (as Table 3.1).
96 well Elisa plates were coated with ovalbumin conjugated N, M and C peptides and
non-specific binding sites were blocked with BSA. Titrated mouse sera was then
added in triplicate and binding was assessed using secondary HRP conjugated
antibodies and the ABTS detection system.
Figure 3.4 represents the results obtained from the primary bleeds, sera from all mice
screened against all three ovalbumin-conjugated peptides. All three groups show that
strong primary responses have been generated to specific peptides and the current
results showing recognition at dilutions of 1 in 5000. However all mice sera also
show strong recognition to alternative peptides, indicating a degree of non-peptide
specific binding. This may be due to the presence of ovalbumin conjugated to the
target peptides, which may be ‘sticky’ due to its innate charge and structure. N
peptide immunised mice show predominantly stronger binding to the N peptide
targets, and both M and C immunised mice show strongest responses to their relative
peptides. A titre of 1 in 10,000 indicates significant response levels for future fusions
and antibody development.
Figure 3.4: Mouse sera titration for presence of peptide specific antibody.
Three groups of mice immunised with KLH conjugated peptides (N, M and C). 5Pg/ml of
ovalbumin-conjugated peptide coated plates overnight at 4qC. Primary and secondary
antibodies were added before using the ABTS system for ELISA detection. Error bars
covered by symbols and plates read at 405nm. Sera from each mouse analysed against all
three synthesised peptides.
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Mouse N2: Immunised
with N-KLH peptide.
Mouse N3: Immunised
with N-KLH peptide.
Mouse M1: Immunised
with M-KLH peptide.
Mouse M2: Immunised
with M-KLH peptide.
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Mouse M3: Immunised
with M-KLH peptide.
Mouse C1: Immunised
with C-KLH peptide.
Mouse C2: Immunised
with C-KLH peptide.
Mouse C3: Immunised
with C-KLH peptide.
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Group immunisations were compared in order to assess which mice were generating
the greatest responses to their target peptides (Figure 3.5) when compared to serum
from an un-immunised individual. All three groups show strong peptide recognition
at dilutions up to 1 in 10000 with significant difference compared to un-immunised
sera. Mice N1, M2 and C1 currently show the greatest level of response to their target
peptides.
Figure 3.5: Mouse Sera titration for presence of peptide specific antibody. Sera
screened against target peptide, compared to sera from an un-immunised mouse.
Plates coated with 5Pg/ml ovalbumin-conjugated peptide overnight at 4q. Primary and
secondary antibodies added before using the ABTS system for ELISA detection. Plates read
at 405nm and error bars are covered by symbols.
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C Group: Immunised
with C-KLH peptide.
As sera from all mice show responsiveness to all ovalbumin-conjugated peptides, new
targets were generated linking N, M and C peptides to BSA. Ovalbumin is a
relatively large, charged molecule, which may induce interactions with antibodies in a
non-specific manner. Figure 3.6 shows primary bleed screens against new
conjugated peptides when compared against un-immunised sera. Cross recognition of
peptides is now reduced to results comparable with un-immunised serum, indicating
removal of non-specific peptide recognition. All mice show strongest response to
their specific peptide to a titre of 1 in 10000.
Figure 3.6: Mouse sera titration for presence of peptide specific antibody. Sera
screened against new BSA-conjugated N, M and C peptides.
New peptide conjugates used to determine if previous cross binding was due to ovalbumin
recognition. 5Pg/ml BSA peptide coated plates at 4qC overnight. Primary and secondary
antibodies were added before using ABTS system for ELISA detection. Plates read at 405nm
and standard deviation covered by symbols. Sera from each mouse were analysed against all
three BSA-conjugated peptides.
Mouse N1: Immunised
with N-KLH peptide.
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Mouse N2: Immunised
with N-KLH peptide.
Mouse N3: Immunised
with N-KLH peptide.
Mouse M1: Immunised
with M-KLH peptide.
Mouse M2: Immunised
with M-KLH peptide.
Sera N2 Dilutions against all three peptides.
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Mouse M3: Immunised
with M-KLH peptide.
Mouse C1: Immunised
with C-KLH peptide.
Mouse C2: Immunised
with C-KLH peptide.
Sera M3 dilutions against all three peptides
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Mouse C3: Immunised
with C-KLH peptide.
As anti-serum has now been shown to recognise target peptides conjugated to
alternative carriers, it can be proposed that antibody responses have been generated to
the target epitope. To assess this, sera were screened against complete native
conformational antigen (CD55), naturally expressed on the osteosarcoma cell line
791T. Figure 3.7 represents primary bleed sera recognition of CD55. 5 x 10
5
791T
cells (CD55 over expressing osteosarcoma line) were coated with 100Pl of titrated
sera and assessed by flow cytometric analysis on the FacScan. BRIC 216 (SCR3
specific) monoclonal antibody was used as a control indicating the presence of
conformational CD55 and PBS was used as a negative control for secondary antibody
alone-labelled cells. Sera were used at 1 in 1000 and 1 in 10000 dilutions, these being
dictated by limited sera volumes, though several previous maximum responses were
seen at 1/10000. Results indicate limited recognition of complete native antigen as
compared to the PBS control.
Primary bleeds indicate that generated antibodies display strong binding to peptide,
although these antibodies did not recognise conformational native CD55. In order to
selectively expand a B cell population, which recognises both peptide and complete
CD55, peptide immunised mice were boosted with Chinese Hamster Ovary (CHO)
cells transfected with a vector expressing complete CD55. As CHO cells are of
rodent origin, many expressed surface proteins may not be immunogenic within the
mouse system. Therefore the most immunogenic region present on the CHO cells
should be conformational CD55.
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Figure 3.7: Indirect labelling of 791T cells with titrated serum to determine if
antibodies generated to peptide recognise native antigen.
5 x 10
5
791T cells coated with 100Pl titrated sera for 1 hour at 4qC. Secondary antibody was
FITC-conjugated and cells were assessed by flow cytometric analysis. Error bars indicate the
range of two data points. Controls used: BRIC 216 and PBS.
FACS analysis of Immunised Mouse Sera Binding to complete 791T cells.
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3.5: CD55 expression on stably transfected CHO cell line
CHO cells were transfected using the lipofectamine reagent method (Invitrogen) with
pApex vector containing CD55 cDNA. Stable lines were generated with puromycin
selection, and labelling of 5 x 10
5
transfected cells with 791T/36 (SCR1-2 specific)
monoclonal antibody determined CD55 expression. Cells were incubated for 1 hour
at 4qC with 791T/36 and washed with PBS. Labelled cells were assessed by flow
cytometry. Figure 3.8 shows four populations of transfected cells assayed when
compared to un-transfected CHO cells. All populations were transfected under the
same conditions using a range of DNA concentrations for the transfection protocol.
The CHO A to E populations show a range of expression levels equating to 0.5, 1.0,
1.5 and 2.0Pg DNA respectively. The CHO high E population showed the greatest
level of CD55 expression and was used to immunise the peptide-primed mice.
Figure 3.8: Cytofluorimetric analysis of CD55 expression on transfected CHO
cells.
5 x 10
5
cells labelled with 791T/36 antibody for 1 hour at 4qC. Cells analysed with FITC-
conjugated Rabbit anti mouse antibody and read by flow cytometry. Transfected cells
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populations compared to non-transfected CHO cells (negative control). All transfectants
produced following identical protocol with varying DNA concentrations. Deviation
expressed as two data points.
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3.6: Screen of secondary bleeds following immunisation with CHO High E cells.
Mice have received two peptide immunisations and one boost with conformational
CD55 on CHO-55 cells. Figure 3.9 represents results of secondary bleeds screened
via ELISA against BSA conjugated target peptides. Results show that responses to
peptide are observed at sera titres of 1 in 10,000 when compared against un-
immunised sera. These results are comparable to previous screen titres against
peptide before cell boost. Mice N1, M1 and C1 show greatest responses to their
target peptides when compared against all mice from within the same group.
Figure 3.9: Mouse sera titration of 2q bleeds for presence of peptide specific
antibody.
New bleeds collected following secondary immunisation with CHO DAF Hi E cells.5Pg/ml
of BSA conjugated peptides coated plates overnight at 4qC. Primary and secondary antibodies
added before using the ABTS system for ELISA detection and read at 405nm. Sera screened
against primary target peptides.
Mouse N1, N2 and N3
screened against N-BSA
peptide.
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Mouse M1, M2 and M3
screened against M-BSA
peptide.
Mouse C1, C2 and C3
screened against C-BSA
peptide.
Sera were again screened to determine whether antibodies showed recognition of
native antigen, which was achieved, by whole cell ELISA (Figure 3.10). Sera were
assessed by indirect labelling of 791T (CD55 expressing) and Colo 205 (Non-CD55
expressing) cell lines. 5 x 10
4
cells were added per well on a 96 well ELISA plate
and fixed with 0.5% gluteraldehyde. Non-specific sites were blocked and assessment
was completed with ABTS reagent. Results indicate slight recognition of CD55 on
791T cells when compared to binding of Colo205 cells. All sera binding was
compared to values generated with un-immunised sera. The responses were shown at
dilutions of up to 1 in 5000 and sera from all groups show greater response to CD55
expressing cells compared to the CD55 negative cell line.
Figure 3.10: Indirect labelling of 791T and colo 205 cells with titrated 2q sera.
5 x 10
4
cells added per well in 96 well ELISA plate, incubated overnight at 37qC and fixed
with 0.5% gluteraldehyde. Titrated mouse serum used as primary antibody, Rabbit anti
mouse HRP conjugate used as secondary antibody prior to use of ABTS system for ELISA
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detection. Plates read at 405nm and deviation shown for two data points (covered by
symbols).
Whole Cell Elisa of 791T cells binding to dilutions of N peptide-
Immunised Mice.
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As sera screens show partial recognition of natively expressed CD55 via whole cell
ELISA but not in the primary bleed FACS analysis, sera were screened against CD55
previously purified from erythrocytes. Analysis was completed via ELISA and 96
well plates were coated with 5ȝg/ml-purified CD55. Sera dilutions were added as
primary antibodies and compared to un-immunised sera and BRIC 216 as controls
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(Figure 3.11). All sera showed significant difference of recognition when compared
to un-immunised serum for purified CD55. Both M and C immunisation groups
showed responses to CD55 at titres if 1 in 5000, with M2 and C1 producing the
strongest positives. However, BRIC216 showed no recognition for the purified CD55
indicating that upon binding to the ELISA plate, the conformational structure of
protein may no longer be native. This finding may support previous results,
indicating that generated antibodies recognise denatured and not conformational
CD55.
Figure 3.11: Screen of 2q bleeds against purified CD55.
5Pg/ml CD55 incubated overnight at 4qC. Primary titrated sera and secondary rabbit anti
mouse HRP conjugate added prior to use of ABTS system for ELISA detection. Optical
density read at 405nm and deviation showed as two data points (covered by symbols). Group
immunisations screened against purified CD55.
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All mice were boosted with peptide conjugates to prevent driving of immune
responses towards other antigenic regions on CD55 and 3q bleeds were screened via
ELISA against BSA conjugated target peptides (Figure 3.12). All groups show
significant response and titres of 1 in 10,000 and a significant difference is observed
with immunised sera compared to un-immunised sera. Mice N1, M1 and C1 show the
greatest response to peptide within their groups.
Figure 3.12: Mouse sera titration of 3q bleeds following target peptide boost for
presence of peptide specific antibody
5Pg/ml BSA-conjugated peptides coated on 96 well ELISA plate. Primary sera dilutions and
secondary rabbit anti mouse-HRP conjugated antibody added before using the ABTS system
for ELISA detection. Optical density read at 405nm and deviation shown for two data points
(hidden by symbols). Sera screened against primary target peptides.
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Elisa for KLH-M Immunised sera binding to M peptide.
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Due to previous strong positives with titres greater than 1/10000 against peptide and
partial recognition against cells assessed by whole cell ELISA and purified CD55
ELISA, mice M1, M2 and C1 were immunised with 100Pg KLH conjugated peptide
intravenously as a final boost. As per protocol (Table 3.1), all three mice were
sacrificed and splenocytes were collected. These cells were fused with the myeloma
cell line NSO for hybridoma production.
3.7: Screening of hybridomas fromM and C group fusions
Mouse C1 and Mice M1 and M2 splenocytes were fused with NSO myeloma cells
with the use of polyethylene glycol. Fusions were grown in HAT selective media
over rat peritoneal exudates cells. Hybridomas were screened for target peptide
recognition (ELISA), complete purified CD55 recognition (ELISA), specificity for
native antigen expressed by osteosarcoma cell line 791T (FACS) and finally
112
inhibition of functional CD55 on 791T cells leading to increased complement
deposition (FACS).
3.8: C hybridoma screens and development
Figure 3.13 represents results obtained for C-hybridomas screened against BSA-C
peptide and purified CD55. Two plates of hybridomas were assayed and only wells
containing viable cells were graphically represented. 5Pg/ml peptide and CD55 were
coated on 96 well plates and BRIC 216 and mouse serum (1/2000) were used as
controls and added with 50Pl hybridomas supernatant as primary antibody. ABTS
substrate was used to assess antibody specificity. BRIC 216 does not recognise
peptide sequence fractions from SCR3 or purified CD55, with results comparable to
PBS negative control. All hybridomas show limited recognition of CD55 in
comparison to peptide binding, suggesting that the produced antibodies recognise
peptide with greater affinity than native CD55. Several clones show significant
responses to peptide producing OD values up to 2.5 times background. CP1 D3 and
CP2 G2 produce the greatest responses to both purified CD55 and BSA conjugated
peptide. Both of these wells were cloned across 96 well plates at 0.3 cells per well.
113
Figure 3.13: Screen of C1 hybridomas for recognition of target peptide and
purified complete CD55.
Mouse C1 fused with NSO myeloma cells and grown in HAT selective media. Supernatants
screened via ELISA for presence of peptide specific antibodies. 5Pg/ml BSA- conjugated C
peptide and purified CD55 were coated on 96 well plates overnight at 4ºC. 50Pl of
hybridoma supernatant was then added as primary antibody and secondary rabbit anti-mouse
HRP conjugate was added and incubated for 1 hour prior to ABTS substrate addition. Plates
were read at 405nm. Only data from wells containing viable cells shown.
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CP1 D3 and CP2 G2 cloned 0.3 cells per well.
Hybridoma supernatants were then screened via flow cytometric analysis for
recognition of native antigen expressed on 791T cells (Figure 3.14). 5 x 10
5
791T
cells were coated with 791T/36, BRIC 216, PBS and 50Pl hybridomas supernatant.
791T/36 and BRIC 216 both show a high level of CD55 recognition compared to
unlabelled cells. All clones produce results comparable to background M.L.F values,
indicating no recognition of conformational CD55 by the generated antibodies. Clone
CP2 G2 showed weak binding, potentially indicating limited recognition and was
cloned across a 96 well plate in order to produce a monoclonal antibody. This
population was allowed to grow for several days and finally screened against C-BSA
peptide to assess for antibody producing clones. Only wells containing viable cells
were analysed (Figure 3.15).
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Figure 3.14: C fusion hybridoma positives screened against whole native CD55
via FACS analysis.
5 x 10
5
791T(CD55 expressing) and colo 205(non CD55 expressing) cells coated with 50Pl
hybridoma supernatant and incubated for 1 hour at 4ºC. Secondary rabbit anti mouse-FITC
conjugate added and incubated for 1 hour at 4ºC. Cells analysed by flow cytometry and
deviation shows two data points.
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In Figure 3.15, sera produced strong OD values compared to PBS background
control. All viable cells show degrees of peptide recognition, which is difficult to
assess due to the number of cells present and speed of antibody production. CP2 G2:
B3 and D8 produced the greatest responses to target peptide.
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Figure 3.15: CP2 G2 Clones: Screen for presence of peptide specific antibody.
96 well plates coated with 5Pg/ml BSA-C peptide overnight at 4ºC. 50Pl of hybridoma
supernatants added as primary antibody and secondary rabbit anti mouse HRP conjugate
added and incubated for 1 hour at room temperature. Plates washed and ABTS substrate
system used for ELISA detection. Plates read at 405nm and deviation expressed as two data
points.
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CP1 D3 clones were screened for peptide specificity (Figure 3.16). Sera and PBS
controls produce expected results, with all hybridoma supernatants producing
significantly elevated peptide recognition levels compared to negative controls
(Increases of up to 5 fold responses).
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Figure 3.16: CP1 D3 Clones: Screen for presence of peptide specific antibody.
96 well plates coated with 5Pg/ml BSA-C peptide overnight at 4ºC. 50Pl of hybridoma
supernatants added as primary antibody secondary rabbit anti mouse HRP conjugate added
and incubated for 1 hour at room temperature. Plates washed and ABTS substrate system
used for ELISA detection. Plates read at 405nm and deviation expressed as two data points.
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Supernatants from many clones were stored at 4qC and cell samples were stored at -
163qC in liquid nitrogen. Cells were stored for potential later expansion and sub-
cloning.
In conclusion, C fusion hybridoma screens indicate strong antibody specificity to
linear peptide but not conformational antigen.
3.9: M Hybridoma screens and development
Mice M1 and M2 fusions were also screened for peptide specific antibody production,
recognition of native antigen and potential CD55 blocking ability. Figure 3.17
represents M1 and M2 hybridoma supernatant screen against BSA-M conjugated
peptide, assayed by ELISA. Serum produced a strong positive OD value of 1.0, while
only clones M1: F1, G4 and H2 gave greater responses to peptide. However, all other
clones produced values ranging from 0.4 to 1.0, indicating the presence of antibody
production. Results are difficult to assess due to potential rate of antibody production
into supernatants, which could vary between different clones, also the presence of
non-producing clones could reduce the comparative total antibody concentration.
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Figure 3.17: Screen of M1 and M2 hybridomas for production of peptide specific
antibody.
M1 and M2 splenocytes fused with NSO cells and selectively grown in HAT media. 96 well
plates coated with 5Pg/ml BSA-M peptide overnight at 4ºC. 50Pl of hybridoma supernatants
added as primary antibody and secondary rabbit anti mouse HRP conjugate added and
incubated for 1 hour at room temperature. Plates washed and ABTS substrate used for
ELISA detection. Plates read at 405nm and deviation expressed as two data points. Only
data for wells containing viable cells in displayed.
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All viable clones assayed for peptide specificity were analysed for recognition of
complete native antigen as expressed on 791T cells and results were obtained via flow
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cytometry. Figure 3.18 shows results for M1 and M2 clones, 791T/36 and BRIC 216
were used as positive controls and gave results 540 and 1083 (M.L.F) respectively.
All other clones except M1: A1 and F1 gave results comparable with unlabelled
control, indicating that most of the antibodies produced show no recognition of native
antigen. While M1 A1 clone produced an M.L.F value of 400, the deviation produced
was also significant, therefore only the M1 F1 clone was sub-cloned across a 96 well
plate at 0.3 cells per well.
Figure 3.18: Screen of M1 and M2 peptide positive clones for recognition of
native CD55 on 791T cell via flow cytometric analysis.
5 x 10
5
791T(CD55 expressing) and colo 205(non CD55 expressing) cells coated with 50Pl
hybridoma supernatant and incubated for 1 hour at 4ºC. Cells washed by centrifugation in
PBS and secondary rabbit anti mouse-HRP conjugate added and incubated for 1 hour at 4ºC.
Cells analysed by flow cytometry and deviation shows two data points.
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Positive M2 clones screen against native CD55
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Figure 3.19 represents analysis of M1 F1 clones screened against BSA-M peptide and
indicates that most of the viable cells produced during the cloning process are
generating antibodies. Antibody supernatants were then assessed by cytofluorimetric
analysis for recognition of conformational CD55 as expressed by 791T cells (Figure
3.20).
Figure 3.19: Screen of M1 F1 sub clones against BSA-M peptide and purified
CD55.
Supernatants screened via ELISA for presence of peptide specific antibodies. 5Pg/ml BSA-
conjugated M peptide and purified CD55 were coated on 96 well plates overnight at 4ºC.
50Pl of hybridoma supernatant was added as primary antibody and secondary rabbit anti-
mouse HRP conjugate was added and incubated for 1 hour prior to ABTS substrate addition.
Plates were read at 405nm. Only data from wells containing viable cells shown.
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Figure 3.20: Cytofluorimetric analysis of M1 F1 peptide positive clones:
recognition of conformational CD55 expressed on 791T cells.
5 x 10
5
791T(CD55 expressing) and Colo 205(non CD55 expressing) cells coated with 50Pl
hybridoma supernatant and incubated for 1 hour at 4ºC. Cells washed by centrifugation in
PBS and secondary rabbit anti mouse-FITC conjugate added and incubated for 1 hour at 4ºC.
Cells analysed by flow cytometry and deviation shows two data points.
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BRIC 216 and 791T/36 used as positive controls gave M.L.F values greater than
1000, demonstrating the high expression level of CD55 upon the cell surface. All
hybridomas produced results on the range of 25 to 35 for both 791T and Colo 205
cells, indicating no significant specificity for 791T cells over Colo 205 (non-
expressing). These findings would imply that like the C-hybridomas, the M clones
are also producing antibodies which only recognise linear peptide and possibly
denatured antigen, but not native conformation. All supernatants were also assessed
for their CD55 blocking ability. Figure 3.21 represents complement deposition assay
results using 791T cells, utilising supernatants from all strong M and C peptide
positive hybridoma clones. 1 x 10
5
791T cells were labelled with BRIC 216 as
positive control, blocking SCR3 domain of CD55 leading to increased C3b/c
deposition. 791T/36(target SCR1-2) was also used as potential control along with
BRIC 220 and unlabelled cells. All samples include cells without human serum as a
negative control. All values produced were comparable with unlabelled negative
control. BRIC 216 produced increased C3b deposition compared to control results,
indicating that a degree of CD55 blockade is occurring. BRIC 220 showed a basal
level of C3b deposition as expected, as it binds to SCR domain 1 and should not
affect CD55 regulatory activity. 791T/36 showed unexpected results, as C3b
deposition results were greater than those produced by BRIC 216, >500 and 300
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respectively. 791T/36 targets domains 1-2 of CD55, and while SCR2 is involved in
some classical and alternative pathway regulatory activity, a result greater than 216
blockade is not expected. Most hybridoma supernatants produce results comparable
with BRIC 220 indicating no alteration in CD55 activity and thus no blocking effect.
The M1 F1 C7 clone does produce an M.L.F value similar to BRIC 216 and may
therefore have some inhibitory effect upon CD55 activity.
Figure 3.21: Strongest peptide positive hybridoma supernatants screen for
CD55 blocking ability.
1 x 10
5
791T cells labelled with BRIC 216, 791T/36, BRIC 220 and 50Pl hybridoma
supernatant. Cells were incubated for 2 hours at 37qC with human donor serum obtained
from three individuals. Polyclonal anti human C3c FITC conjugated antibodies were added
and incubated for 1 hour at 4qC. Cells were assayed by flow cytometry and deviation shows
two data points.
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Figure 3.22 represents a screen of supernatants obtained from hybridomas previously
assayed for decay accelerating factor blocking ability. This assay was carried out to
confirm if produced antibodies bound to native CD55, screened against 791T cells by
indirect FACS analysis. All clones produced limited responses with values
comparable with unlabelled cells, indicating no recognition of native antigen.
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Figure 3.22: Screen of strongest hybridoma peptide positives for whole native
antigen recognition.
5 x 10
5
791T(CD55 expressing) and Colo 205(non CD55 expressing) cells coated with 50Pl
hybridoma supernatant and incubated for 1 hour at 4ºC. Cells washed by centrifugation in
PBS and secondary rabbit anti mouse-HRP conjugate added and incubated for 1 hour at 4ºC.
Cells analysed by flow cytometry and deviation shows two data points.
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Results obtained indicate that immunisation with target peptides produce strong
responses from B cells specific for the linear peptide sequence. However, it appears
that the natively expressed CD55 molecule on target tumour cells does not expose the
same sites as the peptide. This may be due to conformational tertiary structure
masking linear peptide binding sites. The predicted three dimensional models of
peptide sequences as shown in Figure 3.3, display predicted native conformation
based on the SCR domains of CD46. These models incorporate the post translational
modifications of naturally expressed proteins which are not generated by the target
peptides used.
3.10: Assessment of RM1 monoclonal antibody
Peptide positive clones have been repeatedly cloned, and monoclonal populations
expanded to generate high antibody volumes and concentrations. Clone M1 F1 F10
was expanded, and a stable cell line was generated expressing high levels of antibody
specific to the M peptide, having been derived from the human CD55 sequence. This
population was chosen for large scale production of anti-CD55 antibodies as it
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exhibited consistent specificity, as assessed by ELISA, and stability. This antibody
was designated RM1. RM1 antibody was purified via protein G affinity column and
glycine release protocols. Purified antibody was tested via peptide ELISA, western
blot analysis and direct 791T labelling and assessment by FACS analysis to determine
specificity and functionality. Recombinant SCR1-4 Fc fusion protein (Harris C
2001), used to represent structurally native CD55, was electrophoresed on an 8%
SDS-ployacrylamide gel under non-reducing conditions and transferred to a
nitrocellulose matrix. The blot was probed with anti-CD55 antibodies including RM1
(Figure 3.23). BRIC 216, 791T/36 and RM1 all recognised a band approximately
80kDa in size, equating to SCR 1-4 Fc. The control lane, without addition of primary
antibody confirms presence of specific binding. Protein analysed by western blotting
in non-reducing conditions will be partially denatured by the presence of the ionic
detergent SDS, which may alter SCR 3 conformation sufficiently for RM1
recognition.
Figure 3.23: Western blot analysis of SCR 1-4Fc fusion protein.
50ȝg/ml recombinant CD55 [SCR1-4Fc (Harris C. 2000)] electrophoresed on 8% SDS-
polyacrylamide gel under non-reducing conditions and transferred to nitrocellulose matrix.
Blot probed with 2ȝg/ml anti-CD55 antibodies and developed with ECL detection reagents.
1 2 3 4 5 6 7 8 9
Lanes: 1 Molecular weight markers
2 + 3 BRIC 216 (SCR3)
4 + 5 791T/36 (SCR1-2)
6 + 7 RM1 (SCR3)
8 Control lane (No primary antibody)
9 Control lane 708 (Non specific mouse antibody)
Cytofluorimetric analysis of RM1 binding to CD55 as expressed on 791T cells
(Figure 3.24) indicates that there is limited recognition of conformational antigen.
SCR 1-4 Fc
80kb
60kb
50kb
40kb
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RM1 antibody produces mean linear fluorescence comparable to control samples
while BRIC 216 and 791T/36 both produce fluorescence values up to 2 log values
greater.
Figure 3.24: FACS analysis of purified RM1 specificity to native conformational
CD55 as expressed on 791T cells.
1 x 10
5
791T cells labelled with 1Pg primary antibody (RM1, 791T/36 and BRIC 216) for 1
hour at 4qC. Cells were incubated with secondary rabbit anti mouse FITC conjugated
antibody for 30 minutes and cell samples were assessed by flow cytometry. Standard
deviation is expresses as two data points.
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To finally confirm RM1 specificity, a ‘sandwich’ ELISA was used to assess
recognition of native protein (SCR 1-4Fc) and target peptide (M-BSA). It can be
inferred from Figure 3.25, that while RM1 has high specificity for M-BSA peptide
(O.D of 0.65), limited recognition of recombinant protein is achieved (O.D of 0.15),
which is comparable to negative control values. It is worth noting that neither BRIC
216 or 791T/36 recognise M-BSA peptide while both show high OD values for the
complete structural protein, suggesting that BRIC 216’s target epitope is part of the
tertiary structure of CD55 and not linear peptide.
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Figure 3.25: Assessment of RM1 antigen specificity via ELISA.
5Pg/ml target antigen was coated on a 96 well plate and specific binding of several anti-CD55
antibodies was assessed. ABTS substrate was used and results were obtained via a plate
reader. All samples were run in triplicate producing standard deviation expressed as two data
points.
3.11: Assessment of 791T/36 inhibition of CD55 decay accelerating activity
As 791T/36 showed novel results in the complement deposition assay, the procedure
was repeated to produce consistent results. Figure 3.26 represents the results
obtained from C3b/c deposition on 791T cells when CD55 inhibition is attempted
with BRIC 216, BRIC 220 and 791T/36. BRIC 216 was also used to demonstrate the
presence of CD55 on the cell surface, producing M.L.F of 3287. BRIC 220 shows
binding of SCR1 of CD55 and no inhibition of regulatory activity, M.L.F of 260,
while BRIC 216 binding to the SCR3 domain produces increased deposition giving
values of up to 400. 791T/36 however, produces values of 650, displaying a
significant increase in the level of complement deposition and therefore CD55
inhibition. 791T/36 affects CD55 regulatory activity without binding directly to
SCR3, which has been shown in deletion mutants to generate the greatest defects in
CD55 function compared to other domains. It is proposed that 791T/36 inhibits CD55
function either by steric hindrance, masking the main active site, or by inducing
alteration of conformational structure upon binding to SCR1-2.
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Figure 3.26: Repeat of C3b/c deposition assay for 791T/36 blocking ability
compared to BRIC 216 and BRIC 220.
1 x 10
5
791T cells labelled with BRIC 216, 791T/36, BRIC 220. Cells were incubated for 2
hours at 37qC with human donor serum obtained from three individuals. Polyclonal anti
human C3c FITC conjugated antibodies were added and incubated for 1 hour at 4qC. Cells
were assayed by flow cytometry and deviation shows two data points.
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3.12: Discussion
The initial aim of this project was to produce an antibody specifically targeting the
active site of CD55 and inhibiting its decay accelerating activity. As mentioned,
previous studies have identified specific domains within CD55 that maintain its
function. Deletion mutants have shown that SCR domain 3 plays a pivotal role in
disrupting both the alternative and classical complement pathways. This factor
identified SCR 3 as a valid target for monoclonal antibody development. Preliminary
peptide immunisation strategies were chosen in order to direct a response towards the
specific epitope within the SCR domains of CD55.
Through utilisation of hydrophobicity algorithms, the hydrophilic pattern of SCR 3
protein structure was determined. Comparison of the hydrophilic domains within the
sequence against the crystal structure of CD46 enabled prediction of the surface
locations of these specific peptides. These regions from within the SCR 3 peptide
sequence, identified as being exposed on the protein surface, are potentially antigenic
and were therefore successfully synthesised and coupled to carriers to be used in the
immunisation protocol. A preliminary strategy for immunisation was to prime and
boost responses with the peptides in order to generate a B cell population specific for
the target sequences. Later boosting of responses could be achieved through
immunisation with whole cells, where the only common antigens would be regions
within the SCR 3 domain of CD55.
These results would implicate that a preliminary peptide immunisation strategy only
directs antibody development specific for the linear peptide. Peptide synthesis does
not incorporate post translation modifications that occur in vivo, and therefore
generation of native tertiary structure is not produced. Thus native epitopes are not
generated and responses produced are towards the linear structure. Craig et al (1998)
state that when polyclonal antibodies are screened against peptide libraries, the
positive peptide sequences isolated recognise linear regions within the complete
protein structure. This would indicate that peptides are able to generate protein
specific antibodies as long as the specific epitopes tertiary structure is a linear region
within the protein. Wilson et. al., (1995) state that antibodies specific to peptides
interact with their target antigen differently to protein specific antibodies and involve
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the presence of ionic interactions, Van der Waal’s forces and H bonds. While
antibodies possess only limited canonical conformations, their binding sites are
specific to their antigens. Protein specific antibodies possess large, flat binding sites
that enable primary ‘docking’, which then induces conformational changes within
both the antibody and the antigen, thus exposing previously hydrophobic residues,
generating high affinity interactions by increasing complementarity and charge based
interactions (Braden et al, 1995 & Lara-Ochoa et al, 1996). However, peptide
specific antibodies possess smaller, deeper clefts in which peptide sequences bind,
being unable to easily bind protein structures and only with weak affinity. It appears
that to generate successful cross recognition from peptides to proteins, small
sequences from within linear domains of proteins are required. The initial peptide
predictions used in this study produce ‘barrel’ like conformations and hence the initial
docking affinity for complete structural epitopes may be weak. Therefore, to improve
peptide strategies, short sequences containing residues with strong binding potential
should be used. This could be achieved by following methodology used by Craig et.
al. (1998), utilising more superpositional structural assignment computer programs.
This would aid in the evaluation of conformational preference inherent in each
sequence, enabling identification of structural domains in the peptide that match
protein epitopes.
These findings show a functional use for RM1 as an antibody detecting the presence
of CD55 under varying conditions. One particular area of importance is for staining
of paraffin embedded tissue sections, which has been assessed by Dr Zahra Madjd
(2004). There are currently no good anti-CD55 antibodies available for
immunohistochemical analysis. Madjd et. al., have shown utilising RM1, that in a
study of 480 patients with primary breast carcinoma, high expression of CD55 is
associated with low histological grade and good prognosis and that loss of CD55 is
associated with poor prognosis. CD55 expression in breast carcinoma is also
comparable with CD59 expression, and while these findings are controversial, they
suggest further roles for CD55, this providing more evidence of the potential benefit
from targeting CD55 in tumour therapy. 791T/36 mAb has been used to assess CD55
expression on colorectal cells via FACS analysis, with increased antigen expression
associated with poor prognosis (Durrant et al, 2003). These findings would be
predicted, although it is unclear whether CD55 acts predominantly to suppress
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complement mediated attack or as an inhibitor of T cell specific responses via CD97
(Durrant et al, 2003). It appears that CD55 acts via numerous pathways and its
expression is involved with many interactions.
Finally, during complement deposition assays, it was noted that 791T/36 which
specifically binds SCR domains1-2 of human CD55 significantly affected the level of
C3b deposition produced. These findings indicate that while 791T/36 does not
directly bind the active SCR 3 site of CD55, it potentially either blocks the SCR3 via
steric hindrance or it induces a conformational change within the CD55 structure
itself, preventing decay accelerating activity. Results obtained indicate that 791T/36
binds native CD55 on the surface of osteosarcoma cells with similar ability as BRIC
216, a SCR3 targeting antibody. When compared via ELISA against recombinant
protein, 791T/36 generates a greater response than BRIC 216, and also compared via
complement deposition assay against 791T osteosarcoma, the anti SCR 1-2 appears to
enhance C3b deposition with greater ability compared to BRIC 216. In order to
determine whether increased complement deposition was indeed mediated by the
inhibition of CD55 decay accelerating activity, or whether by antibody fixation of
complement, further analysis must be carried out. This could be achieved with the
use of C1q depleted serum, which would remove the complement component, which
binds to the Fc domains of antibodies used within this analysis. By incorporating this
step, any enhanced C3b/c deposition observed would be due to blockade of CD55’s
active site.
The decay accelerating activity of CD55 has been located within domains 2-3 for
classical pathway and 2-4 for alternative pathway activity (Brodbeck et al, 1996).
Mutations within SCR 3 however, have produced the greatest disruption of CD55’s
regulatory activity, although SCR 1-2 transfectants have generated regulation of the
alternative complement pathway (Christiansen et al, 2000).
A recent paper by Lukacik et al (2004) analysing the crystal structure of CD55 has
elucidated several inconsistencies in prior literature. They state that the previous
studies show that interaction between CD55 and the convertases were likely to
involve large areas on the surface of CD55 (classical pathway convertases contact
SCR 2 and 3, whereas alternative pathway convertases contact SCR 2, 3 and 4).
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However, mapping of the key interaction site for both convertases has been
complicated by the fact that the site is centred on residues located at the junction
between SCR 2 and 3. Lukacik et al state that many of these residues only act
indirectly by structural perturbation of CD55 at the SCR2/3 interface.
Mapping of biological function
onto CD55 structure:
Lukacik et al (2004)
Two views of CD55 are shown folded
by 180q rotation about the vertical axis.
(a) Charge distribution is coloured from
blue (positive) to red (negative), via
white (no charge).
(b) Mapping of amino acid positions
where substitution is known to affect
classical pathway regulatory activity.
Positions where substitutions reduces
activity to 10% or less of wild type
activity (Dark blue), and 50% or less
(Light blue).
(c) Mapping of amino acid positions
where substitution affects alternative
pathway convertases to 10% or less of
wild type activity (dark green), and 50%
or less (light green).
They also state that functional protein-protein interactions depend on a combination
of affinity and high specificity, often involving polar (hydrogen bonding and
electrostatic) and apolar (Van der Waals and hydrophobic) contacts. Their analysis of
hydrophobic surface potential suggest a strong candidate for a protein binding site
centred on Leu 171 and Phe 169 near the SCR 1/2 interface. These have been
identified previously, showing that substitutions in Leu 171 decrease CD55 regulatory
ability of both convertases while mutations at Phe169 decrease AP convertase
regulation (Kuttner-Kondo, 2001).
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This data would indicate that an antibody raised to a linear peptide of SCR3, while
useful as a CD55 probe, is unlikely to possess CD55 neutralising capability.
However, as 791T/36 has shown promising results, this new molecular target data
may strengthen the hypothesis that this SCR1-2 specific antibody may at least be
involved in perturbation of CD55 structure or may act by steric hindrance, blocking
the SCR1/2 domain interface.
Spendlove et. al., (2006) have demonstrated that 791T/36 is capable of blocking the
interaction between CD55 and CD97 on activated T cells, thus preventing CD55’s
inhibition of T cell function. These findings suggest that 791T/36 as a SCR 1-2
directed antibody has the potential to not only inhibit CD55 as a regulator of
complement but also as a blocker of T cell responses. This would suggest that
791T/36 could be used to potentially prevent CD55 activity and sensitise target
tumour cells to autologous complement and enhance a cell specific T lymphocyte
response. This can be achieved by humanising 791T/36, as previously discussed.
For many years 791T/36 was used for imaging of a variety of tumours and showed
effective localisation in patients with bone and soft tissue sarcomas (Armitage et al,
1986). As CD55 is also present on most normal cells this could be a potential
problem. However, on osteosarcoma, ovarian, gastric and colorectal cells, CD55 is
present at 10
5
to 10
6
molecules per cell (Spendlove et al, 1999) compared to 10
4
molecules on red blood cells, which has been shown to be sufficient for complement
protection. Within the tumour environment, its elevated expression allows divalent,
higher affinity binding compared to low antigen levels allowing weak monovalent
interactions upon erythrocytes. It is this high-density expression within tumours that
is favoured and enables antibody accumulation on the tumour surface. This has been
shown with patients treated with radio labelled 791T/36 showing only background
levels of radioactivity on peripheral blood mononuclear cells and red blood cells.
Pimm et. al., (1987) stated that 791T/36 not only was useful for immunodetection of
primary and colorectal carcinomas but also showed potential for targeting of
therapeutic agents. 791T/36 was coupled to methotrexate, vindesine and daunomycin,
and these conjugates retained drug activity, antibody function and localised to
colorectal carcinoma xenografts.
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All of these factors indicate a potent use for 791T/36 and other SCR 1-2 targeting
antibodies. Humanisation of this mouse IgG2b could enable it to be used
therapeutically to block CD55 function and target it as a tumour associated antigen.
This would function by recruiting complement and T cells responses as well as
potentially sensitising cells to CD8
+
and NK cell attack. Other therapeutic antibodies
used for the treatment of tumours, such as rituximab, have also shown to be more
effective when used in combination with complement regulatory protein blocking
antibodies (Golay et al, 2000). The biotechnology company Viragen have humanised
791T/36 and are currently assessing its potential as a stand alone anti-cancer therapy.
Preclinical trials are also underway determining the use of this CD55 inhibitor in
combination with other anti cancer antibodies in order to promote anti tumour
responses. In March 2005, Viragen published a press release stating that their CD55
specific antibody was found to significantly enhance cancer cell destruction mediated
by the drug Rituxan

by in vitro assessment.
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Chapter 4: Development and assessment of SCR 1-3 Fc DNA vaccine
eliciting antibody responses to CD55
4.1: Introduction
As our previous peptide immunisations generated antibodies recognising only linear
peptides, we decided to immunise with functional protein to generate CD55
neutralising antibodies. As our own data conforms with current research indicating
than CD55 activity localises to the SCR 1-2 interface and that previous studies have
shown that complement regulation may involve SCR domain 3, new CD55
immunisation strategies were developed. DNA constructs were generated
incorporating SCR 1-3 domains of CD55 into the Signal pIg plus vector, aiming to
generate SCR1-3 Fc fusion proteins. This strategy was used in order to develop
native, functional protein, which could be used both as vaccine and as potential screen
for antibody responses. The DNA constructs could also be used to immunise directly
via Helios

gene gun, with the aim of directing In vivo expression of functional
protein either by cellular uptake or through direct transfection of antigen presenting
dendritic cells or by DC uptake from transfected keratinocytes.
Post DNA immunisation, antigens are presented to the immune system by two main
mechanisms for the development of antigen specific CTL responses, namely direct
priming and cross presentation. Direct priming requires DNA transfection of APCs,
whilst cross presentation involves antigen expression within somatic cells, which are
in turn presented to APCs. Cross presentation, mediated by bone marrow derived
APCs, enables both processing and presentation of exogenous antigens in an MHC
class I restricted manner. It is this process which has been identified as essential in
the generation of CTLs specific to tumour, virus and tissue antigens (Shen et. al.,
2004). Development of cross priming can be mediated by both non-specific
interactions, through pinocytosis, or can be mediated through specific receptors in an
active process. Targeting of proteins to such specific receptors on APCs may enhance
presentation and incorporation into the adaptive immune response. FcJRI is involved
in active antigen uptake and transfer to endocytic compartments involved in
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processing within APCs. Targeting antigen delivery to APC via FcJRI was achieved
by combining target DNA to a human IgG1 tail.
DNA immunisation by gene gun utilises 100 times less DNA then alternative
intramuscular vaccination, and is capable of producing equivalent immune responses.
The increased reliability and reproducibility of gene gun modality indicates that this
mode of administration could easily be translated into human trials in the form of
potential anti-tumour therapy. As ballistic immunisation strategies have already been
developed for vaccination into human epidermis, this strategy for generation of
immunity is viable for translation from mouse models into a human system.
Subsequent DNA immunisations were carried out using gene gun protocols, and
antibodies generated were assayed via ELISA specifically recognising the SCR 1-3 Fc
fusion protein.
Antibodies generated by the SCR 1-3 Fc (Wild Type) construct are compared with
those raised by immunisation with the same construct incorporating a heteroclitic
epitope. Chapter 5 details the rationale and methodology utilised for identification
and development of the construct containing the CTL epitope Z158m. The results are
combined in order to directly compare antibody responses mediated towards the wild
type and mutated vaccines, and to determine what effects alteration of the native
sequence has on immune responses generated.
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Results
4.2: Development of SCR 1-3 Fc DNA vaccine
Human full length CD55 cDNA had been previously isolated from 791T
osteosarcoma cells and TA cloned into the PCR II- TOPO vector. This plasmid is
used as it incorporates a topoisomerase I enzyme allowing the direct insertion of taq
polymerase amplified PCR products. Ligation products were then used to transform
TOP10F competent bacteria and plated on to ampicillin selective LB agar plates.
Single colonies were assessed for incorporation of PCR II TOPO plasmid using M13
forward and reverse primers and mini cultures of positive clones were grown in
selective LB media. Qiagen DNA preparations were made and glycerol stocks of
transformed cells were also made and stored at -80°C.
4.3: PCR amplification of SCR 1-3 products for ligation into Signal pIgplus
vector.
Primers were designed to amplify the CD55 leader SCR 1-3 regions from PCR II-
TOPO, incorporating restriction sites for kpnI in the forward primer and BamHI in the
reverse primer. Figure 4.1 displays the CD55 leader primer and SCR 3 reverse primer
utilised for extraction of the desired sequence from complete CD55. The DSCR23
primer sequence is also displayed which was initially used for amplification of the
SCR 2 domain of CD55 and was used in this case for sequence analysis. The kpnI
restriction site had been incorporated into the Signal pIgplus vector via site directed
mutagenesis along with removal of the factor Xa cleavage site. Figure 4.2 shows full
length CD55 sequence indicating primer binding sites for desired PCR product
amplification. Determination of optimal annealing temperature for the primer set was
determined using standard PCR protocols, varying the annealing temperatures used
(Figure 4.3). Successful amplification was observed via analysis of reaction samples
via visualisation on a 1% agarose gel; desired product is seen as a 697bp band. CD55
leader SCR1-3 PCR product was then ligated into an empty PCR II-TOPO vector,
enzyme digested with kpnI and BamHI. DH5D competent cells were then
transformed with the new ligation and cultured on ampicillin selective LB agar plates.
Single colonies were again cultured and Qiagen maxi preparations were carried out to
isolate the DNA construct (CD55 leader SCR1-3 PCR II-TOPO).
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Figure 4.1: Primer Design for CD55 leader SCR 1-3 incorporation into Signal
pIgplus plasmid
CD55 Leader Forward Primer
5’TT GTT [GGT ACC] CGG CGC GCC ATG ACC3’
kpnI Met Thr
Binds from 46-71bp of CD55 cDNA sequence
26mer
TM = 66
SCR 3 Reverse Primer
5’
G[GGATC]CGC TTC TCT GCA CTC TGG CAA CG 3’
BamHI Glu Arg Cys Glu Pro Leu
Binds from 740-712bp of the CD55 cDNA sequence
29mer
TM = 72.6
DSR 23 Reverse Primer
5’
[GG ATC C]TT ACA AAA TTC GAC TGC TGT GGA C
3’
Bam HI Lys Cys Phe Glu Val Ala Thr Ser
Binds from 547-518bp of the CD55 cDNA sequence
29MER
TM = 72.6
Forward and reverse primers designed to bind to CD55 leader sequence in the 5’ direction and
SCR 3 in the 3’ direction. Amplification of desired sequence from combined primer set
yields a fragment of 697bp.
Figure 4.2: Human CD55 DNA and Protein Sequence
DNA Accession No: BC001288 Protein Acc No:P08174
60-184 CD55 Leader
185-361 SCR 1 35-95 SCR1
371-553 SCR 2 97-159 SCR2
566-739 SCR 3 162-221 SCR3
752-928 SCR4 224-284 SCR4
287-356 SER/THR Rich
M Start of protein sequence
1 gcaactcgct ccggccgctg ggcgtagctg cgactcggcg gagtcccggc ggcgcgtcct
Q L A P A A G R S C D S A E S R R R V L
61 tgttctaacc cggcgcgcca tgaccgtcgc gcggccgagc gtgcccgcgg cgctgcccct
V L T R R A M T V A R P S V P A A L P L
121cctcggggag ctgccccggc tgctgctgct ggtgctgttg tgcctgccgg ccgtgtgggg
L G E L P R L L L L V L L C L P A V W G
181tgactgtggc cttcccccag atgtacctaa tgcccagcca gctttggaag gccgtacaag
D C G L P P D V P N A Q P A L E G R T S
241ttttcccgag gatactgtaa taacgtacaa atgtgaagaa agctttgtga aaattcctgg
F P E D T V I T Y K C E E S F V K I P G
301cgagaaggac tcagtgatct gccttaaggg cagtcaatgg tcagatattg aagagttctg
E K D S V I C L K G S Q W S D I E E F C
361caatcgtagc tgcgaggtgc caacaaggct aaattctgca tccctcaaac agccttatat
N R S C E V P T R L N S A S L K Q P Y I
421cactcagaat tattttccag tcggtactgt tgtggaatat gagtgccgtc caggttacag
T Q N Y F P V G T V V E Y E C R P G Y R
481aagagaacct tctctatcac caaaactaac ttgccttcag aatttaaaat ggtccacagc
R E P S L S P K L T C L Q N L K W S T A
541agtcgaattt tgtaaaaaga aatcatgccc taatccggga gaaatacgaa atggtcagat
V E F C K K K S C P N P G E I R N G Q I
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601tgatgtacca ggtggcatat tatttggtgc aaccatctcc ttctcatgta acacagggta
D V P G G I L F G A T I S F S C N T G Y
661caaattattt ggctcgactt ctagtttttg tcttatttca ggcagctctg tccagtggag
K L F G S T S S F C L I S G S S V Q W S
721tgacccgttg ccagagtgca gagaaattta ttgtccagca ccaccacaaa ttgacaatgg
D P L P E C R E I Y C P A P P Q I D N G
CTAACC . CD55 leader primer binding site. Region in primer mutated to produce GGTACC = kpnI
restriction site in Signal pIgplus vector
CCAG. SCR 3 reverse primer binding site incorporating BamHI site post Glutamic acid (E) position.
Figure 4.3: Optimisation PCR of CD55 Leader SCR 1-3 from PCR II TOPO
construct. Analysis of primer set.
1 2 3 4 5 6
1: CD55 Leader SCR 1-3 53qC
2: CD55 Leader SCR 1-3 54.5qC
3: CD55 Leader SCR 1-3 56.9qC
4: CD55 Leader SCR 1-3 59.7qC
5: CD55 Leader SCR 1-3 61.3qC
6: 100bp ladder
1% agarose gel electrophoresis of PCR amplified products generated with combined CD55
leader-SCR3 primer set. Varying annealing temperatures used to optimise product generation
and no non-specific products present in gel analysis. 55qC chosen as optimal annealing
temperature for combined primer set.
4.4: Cloning of CD55 leader SCR 1-3 into Signal pIgplus vector
The CD55 leader SCR 1-3 domain was isolated from the PCR II-TOPO vector by
kpnI and BamHI restriction endonuclease digestion. PCR II-TOPO without any insert
was digested with both of the enzymes in order to confirm successful digestion of the
plasmid. Restriction digest samples were analysed on a 1% agarose gel (Figure 4.4).
The CD55 leader SCR 1-3 can be seen as a 697bp band and the digested PCR II-
TOPO produces a 4kb DNA band.
The Signal pIgplus plasmid was also cut with kpnI and BamHI restriction enzymes
and the products ran on a 1% agarose gel. The linear Signal pIgplus and 697bp CD55
leader SCR 1-3 fragments were excised from the gels and phenol/chloroform
precipitation was used to clean up the digested products. These digests were then
electrophoresed on a 1% agarose gel to confirm that the DNA had not been lost
during the clean up procedure (Figure 4.5).
~697bp
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Figure 4.4: PCR II TOPO +/- (CD55 leader SCR 1-3) restriction digest with kpnI
and BamHI
1 2 3 4 5 6
1: pCR II TOPO knpI and BamHI
2: pCR II TOPO knpI and BamHI
3: Empty lane
4: pCR II TOPO kpnI
5: pCR II TOPO Bam HI
6: 2-log DNA ladder
1% agarose gel electrophoresis of pCR II Topo CD55 leader SCR 1-3 digested with kpnI and
BamHI restriction endonucleases. Successful removal of CD55 leader SCR 1-3 producing
band of ~697bp and linear pCR II TOPO plasmid ~4000bp.
Figure 4.5: Restriction enzyme digest of CD55 leader SCR 1-3 PCR products
post purification
1 2 3 4
1: Gel extracted CD55 Leader SCR1-3 kpnI and
BamHI
2: Gel extracted CD55 Leader SCR1-3 kpnI and
BamHI
3: Gel extracted Signal pIgplus kpnI and BamHI
4: 2-Log DNA ladder
1% agarose gel electrophoresis of restriction endonuclease digested CD55 leader SCR1-3
PCR product and signal pIgplus plasmid. PCR products excised from agarose and
phenol/chloroform DNA precipitated. Products digested with both kpnI and BamHI for
ligation into Signal pIgplus plasmid. Double digested PCR products show a band of ~697bp.
Restricted plasmid generates a band ~6302bp (removed 39bp of multiple cloning site by
enzyme restriction).
The CD55 leader SCR 1-3 product was then ligated utilising T4 DNA ligase into the
kpnI /BamHI sites of the restricted signal pIgplus vector. DH5D competent bacteria
were then transformed with the new construct and colonies were screened for the
DNA insert via PCR with T7 forward and DSCR23 reverse (binds end of SCR2 of
CD55) primers. Figure 4.6 shows the results of the colony screen with positive
1000bp
500bp
~697bp
~4000bp
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colonies yielding a 541bp fragment. DNA minipreps of positive colonies were
carried out and construct integrity was checked by using a negative control restriction
digest with XHOI. Results are shown in Figure 4.7 displaying super-coiling of all
DNA minipreps as no digestion of the plasmid has occurred.
Figure 4.6: Screen of DH5D colonies transformed with Signal pIgplus containing
CD55 leader SCR 1-3. Screened using T7 and DSCR 23 reverse primers.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1 and 20: 100bp ladder
2-19: Signal pIgplus
CD55 leader SCR 1-3
1% agarose gel electrophoresis of DH5D colonies transformed with Signal pIgplus plasmid
encoding CD55 leader SCR1-3. PCR analysis of colonies with T7 forward primer and DSCR
23 reverse primer yielding a product from positive colonies containing ~541bp fragment.
DSCR 23 reverse primer designed for amplification of SCR 2 region of CD55, yielding
smaller fragment.
Figure 4.7: Control restriction enzyme digest analysis of minipreps containing
CD55 Leader SCR1-3 for assessment of construct integrity
1 2 3 4 5 6 7 8 9 10 11 12
1 and 12: 2-log DNA ladder
2 to 11: Signal pIgplus CD55
leader SCR 1-3 XHOI digested.
1% agarose gel electrophoresis of Signal pIgplus encoding CD55 leader SCR 1-3 Fc
restriction endonuclease digested with XHOI. No restriction site should be present in either
insert or plasmid allowing supercoiling of construct DNA.
1000bp
500bp
500bp
1000bp
3000bp
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Further assessment of the complete construct was required and therefore digested
using BglII and Hind III restriction enzymes. This double digest should generate two
bands one of 1112bp and one of 5740bp. These two enzymes were chosen as BglII
cuts once within the Signal pIgplus sequence, and Hind III cuts once in the CD55
sequence. The results are shown in Figure 4.8 and clearly show the presence of two
bands.
Figure 4.8: Signal pIgplus CD55 leader SCR 1-3 construct restriction digest with
Bgl II and Hind III (assessment of complete construct)
1 2 3 4 5 6 7 8 9 10 11 12
1 and 12: 2-log DNA ladder
2 to 11: Signal pIgplus CD55
leader SCR 1-3 BglII/Hind III
digested.
1% agarose gel electrophoresis of CD55 leader SCR 1-3 Signal pIgplus construct restriction
endonuclease digested with Hind III and BglII enzymes for assessment of complete construct.
Hind III cuts construct at position 266 of CD55 only.
Bgl II cuts Signal pIgplus at position 5394.
CD55 leader SCR 1-3 (71-740bp of CD55) incorporated into plasmid at kpnI / BamHI sites
(6311-5357).
2 fragments expected : (6311-5394) + (266-71) = 1112bp
BglI to start of insert + CD55 to Hind III
: (740-771-266) + (5394-57) = 5740bp
CD55 insert minus 266 cut with HindIII + Signal pIgplus
minus region cut with BglII.
Control digest indicates complete CD55 leader SCR 1-3 has been incorporated into Signal
pIgplus plasmid.
4.5: Sequencing of the CD55 leader SCR 1-3 in Signal pIgplus
The CD55 leader SCR 1-3 Signal pIgplus construct was sequenced using the SCR3
reverse primer (Figure 4.9). The returned sequence was run in the NCBI sequence
alignment program with the full-length human CD55 sequence. Results show
complete alignment of the sequence with no mutations present in the generated
construct. The chosen insert is in frame with restriction sites present in the Signal
1000bp
3000bp
500bp
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pIgplus plasmid and the human IgG Fc tail. Figure 4.10 shows the complete
sequence of the Signal pIgplus plasmid encoding for CD55 leader SCR 1-3 in frame
with Fc tail.
Figure 4.9: Sequence of CD55 leader SCR1-3 in Signal pIgplus vector using SCR
3 Reverse primer
1NGCTNNGNNG ANGGGACCCC CACCCCCCAC CACCTTCGAT GGGATCCGCT TCTCTGCACT60
61CTGGCAACGG GTCACTCCAC TGGACAGAGC TGCCTGAAAT AAGACAAAAA CTAGAAGTCG120
121AGCCAAATAA TTTGTACCCT GTGTTACATG AGAAGGAGAT GGTTGCACCA AATAATATGC180
181CACCTGGTAC ATCAATCTGA CCATTTCGTA TTTCTCCCGG ATTAGGGCAT GATTTCTTTT240
241TACAAAATTC GACTGCTGTG GACCATTTTA AATTCTGAAG GCAAGTTAGT TTTGGTGATA300
301GAGAAGGTTC TCTTCTGTAA CCTGGACGGC ACTCATATTC CACAACAGTA CCGACTGGAA360
361AATAATTCTG AGTGATATAA GGCTGTTTGA GGGATGCAGA ATTTAGCCTT GTTGGCACCT420
421CGCAGCTACG ATTGCAGAAC TCTTCAATAT CTGACCATTG ACTGCCCTTA AGGCAGATCA480
481CTGAGTCCTT CTCGCCAGGA ATTTTCACAA AGCTTTCTTC ACATTTGTAC GTTATTACAG540
541TATCCTCGGG AAAACTTGTA CGGCCTTCCA AAGCTGGCTG GGCATTAGGT ACATCTGGGG600
601GAAGGCCACA GTCACCCCAC ACGGCCGGCA GGCACAACAG CACCAGCAGC AGCAGCCGGG660
721GCAGCTCCCC GAGGAGGGGC AGCGCCGCGG GCACGCTCGG CCGCGCGACG GTCATGGCGC720
781GCCGGGTACC AGCTTGGGTC TCCCTATAAG TGAGTCGTAT TAATTTTCGA TAAGCCAGTA780
GG SCR 3 Reverse primer ACC Former factor Xa cleavage site (GCA)
GGGATC BamHI site
CG CD55 leader forward primer
GGTACC kpnI site cloned into Signal pIgplus plasmid
NCBI alignment of returned sequence with accession number BC001288 [Homo
sapiens decay accelerating factor for complement (CD55, Cromer blood group system)]
50 ttctctgcactctggcaacgggtcactccactggacagagctgcctgaaataagacaaaa 109
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
745 ttctctgcactctggcaacgggtcactccactggacagagctgcctgaaataagacaaaa 686
203 E R C E P L P D S W Q V S S G S I L C F
110 actagaagtcgagccaaataatttgtaccctgtgttacatgagaaggagatggttgcacc 169
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
685 actagaagtcgagccaaataatttgtaccctgtgttacatgagaaggagatggttgcacc 626
183 S S T S G F L K Y G T N C S F S I T A G
170 aaataatatgccacctggtacatcaatctgaccatttcgtatttctcccggattagggca 229
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
625 aaataatatgccacctggtacatcaatctgaccatttcgtatttctcccggattagggca 566
163 F L I G G P V D I Q G N R I E G P N P C
230 tgatttctttttacaaaattcgactgctgtggaccattttaaattctgaaggcaagttag 289
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
565 tgatttctttttacaaaattcgactgctgtggaccattttaaattctgaaggcaagttag 506
143 S K K K C F E V A T S W K L N Q L C T L
290 ttttggtgatagagaaggttctcttctgtaacctggacggcactcatattccacaacagt 349
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
505 ttttggtgatagagaaggttctcttctgtaacctggacggcactcatattccacaacagt 446
123 K P S L S P E R R Y G P R C E Y E V V T
350 accgactggaaaataattctgagtgatataaggctgtttgagggatgcagaatttagcct 409
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
445 accgactggaaaataattctgagtgatataaggctgtttgagggatgcagaatttagcct 386
103 G V P F Y N Q T I Y P Q K L S A S N L R
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410 tgttggcacctcgcagctacgattgcagaactcttcaatatctgaccattgactgccctt 469
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
385 tgttggcacctcgcagctacgattgcagaactcttcaatatctgaccattgactgccctt 326
83 T P V E C S R N C F E E I D S W Q S G K
470 aaggcagatcactgagtccttctcgccaggaattttcacaaagctttcttcacatttgta 529
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
325 aaggcagatcactgagtccttctcgccaggaattttcacaaagctttcttcacatttgta 266
63 L C I V S D K E G P I K V F S E E C K Y
530 cgttattacagtatcctcgggaaaacttgtacggccttccaaagctggctgggcattagg 589
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
265 cgttattacagtatcctcgggaaaacttgtacggccttccaaagctggctgggcattagg 206
43 T I V T D E P F S T R G E L A P Q A N P
590 tacatctgggggaaggccacagtcaccccacacggccggcaggcacaacagcaccagcag 649
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
205 tacatctgggggaaggccacagtcaccccacacggccggcaggcacaacagcaccagcag 146
23 V D P P L G C D G W V A P L C L L V L L
650 cagcagccggggcagctccccgaggaggggcagcgccgcgggcacgctcggccgcgcgac 709
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
145 cagcagccggggcagctccccgaggaggggcagcgccgcgggcacgctcggccgcgcgac 86
3 L L R P L E G L L P L A A P V S P R A V
710 ggtcatggcgcgccgggt 727
||||||||||||||||||
85 ggtcatggcgcgccgggt 68
1 T M
No mutations present in CD55 leader SCR 1-3 compared to wild type CD55.
Insert is in-frame with human IgG (Fc tail) of Signal pIgplus plasmid.
Figure 4.10: Sequence of CD55 leader SCR 1-3 Fc in Signal pIgplus plasmid
AAT T7 Primer ATG  GAC CD55 leader sequence
GGT ACC kpnI restriction site
GAT CCC BamHI restriction site
GGT Former factor Xa cleavage site
KSC Start of human IgG Fc tail
TCT pIgplus SEQ 3’ primer
GAA ATT AAT ACG ACT CAC TAT AGG GAG ACC CCA GCT GGT ACC CGG CGC GCC
T R R A
ATG ACC GTC GCG CGG CCG AGC GTG CCC GCG GCG CTG CCC CTC CTC GGG GAG
M T V A R P S V P A A L P L L G E
CTG CCC CGG CTG CTG CTG CTG GTG CTG TTG TGC CTG CCG GCC GTG TGG GGT
L P R L L L L V L L C L P A V W G
GAC TGT GGC CTT CCC CCA GAT GTA CCT AAT GCC CAG CCA GCT TTG GAA GGC
D C G L P P D V P N A Q P A L E G
CGT ACA AGT TTT CCC GAG GAT ACT GTA ATA ACG TAC AAA TGT GAA GAA AGC
R T S F P E D T V I T Y K C E E S
TTT GTG AAA ATT CCT GGC GAG AAG GAC TCA GTG ATC TGC CTT AAG GGC AGT
F V K I P G E K D S V I C L K G S
CAA TGG TCA GAT ATT GAA GAG TTC TGC AAT CGT AGC TGC GAG GTG CCA ACA
Q W S D I E E F C N R S C E V P T
AGG CTA AAT TCT GCA TCC CTC AAA CAG CCT TAT ATC ACT CAG AAT TAT TTT
R L N S A S L K Q P Y I T Q N Y F
CCA GTC GGT ACT GTT GTG GAA TAT GAG TGC CGT CCA GGT TAC AGA AGA GAA
P V G T V V E Y E C R P G Y R R E
CCT TCT CTA TCA CCA AAA CTA ACT TGC CTT CAG AAT TTA AAA TGG TCC ACA
P S L S P K L T C L Q N L K W S T
GCA GTC GAA TTT TGT AAA AAG AAA TCA TGC CCT AAT CCG GGA GAA ATA CGA
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A V E F C K K K S C P N P G E I R
AAT GGT CAG ATT GAT GTA CCA GGT GGC ATA TTA TTT GGT GCA ACC ATC TCC
N G Q I D V P G G I L F G A T I S
TTC TCA TGT AAC ACA GGG TAC AAA TTA TTT GGC TCG ACT TCT AGT TTT TGT
F S C N T G Y K L F G S T S S F C
CTT ATT TCA GGC AGC TCT GTC CAG TGG AGT GAC CCG TTG CCA GAG TGC AGA
L I S G S S V Q W S D P L P E C R
GAA GCG GAT CCC ATC GAA GGT GGT GGT GGT GGT GTT GTT GAT CCC AAA TCT
E G G G G D P K S
TGT GAC AAA CCT CAC ACA TGC CCA
C D K P H T C P
4.6: Eukaryotic expression of SCR 1-3Fc fusion protein
CHO cells obtained for viability within serum free media were selected as suitable
targets for transfection with SCR 1-3 Fc DNA construct for expression of CD55
fusion protein. Serum free conditions were preferable in order to obtain pure fusion
protein containing no contaminating serum proteins. Transfection of target cells was
carried out using DMRIE C reagent and 2µg, 4µg and 6µg SCR1-3 Fc DNA.
Selective pressure was applied for culture of successfully transfected targets with
500µg/ml G418 sulphate. (As assessed with antibiotic kill curve of non transfected
CHO-SF cells). Transfected cells were cultured for two weeks maintaining selection
pressure and supernatant was collected. Purification of expressed protein was carried
out using protein G columns in order to selectively bind fusion protein mediated via
human Ig Fc tail. Protein was assessed via anti human Fc capture ELISA determining
viable expression of CD55 domains as assessed via CD55 specific antibodies.
A protein assay was initially set up for analysis of protein production and presence
within culture supernatant. The assay was used with SCR3 Fc fusion protein, which
was previously generated following identical methodology as per the SCR 1-3 Fc
construct. Initial ELISA analysis using direct binding of purified protein or culture
supernatant to the plate appeared to prevent specific antibody recognition of SCR 3
domain of CD55, while anti Fc HRP conjugated antibodies were successful at binding
the Fc region of the protein. It was hypothesised that either due to innate charge or
size of the protein and its domains that the SCR 3 region was being ‘masked’ either
by the Fc domain or due to orientation upon the plate surface. The alternative was
that the fusion protein was not being expressed as hoped with altered post
translational modifications, making the SCR 3 domain non-functional. In order to
assess this, a capture protocol was designed using a goat anti human IgG (Fc specific)
monoclonal antibody as the primary coat. This enabled correct orientation of the Fc
fusion protein allowing exposure of the active CD55 component. Figure 4.11 shows
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the optimised protocol for protein assessment. Titrating concentrations of protein
were bound to anti human Fc and SCR3 presence was identified using BRIC 216
antibody (SCR3 specific). This was compared to direct binding of fusion protein or
capture via BRIC 216 coated wells. Results clearly show that with Fc capture of
recombinant protein, the SCR 3 domain is clearly recognised by relative anti CD55
antibodies, compared to assay procedure without capture preventing BRIC 216
recognition of its target.
Figure 4.11: ELISA analysis of SCR 3 Fc fusion protein screen indicating the
necessity for correct orientation of recombinant protein on the ELISA plate.
Optimisation of fusion protein screen
ELISA:Optimisation for SCR 3 of CD55 specific antibodies
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Comparison between Fc captured SCR 3 Fc protein compared to direct binding of protein to
plate without orientation.
96 well flat bottom flexi plates coated with 100µl of 5µg/ml goat anti human IgG (Fc
specific) antibody, BRIC 216 (SCR3 Fc specific) and SCR 3Fc recombinant protein. SCR 3
Fc titrations (1mg/ml stock) applied to coating antibodies in order to assess if protein
orientation affected ability of secondary antibody recognition when compared to fusion
protein as primary coat. Anti-human Fc captured protein was assessed with BRIC 216 (CD55
specific) and horse radish peroxidase conjugated rabbit anti-mouse antibody. BRIC 216
captured fusion protein was assessed directly with goat anti-human Fc HRP conjugated
antibody. ABTS was used as a substrate and plate were read at 405nm. Error bars indicate
standard deviation for two data points.
Figure 4.12 shows analysis of SCR 1-3 Fc fusion protein obtained from transfected
CHO-SF cells. The fusion protein was captured with anti human Fc specific
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antibodies and the presence of functional CD55 domains was assessed by 791T/36
(SCR1-2), BRIC 16 (SCR3) and BRIC 110 (SCR2) monoclonal antibodies. All three
protein batches, from separate transfection protocols, bound to all 3 CD55 specific
antibodies indicating the presence of SCR 1-3 fused to a human IgG Fc domain
protein. This could then be used for both direct immunisation and for screening of
any serum antibodies generated in response to the SCR 1-3 (wild type) Fc DNA
construct vaccine.
Figure 4.12: ELISA of SCR 1-3 Fc fusion protein batches
791T/36 BRIC 216 BRIC 110 No Primary
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ELISA: Screen of SCR1-3 Fc protein batches
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CD55 specific antibody
SCR 1-3 Fc A
SCR 1-3 Fc B
SCR 1-3 Fc C
Non transfected protein
A = 2µg SCR 1-3 Fc DNA
B = 4µg SCR 1-3 Fc DNA
C = 6µg SCR 1-3 Fc DNA
791T/36 specific to human CD55 SCR domains1-2
BRIC 216 specific to human CD55 SCR domain 3
BRIC 110 specific to human CD555 SCR domain 2
96 well flat bottom flexi plate coated with 100µl of 5µg/ml goat anti human Fc capture
antibody and 100µl of 5µg/ml SCR 1-3 Fc protein. Equal concentrations of CD55 specific
antibodies were then incubated at a concentration of 5µg/ml (100µl) and secondary rabbit
anti-mouse peroxidase conjugated antibodies were added. ABTS was used as a substrate and
plates were read at 405nm. Error bars indicate standard deviation for two data points.
All batches of fusion protein contain structurally complete and native CD55 domains.
SCR1-3 Fc protein was also assessed via SDS PAGE (Figure 4.13) and western blot
(Figure 4.14) for determination of purity and functionality. 10% SDS PAGE analysis
under non-reducing conditions generates a double band, indicating several
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glycosylation states of expressed protein, approximately 100kDa in size representing
SCR1-3 Fc domain. No other proteins are visible within the samples indicating a high
degree of purity from purification procedure. Breaking of disulphide bonds under
reducing conditions produces an equivalent band of ~70kDa. Western blot analysis
indicates that both 791T/36 and BRIC 216 bind to the SCR 1-3 domain of the fusion
protein yielding a band of ~100kDa. Antibodies specific for BSA generated no bands
and, as expected, none of the CD55 specific antibodies were able to bind target
domains under reducing conditions (prior analysis has shown under reducing
conditions the CD55 structure is significantly altered to prevent antibody recognition).
Figure 4.13: 10% SDS PAGE analysis of SCR 1-3 Fc recombinant protein under
reducing and non-reducing conditions.
1 2 3 4 5 6 7 8 9 10
1: Broad range kaleidoscope markers
2: Broad range biotinylated standard
3: SCR 1-3 Fc protein
4: SCR 1-3 Fc protein
5: SCR 1-3 Fc protein
6: SCR 1-3 Fc protein
7: SCR 1-3 Fc protein
8: SCR 1-3 Fc protein
9: SCR 1-3 Fc protein
10: SCR 1-3 Fc protein
3-6 Samples in non-reducing conditions 7-10 in reducing conditions
2.4µg of protein were added per well in a 1: 3 ratio with reducing or non- reducing sample
buffer. Samples were electrophoresed for 1 hour at 200 volts and the separating gel was
visualised with coomassie staining of all proteins present. Under non reducing condition SCR
1-3 Fc produces a double band at ~100kDa representing SCR 1-3 Fc component of the
recombined protein with no other bands present within the sample indicating that the protein
samples remains pure. The second visualised band represents alternate glycosylation
products of the expressed protein. Under reducing conditions, a band of ~70kDa is generated
representing the protein with broken disulphide bonds.
128 kDa
82 kDa
147
Figure 4.14: Western blot analysis of SCR1-3 Fc recombinant protein under
reducing and non-reducing conditions.
1 2 3 4 5 6 7 8 9 10
1: Broad range biotinylated standard
2: 791T/36
3: BRIC 216
4: BRIC 216
5: Rabbit anti Bovine serum albumin
6: Rabbit anti Bovine serum albumin
7: 791T/36
8: BRIC 216
9: BRIC 216
1-4 Samples in non-reducing conditions 6-9 in reducing conditions
Western blot analysis of figure 2.13. Proteins transferred form acrylamide gel to
nitrocellulose membrane and blot was probed with CD55 and BSA specific antibodies.
Secondary rabbit anti mouse HRP conjugated antibody was used in conjunction with ECL
chemi-luminescence detection system in order to visualise bands on photo sensitive film. All
antibodies are specific to native proteins and fail to bind reduced targets. Both 791T/36 and
BRIC 216 generate a band ~100kDa in size representing SCR 1-3 Fc protein under non-
reducing conditions. Previous assessment of both CD55 specific antibodies has shown that
under reducing conditions, both antibodies fail to recognise CD55 both as purified protein
ands as natively expressed CD55 on 791T osteosarcoma cell lysates.
4.7: Antibody response to gene gun delivery of SCR 1-3 (WT) Fc DNA vaccine
Antibody responses generated following prime boost immunisation of HHD II
transgenic mice with Helios gene gun delivery were investigated and titres determined
(Figure 4.15). 1µg DNA was coated onto 1 micron gold micro-carriers and used to
immunise the shaved abdomens of HHD II mice. Immunisations were given at
weekly intervals a total of three times, and one week post final vaccination sera were
collected to measure the degree of antibody responses raised. Titrated mouse sera
were screened against SCR 1-3 Fc recombinant protein and human IgG monoclonal
antibodies. Immunised sera were directly compared to responses from naïve serum
from un-immunised mice. All four mice in this initial population raised CD55
specific antibodies to a titre greater than 1 in 10
3
. Human IgG responses were
minimal when compared to un-immunised sera responses to both target proteins.
SCR 1-3Fc
80 kDa
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Figure 4.15: ELISA of sera from SCR1-3 Fc DNA (Wild type) Immunised HHD
II mice (Group 1)
Anti-CD55 specific antibody responses generated from HHDII mice immunised with
heterologous 1µg SCR1-3 Fc DNA, three times at weekly intervals. 1µg of DNA coated onto
1 micron golf micro-particles and immunised via gene gun onto the abdomen of HHD II
transgenic mice. Sera obtained one week post final immunisation. Sera titrations screened
via ELISA against 5µg/ml SCR1-3 Fc fusion protein and 5µg/ml Human IgG control.
Secondary horse radish peroxidase conjugated goat anti mouse IgG antibody was used with
ABTS substrate system and absorbance measured at 405nm. Standard deviation expressed as
range of two data points.
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ELISA:Screen of SCR1-3 Fc (Wild Type) Immunised
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Screen indicates high level of CD55 specificity when compared to human IgG control,
indicating minimal response generated to human IgG region of immunising construct. All
four mice generate CD55 specific antibodies to a titre greater than 1/1000.
A second group of HHD II transgenic mice were immunised with the wild type
construct in order to confirm findings. All four mice in this population raised CD55
specific antibodies to a titre greater than 1 in 10
3
(Figure 4.16). Human IgG
responses were again minimal when compared to un-immunised sera responses to
both target proteins.
Figure 4.16: ELISA of sera from Group 2 SCR1-3 Fc DNA (Wild type)
Immunised HHD II mice (Group 2)
Anti-CD55 specific antibody responses generated from HHDII mice immunised with
heterologous 1µg SCR1-3 DNA, three times at weekly intervals. 1µg of DNA coated onto 1
micron golf micro-particles and immunised via gene gun onto the abdomen of HHD II
transgenic mice. Sera obtained one week post final immunisation. Sera titrations screened
via ELISA against 5µg/ml SCR1-3 Fc fusion protein and 5µg/ml Human IgG control.
Secondary horse radish peroxidase conjugated goat anti mouse IgG antibody was used with
ABTS substrate system and absorbance measured at 405nm. Standard deviation expressed as
range of two data points.
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Screen indicates high level of CD55 specificity when compared to human IgG control,
indicating minimal response generated to human IgG region of immunising construct. All
four mice generate CD55specific antibodies to a titre greater than 1/1000.
These results indicate that if the Fc domain of the expressed vaccine does indeed
enhance processing or delivery of antigen uptake In vivo, minimal antibody response
is generated in this mouse model to the human IgG (Fc) antigen.
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4.8: Antibody response to gene gun delivery of SCR 1-3 Z158m Fc DNA vaccine
Antibody responses were obtained for the SCR1-3 Fc construct containing the CTL
epitope Z158m (Chapter 5). Comparisons are made between the two vaccines in
order to determine if heteroclitic modification of the wild type construct influences
the overall nature of response generated. Immunised sera were directly compared to
responses from naïve serum from un-immunised mice. Two of the four mice assessed
in the initial group raised antibody mediated responses up to a titre of 1 in 10
3
(Figure
4.17). Due to limiting volumes of sera only Mouse 1 from this group was screened
for cross reactivity with human IgG, and results indicate that a limited response was
specific to this antigen when compared with serum from an un-immunised mouse.
Figure 4.17: ELISA of sera from SCR 1-3 Z158m Fc DNA immunised HHD II
mice (Group 1)
Anti CD55 specific antibody responses generated from HHDII mice immunised with
heterologous 1µg SCR1-3 Z158 Fc DNA, three times at weekly intervals. 1µg of DNA
coated onto 1 micron golf micro-particles and immunised via gene gun onto the abdomen of
HHD II transgenic mice. Sera obtained one week post final immunisation. Sera titrations
screened via ELISA against 5µg/ml SCR1-3 Fc fusion protein and 5µg/ml Human IgG
control. Secondary horse radish peroxidase conjugated goat anti mouse IgG antibody was
used with ABTS substrate system and absorbance measured at 405nm. Standard deviation
expressed as range of two data points.
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ELISA: Screen for SCR1-3 fc specific Ab generated
by HHDII Immunised with SCR1-3 Z158 Fc. Mouse 3
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Two out of four mice show antibody responses specific to the SCR 1-3 Fc fusion protein up to
a titre of 1/1000 when compared to analysis of un-immunised sera.
Due to limiting volumes of sera obtained from immunised mice only sera from mouse 1 was
screened for CD55 SCR 1-3 specificity compared to human IgG.
Sera titration analysed via ELISA against 5µg/ml of either SCR 1-3 Fc protein or human IgG.
Rabbit anti mouse HRP conjugated antibodies were used with the ABTS substrate system to
evaluate responses. Absorbance was read at 405nm and standard deviation is expressed as
two data points.
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Fusion proten Vs Human IgG. Mouse 1.
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Mouse 1 shows a SCR1-3 specific response when compared to human IgG indicating that the
Fc domain of the expressed construct does not appear to drive an overwhelming antibody
response.
A second group of HHD II mice were immunised with this construct and sera
assessment showed significantly different results as compared to the previous group
(Figure 4.18). Of the four mice screened, antibodies were present at titres of up to 1
in 10
3
, although the specificity of the response elicited appears to be mixed as both
SCR 1-3 responses and human IgG responses were comparable.
These results could suggest that the mutated vaccine generates a limited CD55
specific antibody response.
Figure 4.18: ELISA of sera from SCR 1-3 Z158m Fc DNA immunised HHD II
mice (Group 2)
Anti CD55 specific antibody responses generated from HHDII mice immunised with
heterologous 1µg SCR1-3 Z158 Fc DNA, three times at weekly intervals. 1µg of DNA
coated onto 1 micron golf micro-particles and immunised via gene gun onto the abdomen of
HHD II transgenic mice. Sera obtained one week post final immunisation. Sera titrations
screened via ELISA against 5µg/ml SCR1-3 Fc fusion protein and 5µg/ml Human IgG
control. Secondary horse radish peroxidase conjugated goat anti mouse IgG antibody was
used with ABTS substrate system and absorbance measured at 405nm. Standard deviation
expressed as range of two data points.
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In this population, antibody specificity appears to be reduced with high levels of human IgG
Fc specific antibodies being present. Antibody titres are present to titres of 1/1000.
4.9: Antibody Isotyping following gene gun delivery of SCR 1-3 Fc (WT) and
Z158m Fc DNA vaccines
Following the immunisation protocol, isotyping of antibody responses was useful in
determining the overall nature of the immune response generated. Standard curves
were set up using the standard capture ELISA protocol in order that analysis remained
consistent with any antibody screen assessment (Figure 4.19a). SCR 1-3 Fc protein
was captured and orientated via the human IgG domain using goat anti human Fc
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antibodies. IgG1 and IgG2a CD55 specific antibodies were then bound to the CD55
domains of the protein, titrated to produce an effective logarithmic scale. Peroxidase
conjugated rabbit anti mouse antibodies were then used for detection of bound
antibodies. The ABTS substrate system was then used to quantify the level of bound
proteins. This standard assay was developed for direct comparison with antibody
screens performed.
Schematic of antibody isotyping protocol
SCR 1-3 (WT) Fc DNA
All four mice produce predominantly IgG1 type antibodies, which are clearly visible
at both the 1/100 and 1/1000 dilutions (Figure 4.19b). Comparison of isotype ratios
in all mice (Figure 4.19c) show that IgG2a antibody levels are between 3 and 4 log
10
lower than IgG1 antibodies.
Figures 4.20a-c show the repeat assessment of the second group of HHD II mice
immunised with this wild type construct. All mice again show a predominantly IgG1
antibody response up to the 1 in 10
3
dilution and IgG2a antibody levels are between 3
and 4 log
10
lower than IgG1 antibodies.
These results indicate that a potent Th2 response is being driven by the SCR 1-3 Fc
DNA vaccine.
Goat anti-human IgG (Fc specific)
SCR 1-3 Fc (recombinant fusion protein)
Mouse anti-human CD55 monoclonal
antibody (IgG1/ IgG2a)Mouse anti-CD55 sera
Rabbit anti-mouse HRP (IgG1/ IgG2a specific)
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Figure 4.19: Isotyping of antibody responses generated by SCR 1-3 (WT) Fc
(Group 1)
Figure 4.19a: Standard curve for CD55 specific isotyped antibodies
Standard curve for mouse anti-CD55 specific antibodies was set up using Fc captured SCR 1-
3 Fc and titrated concentrations of CD55 specific antibodies BRIC 216 (IgG1) and IA10 clone
(IgG2a) bound to 96 well ELISA plates.
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Figure 4.19b: Concentration of isotyped antibody responses
ELISA: Isotping of SCR 1-3 Fc specific antibodies
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CD55 isotyped responses determined via ELISA assessment of SCR 1-3 Fc DNA immunised
mouse sera. Titrated responses observed against SCR 1-3 Fc protein and utilising horse
radish peroxidase conjugated goat anti mouse IgG1 and IgG2a antibodies with ABTS substrate
system, measuring absorbance at 405nm. Standard deviation expressed as range of two data
points.
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Figure 4.19c: Antibody concentrations extrapolated from standard curve and
antibody screen results
IgG1 IgG2a
1/100 1/1000 1/100 1/1000
M1 >10µg/ml 0.12µg/ml 0.012µg/ml 0.001µg/ml
M2 >10µg/ml 0.015µg/ml 0.001µg/ml ~0.0001µg/ml
M3 >10µg/ml 0.012µg/ml ~0.0001µgml ~0.0001µg/ml
M4 0.15µg/ml 0.01µg/ml ~0.0001µg/ml <0.0001µg/ml
SCR 1-3 Fc (WT) immunisation of HHD II mice drives a predominantly Th2 response
producing high titres of IgG1 antibodies compared with IgG2a levels that are between 3 and 4
log
10
lower, these results are observed in all four mice assessed in this population.
Figure 4.20: Isotyping of antibody response generated by SCR 1-3 (WT) Fc
(Group 2)
Figure 4.20a: Standard curve for CD55 specific isotyped antibodies
Standard curve for mouse anti-CD55 specific antibodies was set up using Fc captured SCR 1-
3 Fc and titrated concentrations of CD55 specific antibodies BRIC 216 (IgG1) and IA10 clone
(IgG2a) bound to 96 well plates.
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Figure 4.20b: Concentration of isotyped antibody responses
ELISA: Isotping of SCR 1-3 (Wild type)Fc specific
antibodies
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Figure 4.20c: Antibody concentrations extrapolated from standard curve and
antibody screen results
IgG1 IgG2a
1/100 1/1000 1/100 1/1000
M1 >10µg/ml 01-10µg/ml 0.02µg/ml 0.0003µg/ml
M2 >10µg/ml 0.03µg/ml 0.001µg/ml ~0.0001µg/ml
M3 >10µg/ml 0.02µg/ml ~0.0001µgml ~0.0001µg/ml
M4 >10µg/ml 0.001µg/ml ~0.0001µg/ml <0.0001µg/ml
SCR 1-3 Fc (WT) immunisation of HHD II mice drives a predominantly Th2 response
producing high titres of IgG1 antibodies compared with IgG2a levels that are between 3 and 4
log
10
lower, these results are observed in all four mice assessed in this population.
SCR 1-3 Z158m Fc DNA
Both groups of four mice generate comparable antibody response profiles with all
mice generating much lower levels of antibody when compared to the wild type
construct. Figures 4.21a-c and 4.22a-c display the isotyping results obtained for both
groups. Comparison of isotype ratios indicates that concentrations are similar
indicating a mixed IgG1/IgG2a profile. These results suggest that incorporation of the
Z158m mutation into the SCR 1-3 Fc DNA construct switches the type of response
generated and prevents the production of CD55 specific antibodies.
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Figure 4.21: Isotyping of antibody responses generated by SCR 1-3 Z158m Fc
(Group 1);
Figure 4.21a: Standard curve for CD55 specific isotyped antibodies
Standard curve for mouse anti-CD55 specific antibodies was set up using Fc captured SCR 1-
3 Fc and titrated concentrations of CD55 specific antibodies BRIC 216 (IgG1) and IA10 clone
(IgG2a) bound to 96 well ELISA plates.
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Figure 4.21b: Concentration of isotyped antibody responses
CD55 isotyped responses determined via ELISA assessment of SCR 1-3 Z158m Fc DNA
immunised mouse sera. Titrated responses observed against SCR 1-3 Fc protein and utilising
horse radish peroxidase conjugated goat anti mouse IgG1 and IgG2a antibodies with ABTS
substrate system, measuring absorbance at 405nm. Standard deviation expressed as range of
two data points.
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Figure 4.21c: Antibody concentrations extrapolated from standard curve and
antibody screen results
IgG1 IgG2a
1/100 1/1000 1/100 1/1000
M1 0.012µg/ml 0.0014µg/ml 0.0001µg/ml <0.0001µg/ml
M2 <0.0001µg/ml <0.0001µg/ml <0.0001µg/ml <0.0001µg/ml
M3 <0.0001µgml <0.0001µg/ml <0.0001µgml <0.0001µg/ml
M4 <0.0001µg/ml <0.0001µg/ml <0.0001µg/ml <0.0001µg/ml
The Z158m mutation within the SCR 1-3 Fc DNA vaccine appears to have class switched the
nature of response generated. The ratio between antibody isotypes is no longer defined and
there is a greater level of IgG2a antibodies present, indicating the presence of a more mixed
Th1/2 type response.
Figure 4.22: Isotyping of antibody responses generated by SCR 1-3 Z158m Fc
(Group 2)
Figure 4.22a: Standard curve for CD55 specific isotyped antibodies
Standard curve for mouse anti-CD55 specific antibodies was set up using Fc captured SCR 1-
3 Fc and titrated concentrations of CD55 specific antibodies BRIC 216 (IgG1) and IA10 clone
(IgG2a) bound to 96 well ELISA plates.
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Figure 4.22b: Concentration of isotyped antibody responses
ELISA: Isotype of antibody responses
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CD55 isotyped responses determined via ELISA assessment of SCR 1-3 Z158m Fc DNA
immunised mouse sera. Titrated responses observed against SCR 1-3 Fc protein and utilising
horse radish peroxidase conjugated goat anti mouse IgG1 and IgG2a antibodies with ABTS
substrate system, measuring absorbance at 405nm. Standard deviation expressed as range of
two data points.
Figure 4.22c: Antibody concentrations extrapolated from standard curve and
antibody screen results
IgG1 IgG2a
1/100 1/1000 1/100 1/1000
M1 0.015µg/ml 0.001µg/ml 0.011µg/ml 0.001µg/ml
M2 0.001µg/ml 0.0001µg/ml <0.0012µg/ml ~0.0001µg/ml
M3 0.0018µgml 0.0001µg/ml ~0.0001µgml ~0.0001µg/ml
M4 0.0019µg/ml 0.0001µg/ml 0.0015µg/ml ~0.0001µg/ml
The Z158m mutation within the SCR 1-3 Fc DNA vaccine appears to have class switched the
nature of response generated. The ratio between antibody isotypes is no longer defined and
there is a greater level of IgG2a antibodies present, indicating the presence of a mixed Th1/2
type response.
4.10: Antibody specificity to CD55 natively expressed on tumour targets
In order to assess the potential therapeutic nature of generated antibodies, sera were
screened for ability to recognise native CD55 expressed on the human osteosarcoma
cell line 791T, in comparison to the CD55 negative colorectal carcinoma line Colo
205. Figure 4.23a-d show the results obtained from direct labelling of 1µg of control
CD55 specific antibodies compared to 50µl of 1/100 diluted immunised serum
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applied to both cell types. Secondary rabbit anti mouse FITC conjugated antibodies
were used to enable analysis of binding via flow cytometry. Sera from all four mice
of the SCR 1-3 (WT) Fc immunisation group 1 show high levels of binding to CD55,
displaying up to 3 log
10
greater staining compared to un-immunised sera responses.
Results of sera obtained from mouse 2 of group 1 and all four mice of group 2 SCR 1-
3 Z158m Fc immunisation protocol indicate no recognition of naturally expressed
CD55 with all values comparable with un-immunised sera. No binding of antibodies
is observed to the CD55 negative line Colo 205, with results comparable with un-
immunised sera and negative controls.
These results indicate that SCR 1-3 (WT) Fc DNA immunisations generate antibody
responses with CD55 specificity that recognise natively expressed antigen on a
tumour target cell line. In comparison, the mutant SCR 1-3 Z158m Fc DNA
immunisations generally fail to drive CD55 specific antibody mediated responses.
Figure 4.23a: FACS Binding Assay of sera from SCR 1-3 Fc (WT) and Z158m
DNA immunisations, antibody recognition of natively expressed CD55 on the
surface of tumour cell lines.
791T and Colo 205 cells labelled with 1µg of CD55 specific antibodies and 50µl of 1/100
diluted immunised sera. Rabbit anti-mouse FITC conjugated antibodies added as secondary
label. Cells analysed by flow cytometry.
791T cells (CD55 positive)
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SCR 1-3 Z158m Fc Immunisation (Group 2)
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Table 4.23b: Summary of Fluorescence values generated for sera binding assay
Mean Linear Fluorescence Geometric Mean
No primary antibody 8.22 5.46
791T/36 1068.37 548.52
BRIC 216 1608.91 799.6
Group 1
SCR 1-3 Fc (WT) M1 759.63 366.23
SCR 1-3 Fc (WT) M2 166.27 92.63
SCR 1-3 Fc (WT) M3 68.52 38.24
SCR 1-3 Fc (WT) M4 59.29 30.92
SCR 1-3 Z158m Fc M2 14.61 10.17
Unimunised sera 17.36 7.47
Group 2
SCR 1-3 Z158m Fc M1
SCR 1-3 Z158m Fc M2
13.71
11.63
10.32
10.47
SCR 1-3 Z158m Fc M3 13.24 10.09
SCR 1-3 Z158m Fc M4 13.57 10.23
Binding of BRIC 216 and 791T/36 indicate the level of CD55 expression on 791T cells. Wild
type SCR 1-3 Fc immunised sera shows a high degree of binding and specificity to native
CD55 as expressed by 791T cells. The Z158m DNA construct appears to generate antibodies
of limited specificity to CD55.
Figure 4.23c: Colo 205 cells (CD55 negative)
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Figure 4.23d: Summary of fluorescence values generated for sera binding assay
Mean Linear Fluorescence Geometric Mean
No primary antibody 10.23 6.12
791T/36 82.62 10.57
BRIC 216 94.97 9.68
Group 1
SCR 1-3 Fc (WT) M1 45.91 11.48
SCR 1-3 Fc (WT) M2 17.38 10.17
SCR 1-3 Fc (WT) M3 17.52 10.51
SCR 1-3 Fc (WT) M4 15.57 9.87
SCR 1-3 Z158 Fc M2 11.54 5.46
Unimunised sera 24.4 9.28
Group 2
SCR 1-3 Z158m Fc M1
SCR 1-3 Z158m Fc M2
SCR 1-3 Z158m Fc M3
SCR 1-3 Z158m Fc M4
12.12
11.72
10.78
10.04
7.67
9.43
10.92
7.13
As Colo 205 cells do not express CD55 minimal background binding is observed both with
control antibodies and immunised sera.
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4.11: Discussion
Many successful DNA vaccination trails have shown that significant antibody
responses can be elicited towards a vaccinating antigen as reviewed by Hanlon et al.,
2001. Both the efficacy and nature of DNA elicited responses can be affected by
many factors including the route of delivery (Pertmer et al., 1996), the expression
vector and the form of the DNA encoded antigen (secreted, intracellular or membrane
associated). However, current opinion suggests that the most important factor
influencing raised responses is the nature of the expressed antigen itself. This is
shown with early studies identifying that influenza haemaglutinin antigen is capable
of generating long lived responses in mice (Robinson et al., 1997) compared with an
HIV antigen that raised only transient, low level titres in mice (Lu et al., 1996). In
conclusion, the basic differences in physical structure of antigens and how this
influences interactions within the immune system itself appear to dictate the nature of
specific responses generated (Robinson et al., 1997). T helper responses are critical in
driving immune responses, with Th1 characterised by IFNJ synthesis in conjunction
with IL-2 production mediating cellular responses and Th2 that are characterised by
IL-4 production driving humoral immunity. Of direct relevance to the current study is
the ability to drive Th2 responses activating non phagocytic defences, such as mast
cells while assisting B cells to produce IgG1 antibodies. While the class of response
generated is associated, in part by the nature of the antigen, arguments exist stating
that Th1 and Th2 responses are based upon differing cytokine expression patterns
(reviewed by Hanlon et al., 2001).
Post DNA vaccination, internally expressed antigens are presented by both MHC
classes, eliciting both humoral and cellular responses. In the current context,
administration of plasmid DNA via gene gun is capable of driving responses through
direct transfection of APCs, which are capable of processing and presenting antigen
through both class I and class II pathways, and through transfection of non-APCs such
as muscle cells and keratinocytes, which express whole antigen which is subsequently
transferred to professional antigen presenting cells.
168
Harris et al (2002) support the methodology incorporated into this study. They
generated fusion proteins, via transfection of CHO cells, consisting of the CD55
complement control regions formed as ‘antibody like’ molecules containing antigen
moieties linked to antibody Fc, in the place of Fab arms. Their experimentation
proved that efficient generation of soluble forms of proteins conveniently ‘tagged’
with Fc domains could be achieved, enabling efficient purification from crude tissue
culture supernatant by protein A affinity chromatography. They also show that
immunisation with CD55 fusion proteins can generate antibodies specific to the CD55
short consensus repeats incorporated into the immunogen, and successful screening of
responses could be obtained utilising the fusion proteins as a viable target. However,
in comparison with results obtained in this study, antibodies generated in response to
their human CD55 Fc protein also cross reacted with their control fusion protein,
indicating reactivity with the common Fc domain. This is in contrast with the current
study utilising a SCR 1-3 (WT) Fc DNA construct, eliciting CD55 specific antibody
responses. Interestingly, Harris indicates that epitopes located near the hinge region
of the fusion protein are masked by steric effects, which prevent antibody generation
specific to these domains. In their example, the protein contained all four SCR
domains of CD55 and no antibodies were produced specific to the fourth carboxy-
terminal SCR. They state that in order to obtain mAbs to such areas of protein that
may be masked, the inclusion of spacer regions is important to remove the potential
target from the shadow of the Fc. With respect to this project, the development of
IgG1 antibodies, specific to CD55, were desirable for potential induction of ADCC
responses to tumour targets bearing CD55. The development of antibodies specific to
the SCR 1-2 region, capable of inhibiting the decay accelerating activity of CD55,
would also be desirable, and as these domains are separated from the Fc region within
our construct by the SCR 3 region, the potential for masking would be reduced.
Analysis of the SCR 1-3 (Wild Type) Fc DNA construct indicates that a CD55
specific Th2 response is generated, producing IgG1 antibodies capable of recognising
native antigen expressed by target tumour cells. In contrast, the anchor modified
construct containing the Z158m mutation appears to generate a mixed Th type
response, eliciting both IgG1 and IgG2a antibodies, possessing general specificity to
both the CD55 domain and the human IgG Fc region of the construct. Antibodies
generated by this mutant vaccine also fail to recognise natively expressed protein on
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the surface of tumour cells. This poses an interesting question of whether the Z158m
mutation actually confers conformational changes within the expressed protein,
affecting the generation of functional antibodies. The Z158m mutation is located in
the SCR 1 region of CD55 and it is suggested that this point mutation potentially
alters the complete tertiary structures of both the SCR 1 and 2 domains. In order to
confirm this suggestion, antibody clones would need to be isolated along with their
specific targets, determining whether the mutation prevents all responses to the CD55
domains. The results obtained also suggest a potential switch in class of response
generated when comparing the wild type construct with the mutated variant, although
this may not be a true comparison considering that the Z158m vaccine generates
mixed Fc/CD55 specificity. While further assessment of these findings need to be
carried out, it is clear that the wild type construct generates antibodies with
therapeutic potential. Functional blocking studies also need to be carried out in the
form of complement deposition assays, in order to assess the potential for inhibition
of CD55 decay accelerating activity on tumour targets. This could be achieved
utilising c1q depleted serum, confirming whether increased complement deposition
was due to ADCC or prevention of CD55 activity. The potential for whole
antigen/protein immunisation should also be assessed, when considering other works
this high level of antigen administration successfully boosts responses obtained
(Harris et al., 2002). A final assessment of the therapeutic potential of the DNA
vaccine, and the antibodies produced, would be via a lytic assay determining if direct
cell killing could be mediated by the antibody populations produced.
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Chapter 5: Development of an SCR 1-3 Fc DNA vaccine
incorporating heteroclitic epitopes in order to stimulate CTL
mediated responses
5.1: Introduction
DNA immunisation strategies have been shown to generate efficient immune
responses based on the fact that foreign protein is expressed directly in or is quickly
taken up by professional antigen presenting cells (Takashima and Morita, 1999).
Also, relatively small numbers of activated APCs have been shown following
immunisation to be sufficient at stimulating T cell responses (Casares et al., 1997).
In order to develop a successful anti tumour vaccine, exploitation of potential low
affinity T cells which have escaped thymic tolerance into the periphery, needs to be
achieved. Identification of potential CTL epitopes from within tumour-associated
antigens, such as CD55, would be an effective method of driving immune responses.
Many such epitopes are shown to bind to MHC with only moderate affinity and
therefore initiate poor antigen specific responses. Several studies have shown that by
modifying anchor residues to preferred amino acids that MHC/peptide interactions
can be significantly increased without altering the T cell epitope and improve the
frequency and avidity of immune responses (Berzofsky et al., 2001).
It has been demonstrated that uptake of antibody/antigen complexes via the CD64
receptor results in 1,000 fold enhancement of the presentation of peptides on MHC
class II (Cella et al., 1997). Internalisation of this receptor has also been shown to
activate dendritic cells resulting in increased expression of co-stimulatory molecules
and cross priming of antigens on class I MHC (Regnault et al., 1999). Therefore,
targeting of antigens to this receptor could improve expression of epitopes upon the
MHC of activated dendritic cells whilst providing both signals 1 and 2 in order to
activate moderate avidity T cells. As previous studies highlight the success of Fc
targeting of dendritic cells, the SCR 1-3 domain of human CD55 was cloned in
sequence with human FcJ1.
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Heteroclitic epitopes were identified from within human CD55 and incorporated into
a DNA vaccine in sequence with a human IgG Fc tail in order to assess the responses
generated in HLA-A*201 HHD II transgenic mice.
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Results
5.2: Identification of potential CTL epitopes for vaccine development
Several Internet based epitope prediction algorithms were utilised to identify potential
moderate to high affinity HLA_A*201 epitopes from within the protein sequence of
human CD55. Five programs (section 2.1.2) were utilised in order to generate a
consistent range of sequences predicted not only to effectively bind MHC but also to
show a high probability of native expression. Tables 5.1a-e indicate the top 14
highest ranking predicted epitopes displaying epitope start positions, relative to the N
terminal end of the sequence, and the relative score as allocated by each database.
The 14 highest ranked sequences are shown, as epitopes generating lower scores were
determined to be of too low affinity for potential exploitation.
Analysis of the results generated identified clear trends in the predicted binding
epitopes. The amino acid leucine occurs at a disproportionately high frequency when
compared with other residues, occupying 31% of all residues identified by the
MHCPEP program. This supports the basis on which the databases are generated
suggesting that high leucine content confers enhanced binding properties upon a given
peptide sequence. However, this observation may also reflect the relatively high
frequency of this residue within the CD55 protein sequence. Leucine and valine have
also been previously identified as favourable residues at positions 2 and 9 of peptide
sequences conveying elevated class I binding affinities (Sette et. al., 1994). The
results generated support these findings with many of the top ranking epitope
sequences containing one or both of these residues in the corresponding loci.
Figure 5.1: HLA-A*201 epitope prediction
Several internet based epitope prediction algorithms were utilised to identify potential
moderate to high affinity HLA class I epitopes from within the CD55 protein sequence. All
the sequence databases used employ arbitrary units, ranking peptide sequences in order of
predicted affinity relative to reference peptides, and as such, generated results can not be
directly compared across databases. Analysis was carried out incorporating the following
parameters: Peptides containing 9 amino acids assessing affinity within the HLA-A*201
haplotype. In all tables, “Position” equates to the location of the first amino acid in the
epitope sequence in reference to the N-terminal end of the primary protein sequence of CD55.
See section 2.1.2 for references and website addresses. The 14 highest ranking epitopes are
shown for all program results as epitopes below this ranking were determined to be of too low
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affinity for potential exploitation. Highlighted epitopes correlate with sequences identified
for further analysis.
Table 5.1a: Results obtained from the MHCPEP program
MHCPEP SYFPEITHI
Rank Epitope Position Score Epitope Position Score
1 ELPRLLLLV 16 0.83 ELPRLLLLV 16 0.82
2 LLGELPRLL 13 0.75 PLLGELPRL 12 0.78
3 LLLLVLLCL 20 0.68 LLLLVLLCL 20 0.78
4 PLLGELPRL 12 0.51 SLSPKLTCL 137 0.66
5 RLLLLVLL 19 0.49 LLGELPRLL 13 0.55
6 KLFGSTSSF 194 0.46 RLLLLVLLC 19 0.38
7 GLPPDVPNA 36 0.32 LVLLCLPAV 23 0.24
8 SLSPKLTCL 137 0.26 SLKQPYITQ 107 0.19
9 ALEGRTSFP 47 0.22 ILFGATISF 179 0.15
10 ILFGATISF 179 0.16 YITQNYFPV 112 0.08
11 YITQNYFPV 112 0.1 GELPRLLLL 15 0.07
12 LLVLLCLPA 22 0.06 KIPGEKDSV 70 0.05
13 VLLCLPAVW 24 0.06 KLFGSTSSF 194 0.04
14 FCLISGSSV 202 0.05 GLPPDVPNA 36 0.02
This program incorporates two databases while allocating scores in equivalent units enabling direct
comparison of obtained results.
Table 5.1b: Results obtained from the SYFPEITHI program
The SYFPEITHI program is widely used and referenced. This database is predominantly utilised
within our laboratory as it often produces consistent results with an acceptable degree of accuracy.
Table 5.1c: Results obtained from the HLA ligand/motif database
Rank Epitope Position Score
1 LLLLVLLCL 20 161
2 ELPRLLLLV 16 159
3 PLLGELPRL 12 152
4 LLGELPRLL 13 147
5 SLSPKLTCL 137 142
Rank Epitope Position Score
1 LLLLVLLCL 20 29
2 SLSPKLTCL 137 29
3 AALPLLGEL 9 27
4 PLLGELPRL 12 26
5 LLGELPRLL 13 25
6 LVLLCLPAV 23 24
7 ELPRLLLLV 16 23
8 KIPGEKDSV 70 23
9 GLPPDVPNA 36 22
10 SVPAALPLL 6 21
11 GELPRLLLL 15 20
12 LLLVLLCLP 21 19
13 YITQNYFPV 112 19
14 QIDVPGGIL 172 19
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6 RLLLLVLLC 19 130
7 LLLVLLCLP 21 122
8 LLVLLCLPA 22 119
9 ALPLLGELP 10 114
10 GLPPDVPNA 36 114
11 ILFGATISF 179 111
12 LVLLCLPAV 23 106
13 KLFGSTSSF 194 106
14 GELPRLLLL 15 108
Table 5.1d: Results obtained from the BIMAS program
Rank Epitope Position Score
1 YITQNYFPV 112 382.73
2 LLLLVLLCL 20 309.73
3 LVLLCLPAV 23 88.04
4 CLQNLKWST 144 55.89
5 SLSPKLTCL 137 49.13
6 RLLLLVLLC 19 42.28
7 LLGELPRLL 13 29.78
8 KIPGEKDSV 70 16.40
9 ELPRLLLLV 16 11.99
10 GLPPDVPNA 36 11.43
11 LLVLLCLPA 22 8.45
12 FCLISGSSV 202 7.73
13 SVPAALPLL 6 4.23
14 PLLGELPRL 12 3.99
Table 5.1e: Results obtained from Bioinformatics at Leeds (MHC prediction)
database
Rank Epitope Position TAP Score MHC
Score
Overall
Score
1 LLLLVLLCL 20 5.1 111.2 21.8
2 RSCEVPTRL 95 5.6 111.8 20.1
3 SVPAALPLL 6 6.5 111.9 17.3
4 TYKCEESFV 61 6.8 112.8 16.7
5 LTCLQNLKW 142 6.4 106.9 16.7
6 VLLCLPAVW 24 7 115.2 16.6
7 SLSPKLTCL 137 6.8 107.7 15.7
8 VICLKGSQW 78 7 108.2 15.5
9 GEKDSVICL 73 7 106.6 15.2
10 REPSLSPKL 134 8.1 119 14.8
11 ILFGATISF 179 7.5 108.6 14.6
12 SASLKQPYI 105 7.8 113.1 14.5
13 SFPEDTVIT 53 7.6 108.9 14.4
14 QWSDPLPEC 211 7.6 108.5 14.3
This program generates TAP scores in conjunction with relative predicted binding affinity. TAP values
represent the probability that each peptide will be generated from the native CD55 protein sequence by
the proteosome complex. Lower scores reflect a greater probability of peptide production. The overall
score is obtained by dividing the MHC score by the TAP value, therefore high scores are indicative of
elevated probability that the identified sequence will be processed and presented by HLA-A*201
+
cells
that encounter CD55 protein in it’s native state.
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Figure 5.2 is a scatter plot of the top 28 ranked epitopes identified by the MHCPEP
program and correlates their relative start position in the CD55 sequence with their
predicted HLA-A2 binding score. The locations of predicted epitopes within CD55
appear to predominantly occur towards the N terminal of the complete protein
sequence. Potential preferred epitopes are exclusively identified in the Leader-SCR
1-3 domains of CD55, with the greatest frequency found across the leader-SCR 1
region.
Figure 5.2: Location of CD55 HLA-A2 epitopes as identified by MHCPEP
program (top 28)
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Epitope start position identified from the N terminal of CD55 amino acid sequence
Epitopes identified from the MHCPEP program were correlated with their relative start positions
within the CD55 protein sequence. The top 28 identified epitopes were analysed in order to assess
which domains, if any, contained the most moderate to high affinity epitopes.
The various programs generate a variety of predicted results, as could be expected
with their independent rule and scoring systems. This can clearly be discerned by
comparison of the epitope scores produced by the two SYFPEITHI algorithms, with
some sequences gaining greater binding and ranking scores and other epitopes only
being identified by one program. Upon further analysis, trends in predicted binding
affinities of certain epitopes can be identified with comparative scores and ranked
positions. Table 5.3 shows a summary of the top ten identified epitopes which were
consistently identified from the various prediction programs. The table shows the
amino acid sequence identified and its relative ranked position from each program.
SCR 1 2 3 4
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Results from the Bioinformatics at Leeds database are not included in the summary as
most of the peptides generated are not identified by the other programs, with the
exception of SLSPKLTCL, LLLLVLLCL and an overlap of the region
VLLCLPAVW, all of which were identified as predicted high affinity HLA binders
by alternate systems and were identified for potential modification.
Table 5.3: Summary of top ten ranked epitopes
MHCPEPEpitope Position
SYFPEITHI MHCPEP
HLA
L/M
BIMAS SYFPEITHI
ELPRLLLLV 16 1 1 2 9 7
PLLGELPRL 12 2 4 3 14 4
LLLLVLLCL 20 3 3 1 2 12
SLSPKLTCL 137 4 8 5 5 2
LLGELPRLL 13 5 2 4 7 5
RLLLLVLLC 19 6 5 6 6 ----
ILFGATISF 179 9 10 11 ---- ----
YITQNYFPV 12 10 11 1 13
LVLLCLPAV 23 7 12 12 3 6
GLPPDVPNA 36 14 7 10 10 9
Table displays the top ten wild-type epitopes from within the CD55 protein sequence which were
identified as sources for anchor modification and potential vaccine development. Scores shown
indicate the rank identified by the relative database.
Due to the apparent consistency of predictions by the MHCPEP algorithms,
identifying many of the highest ranked epitopes from all other programs utilised, this
database was used in all future assessment of epitopes evaluated. The SYFPEITHI
website was also used for future comparisons of modified sequences. BLAST (NIH)
assessment was carried out on identified sequences in order to confirm that they were
unique to the CD55 protein sequence.
5.3: Generation and assessment of heteroclitic epitopes for HLA-A201
Having identified potential heteroclitic epitopes from within the protein sequence of
CD55, all of which displayed predicted moderate to high affinity MHC binding
potential, modification of anchor residues was desired to increase peptide affinity for
the MHC molecule in order to enhance immunogenicity. Mutation of anchor residues
on HLA-A2 binding epitopes to known preferred amino acids has been shown to
increase the affinity for MHC without altering the T cell epitope (Ahlers et al 2001,
Irvine et al 1999, Sarobe et al 1998), and thus jeopardising the affinity/avidity of the T
cell- MHC peptide interaction.
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Therefore, binding predictions were ascertained for point mutations within the epitope
sequence for tyrosine, leucine and valine at positions 1, 2 and 9 respectively. The
potential for multiple mutations was also assessed with results displayed in figure 5.4.
Figure 5.4: Predicted binding scores of anchor modified CD55 derived peptides
MHCPEPWild-type Anchor
modified
sequence
SYFPEITHI
score
MHCPEP
score
SYFPEITHI
Score
ELPRLLLLV
YLPLLLLV
0.82
1.08
0.83
1.04
23
28
PLLGELPRL
PLLGELPRV
YPPGELPRL
YLLGELPRV
0.51
0.99
0.77
1.1
0.78
0.88
0.83
1.06
26
26
31
31
LLLLVLLCL
LLLLVLLCV
YLLLVLLCL
YLLLVLLCV
0.78
1.09
0.91
1.15
0.68
0.82
0.86
1.05
29
29
29
29
SLSPKLTCL
SLSPKLTCV
YLSPKLTCL
YLSPKLTCV
0.66
0.78
0.63
0.74
0.26
0.5
0.6
0.8
29
29
29
29
LLGELPRLL
LLGELPRLV
YLGELPRLL
YLGELPRLV
0.55
0.83
0.68
0.91
0.75
0.92
0.86
1.08
25
25
25
25
RLLLLVLLC
RLLLLVLLV
YLLLLVLLC
YLLLLVLLV
0.77
0.99
0.47
1.1
1.07
1.2
0.56
1.23
18
28
20
30
ILFGATISF
ILFGATISV
YLFGATISF
YLFGATISV
0.15
0.98
0.233
1.03
0.16
0.88
0.44
1.15
19
29
19
29
YITQNYFPV
YLTQNYFPV
0.08
0.51
0.1
0.77
19
21
LVLLCLPAV
YVLLCLPAV
LLLLCLPAV
YLLLCLPAV
0.24
0.31
0.97
0.89
0.06
0.1
0.63
0.62
24
24
30
30
GLPPDVPNA
YLPPDVPNA
GLPPDVPNV
YLPPDVPNV
0.02
0.46
0.61
0.72
0.32
0.52
0.87
0.76
22
23
28
29
The MHCPEP and SYFPEITHI databases were utilised to generate predicted binding scores for all
anchor modified epitopes. Primary anchor and P1Y variants were analysed in conjunction with
compound mutated epitopes. Point mutations are identified in bold.
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The results displayed indicate the ten identified wild type epitopes along with their
respective anchor modification and predicted binding scores as allocated by the
SYFPEITHI and MHCPEP programs. The MHCPEP system appears to generally
predict greater increase in affinity scores when compared to the SYFPEITHI database
for all mutated peptides. Five of the wild type epitopes appear to be significantly
enhanced by anchor modification when relative predictions are assessed:
ELPRLLLLV, PLLGELPRL, ILFGATISF, YITQNYFPV and LVLLCLPAV all
show increased affinity scores with all chosen mutations. Interestingly, many of the
primary sequences already incorporated leucine at position 2, being identified as a
contributing factor to the initial predicted score. Tyrosine however, generally appears
to only slightly improve predicted scores when incorporated as a single mutation
although in combination with valine at position 9, overall scores are significantly
elevated. Valine as single mutation appears to confer the greatest improvement in
predicted binding affinity for all wild type epitopes.
Software based predicted binding, while a potential source for identifying successful
epitopes can only be utilised as a guideline and in vitro assessment of chosen peptides
was required. Peptides were synthesised for all 36 epitopes as per section 2.1.1 and
utilised in a T2 Tap
-/-
stabilisation assay as per section 2.1.8. Binding affinity was
evaluated based on ability to stabilise the class I MHC molecules of HLA-A2
+
Tap
-/-
human T2 lymphoblastoid cells by the addition of varying concentrations of
synthesised peptides (100µg and 25µg/ml). Mean stabilisation scores were calculated
as a ratio of mean linear fluorescence with peptide divided by M.L.F. without peptide,
with results corrected for the presence of DMSO. The scores generated can be
evaluated as a fold increase in the level of stabilised MHC molecules present on the
cell surface compared to the level present in the absence of stabilising peptides. Thus
a value of 1 would indicate no increase in MHC presentation and stabilisation.
Figure 5.5 displays the results obtained for T2 stabilisation assays including repeat
analysis of peptides displaying significant increases in MHC binding. To be
potentially immunogenic, both wild type and anchor modified peptides need to exhibit
high T2 scores with modified peptides potentially eliciting elevated scores in
comparison to their wild type counterparts. While there is no proven ‘threshold’
value above which peptides can be guaranteed to elicit immune responses, T2 values
in excess of 2, ideally greater than 3, for both mutant and wild type can indicate
immunogenic potential. Several wild type peptides generate scores, which would
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identify them for possible vaccine constructs, namely Z142, Z68 and Z158. At a
peptide concentration of 100µg/ml, anchor-modified mutants of Z142, Z68 and Z158
all show an increased stabilising affect. Z158 also generated the highest T2
stabilisation value of all wild type epitopes of 4.36, with its Z158m mutant generating
a score of 5.29 at 100µg/ml. Interestingly, all three of these mentioned peptides
generate high stabilising scores at the lower concentration of 25µg/ml with Z158m
producing a value of 5.17, again the highest score of all anchor modified peptides.
Figure 5.5: T2 (Tap
-/-
) stabilisation assay
1 x 10
5
T2 cells were incubated for 16 hours at 37qC, 5%CO2 with specific peptide (100µg/ml
and 25µg/ml) in complete medium containing human E2-microglobulin (100ng/ml). The cells
were then incubated for an hour with brefeldin A (0.5µg/ml) and labelled with BB7.2
antibody (HLA-A2 specific). Cells were then labelled with a FITC conjugated goat anti-
mouse antibody prior to assessment by flow cytometry. Control wells were set up without
peptide and with two concentrations of DMSO (contained in peptide) to enable compensation
of results. Histogram plots were obtained and mean linear fluoresce values collated for each
sample. Stabilisation scores are calculated as a ratio of M.L.F with peptide/M.L.F without
peptide, values corrected for presence of DMSO. Values produced equate to MHC
expression as a factor of a base line score of 1. Therefore, results greater than 1 indicate a
“fold” increase in MHC molecules present on the surface of labelled cells. Results were
obtained in two rounds of experiments, each group consisting of six replicates and 15,000
cells being counted per sample and data is displayed as the mean result obtained. Peptides
generating the greatest degree of stabilisation were re-assessed under identical conditions.
Wild-type Anchor
modified
sequence
Peptide
concentration
µg/ml
Stabilisation
score
(1)
Stabilisation
score
(2)
ELPRLLLLV
YLPLLLLV
100
25
100
25
1.27
1.01
1.23
1.01
PLLGELPRL
PLLGELPRV
YPPGELPRL
YLLGELPRV
100
25
100
25
100
25
100
25
1.34
1.29
1.46
1.47
1.28
1.21
1.38
1.27
LLLLVLLCL
LLLLVLLCV
YLLLVLLCL
YLLLVLLCV
100
25
100
25
100
25
100
25
1.16
1.07
1.19
1.04
1.02
1.03
1.07
1.05
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SLSPKLTCL
(Z142)
(Z143) SLSPKLTCV
YLSPKLTCL
YLSPKLTCV
100
25
100
25
100
25
100
25
3.89
3.2
3.92
3.71
2.71
2.56
3.65
3.34
3.83
3.15
3.70
3.89
LLGELPRLL
LLGELPRLV
YLGELPRLL
YLGELPRLV
100
25
100
25
100
25
100
25
1.34
1.23
1.64
1.63
1.26
1.07
1.42
1.37
RLLLLVLLC
RLLLLVLLV
YLLLLVLLC
YLLLLVLLV
100
25
100
25
100
25
100
25
1.19
0.96
2.69
1.36
1.49
0.97
2.21
1.04
ILFGATISF
ILFGATISV
YLFGATISF
YLFGATISV
100
25
100
25
100
25
100
25
4.03
3.11
1.65
1.13
1.43
1.34
1.46
1.52
YITQNYFPV
YLTQNYFPV
100
25
100
25
1.28
1.05
1.79
1.63
LVLLCLPAV
(Z68)
(Z69)
YVLLCLPAV
LLLLCLPAV
YLLLCLPAV
100
25
100
25
100
25
100
25
2.44
2.08
2.37
2.14
3.03
2.36
2.65
2.43
2.55
2.18
3.22
2.23
GLPPDVPNA
(Z158)
(Z158m)
YLPPDVPNA
GLPPDVPNV
YLPPDVPNV
100
25
100
25
100
25
100
25
4.36
4.27
2.56
2.43
5.29
4.76
3.32
2.98
4.32
3.85
5.17
4.86
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Upon further analysis, several trends appear when considering certain anchor
modifications. The Z158m mutant generates a significant increase in MHC
stabilisation due to the replacement of an alanine at the P9 position with the much
favoured valine residue (Falk et al 1991). Many of the anchor modifications involved
the replacement of leucine with valine residues, which are similar in their aromatic
structure and potential binding properties, which would possibly indicate why many
of the peptides assessed did not generate increased responses. However, this is also
the case for both the Z68 to Z69 and Z142 to Z143 mutations, although as in the case
for these four peptides the wild type structures did confer significant levels of MHC
stabilisation when compared to many of the other wild type peptides screened. This
current assessment of anchor modification does appear to support current evidence
with six of the wild type peptides modified with valine residues producing elevated, if
only slightly, levels of MHC stabilisation. Analysis of P1Y (tyrosine) substitution is
also unclear with most of these variants producing T2 stabilisation scores less than
their wild type counterparts, with only a few examples of potential improved affinity
which may be conferred by the substituted valine residue in compound mutants.
Figure 5.6 displays a summary of the three most successful anchor modifications and
their relative predicted and actual stabilisation scores. This data is also graphically
represented in Figure 5.7, which clearly shows the elevated levels of MHC
stabilisation for all three identified peptides with their respective mutants.
Figure 5.6: Summary of peptides generating the greatest level of MHC
stabilisation
Epitopes were given identifying codes which were relative to peptides/epitopes previously
identified and synthesised within the laboratory.
Epitope Domain Sequence MHCPEP SYFPEITHI T2 score
100µg/ml
T2
score
25µg/ml
Z142 SCR2 SLSPKLTCL 0.66 29 3.89 3.2
Z143 SCR2 SLSPKLTCV 0.78 29 3.92 3.71
Z68 Leader LVLLCLPAV 0.24 24 2.44 2.08
Z69 Leader LLLLCLPAV 0.07 30 3.03 2.36
Z158 SCR1 GLPPDVPNA 0.02 22 4.36 4.27
Z158m SCR1 GLPPDVPNV 0.61 28 5.29 4.76
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Figure 5.7: Tap
-/-
stabilisation results for identified wild-type and mutated
peptides (six highest scoring)
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The T2 stabilisation scores, while allowing a general assessment of each peptide with
their various anchor modifications, do not fully display the expression of MHC upon
stabilisation. This is due to the mean level of labelled MHC molecules being utilised
for the calculation, which does not allow for a range of expression and the general
shift being expressed. Figure 5.8 shows histogram plots for the three most enhanced
peptides obtained from the raw data analysed via the fluorocytometric process. These
plots clearly show how the addition of peptides to the T2 cells significantly increase
fluorescence generated by FITC conjugated anti-HLA-A2 antibodies, representing
increased MHC stabilisation.
It is clear from the actual binding observed by both wild type and subsequent
modified peptides in comparison to the predicted affinity scores that the software
utilised is by no means a definite method of prediction. Figures 5.9a and b are scatter
plots comparing predicted binding scores generated by both the SYFPEITHI and
MHCPEP programs with actual binding scores generated from in vitro assessment.
Both plots indicate that there is little to no correlation between the software generated
results and the observed findings. However, analysis of the SYFPEITHI results does
show a potential trend of elevated actual binding correlating with increased predicted
scores. All peptides identified by the programs do appear to show some level of
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binding and thus stabilisation, although it can be seen that peptides predicted to show
high levels of binding affinity often produce limited response upon assessment.
Figure 5.8: Histogram plots obtained from FACS data of stabilisation assay
results analysed with WINMDI software.
Raw data collected from FACS analysis of labelled T2 cells and the number of events (cells)
was plotted against relative FL-1 values. The graphs show results for the three peptides
generating the most significant increase in MHC stabilisation. Peptides added at a
concentration of 25µg/ml.
FL-1
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Figure 5.9: Scatter plots of CD55 derived HLA-A2 epitopes predicted binding
scores compared with In Vitro T2 MHC stabilisation assay results
Predicted binding scores, generated from MHCPEP and SYFPEITHI programs, of wild-type
epitopes compared against stabilisation scores obtained from assays of T2 cells incubated
with 100µg/ml of target peptides.
Figure 5.9a: Analysis of MHCPEP prediction
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Figure 5.9b: Analysis of SYFPEITHI prediction
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5.4: Development of CD55 specific DNA vaccines incorporating heteroclitic
epitopes
Having identified potential anchor modified epitopes that successfully bind HLA-A2
MHC molecules, the Z143, Z69 and Z158m sequences were chosen to be
incorporated into the existing SCR 1-3 Fc Signal pIgplus DNA construct (see
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Chapter 4). Bioinformatics software available at www.ca.expasy.org was utilised to
generate and assess primers which would incorporate the desired point mutations into
the existing construct. Figure 5.10 displays how the desired modifications were
produced and the sequence of the designed primers, identifying the incorporated
mutation and the relative melting temperatures. As Z142 occurred in the SCR 2
domain of CD55 and both Z68 and Z158 both occur within the SCR 1 region, several
constructs were developed incorporating combinations of the identified epitopes. Site
directed mutagenesis was carried out (section 2.6.19) and DNA products were
sequenced as per section 2.6.15 utilising the SCR 3 reverse primer. Large scale
production of endotoxin free DNA constructs was carried out on successful mutants
as per section 2.6.14 in preparation for immunisation.
Figure 5.10: Incorporation of modified epitopes into CD55 DNA constructs
Z143, Z69 and Z158m epitopes were selected for incorporation into the SCR 1-3 Fc DNA
construct for assessment as a potential vaccine eliciting anti-CD55 immune responses. The
sequences were assessed using a BLAST search (NIH, Bethesda, MD) in order to confirm
that they were unique to the CD55 protein structure.
Primer design and site directed mutagenesis
Forward and reverse primers were designed to incorporate the desired point mutations into the
previously generated SCR 1-3 Fc Signal pIgplus DNA construct. Bioinformatics software
available at www.ca.expasy.org was utilised to assess complementary primers and to prevent
the possibility of self hybridisation, dimer formation and presence of alternate
mutation/binding sites. Site directed mutagenesis was carried out as per section 2.6.19 upon
the SCR 1-3 Fc template DNA and products were sequenced as per section 2.6.15 utilising
the SCR 3 Reverse primer as per Figure 2.9. Returned sequences were analysed by NCBI
alignment with CD55 protein sequence (accession number BC001288) in order to confirm the
presence of desired mutations and to ensure no other mutations within the sequence had
occurred. Large scale production of successful mutants was carried out as per section 2.6.14
generating endotoxin free constructs suitable for DNA immunisation.
Table 5.10a: Primers designed for incorporation of mutated epitopes
CD55 Z143 Forward Primer
5’
CA CCA AAA CTA ACT TGC GTT CAG AAT TTA AAA TGG TCC ACA GC
3’
Pro Lys Leu Thr Cys Val Gln Asn Leu Lys Trp Ser Thr
P K L T C V Q N L K W S T
Binds 498-540bp of CD55 DNA sequence
LeuoVal
L V
43mer
TM=79.21qC
CD55 Z143 Reverse Primer
5’
GC TGT GGA CCA TTT TAA ATT CTG AAC GCA AGT TAG TTT TGG TG
3’
Binds 498-540bp of CD55 DNA sequence
43mer
TM=79.21qC
CD55 Z69 Forward Primer
5’
CGG CTG CTG CTG CTG TTG CTG TTG TGC CTG CC
3’
Arg Leu Leu Leu Leu Leu Leu Leu Cys Leu
ValoLeu
V L
186
R L L L L L L L C L
Binds 137-166bp of CD55 DNA sequence
32mer
TM=84qC
CD55 Z69 Reverse Primer
5’
GG CAG GCA CAA CAG CAA CAG CAG CAG CAG CCG
3’
Binds 137-166bp of CD55 DNA sequence
32mer
TM=84qC
CD55 Z158m Forward Primer
5’
CA GAT GTA CCT AAT GTC CAG CCA GCT TTG GAA GGC
3’
Asp Val Pro Asn Val Gln Pro Ala Leu Glu Gly
D V P N V Q P A L E G
Binds 198-232bp of CD55 DNA sequence
AlaoVal
A V
35mer
TM=80.13qC
CD55 Z158m Reverse Primer
5’
GCC TTC CAA AGC TGG CTG GAC ATT AGG TAC ATC TG
3’
Binds 198-232bp of CD55 DNA sequence
35mer
TM=80.13qC
Binding positions locate to annealing positions on DNA sequence accession number BC001288
(Figure 2.2). Highlighted bases indicate substitutions required to mutate the wild type sequence.
DNA constructs produced for immunisation were:
x SCR 1-3 Z143 Fc
x SCR 1-3 Z69 Fc
x SCR 1-3 Z143 Z69 Fc
x SCR 1-3 Z158m Fc
x SCR 1-3 Z143 Z158m Fc
Immunisation strategy
DNA micro-carriers were prepared as per section 2.1.5 and male and female HLA-A*0201/k
b
(HHDII) mice were immunised as per section 2.1.6 at weekly intervals for a total of three
immunisations. One week post final immunisation, animals underwent schedule1 protocol as
per Home Office guidelines and splenocytes and sera were harvested.
Assessment of responses stimulated by DNA vaccine immunisations
Both humoral (Chapter 4) and cellular responses to the DNA constructs were assessed. This
chapter incorporates results generated from cytotoxic T cell assays, ELISPOT assessment of
cytokine release, and luminex analysis of cytokines present within sera and supernatant
collected from In Vitro stimulated effector cells. The CTL assays required appropriate targets
for obtained effector cells. Ideally, targets will naturally express HLA-A2 MHC and
complete CD55 allowing for natural processing of target epitopes. Several cell lines used
within the laboratory were analysed for this co-expression of desired molecules.
5.5: Assessment of cellular responses to the DNA vaccines
Cytotoxic T cell assays were chosen as one of the main strategies for the assessment
of vaccine induced immune responses. Therefore a viable target cell was required
expressing both human CD55 and HLA-A2 molecules. FACS analysis was carried
out using indirect staining (sections 2.2.8 to 2.2.10) on several cell lines currently
stored within the department. Of the four lines analysed, human tumour lines 791T
and MKN45 both expressed high levels of CD55 (Figure 5.11) although both were
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negative for HLA-A2. Colo 205 cells however, naturally expressed HLA-A2 but
were negative for human CD55.
Figure 5.11: Cell lines assessed by flow cytometry for CD55 and HLA-A2
expression
Standard analysis of CD55 and HLA-A2 expression (Sections 2.2.8 to 22.2.10) was carried
out labelling 1 x 10
5
cells with 100µl of 5µg/ml primary antibody (CD55 and HLA-A2
specific) and subsequently with 400µl of 1/400 FITC conjugated rabbit anti mouse antibodies.
Cells were washed in PBS and 5000 cells per sample were assessed by flow cytometry. Cells
were gated using control samples labelled with secondary antibody alone and with unlabelled
cells.
Mean Liner FluorescenceCell Line
CD55 HLA-A2
791T (human Osteosarcoma)
MKN45 (human gastric carcinoma)
Colo 205 (human colon adenocarcinoma)
T2 (Human lymphoblast)
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As a viable target line was required, Colo 205 cells were transduced with a retrovirus
incorporating full length human CD55 (see sections 2.2.7 to 2.2.9 and 2.2.11). Colo
205 CD55 cells were then cultured under antibiotic selection conditions and a
population of cells, with high expression levels, was isolated using FACS. Figure
5.12a/b shows the results for a standard binding assay for labelled Colo 205,
transduced Colo 205 and T2 cells incubated with chosen peptides at 25µg/ml. Graph
a enables comparison of T2 cells under varying conditions, and as can be seen these
cells are CD55 negative and give an M.L.F for HLA-A2 of 100 and upon addition of
stabilising peptides this value is increased to almost 200, with the greatest level
observed with Z158m peptide. Figure 5.12b allows evaluation of Colo 205 and Colo
205 transduced to express human CD55. The transduced cells clearly show relatively
high levels of CD55 expression. Antibodies specific to SCR domains 1, 2 and 3 were
utilised to confirm expression of the complete CD55 structure and all generated
M.L.F. values in excess of 225. HLA-A2 expression also appears elevated in the
transduced cells in comparison to levels observed in the native Colo 205 cells.
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Figure 5.12a/b: CD55 and HLA-A2 expression of T2, Colo 205 and Colo 205
CD55 cells
1 x 10
5
cells were labelled with CD55 and HLA-A2 specific primary antibodies as per figure
5.11 and were stained with FITC conjugated secondary antibodies. 5000 cells were counted
per sample and relative linear fluorescence was plotted.
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Several groups of immunisations were carried out on male and female HLA-
A*0201/K
b
mice that were between six and twelve weeks of age. DNA was coated
onto 1.0µ gold particles and administered by the Helios Gene Gun (see Sections 2.1.3
to 2.1.6), with mice being immunised at weeks 1, 2 and 3 and spleens were removed
and cells harvested at week 4. Both CTL (Sections 2.7.1 to 2.7.4) and ELISPOT
(Section 2.7.5) assays were carried out on the harvested splenocytes for all groups.
Figure 5.13 displays the results obtained for SCR 1-3 Z143 Fc DNA immunisation.
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Two groups of four mice were immunised and the results assessed with only group 2
results being shown. None of the four mice appear to raise a CTL response capable of
eliciting cell lysis of either peptide pulsed T2 targets or Colo 205 CD55 cells with the
greatest percentage lysis being 4%, observed at an effector: target ratio of 100:1 with
no variation across the different targets. ELISPOT analysis of the same effectors
assessing for antigen specific IFNJ release support the CTL findings, showing that for
10
6
cells seeded only 60 spot forming units were developed for one mouse specific to
the wild type peptide Z142.
Figure 5.13: Immunisation of HHD II mice with SCR 1-3 Z143 Fc DNA
Figure 5.13a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
100:1 50:1 25:1 12:1
0
10
20
30
40
50
Pe
rc
e
n
tL
ys
is
Effector:Target
T2 alone
Colo 205 (CD55)
Colo 205
Z142
Z143
Mouse 1 (HHDII) Immunised with SCR 1-3 Z143 Fc DNA
190
100:1 50:1 25:1 12:1
0
10
20
30
40
50
Pe
rc
e
n
tL
ys
is
Effector:Target
T2 alone
Colo 205 (CD55)
Colo 205
Z142
Z143
Mouse 2 (HHDII) Immunised with SCR 1-3 Z143 Fc DNA
100:1 50:1 25:1 12:1
0
10
20
30
40
50
Pe
rc
e
n
tL
ys
is
Effector:Target
T2 alone
Colo 205 (CD55)
Colo 205
Z142
Z143
Mouse 3 (HHDII) Immunised with SCR 1-3 Z143 Fc DNA
191
100:1 50:1 25:1 12:1
0
10
20
30
40
50
Pe
rc
e
n
tL
ys
is
Effector:Target
T2 alone
Colo 205 (CD55)
Colo 205
Z142
Z143
Mouse 4 (HHDII) Immunised with SCR 1-3 Z143 Fc DNA
Figure 1.13b: ELISPOT analysis of Interferon J production
Standard protocol was followed as per section 2.7.5 utilising the ELISPOT kit from R & D
Systems. 96 well assay plates were coated with cytokine specific capture antibody overnight
at 4qC. Non specific binding sites were blocked and 1 x 106 effector cells were seeded per
well. Splenocytes were then stimulated with and without 10µg/ml target peptide and control
wells were set up containing media alone, cells alone and wells containing cells with PMA
and Ionomycin as a positive control to test viability of cell samples. All conditions were
repeated in triplicate and plates were incubated at 37qC 5% CO2 for 16 hours. Cells were
then removed and cytokine specific capture antibody was added to all wells. The
development module from the kit was then used for development of the assay prior to analysis
on a Bioreader 3000 Pro. Spots were counted and results expressed as the number of spot
forming units [S.F.U (cells)] that produced cytokine in response to specific stimuli.
ELISPOT: IFNγ release
0
20
40
60
80
100
120
140
160
180
200
M1 M2 M3 M4
Stimulant
Sp
o
tF
o
rm
in
g
Un
its
Z143
Z142
No peptide
Media alone
Results shown in S.F.U per 10
6
cells for all mice immunised from the same group.
192
Figure 5.14 displays results obtained for SCR 1-3 Z69 Fc DNA immunisation. Two
groups of four were assessed and results were consistent across both groups. Results
are shown for one of the groups and indicate that a limited CTL response is generated
specific for either peptide pulsed targets or the COLO 205 CD55 cells. 10% lysis is
observed for three out of our mice at 100:1 effector: target ratio but non-specifically
as responses to Z68, Z69 and T2 cells without peptide are similar. No lysis is
observed for natively expressed CD55 when compared with Colo 205 CD55
-/-
cells.
ELISPOT assessment of IFNJ release for the same effectors supports CTL evidence
of limited to no response, as less than 5 spot forming units per 10
6
cells are generated
in response to specific peptides.
Figure 5.14: Immunisation of HHD II mice with SCR 1-3 Z69 Fc DNA
Figure 5.14a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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Figure 1.14b: ELISPOT analysis of Interferon J production
Standard protocol was followed as per section 2.7.5 utilising the ELISPOT kit from R & D
Systems. 96 well assay plates were coated with cytokine specific capture antibody overnight
at 4qC. Non specific binding sites were blocked and 1 x 106 effector cells were seeded per
well. Splenocytes were then stimulated with and without 10µg/ml target peptide and control
wells were set up containing media alone, cells alone and wells containing cells with PMA
and Ionomycin as a positive control to test viability of cell samples. All conditions were
repeated in triplicate and plates were incubated at 37qC 5% CO2 for 16 hours. Cells were
then removed and cytokine specific capture antibody was added to all wells. The
development module from the kit was then used for development of the assay prior to analysis
on a Bioreader 3000 Pro. Spots were counted and results expressed as the number of spot
forming units [S.F.U (cells)] that produced cytokine in response to specific stimuli.
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Compound vaccines were also created incorporating both Z69 and Z143 and Figure
5.15 displays the CTL and IFNJ ELISPOT results obtained for this group. One group
of four mice were immunised and splenocytes from only one mouse generated killing
of any targets. Maximum lysis was calculated at 10% at a 50:1 effector: target ratio,
but again this appears to be a non-specific response as T2 cells alone and Colo 205
cell targets generated equal lysis. ELISPOT analysis for IFNJ release also confirms
that minimal antigen specific responses were stimulated by this construct as only
mouse 4 shows 70 spot forming units +/- 10 stimulated by the wild type peptide Z142
with less than 30 obtained for other stimuli.
Figure 5.15: Immunisation of HHD II mice with SCR 1-3 Z69 Z143 Fc DNA
Figure 5.15a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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Figure 5.15b: ELISPOT analysis of Interferon J production
Standard protocol was followed as per section 2.7.5 utilising the ELISPOT kit from R & D
Systems. 96 well assay plates were coated with cytokine specific capture antibody overnight
at 4qC. Non specific binding sites were blocked and 1 x 106 effector cells were seeded per
well. Splenocytes were then stimulated with and without 10µg/ml target peptide and control
wells were set up containing media alone, cells alone and wells containing cells with PMA
and Ionomycin as a positive control to test viability of cell samples. All conditions were
repeated in triplicate and plates were incubated at 37qC 5% CO2 for 16 hours. Cells were
then removed and cytokine specific capture antibody was added to all wells. The
development module from the kit was then used for development of the assay prior to analysis
on a Bioreader 3000 Pro. Spots were counted and results expressed as the number of spot
forming units [S.F.U (cells)] that produced cytokine in response to specific stimuli.
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Figure 5.16 shows results for another double mutant construct containing both Z143
and Z158m within the SCR 1-3 Fc DNA vaccine. CTL analysis of the double
construct immunisation indicate that significant levels of antigen specific lysis has
been stimulated for all four mice with lysis in ranging from 90% to 50% at an
effector: target ratio of 100:1 for Z158m peptide pulsed targets. The CTLs generated
also effectively kill wild type peptide (Z158) pulsed targets at a range between 60%
and 40% at the same E:T ratio. Antigen specific lysis of both Z158m and Z158
pulsed targets remains consistent through to E:T ratio of 12:1 ranging between 60%
and 30%. However, lysis of either Z143 or Z142 pulsed targets remains below 5%,
equivalent with background levels of lysis for alternate targets including Colo 205
CD55 and Colo 205 cells. ELISPOT assessment for IFNJ support these findings with
both mouse 1 and 3 generating the greatest level of antigen specific responses,
specifically to Z158m and its wild type counterpart. Per 10
6
cells seeded S.F.U
counts were in excess of 350 and in some wells were too dense to count.
Interestingly, IFNJ production was also seen in responses to Z142 in vitro stimulation
although this was only observed in cells from mice which generated the greatest
responses to both Z158m and Z158.
Figure 5.16: Immunisation of HHD II mice with SCR 1-3 Z143 Z158m Fc DNA
Figure 5.16a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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Figure 1.16b: ELISPOT analysis of Interferon J production
Standard protocol was followed as per section 2.7.5 utilising the ELISPOT kit from R & D
Systems. 96 well assay plates were coated with cytokine specific capture antibody overnight
at 4qC. Non specific binding sites were blocked and 1 x 106 effector cells were seeded per
well. Splenocytes were then stimulated with and without 10µg/ml target peptide and control
wells were set up containing media alone, cells alone and wells containing cells with PMA
and Ionomycin as a positive control to test viability of cell samples. All conditions were
repeated in triplicate and plates were incubated at 37qC 5% CO2 for 16 hours. Cells were
then removed and cytokine specific capture antibody was added to all wells. The
development module from the kit was then used for development of the assay prior to analysis
on a Bioreader 3000 Pro. Spots were counted and results expressed as the number of spot
forming units [S.F.U (cells)] that produced cytokine in response to specific stimuli.
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Due to the responses generated with the SCR 1-3 Z143 Z158m Fc DNA construct,
two groups of mice were set up directly comparing this vaccine with the single
epitope vaccine containing Z158m. Figure 5.17 displays the results obtained for the
double epitope construct assessing CTL mediated killing of Z158m and Z158 pulsed
T2 targets and also Colo 205 CD55 and Colo 205 cells. ELIPOT analysis was carried
out analysing both IFNJ and IL-4 release stimulated by the full complement of stimuli
under two concentrations of effector cells namely 10
6
and 5 x 10
5
. Mouse 1 elicited
CTL killing of both Z158m and Z158 pulsed T2 cells ranging from 37% to 10%
titrating down respective to effector cell concentration. 12% killing was also
observed of Colo 205 CD55 cells in comparison with Colo 205 cell lysis which did
not elevate above 2%. Antigen specific IFNJ release again supports this data,
showing that responses are directed against Z158 and Z158m (>100 S.F.U) with
similar frequency showing a titrated effect when assessed in the presence of 5 x 10
5
effector cells (75 S.F.U). Minimal responses were observed for the assessment of IL-
4 release, generating in the range of 35 S.F.U in the presence of all stimuli. Z143 and
Z142 were also screened in tandem again producing limited responses. Mouse 2 also
elicited up 20% antigen specific killing of T2 cells pulsed with Z158 and Z158m at
100:1 E: T ratio with a titrated effect in response to reduced effector cell number. 5%
lysis of Colo 205 CD55 cells was also observed at maximum effector cell density
which was greater than the 1-2% observed for Colo 205 cells. These results may have
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been lower than those for mouse 1, although ELISPOT analysis again showed IFNJ
release for both the Z158 and Z158m stimulated cells with S.F.U. in excess of 100 for
10
6
seeded cells. This antigen specific cytokine release was also observed at effector
concentration of 5 x 10
5
cells. Again Z143 and Z142 stimulated 60 S.F.U. which was
only slightly greater than release for un-stimulated cells. Mouse 3 displayed similar
results as mouse 2 generating between 15 and 20% lysis of Z158 and Z158m pulsed
targets with 10% lysis of Colo 205 CD55 cells being observed compared to no killing
of CD55 negative cells. IFNJ release supported the response to 158m and its wild
type peptide with limited responses to Z143 and Z142 and little to no IL-4 responses
for any test stimuli. Mouse 4 elicited strong CTL responses to Z158 and Z158m
pulsed T2 cells generating between 40 and 50% lysis at an E: T of 100:1 dropping to
27% at a 12: 1 ratio. Colo 205 CD55 lysis was also generated at 10% at 100: 1 E: T
ratio. This high level of antigen specific lysis was also supported by IFNJ release
assessment with up to 200 S.F.U. generated for both Z158 and its mutant. Again
limited IL-4 release was observed with no response to Z143 or Z142 for either
cytokine. A general trend can be observed that while greater overall responses are
directed towards the mutant peptides, as would be expected, significant responses are
still generated towards the wild type sequence.
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Figure 5.17: Immunisation of HHD II mice with SCR 1-3 Z143 Z158m Fc DNA
Repeat analysis of Z143 Z158 double construct as a direct comparison with single mutated
epitope Z158 (experiment ran in tandem with Figure 5.18).
Figure 5.17a: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 1)
Standard protocol followed with assessment of only Z158m and Z158 peptides as previous
analysis indicated no response generated towards Z142 mutant.
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Figure 5.17b: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ
and IL-4 antigen specific release (Mouse 2)
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Figure 5.17c: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 3)
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Figure 5.17d: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 4)
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Standard ELISPOT protocol followed utilising 1 x 10
6
and 5 x 10
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effector cells seeded with both Z158
and Z142 wild type and mutant peptides.
Figure 5.18 displays the results for a repeat SCR 1-3 Z158m Fc DNA immunisation
ran in tandem with the double epitope vaccine. Three of the four mice generate CTL
mediated lysis of Z158 and Z158m pulsed targets between 35% and 60% at 100:1 E:
T ratio with limited to no response against the Colo 205 CD55 cells. Observed lysis
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titrates with limiting effector cell concentration to approximately 15% at a 12:1 ratio.
All three mice generate up to 200 S.F.U. when assessed for antigen specific IFNJ
release. These responses are reduced when 5 x 10
5
effector cells are used with three
out of four mice generating up to 100 S.F.U. IL-4 assessment again showed limited
responses, generating approximately 40 S.F.U. being comparable to base line results.
Mouse 4 showed the weakest of all responses with between 15% and 20% CTL
mediated lysis of peptide pulsed targets, no killing of CD55 positive cells and IFNJ
release displayed at 60 S.F.U with IL-4 release being limited to around 30 S.F.U.
Figure 5.18: Immunisation of HHD II mice with SCR 1-3 Z158m Fc DNA
Figure 5.18a: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 1)
Standard protocols followed for both CTL and ELISPOT assays.
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ELISPOT analysis of mouse 1 (HHDII): INFγ and IL4 release
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Standard ELISPOT protocol followed utilising 1 x 10
6
and 5 x 10
5
effector cells seeded with Z158 wild
type and mutant peptides.
Figure 5.18b: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 2)
Standard CTL protocol followed.
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ELISPOT analysis of mouse 2 (HHDII): INFγ and IL4 release
0
50
100
150
200
250
1x 10 6 5 x 10 5 1x 10 6 5 x 10 5 No peptide M edia alone
Z158m Z158 Contro l
Conditions
Sp
o
tF
o
rm
in
g
Un
its
Gamma IFN
IL4
Standard ELISPOT protocol followed utilising 1 x 10
6
and 5 x 10
5
effector cells seeded with Z158 wild
type and mutant peptides.
Figure 5.18c: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 3)
Standard CTL protocol followed.
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ELISPOT analysis of mouse 3 (HHDII): INFγ and IL4 release
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Standard ELISPOT protocol followed utilising 1 x 10
6
and 5 x 10
5
effector cells seeded with Z158 wild
type and mutant peptides.
Figure 5.18d: Cytotoxic T Cell (CTL) Assay and ELISPOT analysis of IFNJ and
IL-4 antigen specific release (Mouse 4)
Standard CTL protocol followed.
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ELISPOT analysis of mouse 4 (HHDII): INFγ and IL4 release
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Standard ELISPOT protocol followed utilising 1 x 10
6
and 5 x 10
5
effector cells seeded with Z158 wild
type and mutant peptides.
Repeat analysis of the SCR 1-3 Z158m Fc DNA vaccine was set up to confirm
previous trends observed. Figure 5.19 shows the results obtained for CTL and IFNJ
ELISPOT analysis of four mice immunised. Two out of four mice display CTL
mediated killing of Z158 and Z158m pulsed targets between 40% and 65% with no
killing of the CD55 positive cell line. Interestingly, IFNJ assessment showed that all
mice developed an antigen specific response in excess of 200 S.F.U. for both wild
type and mutant peptides. However, at a reduced effector cell concentration of 5 x
10
5
cells only 50 S.F.U. were observed, a value being only slightly greater than
control samples.
Figure 5.19: Immunisation of HHD II mice with SCR 1-3 Z158m Fc DNA
Figure 5.19 a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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Figure 5.19b: ELISPOT analysis of Interferon J production
Standard protocol was followed as per section 2.7.5 utilising the ELISPOT kit from R & D
Systems. 96 well assay plates were coated with cytokine specific capture antibody overnight
at 4qC. Non specific binding sites were blocked and 1 x 106 effector cells were seeded per
well. Splenocytes were then stimulated with and without 10µg/ml target peptide and control
wells were set up containing media alone, cells alone and wells containing cells with PMA
and Ionomycin as a positive control to test viability of cell samples. All conditions were
repeated in triplicate and plates were incubated at 37qC 5% CO2 for 16 hours. Cells were
then removed and cytokine specific capture antibody was added to all wells. The
development module from the kit was then used for development of the assay prior to analysis
on a Bioreader 3000 Pro. Spots were counted and results expressed as the number of spot
forming units [S.F.U (cells)] that produced cytokine in response to specific stimuli.
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ELISPOT: IFNγ release
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In order to assess whether an antigenic boost could be delivered in order to promote
existing responses, a group of four mice were set up to be given two successive
immunisations of the SCR 1-3 Z158m Fc DNA vaccine and a final I.M immunisation
of 100µg SCR 1-3 Fc fusion protein in complete Freund’s adjuvant. This group was
assessed in parallel with a standard group of four mice immunised only with the DNA
construct. Figure 5.20 displays the results obtained for the DNA alone group. Two
out of four mice generate up to 60% CTL mediated lysis of peptide pulsed T2 targets
at an E: T ratio of 100:1 with no response generated towards CD55 positive cells.
Two of the four mice only generated 15% CTL killing of pulsed targets with a
titrating effect observed at reduced effector cell concentration. Antigen specific IFNJ
release was consistent with the CTL results, with two of the four mice eliciting up to
100 S.F.U to both Z158 and Z158m peptide stimuli. Figure 5.21 shows the results
obtained for the four mice immunised twice with the DNA vaccine and once with a
protein boost. As can be seen no CTL mediated killing is observed for any targets
and only one mouse showed a degree of antigen specific IFNJ release to Z158 and its
mutant peptide giving up to 100 S.F.U. per 10
6
cells stimulated.
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Figure 5.20: Immunisation of HHD II mice with SCR 1-3 Z158m Fc DNA
Assessment of standard triple SCR 1-3 Z158m Fc DNA immunisation in direct comparison
with SCR 1-3 Fc protein boost following two DNA immunisations (Figure 5.21).
Figure 5.20a: Cytotoxic T Cell (CTL) Assay
All mice immunised three times with SCR 1-3 Z158m DNA vaccine and standard assay
protocol was followed.
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Figure 5.20b: ELISPOT analysis of Interferon J production
Standard assay protocol was followed utilising the R & D systems kit.
ELISPOT: IFNγ release
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Figure 5.21: Immunisation of HHD II mice twice with SCR 1-3 Z158m Fc DNA
construct and once with 100µg SCR 1-3 Fc fusion protein
Standard immunisation protocols were followed as per sections 2.1.3 and 2.1.6 with the
protein boost being administered intramuscularly in a total volume of 100µl combined in a
1:1 ratio with incomplete Freund’s adjuvant.
Figure 5.21a: Cytotoxic T Cell (CTL) Assay
Standard assay protocol was followed.
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Figure 5.21b: ELISPOT analysis of Interferon J production
ELISPOT: IFNγ release
0
20
40
60
80
100
120
M1 M2 M3 M4
Stimulant
Sp
o
tF
o
rm
in
g
Un
its
Z158m
Z158
No peptide
Media alone
Results shown in S.F.U per 10
6
cells for all mice immunised from the same group.
A group of three mice were immunised with the SCR 1-3 Z158m Fc DNA construct
in order to assess the avidity of generated responses. This was determined via antigen
specific IFNJ release as assessed by ELISPOT (Figure 5.22). Titrations of peptides
were utilised ranging from 10 to 1 x 10
-5
ug/ml in order to generate IC50 values for the
generated responses. All there mice elicited up to 160 S.F.U for both Z158 and the
mutant peptide at a concentration of 10µg/ml in the presence of 10
6
effector cells.
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Two of the three mice showed IC50 values of 0.00015µg/ml and 0.0015µg/ml for
Z158m and Z158 respectively. These values indicate a potential log difference in
avidity of response towards the mutant peptide sequence. Mouse 2 displayed reduced
values indicating a ½ log difference in avidity.
Figure 5.22: Immunisation of HHD II mice with SCR 1-3 Z158m Fc DNA to
determine avidity of generated responses
ELISPOT analysis of IFNJ production
Standard protocol was followed seeding 1 x 10
6
effector cells with titrated concentrations of
Z158 and Z158m peptides.
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ELISPOT:HHD II Mouse 3 Immunised with SCR 1-3
Z158 Fc
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In order to confirm the need for the incorporated mutation within the DNA construct,
an experiment was set up comparing a wild type immunisation of SCR 1-3 Fc with a
group immunisation of SCR 1-3 Z158m Fc, both groups containing 3 mice. Figures
5.23a/b show the CTL results obtained from this vaccination protocol. As can be
seen, no CTL mediated killing was observed for mice immunised with the wild type
SCR 1-3 Fc construct in comparison to the mutant construct, which generated up to
50% lysis of both Z158 and Z158m pulsed T2 targets in two out of three mice.
Mouse three of the mutant group still generated CTL mediated killing of peptide
pulsed targets of up to 20%, with all mice generating limited responses to CD55
expressing cells.
Figure 5.23: Immunisation of HHD II mice with SCR 1-3 Z158m Fc DNA and
SCR 1-3 Fc (Wild Type) DNA
Figure 5.23a: Cytotoxic T Cell (CTL) Assay (SCR 1-3 WT Fc)
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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Figure 5.23b: Cytotoxic T Cell (CTL) Assay (SCR 1-3 Z158m Fc)
Standard assay protocol was followed as per sections 2.7.1 to 2.7.4. Target cells were
labelled with 1.85MBq sodium [
51
Cr] chromate for 1 hour with or without 100µg/ml specific
peptide, washed and repeat labelled with or without specific peptide for a further hour. 5000
cells were seeded into 96 U well plates and co cultured with titrated numbers of effector cells
in an assay volume of 200µl of complete media. Prior to the assay, effector cells had been co
cultured In Vitro with 1 x 10
6
irradiated LPS blasts which had previously been incubated with
10µg/ml target peptides. Plates were incubated at 37qC 5% CO2 for 4 hours and 50µl of
assay culture media was transferred to lumaplates. Plates were allowed to air dry and were
then analysed on a scintillation counter. Percent lysis was calculated relative to spontaneous
and maximum lysis results.
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ELISPOT analysis was carried out for all mice and the murine counterpart of Z158
was synthesised and utilised in order to assess the cross reactivity for a potential self
epitope. Figure 5.23c displays the results generated and highlights the two base
differences in the murine sequence as compared to the human. SCR 1-3 Fc fusion
protein was also included within the assay and both IL-4 and IFNJ release were
assessed. Analysis of antigen specific IL-4 release indicated limited responses giving
a maximum of 60 S.F.U. for stimulation with the complete fusion protein in mouse 3
of the wild type immunised group. Expression of IL-4 was generally consistent for all
conditions although mice immunised with the modified sequence do appear to
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produce slightly elevated responses. IFNJ release was consistent with previous
findings with wild type immunised mice producing between 20 and 40 S.F.U for most
stimuli, as opposed to Z158m immunised mice giving rise to S.F.U. in excess of 100
for both Z158 and Z158m. Interestingly two mice immunised with the mutant also
indicated a response to the fusion protein as did mouse 1 of the wild type group
generating approximately 80 S.F.U. Responses to murine Z158 were limited in all
experimental conditions with the greatest response observed for IFNJ release from
splenocytes harvested from mouse 2 of the mutant immunised group producing ~60
S.F.U.
Figure 5.23c: ELISPOT analysis of IL-4 and IFNJ production
Standard ELISPOT protocol was followed assessing both IL-4 and IFNJ release from
splenocytes harvested from mice immunised with wild type and modified constructs. The
murine equivalent of Z158 (wild type) peptide was also synthesised and assessed within this
experiment (mZ158) as a comparison for native expressed protein.
Z158: G L P P D V P N A
Z158M: G L P P D V P N V
mZ158: G P P P D I P N A
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ELISPOT: IFNγ release
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5.6: Luminex analysis of splenocyte culture supernatant and mouse sera
Luminex analysis of cytokines found within the culture supernatants of in vitro
stimulated splenocytes (used for CTL assays) and sera obtained from the cardiac
blood of immunised mice was carried out to allow further elucidation of responses
generated by the various construct immunisations and determination of the cytokine
environment stimulated. Bioplex kits were obtained with 10plex beads enabling
assessment of mouse cytokines: Il-2, IL-3, IL-4, IL-5, IL-6, IL-10, Il-12p40, IL-
12p70, IFNJ and TNFD. The standard assay protocol was followed as per section
2.5.7 using supernatant samples collected from CTL cultures (Figure 5.23) and sera
collected from immunised mice at the time of harvest (SCR 1-3 Z158m and WT Fc
DNA). Sera were also assessed which had been stored at -20qC from experiments
correlating with Figure 5.19 (SCR 1-3 Z158 Fc) and Figure 5.16 (SCR 1-3 Z143
Z158Fc).
Figure 5.24a-f display all the results obtained from one experiment analysing the
concentration of ten mouse cytokines.
IL-2 analysis showed that no levels were detected greater than base line un-
immunised samples.
IL-3 analysis showed that in collected sera no levels were obtained greater than base
line un-immunised results. Assessment of culture supernatant however, indicated that
for two mice immunised with the wild type construct and stimulated in vitro with
fusion protein contained 37pg/ml and 17pg/ml, which appear to be significantly
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greater than results from other cultures with a base line of approximately 5pg/ml
found in cell cultures from un-immunised mice (Figure 5.24a).
Figure 5.24: Luminex analysis of supernatant from In Vitro stimulated
splenocytes (cultured as per CTL assay) & sera collected from cardiac blood of
immunised mice
The standard Bioplex protocol was followed as per section 2.5.7. 10plex beads were used to
assess for the following mouse cytokines: IL-2, IL-3, IL-4, IL-5 IL-6 IL-10, IL-12p40, IL-
12p70, IFNJ and TNFD. A 96 well plate was coated with 1.25µl of 10plex beads, washed and
25µl of samples (supernatants and sera) were added per well. The plate was incubated for 1
hour at room temperature under agitation and then washed as per standard protocol. 12.5µl of
detection antibody was added per well and the plate was incubated for a further hour at room
temperature. The plate was washed and 25µl of Streptavidin-PE was added per well and
incubated at room temperature on a micro-plate shaker for 10 minutes. The plate was washed
and beads were analysed in 125µl of assay buffer per sample. Supernatants were collected
from CTL cultures used in Figure 5.23 and sera were collected from the immunised mice at
the time of cell harvest (Immunisations with SCR 1-3 Z158m and WT Fc DNA). Sera was
also assessed which had been stored at -20qC from experiments correlating with figure 5.19
(SCR 1-3 Z158 Fc) and figure 5.16 (SCR 1-3 Z143 Z158 Fc).
Figure 5.24a: IL-3 assessment within culture supernatant
Luminex analysis of IL-3: Supernatant of In Vitro stimulated splenocytes
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Figure 5.24a (2): IL-3 assessment of immunised sera
No results greater than un-immunised values
All assessment for both IL-4 and IL-5 in supernatants and sera samples revealed that
no detectable levels were present.
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Analysis of all samples for the presence of IL-6 indicated a potential Th2 environment
as supernatant samples from three mice immunised with the mutant construct
contained IL-6 ranging from 400pg/ml to 700pg/ml compared to un-immunised levels
of 100pg/ml (Figure 5.24b). Interestingly, two mice immunised with the wild type
construct also show high levels of IL-6, one of 600pg/ml and one >1400pg/ml. Sera
collected from these mice also showed levels of up to 70pg/ml compared to
undetectable amounts present in sera from un-immunised mice. Sera from one mouse
immunised with the double construct SCR 1-3 Z143 Z158 Fc also contained high
levels of IL-6 of over 1000pg/ml compared with a baseline level of zero, but the
greatest sera response was observed in mice immunised with SCR 1-3 Z158 Fc. Of
the four mice assessed results were 800pg/ml, 2145.29pg/ml, 200pg/ml and 500pg/ml
again compared to levels found in the sera of an un-immunised mouse that did not
contain detectable levels.
Figure 5.24b: IL-6 assessment within culture supernatant
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Figure 5.24b (2): IL-6 assessment of immunised sera
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M2= 2145.29pg/ml
IL-10 levels were varied in the supernatant samples assessed, with almost 150pg/ml
present in cultured splenocytes from an un-immunised mouse having been in vitro
stimulated with fusion protein (Figure 5.24c). Supernatant from splenocytes taken
from a mouse in the Z158m immunised group did contain higher levels of IL-10,
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being 200pg/ml. Many samples contained lower levels upon the addition of in vitro
applied protein, which may indicate a general dampening of a Th1 response upon the
addition of the foreign fusion protein. Il-10 was undetectable in all serum samples
assessed.
Figure 5.24c: IL-10 assessment within culture supernatant
Luminex analysis of IL-10: Supernatant of In Vitro stimulated
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Figure 5.24c (2): Il-10 assessment of immunised sera
No results greater than un-immunised
Assessment of supernatant for the presence of IL-12p40 also showed that in all
samples, a baseline concentration of ~40pg/ml was present, with cultures from only
two mice from the wild type immunised group containing higher levels of >100 and
>60pg/ml (Figure 5.24d). Assessment of mouse sera showed that one Z158m
immunised mouse contained 700pg/ml and two mice from the wild type immunised
group contained 650pg/ml and 500pg/ml, these values compared to an un-immunised
concentration of 210pg/ml.
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Figure 5.24d: IL-12p40 assessment within culture supernatant
Luminex analysis of IL-12 p40: Supernatant of In Vitro stimulated
splenocytes
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Figure 5.24d (2): IL-12p40 assessment of immunised Sera
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Analysis of samples for the presence of IL-12p70 indicated that no detectable levels
could be obtained.
Quantification of IFNJ levels (Figure 5.24e) within culture supernatants showed that
only one mouse from the Z158m immunised group contained 300pg/ml and that two
mice from the wild type group produced 210pg/ml and >1200pg/ml respectively.
These observations were compared to baseline concentrations that were <40pg/ml in
un-immunised cultures. Undetectable levels were found in the mouse serum samples.
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Figure 5.24e: IFNJ assessment within culture supernatant
Luminex analysis of IFNγ: Supernatant of In Vitro stimulated splenocytes
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Figure 5.24e (2): IFNJ assessment of immunised Sera
No results greater than un-immunised values
Analysis of all samples for the presence TNFD generated results comparable with
baseline levels.
Figure 5.24f displays summary tables combining the results obtained from the
cytokine profile. The presence of each cytokine is identified by either (+) or (-)
symbols that indicate the general level detected in either supernatant or serum as a
direct comparison with baseline levels.
Results for antibody responses to both SCR 1-3 Fc (WT) and Z158m are shown in
Chapter 4 and are of interest when analysed with the luminex data as isotyping data
would indicate the presence of a Th2 immune environment driven by the mutant
construct.
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Figure 5.24f: Summary tables of cytokine profile generated by immunisation
The tables incorporate cytokine expression levels as a comparison with serum and culture
supernatant form un-immunised mice. Expression is conferred by the number of (+) symbols
as a relative fold increase compared with baseline concentrations. The (-) symbol denotes
that no detectable levels were observed in comparison to control values.
IL-3 IL-6 IL-10 IL-12p40 IFNJ
SCR 1-3
Z158m Fc
Supernatants
M1 (with) - + - - +
M1 (without) - - - - -
M2 (with) - + - - +
M2 (without) - - - - -
M3 (with) - ++ + + +
M3 (without) - - - - -
Sera
M1 - + - +++ -
M2 - ++ - + -
M3 - - - - -
IL-3 IL-6 IL-10 IL-12p40 IFNJ
SCR 1-3 (WT)
Fc
Supernatants
M1 (with) ++++ - - ++ --
M1 (without) + - - - -
M2 (with) - ++ - - -
M2 (without) - - - - -
M3 (with) ++ ++++ - + -
M3 (without) + - - - -
Sera
M1 - + - ++ -
M2 - + - + +
M3 - ++ - ++ +++
Sera
IL-6
SCR 1-3 Z143 Z158m Fc
M1 ++++
M2 -
M3 +
M4 -
SCR 1-3 Z158m Fc
M1 ++++
M2 +++++
M3 +
M4 +++
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5.7: Discussion
The discovery of tumour associated antigens has enabled multiple studies to be
devised analysing potential therapeutic approaches that promote anti-tumour T cell
responses. However, as is well documented, the majority of currently identified
antigens consist of ‘self’ proteins which arise due to the over expression of normal
cellular genes (Rosenberg et al., 1999). Unfortunately for the battle against tumour
development, the immune system has developed complex mechanisms that promote
self tolerance and inhibit the potential for autoimmune disease. While the thymus
induces tolerance, many autoreactive T cells escape into the periphery and still show
potential for recognising tissue-specific antigens albeit at low avidity. This central
tolerance is complemented by peripheral tolerance mechanisms that are mediated by
the concentration of self antigens (Kurts et al., 1998 and Morgan et al., 1999). If low
levels of antigen are expressed, minimal presentation occurs and self reactive
“ignorant” T cells remain. However if antigens are expressed at high levels in a pro-
inflammatory environment with signals inducing DC maturation, these ignorant T
cells become activated. Memory T cells are also regulated by this mechanism
causing a tolerant state in a cognate antigen concentration dependent manner
(Kreuwel et al., 2002). These findings illustrate that induction of immune responses
to overexpressed self antigens may be possible but they may be regulated by the
peripheral tolerance induced by memory T cells. If low affinity T cells, which have
‘escaped’ into the periphery can be induced to kill cells expressing certain self
antigens, this would be a potential viable methodology for successful tumour
immunotherapy.
A variety of methodologies have been used to identify potential CTL epitopes for
incorporation into tumour vaccines. The elution of peptides from the MHC of tumour
cells has often been utilised (Maeurer et al., 1996 and Nakatsuka et al., 1999) and the
results of which have been incorporated into several on line databases. Expression
cloning (Aarnoudse et al., 1999, Boel et al., 1995 and Kawakami et al., 1994) has also
been utilised along with the generation of overlapping peptides used to stimulate CTL
responses (Beattie et al., 2004). However, these methods are labour intensive and
often identify epitopes to which the immune system has either already failed to mount
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a successful response or has generated regulatory T cells. A possible method for the
identification of successful epitopes avoiding antigenic competition and preventing
the stimulation of regulatory T cells is to utilise CTL epitopes identified from within
tumour associated antigens. Many of these epitopes are shown to only bind with
moderate affinity to MHC, and are thus only presented at low frequency to the T cell
receptors and therefore initiate poor responses. Many studies have shown that by
mutating HLA-A2 binding epitopes to preferred amino acids, the affinity of the
MHC/peptide complex can be significantly increased without altering the residues
bound by the T cell receptor (Ahlers et al., 2001, Irvine et al., 1999 and Sarobe et al.,
1998). This process has been shown to improve the frequency and avidity of immune
responses in many cases, as reviewed by Berzofsky et al (2001). It was determined to
use HLA-A*201 transgenic mice as this allows epitopes to be identified that can be
presented by this common human class I antigen. Specifically HHD II transgenic
mice were used as several studies have shown that the absence of mouse class I
molecules results in both quantitative and qualitative responses mediated by CD8
+
cells generated after DNA immunisation (Ramage et al., 2004 and Hüseyin et
al.,2002).
HLA-A*201 epitopes were identified within the primary protein sequence of human
CD55 utilising several internet based prediction algorithms. These programs
incorporate data from elution studies identifying epitopes by specific residues purified
from the MHC molecules of tumour cells and equate to the specificity and differential
affinity with varying HLA allotypes. Varying degrees of consistency were observed
across predicted epitopes as could be expected with each program possessing
differing scoring systems. However several trends were noted and many of the
peptides with the highest predicted binding affinities were identified by at least four
of the programs used. In order to potentially overcome pre existing antigen
“ignorance” to the epitopes identified, residue modifications were incorporated into
the peptide sequences based on several studies (Tourdot et al., 2000, the
Bioinformatics group at Leeds University and other cited groups). The premise being
that by increasing the affinity for MHC, elevated levels of antigen could be presented
to effector cells. The binding affinity of five of the wild type epitopes appear to be
significantly enhanced by anchor modification, relative to program predicted scores,
supporting previous findings. Binding potential was assessed by T2 stabilisation
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assay, the results of which indicate a distinct discrepancy between predicted binding
affinity and observed MHC stabilisation. Only three of the predicted wild type high
affinity binding peptides displayed this property, namely Z142, Z68 and Z158, all of
which generate high actual stabilisation scores with the mutants Z143, Z69 and
Z158m all showing significantly increased binding affinity at both peptide
concentrations assessed. While both concentrations utilised are significantly higher
than amounts that would be present in vivo, conclusions can be drawn relative to the
experimental conditions. As the T2 stabilisation assay is a viable experiment,
recycling of MHC and the association and disassociation of peptide/MHC complexes
must be taken into account. It is arguable that complete saturation of available MHC
molecules is obtained at both 100µg/ml and 25µg/ml. However, results obtained
could indicate not only the affinity of interaction but possibly the avidity relative to
the number of interactions, due to the maintenance of high stabilisation scores at
lower concentrations, acknowledging a decrease in score at reduced peptide presence.
In comparison with all peptides assessed, Z158 and Z158m peptides produce the
greatest level of observed stabilisation. The results indicate that certain anchor
modifications are favourable as in the case of the Z158 to Z158m modification
replacing alanine to a preferred valine residue (Falk et al., 1991). Many of the
mutations assessed incorporated leucine to valine substitutions which are similar in
aromatic structure and potential binding properties, which may indicate unsuccessful
enhanced stabilisation for many peptides. However, this mutation was also utilised
for the wild type peptides Z68 and Z142 conferring elevated scores although the wild
type peptides did confer relatively high stabilisation when compared to many of the
alternate sequences screened. Z69 is an example when the naturally occurring peptide
contains the marginally less preferred valine as opposed to the mutated leucine
residue at position 2. It is therefore, possibly expected that comparative binding
properties of this wild type and mutant are similar. These results would suggest that
the effectiveness of incorporated mutations largely depends upon the nature of the
residue being replaced. It is clear that software based predicted binding score is by no
means a definite method of ascertaining potential increased MHC affinity. It appears
that there is little to no correlation between predicted values when compared with in
vitro obtained results, confirming the necessity for T2 stabilisation assessment, a
factor supported by Ramage et al., (2006) and Anderson et al., (2000) who suggest
that the same computer programs did not accurately correspond with obtained
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findings. A possible reason for this would be that elution studies assess individual
residues as a frequency of occurrence at certain positions. While this alone may
support the potential of “preferred” locations, this may not consider overall
interactions within complete peptide sequences and thus structure and overall
properties defined by all local interacting residues.
To determine whether a repertoire of T cells exist that recognised CD55, transgenic
mice were immunised with DNA constituting either wild type constructs or constructs
incorporating each of the three epitopes and compound mutants that conferred
enhanced MHC binding. Of all the constructs analysed only the SCR 1-3 Z158m Fc
and the compound mutant incorporating Z158m and Z143 generated antigen specific
CTL mediated killing of pulsed targets, a fact supported by the expression of IFNJ in
responses to antigen stimulation. The lack of responses to both the Z69 and Z143
(single modification) constructs could be due to the fact that both show reduced MHC
stabilisation when compared to the Z158m peptide. Also it is possible that within the
mice immunised the epitopes may not be processed and presented on the HLA-
A*201. As mentioned, the Z158m peptide elicited the greatest level of MHC
stabilisation and the vaccine generated up to 60 percent lysis of both the wild type and
mutant epitope targets. Analysis of the avidity of responses generated indicate that a
log difference is generated comparing the mutant Z158m to the wild type epitope with
a frequency of over 1 in 1 x 10
4
cells expressing IFNJ in an antigen dependent
manner. Furthermore, the wild type vaccine failed to elicit CTLs that recognise these
epitopes even though the native peptide displayed significantly enhanced stabilisation
of HLA-A*201. This implies that the epitope with higher binding affinity would have
a greater occupancy upon MHC and therefore could stimulate naïve T cells. These
findings agree with other studies stating that the concentration of self epitopes
presented is important in breaking tolerance to self antigens (Kurtset al., 1999,
Morgan et al., 1999 and Ramage et al., 2004). With respect to the current study the
idea of stimulating naïve T cell responses with modified epitopes generating immune
responses to wild type epitopes can be clearly observed. However, when considering
the possibility of overcoming tolerance to self antigens this study can not be
conclusive. Human CD55 shares 49.2 percent homology with its mouse counterpart
and therefore the question of this system analysing a foreign epitope is valid. A
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summary of the epitopes assessed is shown below displaying homology between
mouse and human epitopes with highlighted amino acids indicating differing residues.
Z68 Z158 Z142
Human LVLLCLPAV GLPPDVPNA SLSPKLTCL
Mouse SLLLLSTPV GPPPDIPNA PLPGKATCL
33.3% homology 77.8% homology 55.55% homology
Interestingly, the epitope which generated the greatest overall responses also shows
the greatest level of homology between the murine and human sequence. However
when the construct was assessed via ELIPOT analysis, limited responses were
observed towards the murine peptide, which would indicate that a break in tolerance
cannot be implied and that further assessment of this system is required. Ideally,
HHD II transgenic mice expressing human CD55 would be the most ideal model to
asses this system in terms of assessing overcoming tolerance. CTLs recognising
epitopes are only of true relevance if they successfully recognise naturally processed
antigen. For epitopes to be presented, they would have to be processed and presented
as any other whole antigen, generated by the DNA construct, thus in terms of the
vaccine, results indicate that the CTL epitope was naturally processed and loaded onto
the class I MHC. However, CTL mediated lysis of the colorectal carcinoma cell line
transduced to express human CD55 was limited with the greatest level observed from
mice immunised with the double construct SCR 1-3 Z143 Z158m Fc generating up to
15 percent lysis at an effector target ratio of 100:1. This restricted level of CTL
mediated killing would possibly be due to the “low” avidity of responses generated.
Other possibilities would be that processing of the human CD55 protein in mice could
differ to that of human responses due to variation in the proteases in the murine
model, although successful targeting of peptides may dispute this. Another possibility
would be that the incorporated Fc tail could affect the nature of processed products
even when considering the advantages offered by Fc targeting of vaccines (You et al.,
2001 and Durrant et al., 2001). Assessment of a wider panel of potential targets,
including cells which naturally express both CD55 and HLA-A202, would be needed
in order to obtain more conclusive results. This double construct also appears to
generate the greatest overall level of responses with respect to CTL lysis of targets
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expressing both the Z158m and Z158 peptides, eliciting CTL mediated lysis of
between 50 and 90 percent and also generated IFNJ at a frequency in excess of 2 cells
in 1 x 10
4
seeded effectors. This observation, in combination with the fact that the
construct containing Z143 alone failed to generate any significant responses could
suggest the potential that the Z143 mutation has incorporated a CD4
+
epitope and
therefore generates T cell help. This hypothesis would need further analysis
incorporating the depletion of CD4
+
and CD8
+
cells. However, antigen specific
release of IL-4 did not appear to be significant although possibly raised in comparison
to levels observed in single mutant constructs. Another possible explanation for the
responses to both the Z143 and Z142 peptides could be due the presence of epitope
spreading. This phenomenon was initially characterised by an exacerbating factor in
CD4
+
T cell dependent autoimmune disease and believed to occur due to presentation
of antigens liberated by tissue destruction. Several groups have shown that epitope
spreading can occur for class I restricted peptides during tumour rejection.
Specifically, Markiewicz et al (2001) showed that immunisation against the single
tumour peptide P1A (utilising the P815 tumour model), followed by rejection of P1A
+
tumour, subsequently yielded CTL activity and tumour protection against a P1A
-
tumour variant, and that CTLs developed were specific to a second defined epitope
P1E. Mamouz et al., (2002) also confirmed this observation in a similar model,
obtaining tumour rejection with the development of CTLs against additional P815
antigens which were not incorporated in their initial immunisation. While these
examples are obtained from tumour immunisation/rejection models, it can be
postulated that the Z158m double construct used in this study drives such a potent anti
epitope (Z158) response that CTLs recognising the Z143 epitope could be enhanced
by the pro inflammatory environment driven by activated DCs that cross reactivity is
observed.
Analysis of the cytokine profile obtained from both sera and culture supernatants
indicate the presence of a mixed environment displaying both Th1 and Th2 responses.
Mice immunised with both the SCR 1-3 Z158m Fc DNA vaccine and the wild type
counterpart generate levels of IFNJ and IL-12p40 within culture supernatants and
cardiac sera respectively. Both of which are involved in Th1 mediated responses with
IFNJ promoting IL-12 induction of acquired immune responses interacting with
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innate responses (Kaminski et al., 1996). Both mediate multiple effects driving T
lymphocyte growth and development, stimulating release of other Th1 cytokines.
Interestingly, Il-12-p40 is also produced by B cells and dendritic cells which equate
with the Th2 profile which is also observed. A mixed profile is obtained for IL-10
results as the greatest level was observed in the supernatant from one of the wild type
immunised mice. IL-10 while being a potent Th2 cytokine is also known to reduce
IL-6 expression and stimulate Treg cells. However, IL-6 happens to be generated in
both supernatant and sera of mice immunised with the Z158m and Z158 constructs.
Many of the mice so immunised generate high levels of this cytokine that targets
proliferating B cells, plasma cells and myeloid stem cells, promoting terminal
differentiation into plasma cells stimulating antibody secretion and the induction of
acute phase proteins. The results indicate that higher levels are located within the sera
of immunised mice with the greatest levels found in mice immunised with the wild
type construct. This is interesting, as it appears to support the findings obtained in
chapter 4 suggesting that both the wild type and mutant constructs of Z158 elicit a
defined antibody mediated response.
Pasare and Medzhitov (2003) postulated that the ligation of TLRs on dendritic cells
was able to overcome CD4
+
CD25
+
T cell mediated suppression of immune
responses. They initially identified that CD4
+
CD25
+
Treg cells could effectively
suppress CD4
+
CD25
-
T cell activation when freshly isolated splenic DCs were used
as antigen presenting cells. They then proved that blocking of Treg suppression was
independent of co-stimulatory molecules. This was achieved utilising MyD88
deficient DC’s as TLR4 signals through this pathway in a dependent manner in order
to produce inflammatory cytokines and in an independent manner to upregulate MHC
class II and co-stimulatory molecules (Kaisho, 2001). When these cells were utilised
as APCs, neither treatment with LPS or CpG was capable of interfering with Treg
suppression, despite the normal upregulation of CD80, CD86 and CD40. In order to
determine if cytokines mediate the observed suppression, conditioned media from
LPS or CpG treated DCs was applied to the current assay using MyD88 DCs as
APCs. The addition of the media led to complete blockade of Treg mediated
suppression. Having confirmed that cytokines were responsible for the observed
blockade, antibodies were used to neutralise the cytokines found within the media
obtained from stimulated DCs. The paper concluded that only blockade of IL-6
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completely abrogated the ability of DC medium to block Treg suppression. Other
groups have supported these findings such as Powrie et al., (2003) who state that IL-6
is a requirement for the blockade of Treg activity obtained from activated DCs
although other TLR induced factors are also required. Kubo et al., (2004) generated
conflicting results although they justified their observations in that their DC
populations were myeloid derived and not the more heterogeneous population of
splenic DCs used by Pasare and Medzhitov. These findings indicate that in the
current model, while IL-6 could be acting as a Th2 mediator, its presence could be
inhibiting potential Treg suppression of generated immune responses. Thus, the Fc
targeting of DCs incorporated into the vaccine may lead to upregulation of DCs,
increased IL-6, decreased Treg activity and may indicate why responses are generated
to both the Z158m and wild type constructs.
A potential criticism of luminex obtained data, would be in the case of supernatant
obtained from cultured splenocytes being stimulated with whole Fc-fusion protein and
not peptide, which may be driving new responses to the foreign protein. However,
serum cytokine levels also support many of the findings although repeat assessment
could possibly answer some of the questions raised.
The results obtained indicate that there is a repertoire of T cells in HLA-A*201 HHD
II transgenic mice that recognise and lyse cells loaded with associated antigen. The
system utilised supports current evidence for epitope anchor modification while
confirming the requirement for T2 stabilisation assessment in vitro in combination
with program based prediction protocols.
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Chapter 6: General Discussion
The premise of this project was to develop potential immunotherapeutic strategies for
targeting the complement regulatory protein (CRP) CD55 in the context of it being a
tumour associated antigen. The cytoprotective role of CD55 and other CRPs has
made them viable targets in many clinical situations, and in recent years they have
become the target of many tumour antibodies. These clinical antibodies not only
inhibit complement regulatory activity, enabling complement dependent cytotoxicity,
but also have the potential of activating complement and associated cellular
mechanisms. Antibody dependent cellular cytotoxicity relies upon the recognition of
the Fc domain of antibodies by FcJ receptors expressed by NK cells, monocytes,
macrophages and granulocytes. Binding of this receptor results in the activation of
phagocytic/lytic functions of these effector cells. The differential expression of CRPs
on tumours has been shown to vary, with a trend towards increased levels upon many
tumour types as reviewed by Fischelson et al., 2003. CD55 expression has been
assessed on numerous tumours indicating significant increases upon many types
studied, including colorectal and gastric cancer (Li et al., 2001). Studies utilising
tissue micro arrays have assessed whether altered expression levels of CRPs can be
used as a prognostic factor. Colorectal carcinoma for example, has shown to
significantly overexpress CD55 and CD59, both of which have been shown to be
markers of worsening prognosis (Durrant et al., 2003, and Watson et al., 2005).
Interestingly in both of these studies, CD46, while expressed on most tumours,
displayed limited variation in its levels. These findings support the theory that CRPs
are de-regulated on many tumours and loss of one often coincides with
overexpression of another. The reasons for this observation remain unclear, but the
potential of either immune surveillance involving complement promoting altered
expression, or the de differentiation of tumours are both possibilities.
Initial immunoscintigraphy of multiple tumour types utilising the 791T/36 antibody
identified the specificity gained when targeting CD55, as explant and histological
analysis indicated localisation of the antibody to the stromal and cellular components
of the tumours analysed (Pimm et al., 1985). During this analysis of over 100 patients
243
no adverse effects were observed, a finding that supports the potential use of
immunotherapeutics targeting this antigen.
Soluble CD55 has been observed in a range of pathological conditions including the
synovial fluid of rheumatoid arthritis (Jones et al., 2004), and in colorectal cancer
sCD55 is present in stool samples (Kohno et al., 2005). Many cell lines from
differing tumours have been shown to deposit CD55 into their extracellular matrix
(Morgan et al., 2002), which is mediated by MMP-7, with the SCR 1-3 domains
remaining intact (Liszewski et al., 1996). Previous assessment of sCD55 has shown
that it preserves its capacity to inhibit both classical and alternate pathways of
complement activation (Seya et al., 1987, and Moran et al., 1992), and can also
incorporate into the membranes of NK cells, decreasing their ability to mediate killing
via ADCC (Finberg et al., 1992).
CD55 has been shown to be a ligand of the T cell early activation marker CD97, a
member of the EGF-TM7 family of receptors (Davis et al., 1998). This was identified
when CD97 transfected cells were proven to interact with red blood cells, an
interaction that could be prevented by the addition of antibodies to both CD55 and
CD97 (Hamman et al., 1996). Work utilising CD55 knockout mice has indicated that
in these models significant increases in the magnitude of immune responses were
observed (Liu et al., 2005 and Heeger et al., 2005). Miwa et al., (2002) have
suggested that this observation could be due to the interaction of CD55, expressed by
macrophages, with CD97 on circulating T cells. Leemans et al., (2004) have also
shown that CD55/CD97 interaction has a vital role in the migration of neutrophils in
models of pneumonia and inflammatory bowel disease. While these models indicate
a role for CD55 in both the regulation of complement and adaptive responses,
differences in expression patterns in respective species must be considered. More
recently, Spendlove et al., (2006) have demonstrated that sCD55 is capable of
inhibiting T cell effector function, an indication reflected in the observed decrease in
proliferation and IFNJ secretion in cultures of adherent monocytes and T cell clones.
These findings were confirmed utilising CD55 antibody blocking studies which
neutralise the sCD55 effects.
244
These multiple roles of both membrane and soluble CD55 raise many questions
concerning the complex interactions in which this molecule is involved. In respect to
the current study, CD55 may protect tumour cells from not only complement
mediated lysis, but may also protects its environment by the release of CD55 onto
surrounding matrices. Soluble CD55 released into the tumour environment, while
remaining functionally active, may not only prevent complement deposition onto the
tumour itself, but may interact directly with activated T cells inhibiting their effector
function. These observations support the directing of immune therapies towards this
molecule.
The human anti-idiotypic antibody 105/AD7 was isolated from a colorectal cancer
patient receiving 791T/36 antibody for radio immununo-scinitgraphy of liver
metastases. The anti-idiotypic antibody recognised the binding site of 791T/36 and
mimics the tumour associated antigen CD55 (Austin et al., 1989). Spendlove et al.,
(2000), showed that amino acid and structural homology were shown between
105/AD7 and CD55, specifically within the first two SCR domains of CD55. Durrant
et al., (2001) utilised 105/AD7 as an immunogen in colorectal cancer patients, and
showed that anti-idiotypic antibodies are good immunogens due to targeting of Fc
receptors on antigen presenting cells, allowing efficient stimulation of both helper and
T cell mediated responses. Results were measured by analysis of in vitro T cell
proliferation, IFNJ secretion and redirected cytotoxicity in un-primed T cells from
healthy donors. In 2000, results were published by Durrant et al., stating that 12
colorectal cancer patients received 105/AD7 therapy and that 10 of those
demonstrated accumulation of CD8
+
RO cells or tumour killing. They concluded that
treatment with this antibody could stimulate CD4
+
and CD8
+
responses, although
continued immunisation was required to sustain memory responses. More recently,
Pritchard-Jones et al., (2005), assessed this anti-idiotypic antibody in osteosarcoma
patients following myelosuppressive chemotherapy. Their results indicated that 20
out of 28 patients showed significant T cell responses in vitro to the immunogen and
that 13 out of 22 patients showed antigen specific IFNJ release. They also state that 9
out of 22 patients made antibody responses to CD55. They conclude that potentially
therapeutic responses can be elicited, with regards to T helper responses, when
vaccination was commenced post chemotherapy treatment, and that no clinically
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significant toxicity was observed. These findings and on going clinical trials
involving this CD55 mimicking antibody suggest the potential use of vaccination
strategies exploiting the tumour associated antigen CD55.
As many tumour associated antigens have been identified, the development of new
immunotherapies for the treatment of solid tumours has become possible. Focus has
been placed on the production of cancer vaccines, largely due to the widespread
success of vaccines in the prevention of viral diseases, which has enabled greater
understanding of immunological processes and the theoretical framework for
immunisation against cancer. Practical reasons for the development of cancer
vaccines are also accepted, as they are easily administered to outpatients with limited
side effects (reviewed by Rosenberg et al., 2004). Attempts to develop therapeutic
cancer vaccines are based upon stimulating anti-tumour T cells capable of recognising
cancer antigens (Rosenberg et al., 2001). The induction of CD8
+
cells possessing
specific immune reactivity depends on interactions with other cell types such as CD4
+
cells and APCs, although the major effector in many models is the CD8
+
lymphocyte
(Rosenberg 2004). Several immunising vectors have been tested in humans,
including peptides, proteins, antigen presenting cells, DNA and recombinant viruses.
The administration of peptides emulsified in adjuvant is currently the most effective
means for the in vivo development of anti-tumour T cells in humans (Rosenberg et al.,
2006). Several requirements are needed for the successful immunologic destruction
of established tumours, including the generation of significant numbers of high
avidity T cells capable of recognising tumour antigens that effectively traffic and
infiltrate tumour stroma. These cells must in turn be activated at the tumour site, in
order to generate appropriate effector mechanisms like cytokine secretion and direct
cell lysis.
A concern with mouse tumour models is the rapid growth of extensively passaged
tumour cells in vivo, and thus many vaccine models are assessed by their ability to
prevent the outgrowth of the tumour itself. Often in these models, the presence of
even large numbers of cells recognising tumour antigens in mice is insufficient to
mediate tumour regression (Overwijk et al., 2003 and Speiser et al., 1997). Several
factors critically affect the success of potential vaccines, including avidity of immune
cells generated, inability of the tumour to activate quiescent lymphocytes, suppressor
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influences generated by either the tumour itself or by the immune system itself and
tolerance mechanisms including anergy (Marincola et al., 2000). All of these
mechanisms for the inhibition of anti-tumour responses must be overcome in order to
generate a successful vaccine.
Current successful strategies incorporate the use of the adoptive transfer of anti-
tumour T cells mediating the rejection of large vascularised tumours in mice under
conditions of host immunosuppression. B16 melanomas have been rejected in mice,
post lymphodepletion, transferring anti-tumour T cells in conjunction with antigen
specific vaccination and IL-2 (Overwijk et al., 2003). Recent human clinical trials
have demonstrated this approach (Dudley et al., 2002). The trial enrolled patients
with metastatic melanoma refractory to treatment with high dose IL-2 and
chemotherapy. In vitro activated and expanded autologous anti-tumour lymphocytes
plus IL-2 were transferred to the lymphodepleted patients, resulting in objective
cancer regression in 6 of 13 patients. The transferred cells were shown to persist up
to four months post transfer. Rosenberg (2004) summarises the effectiveness of cell
transfer therapies, indicating that many alternate strategies, while potentially
generating relatively high frequencies of antigen-reactive T cells, are often of low
avidity for tumour recognition. This contrasts with cells generated in vitro from
tumour infiltrating lymphocytes, which are selected for high avidity recognition of
tumour antigens (Rosenberg et al., 1998). When these cells are transferred into
lymphodepleted hosts, this has resulted in up to 75% of circulating CD8
+
cells
possessing anti-tumour activity.
In contrast to solid tumours, lymphoid tumours often express co-stimulatory
molecules, a fact that may explain clinical responses observed in B cell lymphoma
trials to dendritic cell vaccines (Timmerman et al., 2002). Solid tumours do not
express these molecules or produce inflammatory environments necessary to convert
quiescent precursor lymphocytes required for tumour destruction (Rosenberg 2004).
It can be observed that a major challenge in the development of cancer vaccines is the
potential to develop long term memory responses in combination with the direct
activation of these cells. Potential ways of achieving these targets is by enhancing
stimulation of antigen presenting cells with adjuvants or by generating a pro
247
inflammatory environment at the tumour site in order to encourage homing of effector
cells.
Another challenge in the development of effective anti-tumour vaccines is the
presence of active suppressor mechanisms produced by both tumours and the immune
system itself (Hori et al., 2003 and Shevach et al., 2001). A major contributor to
suppressive effects is the presence of Treg/ CD4
+
CD25
+
cells that inhibit proliferation
and effector functions of immune cells. Rosenberg states that a major advantage of
adoptive transfer therapies is the ability to deplete host lymphocytes, including
regulatory cells, prior to cell transfer, a common methodology being the use of
chemo/radiotherapy. However complete lymphodepletion can not be utilised with
vaccine strategies as host effector cells are critically required for developed responses.
Several alternative strategies are being assessed for the specific removal of regulatory
T lymphocytes.
Attia et al., (2005), show results from a clinical trial with metastatic melanoma
patients treated with HLA-1*0201 restricted peptides from the gp100 melanoma
associated antigen, in combination with anti CTLA-4 antibodies. Cytotoxic T-
lymphocyte antigen-4 binds to CD80 and CD86 on APCs and acts antagonistically,
preventing CD28 interaction that enhances T cell activation, proliferation and the
production of IL-2 (Koulova et al., 1991). Treg cells constitutively express CTLA-4
and are identified by their capacity to inhibit the proliferation of other T cells
(Shevach et al., 2002). Attia used CTLA-4 blockade to prevent interaction of Treg
cells and shows that an overall objective response rate was observed of 13%, with
tumour regression observed in lung, liver, brain, lymph nodes and subcutaneous sites.
These responses were observed in the presence of auto immune toxicity and
comparative dose regimes were analysed. 5% of patients clinically responding to
treatment showed no toxicity, compared with 36% responses observed within patients
displaying signs of auto immune disease. They concluded that CTLA-4 blockade in
combination with peptide vaccination causes durable objective responses and that
with aggressive medical management autoimmune toxicities could be controlled and
reversed.
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As mentioned previously, peptide vaccination strategies are shown to elicit strong
antigen specific responses, although the need to develop in vivo high frequency
phenotypically and functionally characteristic anti-tumour T cells is required for
tumour elimination. Powell et al., (2004) utilised gp100 peptide immunogens in
melanoma patients and showed that after a multiple course immunisation strategy, a
phenotypic shift of native peptide specific CD8
+
T cells from early effector to effector
memory (CD27
-
CD28
-
CCD62L
-
CD45RO
+)
displaying functional maturation. One
year post final immunisation, circulating vaccine specific CD8
+
T cells persisted in
patients’ peripheral blood mononuclear cell populations, maintaining effector memory
phenotype.
Mode and site of immunisation are also observed to affect the nature of T cell
responses which may be generated by anti-tumour immunisation. Rosenberg et al.,
(2006) show in malignant melanoma patients that combining peptides within the same
emulsion can alter reactivity when compared with peptides injected at separate sites.
They postulate that observed results may be mediated by mechanisms based on the
induction of localised non specific inflammation or competitive binding of peptides to
MHC molecules. Patients were administered a highly immunogenic gp100 peptide
and a less immunogenic tyrosinase peptide. Two trials were set up, the first using 31
patients immunised at separate sites and the second, using 33 patients, with both
peptides being immunised at one injection site. Separate vaccination generated
significant anti-peptide activity, as assessed by tetramer staining and ELISpot,
towards the gp100 peptide, whereas the tyrosinase peptide generated limited
responses. When the peptides were emulsified together and injected at the same site,
gp100 specificity dropped and tyrosinase responses were enhanced.
As mentioned, tumour infiltration and the development of a pro inflammatory
environment are required for successful anti-tumour immunotherapy. Lurquin et al.,
(2005), show that melanoma patients vaccinated with a MAGE-3 antigen develop
anti-MAGE-3.A1 T cells at a frequency of 1.5 x 10
-5
of CD8
+
T cells in invaded
lymph nodes. However, they also show that anti-tumour cytotoxic T cells recognising
alternate antigens were approximately 10,000 times more frequent than anti-vaccine
cells within metastases, representing the majority of cells present. The group suggest
that anti-vaccine CTLs are not the effectors that kill the bulk of tumour cells, but that
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their interaction with the tumour itself promotes conditions enabling the stimulation
of large numbers of anti-tumour CTLs that proceed to destroy the tumour. In this
assessment, naïve T cells appeared to be stimulated as new anti-tumour clonotypes
were generated post vaccination. These findings have also been identified in other
studies and trials relating to melanoma vaccination strategies as summarised by Boon
et al., (2005).
While many current studies and trials show limited clinical effectiveness, relative to
tumour regression, successful approaches have been developed for mediating high
avidity and frequency effectors. In order to promote clinically significant responses,
multi-potent strategies need to be developed. By incorporating mechanisms for the
stimulation of CD4
+
cells recognising MHC class II restricted antigens could sustain
the activation and survival of CD8
+
effectors. Effective adjuvants such as toll like
receptor agonists (Takeda et al., 2003) could be utilised in order to activate innate
immune processes. The co-administration of homeostatic cytokines such as IL-15,
IL-2 and other pro-inflammatory mediators could also be used to promote anti-tumour
activity (Waldmann et al., 2001). The introduction of co-stimulatory molecules in
combination with specific antigen may also be used to activate quiescent precursors in
successful anti-cancer strategies (Hodge et al., 2001). The potential of selective
suppression of immunosuppressive cytokines or regulatory cells also show promise in
promoting many responses. The most successful clinical outcomes gained are often
observed in adoptive transfer studies, despite the intensity of labour required, as the
regression of large vascularised tumours has been demonstrated in both mice and
humans.
In the context of the current study, both CTL and antibody mediated responses were
observed, with the potential presence of DC released IL-6 which could be exploited
for the down regulation of regulatory T cells. While further analysis of the precise
methodology could be achieved, the principle of targeting CD55 as a tumour antigen
remains viable. The administration of CD55 specific antibodies could not only be
utilised to inhibit all CD55 interactions, but could also be exploited for the homing
and development of ADCC mediated killing of tumour targets. Antibody mediated
therapy, in combination with an Fc targeting DNA vaccine with the potential to elicit
high avidity, high frequency CTL effectors, could be used to promote anti-tumour
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responses. Incorporation of CD4
+
epitopes would also have the potential to sustain
and promote responses, and cytokines such as IL-2 could be assessed in the promotion
of effector responses observed. Initial priming of responses that could target CD55
expressing tumours would potentially disseminate cells leading to the release of
alternate tumour antigens, which may promote a more significant anti-tumour
response. There is also potential for the limited application of regulatory cell
inhibitors such as anti CTLA-4 antibodies in order to stave off suppressive effects,
enabling the generation of a more complete pro-inflammatory environment.
In conclusion, the methodology used and results obtained indicate the potential
successes for this strategy. Questions are raised due to the avidity of responses
generated and the functional abilities of antibodies raised. Future assessment would
need to incorporate human CTL responses to the modified epitope, and immunisation
strategies within transgenic mice expressing both HLA-A2 and human CD55 would
be needed in order to assess the potential for overcoming immune tolerance. The
inclusion of MHC class II epitopes, required for licensing of antigen presenting cells,
would have the potential to increase the efficiency of responses generated. Further
assessment of the importance of the Fc region of the construct could be elucidated by
the addition of a ‘stop’ codon into the vaccine itself, and the frequency of responses
determined for a more complete analysis of the current construct.
CD55 remains a viable target for the development of anti-tumour
immunotherapeutics. Further characterisation of responses generated in this study,
assessing the CD55 inhibitory potential of antibodies generated and the ability of
CD8
+
cells to mediate killing of tumours expressing CD55, and the incorporation of
methods to stimulate multiple arms of the host immune system should be utilised for
the development of a potential therapeutic treatment.
251
Bibliography
AAHLERS,J.,BELYAKOV,I.,THOMAS,E.,BERZOFSKY,J. (2001) High affinity T
helper epitope induces complementary helper APC polarisation, increased CTL and
protection against viral infection.. J Clin Invest. 108:1677-1685.
ARMITAGE,N.C., HARDCASTLE,J.D.,et al. (1986) Imaging of bone tumors using a
monoclonal antibody raised against osteosarcoma cells. Cancer, 1; 58(1). 37-42.
AARNOUDSE,C.,VAN DEN DOEL,P.,HEEMSKERK,B.,SCHRIER,P. (1999)
Interleukin-2 induced, melanoma specific T cells recognise CAMEL, an unexpected
translation production of LAGE. International Journal of Cancer. 82:442-448.
ALI,S.,REES,R. (2004) Anti tumour therapeutic efficacy of OX40L in murine tumour
model. Vaccine.22: 3585.
ALLAVENA,P.,GIARDINA,G.,SEN,S.,COLELLA,G.,BROGGINI,M.,DINCALCI,
M. (1998) IFN beta partially counteracts inhibition of natural killer activity indiced by
some ant-tumour agents. Journal of Interferon and Cytokine Research. 18: 87-93.
ANDERSON,M.,TAN,L.,SONDERGAARD,I.,ZEUTHEN,J.,ELLIOTT,T.,HAURU
M,J. (2000) Poor correspondence between predicted and experimental binding of
peptides to class I MHC molecules. Tissue Antigens, 55:519-531.
ASSIKIS,V.,DALLIANI,D.,PAGLIARO,L. (2003) Phase II study of an autologous
tumour derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients
with metastatic renal cell carcinoma (mRCC). Procedures from the American Society
of Clinical Oncology. 22: 1522 (Abstract).
ASSUDANI,D.,AHMAD,M.,LI,G.,REES,R.,ALI,S. (2006) Immunotherapeutic
potential of DISC-HSV and OX40L in cancer. Cancer Immunology
Immunotherapy.55: 104-111.
ATTIA,P., ROSENBERG,S. ET AL.(2005) Autoimmunity correlates with tumour
regression in patients with metastatic melanoma treated with anti-cytotoxic T-
Lymphocyte Antigen-4. Journal of Clinical Oncology. 1;23(25): 6043-6053.
AUSTIN,E.,ROBINS,R.,DURRANT,L.,PRICE,L.,BALDWIN,R. (1989) Human
monoclonal anti-idiotypic antibody to the tumour associated antibody 791T/36.
Immunology. 67:525-530.
AUSTYN,J. (2002) Plasmacytoid dendritic cells: both a turn on and a turn off. Blood.
100(2): 373-373
BANCHEREAU,J., STEINMAN,R. (1998) Dendritic cells and the control of
immunity. Nature. 392: 245-249
BANNERJI,R.,BYRD,J.C.,et al.(2003) Apoptotic regulatory and complement
protecting protein expression in chronic lymphocytic leukaemia: relationship to in
vivo resistance. Journal of Clinical Oncology,21(8):1466-71.
252
BASU,S.,BINDER,R.,RAMALINGAM,T.,SRIVASTAVA,P. (2001) CD91 is a
receptor for heat shock proteins gp96, hsp70 and calreticulin. Immunity. 14: 303-313.
BEATTIE,TJKAUL,R.,ROSTRON,T.,DONG,T.,EASTERBROOK,T.,JAOKO,W.,KI
MANI,J.,PLUMMER,F.,MCMICHAEL,A.,ROWLAND-JONES,S. (2004) Screening
for HIV specific T cell responses using overlapping 15mer peptide pools or optimised
epitopes. AIDS, 18: 1595-1598.
BEHAR,S.,PORCELLI,A.,BECKMAN,E.,BRENNER,M. (1995) A pathway of
costimulation that prevents anergy in CD28 T cells: B7-independent costimulation of
CD1-restricted cells. Journal of Experimental Medicine, 182: 2007-2018.
BENDELAC,A.,HUNZIKER,R.,LANTZ,O. (19996) Increased Interleukin 4 and
immunoglobulin E production in transgenic mice overexpressing NK1 T cells.
Journal of Experimental Medicine. 184(4): 1285-93.
BENDELAC,A.,RIVERA,M.,PARK,S.,ROARK,J. (1997) Mouse CD1-specific NK1
T cells: development specificity, and function. Annual Reviews in immunology. 15:
535-62.
BENLAGHA,K.,WEISS,A.,BEAVIS,A.,TEYTON,L.,BENDELAC,A. (2000) In vivo
identification of glycolipid antigen-specific T cell using fluorescent CD1d tetramers.
Journal of Experiment Medicine. 191(11): 1895-903.
BENLAGHA,K.,BENDELAC,A. (2000) CD1d-restricted moue V alpha 14 and
human V alpha 24 T cells: lymphocytes of innate immunity. Seminar Immunology.
12(6): 537-42.
BERZOFSKY,J.,AHLERS,J.,BELYAKOV,I. (2001) Strategies for designing and
optimising new generation vaccines. National Reviews in Immunology. 1:1209-217.
BIELAS,H.,LOEB,K.,RUBIN,B.,TRUE,L.,LOEB,L. (2006) Human cancers express a
mutator phenotype. PNAS. 103 (48): 18238-18242.
Bioinformatics and Molecular Analysis Section, Computational Bioscience and
Engineering Lab, Center for information Technology, National Institute of Health.
Bioinformatics group under the direction of JH Parish, School of Biochemistry and
Molecular Biology. University of Leeds.
BLACH-OLSZEWSKA,Z.(2005) Innate immunity: cells, receptors, and signalling
pathways. Arch. Immunol. Ther. Exp. 53: 245-253.
BLOK,V.T.,DAHA,.R.,TIJSMA,O.,HARRIS,C.L.,MORGAN,B.P. (1998) A
bispecific monoclonal antibody directed against both the membrane bound
complement regulator Cd55 and the renal tumour associated antigen G250 enhances
C3 deposition and tumour cell lysis by complement. The Journal of Immunology,
160.:3437-3433.
253
BOEL,P.,WILDMAN,C.,SENSI,M.,BRASSEUR,R.,RENAULD,J.,CUOLLE,B.,BO
ON,T. (1995) BAGE: a new gene encoding an antigen recognised on human
melanomas by cytolitic T lymphocytes. Immunity, 2:167-175.
BOON,.,OLD,L. (1997) Tumour antigens. Current Opinions in Immunology. 9: 681-
683.
BOON,T.,COULIE,P.,BENOIT,J.,VAN DEN EYNDE.,VAN DEN BRUGGEN,P.
(2005) Human T cell responses against melanoma. Annual Reviews in Immunology.
176-208.
BORREGO,F.,KABAT,J.,KIM,D.,LIETO,L.,MAASHO,K.,PENA,J.,SOLARNA,R.,
COLIGAN,J. (2002) Structure and function of majot histocompatibility complex
(MHC) class I specific receptors expressed on human natural killer (NK) cells.
Molecular Immunology. 38: 637-660.
BOYLE,J.,SILVA,A.,BRADY,J.,LEW,A. (1997) DNA immunization: induction of
higher avidity antibody and effect of route on T cell cytotoxicity. Proc. Natl. Acad.
Sci. USA. 94(26): 14626-31.
BRADEN,B.C,.POLJAK,R.J. (1995) Structural features of the reactions between
antibodies and protein antigens. FASEB Journal, 9:9-16.
BRODBECK,W.G.,KUTTNER-KONDO,L.,MOLD,C.,MEDOF,M.E. (2000)
Structure/function studies of human decay accelerating factor. Immunology, 101:104-
111.
BRODBECK,W.G.,MOLD,C.,ATKINSON,J.P.,MEDOF,M.E. (2000) Cooperation
between decay accelerating factor and membrane cofactor protein in protecting cells
from autologous complement attack. The Journal of Immunology, 165:3999-4006.
BRODBECK, W. G., LIU, D. SPERRY, J. et al., (1996) Localization of classical and
alternative pathway regulatory activity within the decay accelerating factor. Journal
of Immunology, 156: 2528-2533.
BUENTKE,E.,,HEFFLER,L.,WILSON,J.,WALLIN,R.,LOMAN,C.,CHAMBERS,B.,
LJUNGGREN,H.,SCHEYNIUS,A. (2002) Natural killer and dendritic cell contact in
lesional atopic dermatitis skin-Malassezia-influenced cell interaction. Journal of
Investigative Dermatology. 119(4): 850-7.
ROSSART,P.,GRUNEBACH,F.,STUHLER,G.,REICHARDT,V.,MOHLE,R.,KANZ,
L.,BRUGGER,W. (1998) Generation of functional human dendritic cells form
adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-
macrphage colony stimulating factor. Blood.92:4238-4247.
CARRINGTON, C. A. AND dos SANTA CRUZ, G. (2001) Effect of cell surface
concentration of human DAF on transgenic pig aortic endothelial cells on the degree
of protection afforded against human complement deposition. Xenotransplantation,
8:100-105.
254
CAHILL,D.,KINZLER,K.,VOGELSTEIN,B.,LENGAUER,C. (1999) Genetic
instability and darwinian selection in tumours. Trends in Biochemical Sciences. 24:
M57-M60.
CALVERT,P.,FRUCHT,H. (2002) The genetics of colorectal cancer. Annals of
Internal Medicine. 137: 603-612.
Cancer Research UK 2002.
http://www.cancerrresearchuk.org
CARSON,W.,GIRI,J.,LINDEMANN,M. (1994) Interleukin (IL) 15 is a novel
cytokine that activates human natural killer cells via components of the IL-2 receptor.
Journal of Experimental Medicine. 180: 1395-1403.
CASARES,S.,INABA,K.,BRUMEANU,T.,STEINMAN,R.,BONA,C. (1997) Antigen
presentation by dendritic cells after immunisation with DNA encoding a major
histocompatibility complex class II-restricted viral epitope. Journal of experimental
Medicine. 186(9): 481-6.
CERNY,T.,ROSE,A.L.,et al. (2002) mechanism of action of rituximab. Anticancer
Drugs, 13 Suppl 2:S3-10.
CHAPMAN,P.,MORISSEY,D.,PANAGEAS,K. (2000) Introduction of antibodies
against GM2 ganglioside by immunising melanoma patients using GM2-keyhole
limpet hemocyanin and QS2 vaccine: a dose dependent study. Clinical Cancer
Research. 6: 874-879.
CHAPMAN,P. (2003)Vaccinating against GD3 ganglioside using BEC2 anti-
idiotypic monoclonal antibody. Current Opinions Investigating drugs. 4: 4710-715.
CHRISTIANSEN,D.,LOVELAN,B.,KYRIAKOU,P.,LANTERI,M.,RUBINSTEIN,
E., GERLIER,D. (2000) Chimeric CD46/DAF molecules reveal a cryptic functional
role for SCR1 of DAF in regulating complement activation. Molecular Immunology,
37(12-13):687-96.
CHOWDHURY,P.,VEINER,J.,BEERS,R.,PASTAN,I. (1998) Isolation of a high-
affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by
phage display and conbstruction of a recombinant immunotoxins with anti-tumour
activity. Proc.Natl.Acad.Sci.USA. 95(2): 669-74.
CLARK,M. (2000) Antibody humanization: a case of the ‘Emperor’s new clothes’?.
Immunology Today Reviews, 21:397-402.
COYLE,A.,GUTIERREZ-RAMOS,J. (2001) The expanding B7 superfamily:
increasing complexity in costimulatory signals regulating t cell function. Nature
Immunology.2: 203-209.
CRAGG,M.S., et al. (1999) Signalling antibodies in cancer therapy. Current Opinions
in Immunology, 11:541-547.
255
CORINTI,S.,FANALESBELASIO,E.,ALBANESI,C.,CAVANI,A.,ANGELISOVA,P
.,GIROLOMONI,G. (1999) Cross-linking of membrane CD43 mediates dendritic cell
maturation. Journl of Immunology.162: 6331-6336.
COSIO, F.G.,SEDMAK,D.D.,MAHAN,J.D.,NAHMAN,N.S. (1989) Localisation of
decay accelerating factor in normal and diseased kidneys. Kidney International, 36:
100.
COYNE, K. E., HALL, S., THOMPSON, M.A., ARCE, T.,KINOSHITA,
T.,FUJITA., ANSTEE,W.,ROSSE.,LUBLIN,D.M. (1992) Mapping of epitopes,
glycosylation sites, and complement regulatory domains in human decay accelerating
factor. Journal of Immunology, 149:2906.
CRAIG,L.,SANSCHSGRIN,P.C.,ROZEK,A.,LACKIE,S.,KUHN,L.A.,SCOTT,K.
(1998) Journal of molecular Biology, 281:183-201.
CROWE,N.,SMYTH,M.,GODFREY,D. (2002) A critical role for natural killer T
cells in immunosurveillance of methylcholanthrine-induced sarcomas. Journal of
Experiment Medicine. 196(1): 119-27.
DALMASSO,A.P.,PATT,J.L. (1993)Prevention of complement mediated activation
of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection
by C1 inhibitor. Transplantation, 56(5):1171-1176.
DAVIS,L.S.,PATEL,S.S.,ATKINSON,J.P., et al. (1988) Decay accelerating factor
functions as a signal transducing molecule for human T cells. Journal of Immunology.
141:2246-2252.
DAVIS,M.,BONIFACE,J.,REICH,Z.,LYONS,D.,HAMPI,J.,ARDEN,B.,CHIEN,Y.
(1998) Ligand recognition by DE T cell receptors. Annual Reviews in Immunology.
16: 523-544.
DEFRANCE,T.,CASAMAYOR-PALLEJA,M.,KRAMMER,P. (2002) The life and
death of a B cell. Advances in Cancer Research. Vol 86: 195-225.
DI GAETANO,N.,GOLAY,J. et al. (2003) Complement activation determines the
therapeutic activity of rituximab in vivo. Journal of Immunology, 1;171(3):1581-7.
DONNELLY,G.,ULMER,J.,SHIVER,J.,LIU,M. (1997) DNA vaccines. Annual
Review Immunology. 15:617-48.
DONNES,P.,ELOFSSON,A. (2002) Prediction of MHC class I binding peptides
using SVMHC. BMC Bioinformatics. 3:25.
DUDLEY,M. (2002) Cancer regression and autoimmunity in patients following
clonal repopulation with anti tumour lymphocytes. Science. 298:850-854.
DUNN,G.,BRUCE,A.,IKEDA,H.,OLD,L.,SCHREIBE,R. (2002) Cancer
Immunoediting: from immunosurveillance to escape. Nature Immunology.3: 991-998.
256
DUNN,G.,OLD,L.,SCHREIBE,R. (2004) The immnobiology of Cancer
Immunosurveillance and immunoediting. Immunity. 21: 137-148.
DURRANT,L.G.,SPENDLOVE,I. (2001) Immunisation against tumour cell surface
complement regulatory proteins. Curr Opin Inevestig Drugs, Jul;(27): 959-966.
DURRANT,L. et al (2003) Enhanced expression of the complement regulatory
protein CD55 provides poor prognosis in colorectal cancer patients. Cancer
Immunological Immunotherapy, 52(10):638-642
DURRANT,L.G.,ROBINS,R.A.,BALDWIN,R.W. (1989) Flow cytometric screening
of monoclonal antibodies for drug or toxin targeting to human cancer. J Nat Cancer
Inst, 3;81(9):688-96.
DURRANT ,L.,BUCKLEY,D.,ROBINS,A.,SPENDLOVE,I. (2000) 105/AD7 cancer
vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal
cancer patients but repeated immunisations are required to maintain these responses.
International Journal of Cancer. 85:97-92.
DURRANT,L.,PARSONS,T.,MOSS,R.,SPENDLOVE,I.,CARTER,G.,CARR,F.
(2001) Human anti idiotypic antibodies can be good immunogens as they target Fc
receptors on antigen presenting cells allowing efficient stimulation of both helper and
cytotoxic T cell responses. International Journal of Cancer. 92:414-420
DURRANT,L.,SPENDLOVE,I. (2003) Cancer vaccines entering phase III clinical
trials. Expert Opinion, Emerging Drugs. 8(2): 1-12.
DYALL,R., BOWNE,W., WEBER,L., LEMAOULT,J., SZABO,P., MOROI,Y.,
PISKUN,G., LEWIS,J., HOUGHTON,A., NIKOLIC-ZUGLIC,J. (1998) Heteroclitic
immunization induces tumour immunity. Journal of Experimental Medicicne. 188(9):
1553-1561.
FANGER,N.,WARDWELL,K.,SHEN,L.,TEDDER,T.,GUYRE,P. (1996) Type I
(CD64) and type II ( CD32) Fc-J receptor-mediated phagocytosis by human blood
dendritic cells. Journal of Immunology. 157: 541-548.
FEHNIGER,T.,CALIGIURI,M. (2001) Interleukin 15: Biology and relevance to
human disease. Blood. 97: 14-32.
FEHNIGER,T.,CARSON,W.,CALIGIURI,M. (1999) Cytokine induced apoptosis of
human natural killer cells identifies a novel mechanism to regulate the innate immune
response. Blood. 89: 910-918.
FERLAZZO,G.,PACK,M.,THOMAS,D.,PALUDAN,C.,SCHMID,D.,STROWIG,T.,
BOUGRAS,G.,MULLER,W.,MORETTA,L.,MUNZ,C. (2004) Distinct roles of IL-12
and IL-15 in human natural killer cell activation by dendritic cells from secondary
lymphoid organs. Proc. Natl. Acad. Sci. USA. 101(47): 16606-11.
FERNANDEZ,N.,LOZIER,A.,FLAMENT,C.,RICCIARDI-CASTAGNOLI,P.,
BELLET,D.,SUTER,M.,PERRICAUDET,M.,TURSZ,T.,MARASKOVSKY,E.,ZITV
257
OGEL,L. (1999) Dendritic cells directly trigger NK cell functions: cross talk relevant
in innate anti-tumour immune responses inn vivo. Nature Medicine. 5(4): 405-11.
FINBERG,R.,WHITE,W.,NICHOLSON-WELLER,A. (1992) Decay accelerating
factor expression on either effector or target cells inhibits cytotoxicity by human
natural killer cells. Journal of Immunology. 149:2055-2060.
FIRAT,H.,GARCIA-PONS,F., TOURDOT,S., PASCOLO,S., SCARDINO,A.,
GARCIA,Z., MICHEL,M., JACK,R., JUNG,G., KOSMATOPOULOS.K.,
MATEO,L., SUHRBIER,A.,LEMONNIER,F.,LANGLADE-DEMOYEN,P. (1999)
H-2 class knockout, HLA-A2.1-transgenic mice: a versatile animal model for
preclinical evaluation of antitumour immunotherapeutic strategies. European Journal
of Immunology. 29: 3112-3121.
FISHELSON,Z.,DONIN,N.,ZELL,S.,SCHULTZ,S.,KIRCHFINK,M. (2003)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory
proteins (mCRs) in tumours. Molecular Immunology, 40: 109- 123.
FRANCIS,R.J.,BEGENT,R.H., SHARMA,S.K., SPRINGER,C.,GREEN,A.J., HOPE-
STONE,L.D.,SENA.L.,MARTIN,J.,ADAMSON,K.L.,ROBBINS,A.,GUMBRELL,L.
,O’MALL,D.,TSIOMPANOU,E.,SHAHBAKHTI,H.,WEBLEY,S.,HOCHHAUSER,
D.,HILL,A.J.,BLAKEY,D.,BEGENT,R.H. (2002) A Phase 1 trial of antibody directed
enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or
other CEA producing tumours. British Journal of Cancer, 9:87(6):600-607.
FRANK,M.M.,FRIES,L.F. (1991) The role of complement in inflammation and
phagocytosis. Immunology Today,12:322-326.
FREEMAN,G.,LONG,A.,IWAI,Y.,BOURQUE,K.,CHERNOVA,T.,NISHIMURA,H.
,FITZ,L.,MALENKOVICH,N.,OKAZAKI,T.,BYRNE,M.,HORTON,H.,FOUSER,L.,
CARTER,L.,CARRENO,B.,COLLINS,M.,WOOD,C.,HONJO,T. (2000) The B7-
homologue PD-L is the ligand of the PD-1 immunoinhibitory receptor. FASEB
Journal.14: A1170-A1170.
FUJITA, T., T., INOUE,K., OGAWA, K., LIDA, N. TAMURA. (1987) The
Mechanism of DAF. DAF Inhibits the assembly of the C3 covertases by dissociating
C2a and Bb. Journal of Experimental Medicine, 166:1221-1228.
GABRILOVITCH,D.,CHEN,H.,GIRGIS,K.,CUNNIGHAM,H.,MENY,G.,NADAF,S.
,KAVANAUGH,D.,CARBOE,D. (1996) Production of vascular endothelium growth
factor by human tumours inhibits the functional maturation of dendritic cells. Nature
Medicine. 10: 1096-1103.
GALLEZ-HAWKINS,G., VILLACRES,M., LI,X., SANBORN,M., LOMELI,N.,
ZAIA,J. (2003) Use of transgenic HLA A*201/kb and HHD II mice to evaluate
frequency of cytomegalovirus 1E1-derived peptide usage in eliciting human CD8
cytokine response. Journal of Virology. 77(7): 4457-4462.
258
GAN,X.,BONAVIDA,B. (1999) Preferential induction of TNF alpha and IL-1 beta
and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic
aza-alkyl lysophospholipids. Cellular Immunology. 193: 125-133.
GARBOCZI,D., GHOSH,P., UTZ,Q., FAN,W., BIDDISON,W., WILEY,D. (1996)
Structure of the complex between human T-cell receptor, viral peptide and HLA-A2.
Nature. 384:134-141.
GARCIA,C., DEGANO,M., STANFIELD,R., BRUNMARK,A., JACKSON,M.,
PETERSON,P., TEYTON,L., WILSON,I. (1996) An DE T cell receptor structure at
2.5 A and its orientation in the TCR-MHC complex. Science. 274:209-216.
GAUSE,A.,BEREK,C. (2001) Roles of B cells in the pathogenesis of rheumatoid
arthritis-Potential implications for treatment. Biodrugs. 15: 73-79.
GELDERMAN,K.A.,KUPPEN,J.K.,BRUI,W.,JAN FLEUREN,G.,GORTER,A.
(2002) Enhancement of the complement activating capacity of 17-1A mAb to
overcome the effect of membrane bound complement regulatory proteins on
colorectal carcinoma. European Journal of Immunology, 32:128-135.
GLENNIE,M.J.,JOHNSON,W.M. (2000) Clinical trials of antibody therapy. Review
Immunology Today,21:403-410.
GODFREY,D.,HAMMOND,K.,POULTON,L.,SMYTH,M.,BAXTER,A. (2000)
NKT cell: facts functions and fallacies. Immunology Today.21(11): 573-83.
GOLAY,J.,INTRONA,M.,et al. (2000) Biologic response of B lymphoma cells to anti
CD20 monoclonal antibody rituximab in vitro: Cd55 and CD59 regulate complement
mediated cytotoxicity. Blood,15;95(12):3900-8
GOLD,J., FERRONE,C., GUEVARA-PATINO,J., HAWKINS,W., DYALL,R.,
ENGELHORN,M., WOLCHOK,J., LEWIS,J., HOUGHTON,A. (2003) A single
heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization
against a tumour differentiation antigen. Journal of Immunology. 170:5188-5194.
GOLD,M. (2002) To make antibodies or not: signalling by the B cell antigen receptor.
Trends in Pharmacological Sciences. 23: 316-324.
GORTER,A.,MERI,S. (1999) Immune evasion of tumour cells using membrane
bound complement regulatory proteins. Immunology Today Review, 20:576-582.
GRAFF-DUBOIS,S., FAURE,O., GROSS,D., ALVES,P., SCARDINO,A.,
CHOUAIB,S., LEMONNIER,F., KOSMATOPOULOS,K. (2002) Generation of CTL
recognizing HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -
A6, -A10 and –A12 tumor antigens: Implication in abroad spectrum tumour
immunotherapy. Journal of Immunology. 169:576-580
GRANUCCI,F.,ZANONI,I.,PAVELKA,N.,VANDOMMELEN,S.,ANDONIOU,C.,B
ELARDELLI,F.,DEGLI ESPOSTI,M.,RICCIARDI-CASTAGNOLI,P. (2004) A
259
contribution of mouse dendritic cell-derived IL-2 for NK cell activation. Journal of
Experimental Medicine. 200(3): 287-95.
GRAY,J.X., HAINO,M.,ROTH,M.J., MAGUIRE,J.E., JENSEN,P.N., YARME,A.,
STETLER-STEVENSON,M.A.,SIEBENLIST,U.,KELLY,K. (1996) CD97 is a
processed, seven transmembrane, heterodimeric receptor associated with
inflammation. Journal of Immunology, 15;157(12):5438-5447.
GROH,V.,RHINEHART,R.,RANDOLPH-HABECKER,J., TOPP,M.,
RIDDELL,S.,SPIES,T. (2001) Co-stimulation of CD8DE T cells by NKG2D via
engagement by MIC induced on virus-infected cells. Nature Immunology. 2: 255-258.
GROH,V.,RHINEHART.R.,SECRIST,H.,BAUER,S.,GRABSTEIN,K.,SPIES,T.
(1999) Broad tumour associated expression and recognition by tumour derived
gamma delta T cells of MICA and MICB. PNAS. 96: 6879-6884.
GUMPERZ,J.,ROY,C.,MAKOWSKA,A.,LUM,D.,SUGITA,M.,PODREBARAC,T.,
KOEZUKA,Y.,PORCELLI,S.,CARDELL,S.,BRENNER,M.,BEHAR,S. (2000)
Murine CD1d-restricted T cell recognition of cellular lipids. Immunity. 12(2): 11-21.
HAMANN, J.,EICHLER, W.,HAMANN,D., KERSTENS,H.M.J., PODDIGHE,P.J.,
HOOVERS,N., HARTMA,E.,STRAUSS,M.,VAN LIER,R.A.W. (1995) Expression
cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new
seven transmembrane molecule of the secretin receptor superfamily with an unusual
extracellular domain. Journal of Immunology, 155:1942.
HAMANN,J.,et al. (1998) Characterization of the CD55 (DAF) binding site on the
seven transmembrane receptor CD97. European Journal of Immunology, 28:1701-
1707.
HAMANN,J.,VAN LIER,R.A.et al. (1996) The seven transmembrane receptor CD97
has a cellular ligand DAF. Journal of Experimental Medicine, 1;184(3):1185-9.
HAMAERMAN,J.,OGASAWARA.K.,LANIER,L. (2005) NK cells in innate
immunity. Current Opinions in Immumnology. 17(1): 29-35.
HAMMIL,F. (2003) Histamin dihydrachloride and cancer. Cancer Ther. 2:91-93.
HANKE,T.,SCHNEIDER,J.,GILBERT,S.,HILL,A.,MCMICHAEL,A.(1998) DNA
multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in
mice. Vaccine. 16: 426-435.
HANLON,L.,ARGYLE,D.J. (2001) The Science of DNA vaccination. The Infectious
Disease Review, 3(1):2-12.
HARRIS,C.,LUBLIN,D.M.,MORGAN,B.P. (2002) Efficient generation of
monoclonal antibodies for specific protein domains using recombinant immunological
fusion proteins: pitfalls and solutions. Journal of Immunological Methods, 268:245-
258.
260
HASHIMOTO,S.,SUZUKI,T.,DONG,H.,NAGAI,S.,YAMAZAKI,N.,MATSUSHIM
A,K. (1999) Serial analysis of ene expression in human monocytes-derived dendritic
cels. Blood. 94: 845-852.
HATNAKA,M.,SHIIZU,A. et al. (1998) Cellular distribution of GI anchored
complement regulatory protein CD59. Journal of Biochemistry, 123:579.
HAWN,T.,OZINSKY,A.,UNDERHILL,D.,BUCKNER,F.,AKIRA,S.,ADEREM,A.
(2002) Leishmania major activates IL-1 alpha expression in macrophages through a
MyD88-dependent pathway. Microbes. Infect. 4(8): 763-71.
HAYDAY,A.,TIGELAAAR,R. (2003) Immunoregulation in the tissues by gamma
delta T cells. Nation Reviews in Immunology. 3: 233-242.
HECKL-OSTREICHER,B.,WOSNIK,A.,KIRSCHFINK,M. (1996) Protection of
porcine endothelial cells from complement mediated cytotoxicity by the human
complement regulators CD59,C1 inhibitor, and soluble complement receptor 1.
Analysis in a pig to human in vitro model relevant to hyperacute xenograft rejection.
Transplantation, 62:1693-1969.
HEEGER,P.,LALLI,P.,LIN,F.,VALUJSKIKH,A.,LIU,J.,MUQIM,N.,XU,Y.,MEDOF
,M. (2005) Decat accelerating factor modulates induction of T cell immunity. Journal
of Experimental Medicine. 201:1523-1530.
HERIOT,A.,MARRIOT,J.,COOKSON,S.,KUMAR,D.,DALGLEISH,A. (2000)
Reduction in cytokine production in colorectal cancer patients: association with stage
and reversal by resection.British Journal of Cancer. 82: 1009-1012.
HIGGINS,P.J.,KO,J.L.,LOBELL,R.,SARDONINI,C.,ALESSI,M.K.,YEH,C.G.
(1997) A soluble chimeric complement inhibitory protein that possesses both decay
accelerating and factor 1 cofactor activities. Journal of Immunology, 152:2872.
HINDMARSH,E.J.,MARKS,R.M. (1998) Complement activation occurs on
subendothelial extracellular matrix in vitro and is initiated by the retraction or
removal of overlying endothelial cells. Journal of Immunology, 160:6128-6136.
HINDMARSH,E.J.,MARKS,R.M. (1998) Decay accelerating factor is a component
of subendothelial extracellular matrix in vitro, and is augmented by activation of
endothelial protein kinase C. European Journal of Immunology, 28:1052.
HLA Ligand /Motif Database under the direction of William Hilderbrand and funded
by National Institute of Health. University of Oklahoma Health Sciences Center.
HODGE ,J. (2001) Enhancing the potency of peptide pulsed antigen presenting cells
by vector driven hyperexpression of a triad of costimulatory molecules. Vaccine.
19:3552-3567.
HORI,S.,TAKAHASHI,T.,SAGAGUCHI,K. (2003) Control of immunity by naturally
arising regulatory CD4 cells. Adv Immunology. 81:331-371.
261
HSUEH,E.,ESSNER,R.,FOSHAG,L. (2002) Prolonged survival after complete
resection of disseminated melanoma and active immunotherapy with a therapeutic
cancer vaccine. Journal of Clinical Oncology. 20: 4549-4554.
INFANTE-DUARTE,C.,KAMRADT,T. (1999) TH1/Th2 balance in infection.
Springer Seminars in Immunopathology. 21: 317-338.
IRVINE,K.,PARKHURST,M.,SHULMAN,E.,TUPESIS,J.,CUSTER,M.,TOULOUKI
AN,C.,ROBBINS,P.,YAFAL,A.,GREENHALGH,P.,ROSENBERG,S.,RESTIFO,N.
(1999) Recombinant virus vaccination against “self” antigens using anchor-fixed
immunogens. Cancer Research. 59:2536-40.
JAKOB,T.,WALKER,P.,KRIEG,A.,UDEY,M.,VOGEL,J. (1998) Activation of
cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for
dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Journal of Immunology. 161(6): 3042-9.
JOACHIM DEEG,H. et al (2001) Treatment of steroid refractory acute graft versus
host disease with anti CD147 monoclonal antibody ABX-CBL. Blood, 98:2052-2058.
JONES ,E.,ENGLISH,A.,HENSHAW,K.,KINSEY,S.,MARKHAM,A.,EMERY,
P.,MCDOUGAL,D. ( 2004) Enumeration and phenotypic caracterisation of synovial
fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative
arthritis. Arthriris rheumatology. 50:817-27
JUWEID,M. (2003) Technology evaluation: epratuzumab, Immunomedics/Amgen.
Curr. Opin. Mol. Ther., 5(2):192-198.
KAISHO,T. (2001) CD4
+
CD25
+
regulation. Journal of Immunology. 5688
KAKUMU,S.,OKUMURA,A.,ISHIKAWA,T.,YANO,M.,ENOMOTO,A.,NISHIMU
RA,H.,YOSHIOKA,K. (1997) Serim levels of IL-10, IL-15 and solubletumour
necrosis factor-alpha (TNFD) receptors in type C chronic liver disease. Clin. Exp.
Immunol. 109: 458-463.
KAMINSKI,M.,ESTES,J.,ZASADNY,K.,FRANCIS,I.,ROSS,C.,TUCK,M.,REGAN,
D.,FISHER,S.,GUTIRREZ,J.,KROLL,S.,STAGG,R.,TIDMARSH,G.,WAHL,R.
(2000) Radioimmunotherapy with Iodine
131
I tositumomab for relapsed or refractory
B-cell non-Hodgkin lymphoma: updated results and long term follow up of the
University of Michigan experience. Blood, 96(4):1259-1266.
KARP,C.C.,WYSOCKA,M.,WAHL,L.M.,AHEARN,J.M.,CUOMO,P.J.,SHERRY,B.
,TRINCHIERI,G.,GRIFFIN,D.E. (1996) Mechanism of suppression of cell mediated
immunity by measles virus. Science, 273:228-231.
KAWAKAMI,Y.,ELIYAHU,S.,DELGADO,C.,ROBBINS,P.,RIVOLTINI,L.,TOPAL
IAN,S.,MIKI,T.,ROSENBERG,S. (1994) Cloning of he gene coding for a shared
human melanoma antigen recognised by autologous T cells infiltrating into tumour.
Procedures from the National Academy of Science, 91:3515-3519.
262
KILPATRICK,K.,CUTLER,T.,WHITEHORN,E.,DRAPE,R.,MACKLIN,M.,WITHE
RSPOON,S.,SINGER,S.,HUTCHINS,J.(1998) Gene gun delivered DNA-based
immunisations mediate rapid production of murine monoclonal antibodies to the Flt-3
receptor. Hybridoma. 17(6): 569-76.
KINOSHITA,T.,MEDOF,M.E.,SILBER,R.,NUSSENZWEIG,V. (1985) Distribution
of decay accelerating factor in the peripheral blood of n normal individuals and
patients with paroxysmal nocturnal hemoglobinurea. Journal of Experimental
Medicine, 162:75.
KINOSHITA,T. (1991) Overview of Complement Biology. Immunology Today,12.:
291-300.
KIRSCHFINK,M . (2001) Targeting complement in therapy. Immunological Reviews,
180:177-189.
KITAMURA,H.,OHTA,A.,SEKIMOTO,M.,SATA,M.,IWAKABE,K.,NAKUI,M.,Y
AHATA,T.,MENG,H.,KODA,T.,NISHIMURA,S.,KAWANO,T.,TANIGUCHI,M.,N
ISHIMURA,T. (2000) alpha-galctosylceramide induces early B cell activation
through IL-4 production by NKT cells. Cell Immunology. 199(1): 37-42.
KOHNO,H.,MIZUNO,M.,NASU,JMAKIDONO,C.,HIRAOKA,S.,INABA,T.,YAMA
MOTOTO,K.,OKADA,H.,FUJITA,Y.,SHIRATORI,Y. (2005) Stool decay
accelerating factor as a marker for monitoring the disease activity during leukocyte
apheresis therapy in patients with refractory ulcerative colitis. Journal of
gastroenterology hepatology. 20:73-78
KOJIMA,A.,IWATA,K.,SEYA,T et al. (1993) Membrane cofactor protein
(CD46)protects cells predominantly from alternative complement pathway mediated
C3 fragment deposition and cytolysis. Journal of Experimental Medicine,151:1519.
KORETZ,K.,BRUDERLEIN,S.,HENNE,C.,et al. (1992) Decay accelerating factor
(DAF:CD55) in normal colorectal mucosa, adenomas and carcinomas. British
Journal of Cancer, 66:810-814.
KORSGREN,M.,PERSSON,C.,SUNDLER,F.,BJERKE,T.,HANSSON,T.,CHAMBE
RS,B.,HONG,S.,VAN KAER,L.,LJUNGGREN,H.,KORSGREN,O. (1999) Natural
killer cells determine development of allogen-induced eosinophillic airway
inflammation in mice. Journal of Experimental Medicine. 189(3): 553-62.
KOOYMAN,D.L. et al. (1995) In vivo transfer of GPI-linked complement restriction
factor from erythrocytes to the endothelium. Science,260:89-92.
KOULOVA,L.,CLARK,E.,SHU,G ET AL. (1991) The CD28 ligandB7/BB1 provides
costimulatory signal for alloactivation of CD4
+
T cells. Journal of Experimental
Medicine.173:759-761.
KREUWEL,H.,AUNG,S.,SILAO,C.,SHERMAN,L. (2002) Memory CD8
+
T cells
undergo peripheral tolerance. Immunity.17:73-81.
263
KRIEG,A.,YI,A.,MATSON,S.,WALDSCHMIDT,T.,BISHOP,G.,TEASDALE,R.,KO
RETZKY,G.,KLINMAN,D. (1995) CpG motifs in bacterial DNA trigger direct B cell
activation. Nature. 374(6522):546-9.
KRONENBERG,M. (2005) Toward an understanding of NKT cell biology: progress
and paradoxes. Annual Review immunology. 23: 877-900.
KUBO,T.,HATTON,R.,OLIVER,J.,LIU,X.,ELSON,C.,WEAVER,C. (2004)
Regulatory T cell suppression by proinflammatory cytokines produced by TLR
activated dendritic cells. Journal of Immunology. 7249-7258.
KURAYA,M.,FUJITA,T. (1997) Signal transduction via a protein associated with a
glycosylphosphatidylinositol-anchored protein, decay accelerating factor
(DAF/CD55). International Immunology, 10:473-480.
KURTS,C.,SUTHERLAND,R.,DAVEY,G.,LI,A.,LEW,A.,BLANAS,E.,CARBONE,
F.,MILLER,J.,HEATH,W. (1999) CD8 T cell ignorance or tolerance to islet antigens
depends on antigen dose. Procedures in the National academy of Science. 96:12703-
7.
KUTTNER-KONDO,L.,MITCHELL,L.,HOURCADE,D.,MEDOF,M. ( 2001)
Characterization of the active sites in decay accelerating factor. Journal of
Immunology. 167: 2164-2171.
LARA-OCHOA,F.,ALMAGRO,J.C.,VARGAS-MADRAZO,E.,CONRAD,M. (1996)
Antibody-antigen recognition: A canonical structure paradigm. Journal of Molecular
Evolution,43:678-684
LARSON,R.A. (2001) Current use and future development of gemtuzumab
ozogamicin. Semin. Hematology, 38(3Suppl):24-31.
LATCHMAN,Y.,WOOD,C.,CHERNOVA,T.,CHAUDHARY,D.,BORDE,M.,CHER
NOVA,I.,IWAI,Y.,LONG,A.,BROWN,J.,NUNES,R.,GREENFIELD,E.,BOURQUE,
K.,BOUSSIOTIS,V.,CARTER,L.,CARRENO,B.,MALENKOVICH, N..,
NISHIMURA,H.,OKAZAKI,T.,HONJO,T.,SHARPE,A.,FREEMAN,G. (2001) PD-
L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology. 2:
261-269.
LEEMANS,J.,VELT,A.,FLORQUIN,S.,BENNINK,R.,DEBRUIN,K.,VAN LIER,
VAN DER POLL,T.,HAMANN,J. (2004) The epidermal growth factor seven
membrane (EGF-TM7) receptor CD97 is required for neutrophils migration and host
defence. Journal of Immunology. 172:1125-31.
LEITE-DE-MORAES,M.,MOREAU,G.,ARNOULD,A., MACHAVOINE,F .,
GARCIA,C.,PAPIERNIK,M.,DY,M. (1998) IL-4-producing NK T cells are biased
towards IFN gamma production by IL-12. Influence of the microenvironment on the
functional capacities of NK T cells. European Journal of Immunology. 28(5): 1507-
15.
264
LEITE-DE-MORAES,M.,HAMEG,A.,ARNOULD,A.,MACHAVOINE,F. ,
KOEZUKA,Y.,SCHNEIDER,E.,HERBELIN,A.,DY,M., (1999) A distinct IL-18-
induced pathway to fully activate NK T lymphocytes independently from TCR
engagement. Journal of Immunology. 163(11): 5871-6.
LEVENTHAL,J.R.,SAKIYALAK,P.,WITSON,J.,SIMONE,P.,MATAS,A.J.,BOLMA
N,R.M.,DALMASSO. (1994) The synergistic effect of combined antibody and
complement depletion on discordant cardiac xenograft survival in nonhuman
primates. Transplantation, 27;57(6):974-978.
LEWIS,P.,BABIUK,L. (1999) DNA vaccines: a review. Adv.Virus Res. 54:129-88.
LI,L.,SPENDLOVE,I.,MORGAN,J.,et al. (2001) CD55 is overxpressed in the tumour
environment. British Journal of Cancer,84:80-86
LISZEWSKI,M.,FARRIES,T.,LUBLIN,D.,ROONEY,I.,ATKINSON,J. (1996)
Control of the complement system. Advances in Immunology. 61:201-283.
LIU,J.,MIWA,T.,HILLIARD,B.,CHEN,Y.,LAMBRIS,J.,WELLS,A.,SONG,W.
(2005) The complement inhibitory protein DAF (CD55) suppresses T cell immunity
in vivo. Journal of Experimental Medicine.201:567-577.
LUBLIN,D.M., LEMONS,R.S., LE BEAU,M.M., HOLERS,V.M.,
TYKOCINSKI,M.,MEDOF,M.E., ATKINSON,J.P. (1987) The gene encoding decay
accelerating factor (DAF) is located in the complement regulatory locus on the long
arm of chromosome 1. Journal of Experimental Medicine, 1;165(6):1731-1736.
LUKACIK,P.,ROVERS,P.,WHIT,J.,ESSER,D.,SMITH,G.,BILLINGTON,J.,WILLI
AMS,P.,RUDD,P.,WORMALD,M.,HARVEY,D.,CRISPIN,M.,RADDCLIFF,C.,DW
EK,R.,EVANS.,MORGAN,B.,SMITH,R.,LEA,S. (2004) Complement regulation at
the molecular level: The structure of decay accelerating factor. PNAS.101(5): 1297-
1284.
LURQUIN,C.,LETHE,B.,DE PLAEN,E.,CORBIERE,V.,THEATE,I.,VAN
BAREN,N.COULIE,P.,BOON,T. (2005) Contrasting frequencies of antitumour and
anti vaccine T cells in metastases of melanoma patient vaccinated with a MAGE
tumour antigen. Journal of Experimental Medicine. 201(2):249-257.
LU,S.,ARTHOS,J.,MONTEFIORI,D.,YASUTOMI,Y.,MANSON,.,MUSTAFA,F.,JO
HNSON,E.,SANTORO,J.,WISSINK,J.,MULLINS,J. (1996) Simian
immunodeficiency virus DNA vaccine trial in macaques. Journal of Virology.
70(6):3978-91.
MADDEN,D. (1995) The three dimensional structure of peptide-MHC complexes.
Annual Review Immunology. 13:587-622.
MADJD,Z.,BRADLEY,R.,DURRANT,L.G.,SPENDLOVE,I.,ELLIS,I.O.,PINDER,S.
E. (2004) Loss of CD55 is associated with aggressive breast tumours. Journal of
Clinical Cancer Research. 10:2797-2803.
265
MATTHES,T.,TULLEN,E.,POOLE,J.,DANIELS,G., et al. (2002) Acquired and
transient RBC CD55 deficiency (Inab phenotype) and anti IFC. Transfusion, 42:
1448-1457.
MATZINGER,P. (1994) Tolerance,danger and the extended family.
Annu.Rev.Immunol, 12:991-945
MAEURER,J.,MARTIN,D.,ELDER,E.,STORKUS,J.,LOTZE,M. (1996) Detectionof
naturally processed and HLA-A1 presented melanoma T-cell epitopes defined by
CD8
+
T-cells’ release of granulocte-macrophage colony stimulating factor but not by
cytolysis. Clinical Cancer Research, 2:87-95.
MARKIEWICZ,M.,FALLARINO,F.,ASHIKARI,A.,GAJEWSKI,T.(2001) Epitope
spreading upon P815 tumour rejection triggered by vaccination with the single class I
MHC restricted peptide P1A. International Immunology. 13(5):625-632
MARINCOLA,F.,JAFFE,E.,HICKILIN,D.,FERRONE,S. (2000) Escape of human
solid tumours from T-cell recognition: molecular mechanisms and functional
significance.Adv immunology. 186:645-653
MATSUDA,J.,GAPIN,L.,BARON,J.,SIDOBRE,S.,STETSON,D.,MOHRS,M.,LOCK
SLEY,R.,KRONENBERG,M. (2003) Mouse V alpha 14i natural killer T cells are
resisitant to cytokine polarization in vivo. Proc. Natl, Acad, Sci,USA. 100(14):8395-
400.
MAZOUZ,N.,OOMS,A.,MOULIN,V.,VAN MEIRVENNE,S.,UYTTENHOVE,C
.,DEGIOVANNI,G. (2002) CD40 triggering increases the efficiency of dendritic cells
for antitumoral immunisation. Cancer Immunity. 2:2-16.
MEDOF,M.E.,WALTER,E.I.,ROBERTS,W.I. (1986) Decay accelerating factor of
complement is anchored to cells by a C terminal glycolipid. Biochemistry, 25:6740-
6747.
MEYLAN, E.,TSCHOPP,J.,KARIN,M. (2006) Intracellular pattern recognition
receptors in the host response. Nature Reviews, 442:39-44.
MCCOY,R.,PERLMUTTER,D.H. et al. (1995) Formylpeptide and complement C5a
receptors are expressed in liver cells and mediate hepatic acute phase gene regulation.
Journal of Experimental Medicine, 182:207
MEDOF,M.W.,WALTER,E.I.,RUTGERS,J.L.,KNOWLES,D.M.,NUSSENZWEIG,V
. (1987) Identification of the complement decay accelerating factor (DAF) on
epithelium and glandular cells and in body fluids. Journal of Experimental Medicine,
165:848.
MENU,E.,TSAI,B.C.,BIERER,B.E. et al. (1994) CD59 costimulation of T cell
activation. Journal of Immunology,153:2444.
MEYLAN,E., TSCHOPP,.J., KARIN,M. (2006) Intracellular pattern recognition
receptors in the host response. Nature Reviews. 442(6):39-44.
266
MILLER,R.A.,MALONEY,D.G.,WARNKE,R.,LEVY,R. (1982) Treatment of B-cell
lymphoma with a monoclonal anti-idiotype antibody. New England Journal of
Medicine, 4;306(9):517-522.
MIWA,T.,MALDONADO,M.,ZHOU,L.,SUN,X.,LUO,H.,CAI,D.,WERTH,V.,MAD
AIO,M.,EISENBERG,R.,SONG,W. (2002) Deletion of decay accelerating factor
(CD55) exacerbates autoimmune disease development in MRL/lpr mice. American
Journal of Pathology. 161:1077-1086.
MIYAMTOT,K.,MIYAKE,S.,YAMAMURA,T. (2001) A synthetic glycolipid
prevents auto immune encephalomyelitis by inducing Th2 bias of natural killer T
cells. Nature. 413(6855): 531-4.
MOORE,K.,O’HARRA,A.,DE WAALMALEFYT,R.,VIERA,P.,MOSMANN,T.
(1994) Interleukin 10. Ann. Rev. Immunol. 11: 165-190.
MORAN,P.,BEASLEY,H.,GORRELL,A. (1992) Human recombinant soluble decay
accelerating factor inhibits complement activation in vitro and in vivo. Journal of
Immunology. 149:1736-1743.
MORETTA,L.,MORETTA,A. (2004) Killer immunoglobulin like receptors. Current
Opinion in Immunology. 16(5): 626-33.
MORRETA,L.,BIASSONI,R.,BOTTINO,C.,MINGARI,M.,MORRETTA,A. (2000)
Human NK cell receptors. Immunoogy Today. 21: 420-422.
MORGAN, B. P. and HARRIS, C. L. (1999) Complement Regulatory Proteins.,
London: Academic Press.
MORGAN,J.,SPENDLOVE,I.,DURRANT,L.G. (2002) The role of CD55 in
protecting the tumour environment from complement attack. Tissue Antigens, 60:
213-223.
MORGAN,D.,KREUWEL,H.,SHERMAN,L. ( 1999) Antigen concentration and
precursor frequency determine the rate of CD8
+
T cell tolerance to peripherally
expressed antigens. Journal of Immunology. 163:723-7.
MROZEK,E.,ANDERSON,P.,CALIGIURI,M. (1996) Role of interleukin-15 in the
developmet of human CD56
+
natural killer cells from CD34
+
hematopoietic
progenitor cells. Blood. 87(7): 2632-40.
MURPHY,G.,MESSADI,D.,FONFERKO,E.,HANGCOCK,W. (1986) Phenotypic
transformation of macrophages to Langerhan cells in the skin. AJP. 123: 401-406.
NAKATSUKA,K.,SUGIYAMA,H.,NAKAGAWA,Y.,TAKAHASHI,H. (1999)
Purification of antigenic peptide from murine hepatoma cells recognised by class I
major histocompatibility complex molecule restricts cytotoxic T Lymphocytes
induced with B7-1-gene transfected hepatoma cells.Journal of hepatol. 30:119-1129.
267
NEMECEK,E.R.,MATHEWS,D.C. (2002) Antibody based therapy of human
leukemia. Current Opinions in Hematology, 9:316-321.
NICHOLSON-WELLER,A.,WANG,C.E. (1994) Structure and function of decay
accelerating factor CD55. J Lab Clin Med, 123:485-491.
NIEHANS,G.A.,CHERWITZ,D.L.,STALEY,N.A.,et al. (1996) Human carcinomas
variably express the complement inhibitory proteins CD46 (Membrane cofactor
protein), CD55(Decay accelerating protein), and CD59 (Protectin). American Journal
of Pathology, 149:129-141.
NOSSAL,G. (1994) Negative selection of lymphocytes. Cell. 76:229-240.
NOWAK,M.,KOMAROVA,N.,SENGUPTA,A.,JALLEPALLI,P.,SHIH,I.,VOGELST
EIN,B.,LENGAUER,C. (2002) The role of chromosomal instability in tumour
initiation. PNAS. 99: 16226-16231.
OVERWIJK,W. (2003) Tumour regression and autoimmunity after reversal of
functionally tolerant state of self reactive CD8
+
T cells. Journal of Experimental
Medicine. 198:569-580.
PANDEY,S.,AGRAWAL,K. (2006) Immunobiology of Toll-like receptors: Emerging
trends. Immunology and Cell Biology. 84:333-341.
PANGBURN,M. (1986) Differences between the binding sites of the complement
regulatory proteins DAF, CR1, and factor H on C3 convertases. Journal of
Immunology. 136(6); 2216-21.
PARKER,K.,BEDNEREK,M.,COLIGAN,J. (1994) Scheme for ranking potential
HLA-A2 binding peptides based on independent binding of individual side chains.
Journal of Immunology. 152:163-175
PARKHURST,M. (1996) Improved induction of melanoma reactive CTL with
peptides from the melanoma antigen gp100 modified at HLA-A*201 binding
residues. Journal of Immunology. 157: 2539-2548.
PASARE,C.,MEDZHITOV,R. (2003) Toll pathway dependent blockade of CD4
+
CD25
+
T cell mediated suppression by dendritic cells. Science. 229:1033-1036.
PERTMER,T.,ROBERTS,T.,HAYNES,J. (1996) Influenza virus Nucleoprotein
specific immunoglobulin G subclass and cytokine responses elicited by DNA
vaccination are dependent on the route of vector delivery. Journal of Virology.
70(9):6119-25
PENNINGTON,S.,SILVIA-SANTOS,B.,HAYDAY,A. (2005) JG T cell development-
having the strength to get there. Current opinion in Immunology. 17: 108-115.
PIMM,M.V.,et al. (1987) Imaging of primary metastatic colorectal carcinoma with
monoclonal antibody 791T/36 and the therapeutic potential of antibody drug
conjugates. Cancer Detect Prev Suppl,1:249-62.
268
PIMM,M.,PERKINS,A.,ARMITAGE,N.,BALDWIN,R., (1985) Localisation of anti-
osteogenic sarcoma monoclonal antibody 791T/36 in a primary human osteogenic
sarcoma and its subsequent xenograft in immunodeprived mice. Cancer Immunology
and Immunotherapy. 19:18-21.
POWELL,D.,ROSENBERG,S. (2004) Phenotypic and functional maturation of
tumour antigen reactive CD8
+
T lymphocytes in patients undergoing multiple course
peptide vaccination. Journal of Immunotherapy. 27(1): 36-47
PRITCHARD-JONES,K.,SPENDLOVE,I.,WILTON,C.,WHELAN,J.,WEEDON,S.,
LEWIS,J.,HALE,J.,CAMPBELL,B.,ALVAREZ,P.,HALBERT,G.,DURRANT,L.
(2005) Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive
chemotherapy for osteosarcoma. British Journal of Cancer. 92:1358-1365.
RAMAGE,J.,SPENDLOVE,I.,REES,R.,MOSS,R.,DURRAN,L. (2006) The use of
reverse immunology to identify HLA-A2 binding epitopes in Tie-2. Cancer
Immunology Immunotherapy, Robert Baldwin symposium: 50 years of cancer
immunotherapy.
RAMAGE,J.,METHERINGHAM,R.,CONN,A.,SPENDLOVE,I.,MOSS,R.,PATTON
,D.,MURRAY,J.,REES.R.,DURRANT,L. (2004) Identification of an HLA-A*201
cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int J
Cancer. 110:245-250.
RAMAGE,J.,METHERINGHAM,R.,MOSS,R.,SPENDLOVE,I.,REES,R.,DURRAN
T,L. (2004) Comparison of the immune response to a self antigen after DNA
immunisation of HLA*201/H-2kb and HHD II transgenic mice. Vaccine. 22:1728-
1731.
RAMMENSEE,H.,BACHMANN,J.,EMMERICH,NN.,BACHOR,O.,ATEVANOVIC
,S. (1999) SYFPEITHI: database for MHC ligands and peptide motifs.
Immunogenetics. 50:213-219.
REID,K.B.,TURNER,M.W. (1994) Mammalian lectins in activation and clearance
mechanisms involving the complement system. Springer Semin. Immunopathol,
15(4):307-326.
ROBERTSON,M.,RITZ,J. (1990) Biology and clinical relevance of human natural
killer cells. Blood. 76: 2421-2438.
ROBINSON,H.,TORRES,C. (1997) DNA Vaccines. Seminars in Immunology.
9(5):271-83.
ROBINSON,H.,BOYLE,C.,FELTQUATE,D.,MORIN,M.,SANTORO,J.,WEBSTER,
R. (1997) DNA immunisation for influenza virus: studies using hemaglutinin and
nucleoprotein expressing DNAs. Journal of Infectious Diseases. 176 Suppl 1:S50-55
ROLLINS,S.A.,MATIS,L.A.,SPRINGHORN,J.P.,SETTER,E.,WOLFF,D.W. (1995)
Monoclonal antibodies directed against human C5 and C8 block complement
mediated damage of xenogeneic cells and organs. Transplantation, 60:1284.
269
ROSENBERG,S. (1999) A new era for cancer immunotherapy based on the genes
that encode cancer antigens. Immunity. 10:281-287.
ROSENBERG,S.,YANG,J.,RESTIFO,N. (2004) Cancer immunotherapy: moving
beyond current vaccines. Nat Med. 10(9):909-915
ROSENBERG,S. (1998) Immunologic and therapeutic evaluation of a synthetic
peptide vaccine for the treatment of patients with metastatic melanoma. Nature
Medicine. 4:321-327
ROSENBERG,S.,SHERRY,R.,MORTON,K.,TANG,J.,TOPALIAN,S.,ROYAL,R.,K
AMMULA,U.,RESTIFO,N.,HUGHES,M.,SCHWARZ,S.,NGO,L.,MAVROUKAKIS
,S.,WHITE,D. (2006). Journal of immunotherapy. 29(2) 224-231.
ROSENBERG,S. (2001) Progress in human tumour immunology and
immunotherapy. Nature. 411:380-384.
ROSSI,M.,YOUNG,J. (2005) Human dendritic cells: potent antigen-presenting cells
at the crossroads of the innate and adaptive immunity. Journal of Immunology.
175(3): 1373-81.
ROTHER,R., SQUINTO,P. (1996) The D-galactosyl epitope: A sugar coating that
makes viruses and cells umpallatable. Cell, 86:185-188.
SAHIN.U/.TURECI,O.,SCHMIDTT,H.,COCHLOVIUS,B.,JOHANNES,T.,SCMITS,
R.,STENNER,F.,LUO,G.,SCHOBERT,I.,PFREUNDSCHUH,M. (1995) Human
neoplasms elicit multilple immune responses in the autologous host.
Proc.Natl.Acad.Sci.USA. 92: 11810-11813.
SAROBE,P.,PENDLETON,T.,ATASUKA,T.,LAU,D.,ENGLEHARD,V.,FEINSTON
E,S.,BEROFSKY,J. (1998) Enhanced antigen potency and in vivo immunogenicity of
a CTL epitope from hepatitis C virus core protein following amino acid replacement
ay secondary HLA-A2.1 binding positions. J Clin Invest. 102:1239-1248
SCMIDT,H.,LARSENS,S.,BASTHOLT,L. (2002) A phase II study of outpatient
subcutaneous histamine dihydrochloride, interleukin-2 and interferon alpha in patients
with metastatic melanoma. Ann.Oncology. 13: 1919-1924.
SCHMIDT-SUPPRIAN,M.,TIAN,J.,GRANT,E.,PASPARAKIS,M., MAEHR,R.,
OVAA,H.,PLOEGH,H.,COYLE,A.,RAJEWSKY,K. (2004) Differential dependence
CD4
+
CD25
+
regulatory and Natural killer like T cells on signals leading to NF-
kappaB activation. Proc. Natl.Acad. Sci. USA. 101(13): 4566-71.
SCMIDT-SUPPRIAN,M.,TIAN,J.,JI,H.,TERHORST,C., BHAN,A.,
GRANT,E.,PASPARAKIS,M.,CASOLA,S.,COYLE,A.,RAJEWSKY,K. (2004) I
kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help,
germinal center reactions, and homeostatic expansion. Journal of Immunology.
173(3): 1612-9.
270
SEMAC,I.,PALOMBA,C.,KULANGARA,K.,KLAGES,N.,HOESSELI,D.C.et al.
(2003) Anti CD20 therapeutic antibody rituximab modifies the functional
organisation of rafts/microdomans of B lymphoma cells. Cancer Research, 63:534-
540.
SEREX/Cancer Immunome: www.licr.org/05-pro/serex.htm
SETTE,A., VITIELLO,A., REHERMAN,B., FOWLER,P., NAYERSINA,R.,
KAST,W., MELIEF,C., OSEROFF,C., YUAN,L., RUPPERT,J. (1994) The
relationship between class I binding affinity and immunogenicity of potential
cytotoxicity T cell epitopes. Journal of Immunology. 153: 5586-5597.
SEYA, T.,ATKINSON,J.P. (1989)Functional properties of membrane cofactor
protein of complement. Biochemical Journal, 264:581.
SEYA,T.,FARRIES,T.,NICKELLS,M.,ATKINSON,J. (1987) Additional forms of
decay accelerating factor (DAF). Journal of Immunology. 139:1260-1267.
SHANKARAN,V.,IKEDA,H.,BRUCE,A.,WHITE,J.,SWANSON,P.,OLD,L.,SCHRE
IBER,R. (2001) IFN gamma and lymphocytes prevent primary tumour development
and shape tumour immunogenicity. Nature. 410: 1107-1111.
SHEN,L., ROCK,K. (2004) Cellular protein is the source of cross-priming antigen in
vivo. PNAS. 101(9): 3035-3040.
SHENOYSCARIA,A.M., KWONG,J.,FUJITA,T., OLSZOWY,M.W., SHAW,A.S.,
LUBLIN,D.M. (1992) Signal transduction through decay accelerating factor.
Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine
kinasesp56lck and p59fyn 1. Journal of Immunology, 149:3535.
SHEVACH,E.,MCHUGH,R.,PICCIRILLO,C.,THORNTON,A. (2001) Control of T
cell activation by CD4
+
CD25
+
suppressor T cell. Immunological Reviews. 182:58-67.
SHEVACH,E. CD4
+
CD25
+
suppressor T cells: More questions than answers.
National Reviews in Immunology. 2:389-400.
SHIBUYA,K.,ABE,T.,FUJITA,T. (1992) Decay accelerating factor functions as a
signal transducing molecule for human monocytes. Journal of Immunology, 149:
1758-1762.
SHIH,I.,ZHOU,W.,GOODMAN,S.,LENGAUER,C.,KINZLER,K.,VOGELSTEIN,B.
(2001) Evidence that genetic instability occurs at an early stage of colorectal
tumorigenesis. Cancer Research. 61: 818-822.
SMITH,A.,HAYDAY,A. (2000) An ab T cell immunoprotective response towards gut
coccidian is supported by gd cells. Immunology. 101: 325- 332.
SIVAKUMAR,V.,HAMMOND,K.,HOWELLS,N.,PFEFFER,K.,WEIH,F. (2003)
Differential requirement for Rel/nuclear factor kappa B family members in natural
killer T ce;ll development. Journal of Experimental Medicine. 197(12): 1613-21.
271
SMYTH,M.,KROWE,N.,PELLICCI,D.,KYPARISSOUDIS,K.,KELLY,K.,TAKEDA
,K.,YAGITA,H.,GODDFREY,D. (2002) Sequential production of interferon-gamma
by NK1.1(+) T cells and natural killer cells is essential for the anti metastatic effect of
alpha-galactosylceramide. Blood. 99(4): 1259-66.
SOLINGER,A., ULTEE,E., MARGOLIASH,E., SCHWARTZ,R. (1979) T
lymphocyte response to cytochrome c. Demonstration of a T-cell heteroclitic
proliferative response and identification of a topographic antigenic determinant on
pigeon cytochrome c whose immune recognition requires two complementing major
histocompatibility complex-linked immune response genes. Journal of Experimental
Medicine. 150:830-848.
SONODA,K.,EXLEY,M.,SNAPPER,S.,BALK,S.,STEIN-STREILEIN,J. (1999)
CD1-reactive natural killer T cells are required for development of systemic tolerance
through an immune-privileged site. Journal of Experimental Medicine. 190(9): 1215-
26.
SPEISER,D. (1997) Self antigens expressed by solid tumours do not efficiently
stimulate naïve or activated T cells: implications for immunotherapy. Journal of
Experimental Medicine. 186:645-653.
SPENDLOVE,I.,LI,L.,CARMICHAEL,J.,DURRANT,L. (1999) Decay accelerating
factor(CD55): A target for cancer vaccines?. Cancer Research,59:2282-2286.
SPENDLOVE,I.,LI,L.,POTTER,V.,CHRISTIANSEN,D.,LOVELAND,B.,DURRAN
T,L. (2000) A therapeutic human anti-idiotypic antibody mimics CD55 in three
distinct regions. European Journal of Immunology. 30: 2944-2953.
SPENDLOVE,I.,RAMAGE,J.,BRADLEY,R.,HARRIS,C.,DURRANT,L. (2006)
Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunology
and Immunotherapy. Robert Baldwin symposium: 50 years of Cancer
Immunotherapy.
STANFIELD,R.L.,TAKIMOTO-KAMIMURA,M., RINI,J.M., PROFTY,A.T.,
WILSON,I.A. (1993) Major antigen induced domain rearrangements in an antibody.
Structure, 1:83-93.
STANIC,A.,SHASHIDHARAMURTHY,R.,BEZBRADICKA,J.,MATSUKI,N.,YOS
HIMURA,Y.,MIYAKE,S.,CHOI,E.,SHELL,T.,VAN
KAER,L.,TEVETHIA,S.,ROOPENIAN,D.,YAMAMURA,T.,JOYCE.S. (2003)
Another view of T cell antigen recognition: cooperative engagement of glycolipid
antigens by Va14Ja18 natural T(NKT) cell receptor[corrected]. Journal of
Immunology 171(9) 4539-51, erratum Journal of Immunology 2004 172(1):717
STANIC,A.,DE SILVA,A.,PARK,J., SRIRAM,V.,ICHIKAWA,S.,HIRABYASHI,Y.,
HAYAKAWA,K.,VAN KAER,L.,BRUTKIEWICZ,R.,JOYCE,S. (2003) defective
presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen
caused by E-D-glucosylceramide synthase deficiency. Procedures drom National
Academy of Sciences, USA. 100(4): 1849-54.
272
STEFANOVA,I.,HOREJSI,V. (1991) Association of the CD59 and CD55 cell surface
glycoproteins with other membrane molecules. Journal of Immunology. 147:1587.
SUGAMURA,K.,ISHII,N.,WEINBERG,A. (2004) Therapeutic targeting of the
effector T cell co stimulatory molecule OX40. National Reviews in Immunology.
4:420.
TAKAHASHI,T.,NIEDA,M.,KOEZUKA,Y.,NICOL,A.,PORCELLI,S.,ISHIKAWA,
Y.,TADOKORO,K.,HIRAI,H.,JUJI,T. (200) Analysis of human VD24+CD4+NKT
cells activate by D-glusocylceramide-pulsed monocytes-dervide dendritic cells.
Journal of Immunology. 164(9): 4458-64.
TAKASHIMA,A.,MORITA,A. (1999) Dendritic cells in genetic immunisation.
Journal of Leukocyte Biology. 66(2): 350-6.
TAKEDA,K.,KAISHO,T.,AKIRA,S. (2003) Toll like receptors. Annual Reviews in
Immunology. 21:335-376.
TAKEDA,K.,SMYTH,M.,KRETNEY,E.,HIYAKAWA,Y.,YAMAGUCHI,N.,YAGI
TA,H.,OKUMURA,K. (2003) Involvement of tumour necrosis factor-related
apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent
suppression of subcutaneous tumour growth. Cell Immunology. 214(2): 194-200.
TAKEDA,K.,HAYAKAWA,Y.,ATSUTA,M.,HONG,S.,VAN KAER,L.,
KOBAYASHI,K.,ITO,M.,YAGITA,H.,OKUMURA,K. (2000) Releative contribution
of NK and NKT cells to the anti-metastatic activities of IL-12. Int. Immunology.12(6):
909-14.
TANG,D.,DEVIT,M.,JOHNSTON,S. (1992) Genetic immunisation is a simple
method for eliciting an immune response. Nature. 356(6365): 152-4.
TELEN,M.J., GREEN,A.M. (1989) The Inab phenotype: characterisation of the
membrane protein and complement regulator defect. Blood 74(1):437-441.
TEW,J.,WU,J.,FAKHER,M.,SZAKAL,A.,QIN,D. (2001) Follicular dendritic cells:
beyond the necessity of T cell help. Trends in immunology. 22(7): 361-7.
TIGHE,H.,CORR,M.,ROMAN,M.,RAZ,E. (1998) Gene vaccination: plasmid DNA is
more than just a blueprint. Immunology Today. 19(2): 89-97.
TILL,G.O. (1986) Chemotactic factors. Complement System: 354.
TIMMERMAN,J. (2002) Idiotype pulsed dendritic cell vaccination for B cell
lymphoma: clinical and immune responses in 35 patients. Blood. 99:1517-1526.
TOURDOT ET AL. ( 2000) A general strategy to enhance immunogenicity of low
affinity HLA-A2.1 associated peptde: implication in the identification of cryptic
tumour epitopes. European Journal of Immunology. 30:3411-3421.
273
TOWNSEDND,M.,WINMANN,A.,MATSUDA,J.,SALOMON,R.,FARNHAM,P.,BI
RON,C.,GAPIN,L.,GLIMCHER,L. (2004) T-bet reglates the terminal maturation and
homeostasis of NK and Valpha14i NKT cells. Immunity. 20(4): 477-94.
UHRINOVA,S.,LIN,F.,BALL,G.,BROMEK,K.,UHRIN,D.,MEDOF,M.,BARLOW,P
. (2003) Solution structure of functionally active fragment of decay accelerating
factor. PNAS. 100(8): 4718-5723.
VAUGHAN,T.J. et al. (1998) Human antibodies by design. Biotechnology. 16:535-
539.
VERHASSELT,V.,BUELENS,C.,WILLEMS,F.,DEGROOTE,D.,HAEFFNER-
CAVAILLON,N.,GOLDMAN,M. (1997) Bacterial lipopolysaccharide stimulates the
production of cytokines and the expression of costimulatory molecules by human
peripheral blood dendritic cells- Evidence for a soluble CD14 pathway. Journal of
immunology. 158:2919-2925.
WALDMAN,T.,DUBOIS,S.,TAGAT,Y. (2001)Contrasting roles of IL-2 and IL-15 in
the life and death of lymphocytes: implications for immunotherapy. Immunity.14:105-
110.
WATSON,N.,DURRANT,L.,MADJD,Z.,ELLIS,I.,SCHOEFIELD,J.,SPENDLOE,I.
(2005) Expression of the membrane complement regulatory protein CD59 (protectin)
is associated with reduced survival in colorectal cancer patients. Cancer Immunology
and Immunotherapy.1-8.
WANG,D.,YANG,E.,CHENG,L. (1997) Effects of IFNJ, TNFD and EGF on the
expression of HLA class I antigen and the proliferation of human hepatocellular
carcinoma HepG2 cell. Anticancer Research. 17: 10-18
WANG,R. (Induction of antigen specific T lymphocytes in humans by malaria DNA
vaccine. Science. 282: 476-480.
WEINBERG,A.,VELLA,A.,CROFT,M. (1998) OX-40: Life beyond the effector T
cell stage. Seminars in Immunology.10: 471-480.
WHITE,C.A.,WEAVER,R.L.,GRILLO-LOPEZ,A.J. (2001) Antibody targeted
immunotherapy for treatment of malignancy. Ann Rev Med. 52:125-145.
WHITLOW,M.B.,IIDA,I.,STEFANOVA,A.,BERNARD,A.,NUSSENZWEIG,V.
(1990) H19, a surface membrane molecule involved in T cell activation, inhibits
channel formation by human complement. Cellular Immunology. 126:176.
WILLIAMS,N.,MOORE,T.,SCHATZLE,J.,PUZANOV,I.,SIVAKUMAR,P.,ZLOTNI
K,A.,BENNETT,M.,KUMAR,V. (1997) Generation of lytic natural killer1.1
+
, Ly-49-
cells form multipotential murine bone marrow progenitors in a stroma-free culture:
definition of cytokine requirements and developmental intermediates. Journal of
Experimental Medicine. 186(9): 609-14.
274
WILSON,M.,JOHANSSON,C.,OLIVARES-VILLAGOMEZ,D.,SINGH,A.,
STANIC,A., WANG,C., JOYCE,S.,WICK,M.,VAN KAER,L. (2003) The response
of natural killer T cells to glycolipid antigens is characterized by surface receptor
down-modulation and expansion. Proc. Natl. Acad, Sci.USA. 100(19): 10913-8.
WOLFF,J.,BUKER,V. (2005) The mechanism of naked DNA uptake and expression.
Advanced genetics. 54: 3-20.
YAMAZAKI,S.,IYODA,T.,TARBELL,K.,OLSON,K.,VELINZON,K.,INABA,K.,ST
EINMAN,R. (2003) Direct expansion of functional CD25
+
CD4
+
regulatory T cells by
antigen processing dendritic cells. Journal of Experimental Medicine. 198(2):235-
247.
YANAGIHARA,S.,KOMURA,E.,NAGAFUNE,J.,WATARAI,H.,YAMAGUCHI,Y.
(1998) EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-
regulated upon maturation. Journal of Immunology. 161: 3096-3102.
YANG,R.,MAES,H.,CORSI,M.,DELLNER,F.,TAO,W.,KIESSLING,R. (1998)
Interferon gamma impairs the ability of monocyte-derived dendritic cells to present
tumour-specific and allo-specific antigens and reduces their expression of CD1a,
CD80 and CD4. Cytokine. 10: 747-755.
YOU,Z.,HUANG,X.,HESTER,J.,TOH,H.,CHEN,S. (2001) Targeting dendritic cells
to enhance DNA vaccine potency. Cancer Research. 61:3704-11.
ZENG,D.,LEWIS,D.,DEJBAKHSH-JONES,S.,LAN,F.,GARCIA-OJEDA,M.,
SIBLEY,R.,STROBA,S. (1999) Bone marrow NK1.1(-) and NK1.1(+) T cells
reciprocally regulate acute graft versus host disease. Journal of Experimental
Medicine. 189(7): 1073-81.
ZHONG. et al. (1995) Homologous restriction of complement mediated cell lysis can
be markedly enhanced by blocking decay accelerating factor. British Journal of
Haemotology, 91(2):269-274.
ZINKERNAGEL,R. (2002) Uncertainties-discrepancies in immunology.
Immunological Reviews. 185: 103-125.
